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Abstract	 	Elephant	 endotheliotropic	 herpesviruses	 (EEHVs)	 are	 responsible	 for	 a	 highly	 fatal	haemorrhagic	 disease	 (EEHV-HD),	 threatening	 the	 overall	 sustainability	 of	 the	 Asian	elephant	 (Elephas	 maximus)	 population.	 The	 viruses	 were	 first	 reported	 in	 tissue	sections	of	a	fatal	case	of	an	Asian	elephant	in	1988.	 	In	recent	years,	there	has	been	a	gradual	 increase	 in	 our	 understanding	 of	 the	 viruses	 highlighted	 by	 decoding	 their	complete	genome	sequences.	However,	lack	of	an	animal	model	and	a	cell	culture	system	has	 restricted	 studies	 on	 the	 pathogenesis	 of	 the	 viruses,	 assessing	 control	measures,	and	 development	 of	 a	 vaccine.	 This	 project	 therefore	 aimed	 to	 achieve	 a	 better	understanding	 of	 the	 viruses’	 pathogenesis	 studying	 several	 EEHV	 surviving	 and	 fatal	cases,	and	to	advise	accordingly	on	the	control	measures.		The	results	revealed	coincidence	of	highest	blood	viral	load	with	clinical	signs,	viruses’	shedding	in	trunk	secretion	during	convalescence,	complementary	haematological	tests	to	 aid	 detection	 and	 clinical	 prognosis	 of	 EEHV	 infections	 and	 the	 inadequacy	 of	famciclovir	 treatment	 to	 alter	 EEHV	 infections.	 Analysis	 of	 tissues	 from	 fatal	 cases	detected	viruses’	co-infections	(EEHV-1	and	4)	and	widespread	organ	distribution	with	liver,	heart,	mesenteric	 lymph	node,	 thymus,	and	 tongue	having	 the	highest	viral	 load,	thereby	 highlighting	 implications	 for	 EEHV	 diagnosis	 and	 future	 in	 vitro	 isolation.	Further,	 this	 study	 isolated	 elephant	 endothelial	 cells	 and	 PBMCs	 and	 used	 these	established	 elephant	 cells	 alongside	 common	 laboratory	 cell	 lines	 to	 assess	 their	suitability	for	EEHV-1A	isolation.	Despite	indication	of	limited	increase	in	EEHV-1	DNA	in	 PBMCs	 and	 mouse	 embryo	 fibroblast	 supernatants,	 conclusive	 in	 vitro	 virus	replication	could	not	be	demonstrated.		
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In	 conclusion,	 the	 outcomes	 of	 this	 PhD	 study	 further	 advance	 our	 knowledge	 on	pathogenesis	 of	 EEHV	 strains	 and	 provide	 new	 insights	 on	 their	 control	 to	 minimise	their	respective	impact	on	the	Asian	elephant	population.			 	
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CHAPTER	1:	INTRODUCTION	
	
	
1.1. General	introduction		The	name	“Herpesvirus”	is	derived	from	the	Greek	word	herpein	("to	creep"),	referring	to	the	herpesvirus’	ability	to	cause	latent	and	recurring	infections	(Beswick,	1962).	Herpesviruses	are	ubiquitous	in	nature	and	well	over	150	different	herpesvirus	species	have	been	identified	to	date,	which	can	cause	a	variety	of	diseases	 in	nearly	all	animal	species,	ranging	from	inapparent	infections	to	death	(McGeoch	et	al.,	1995;	Contreras	&	Slots,	2000).	During	viral	discovery	projects,	herpesviruses	are	still	detected	regularly	in	all	kinds	of	species.	Elephant	Endotheliotropic	Herpesvirus	(EEHV)	was	only	detected	in	Asian	 elephants	 in	 1988	 (Pilaski,	 1988)	 and	 is	 now	 recognised	 as	 one	 of	 the	 major	threats	to	the	overall	conservation	of	Asian	elephants	worldwide	(Wiese,	2000;	Long	et	al.,	 2015).	 It	 can	 cause	 a	 generalised	 haemorrhagic	 disease,	 referred	 to	 as	 EEHV	haemorrhagic	 disease	 (EEHV-HD),	 which	 mostly	 affects	 juvenile	 Asian	 elephants	between	the	age	of	1	and	18	years.	It	is	speculated	that	as	many	as	60%	of	all	fatalities	in	juvenile	 Asian	 elephants	 are	 due	 to	 EEHV	 infection	 (Long	 et	 al.,	 2015).	 In	 contrast	 to	previous	believes,	it	is	now	understood	that	the	virus	is	endogenous	also	in	free	ranging	elephants	 in	 Asia	 (Zachariah	 et	 al.,	 2013;	 Sripiboon	 et	 al.,	 2013).	 To	 date,	 there	 is	 no	known	cure	to	the	disease	or	vaccination	against	this	highly	pathogenic	virus.		
	
1.1.1. Herpesvirus	Structure	All	herpesvirus	virions	have	a	similar	enveloped	structure	consisting	of	a	core	of	linear	double-stranded	 DNA	 (ds-DNA),	 an	 icosahedral	 capsid	 surrounding	 the	 DNA,	 and	 an	amorphous-appearing	tegument	(Figure	1.1).	The	envelope	encloses	the	virus	particle	and	can	vary	in	size	leading	to	virions	ranging	in	diameter	from	120	to	260	nm	(Gibson,	1996).	All	herpesviruses	express	several	glycoproteins	or	glycoprotein	complexes	such	
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as	gB	and	gH/gL,	which	are	forming	spikes	on	the	outer	surface	of	the	envelope	and	are	essential	for	virus	attachment	and	entry	into	the	host	cell	(Connolly	et	al.,	2011;	King	et	al.,	2012).				
	
Figure	1.1:	Schematic	drawing	of	a	typical	herpesvirus	particle.	The	herpesvirus	is	composing	of	a	double	stranded	DNA,	a	capsid,	a	tegument,	and	an	envelope.	Glycoprotein	complexes	are	embedded	in	the	lipid	envelope	(Kukhanova	et	al.,	2014).			
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Herpesvirus	 genomes	 are	 of	 remarkable	 genetic	 variation	 in	 composition,	 size,	 and	organisation,	with	a	broad	host	variation,	 leading	 to	different	genetic	groupings	of	 the	order	Herpesvirales.		
1.1.2. Herpesviruses	Classification	
The	Herpesvirales	order	is	divided	into	3	distinct	families:	The	Herpesviridae	(mammals,	birds,	and	reptiles),	 the	Alloherpesviridae	 (fish	and	frogs),	and	the	Malacoherpesviridae	(oysters).	 The	 classification	 of	 the	 Herpesviridae	 was	 initially	 determined	 by	 their	structure	and	biological	properties,	such	as	host	ranges,	reproductive	cycles,	and	latency	sites.	Today,	molecular	characteristics	are	also	considered	in	classifying	herpesviruses. Therefore,	 the	 family	 Herpesviridae	 is	 further	 divided	 into	 three	 subfamilies	
Alphaherpesvirinae,	 Betaherpesvirinae,	 and	 Gammaherpesvirinae,	 based	 on	recommendations	 of	 the	 International	 Committee	 on	 Taxonomy	 of	 Viruses	 (ICTV,	http://www.ictvonline.org).	 A	 notable	 exception	 may	 be	 the	 recently	 described	herpesvirus	of	elephants,	for	now	still	listed	as	part	of	the	betaherpesviruses	(Richman	et	al.,	1999),	which	will	be	discussed	later.	The	classification	of	common	herpesviruses	is	listed	in	Table	1.1. 
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Table	 1.1:	 Classification	 of	 common	 herpesviridae	 and	 their	 host	 and	 disease	
association.	The	classification	of	the	probosciviruses	is	currently	under	discussion	but	is	for	now	listed	as	part	of	the	betaherpesviruses.	
	 Genus		 Formal	name		 Common	name		 Host		 Disease		
	
a		
Simplexvirus		 Human	herpesvirus	1,2		 Herpes	simplex	virus	type	1,2		 Human		 Cold	sore,	Recurrent	herpetic	stomatitis		
Varicellovirus		 Human	herpesvirus	3,	Suid	herpesvirus	1		 Varicella-zoster	virus	(VZV),	Aujeszky's	disease	virus	 Human,	Swine		
Chickenpox,	shingles;	Aujeszky's	disease	or	pseudorabies		
	 Mardivirus		 Gallid	herpesvirus	2,	3		 Marek's	disease	virus		 Chicken		 T	cell	lymphoma		
	
b		
Cytomegalovirus		 Human	herpes	virus	5		 Human	cytomegalovirus	(HCMV)		 Human		 Mononucleosis		Muromegalovirus		 Murid	herpesvirus	1		 Mouse	cytomegalovirus		 Mouse		 Hepatitis		Roseolovirus		 Human	herpesvirus	6,	7		 Human	herpesvirus	6,	7		 Human		 Roseola	infantum,	Encephalitis		
	 Proboscivirus*	 Elephant	endotheliotropic	herpesvirus	 Elephant	endotheliotropic	herpesvirus	(EEHV)	1-6	 Elephant	 EEHV	haemorrhagic	disease	
g		
Lymphocryptovirus		Human	herpesvirus	4		 Epstein-Barr	virus		 Human		 Infectious	mononucleosis,	Burkitt's	lymphoma		
Rhadinovirus		
Human	herpesvirus	8		 Kaposi's	sarcoma-associated	herpesvirus		 Human		 Kaposi's	sarcoma,	Castleman's	disease		Murid	herpesvirus	4		 Murine	gammaherpesvirus	68		 Mouse		 Lymphoma		Saimiriine	herpesvirus		 Herpesvirus	saimiri		 Monkey		 Lymphoproliferative	disease		Macavirus		 Alcelaphine	herpesvirus	1		 Malignant	catarrhal	fever	virus		 Cattle		 Lymphoproliferative	disease		Percavirus		 Equine	herpesvirus	2,	5		 Equine	herpesvirus	2,	5		 Horse		 Respiratory	disease		*classification	still	in	discussion			
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Alphaherpesvirinae	are	generally	seen	as	the	most	pathogenic	of	these	three	subfamilies	and	 characterised	 by	 a	 very	 short	 replication	 cycle	 of	 just	 a	 few	 hours	 leading	 to	 the	prompt	 destruction	 of	 their	 host	 cells	 during	 the	 lytic	 stage	 of	 infection.	 The	 viruses	show	 a	 wide	 and	 variable	 host	 range	 and	 can	 replicate	 in	 various	 cells	 of	 the	 host,	including	 epithelial	 and	 endothelial	 cells,	 keratinocytes,	 T	 cells,	 sebocytes,	monocytes,	Langerhans	 cells,	 and	 peripheral	 blood	 mononuclear	 cells	 (PBMCs).	 They	 are	 often	neuroinvasive	 and	 establish	 latent	 infections	 in	 sensory	 nerve	 ganglia	 (reviewed	 by	Penkert	 &	 Kalejta,	 2011).	 Well	 known	 examples	 for	 alphaherpesviruses	 are	 listed	 in	
Table	1.1.	
Betaherpesvirinae,	in	contrast,	replicate	more	slowly	than	alpha	herpesviruses,	with	the	viruses’	reproductive	life	cycle	in	cell	culture	taking	up	to	a	few	days.	They	have	a	very	limited	host	 range,	but	are,	however,	also	capable	of	 infecting	a	variety	of	 cells	within	their	 host,	 including	 endothelial	 and	 epithelial	 cells,	 macrophages,	 dendritic	 cells,	smooth	muscle	cells,	and	fibroblasts,	and	establish	latency	in	progenitor	cells	of	the	bone	marrow,	monocytes,	and	T-cells,	which	are	all	part	of	the	immune	system	(reviewed	by	Penkert	&	Kalejta,	2011).	Furthermore,	the	viruses	often	establish	a	stable	host-parasite	relation	in	healthy	individuals	with	restricted	replication	cycle	or	cell	lysis	effects,	only	causing	mild	localised	pathological	damage.	Severe	disease	seems	to	only	occur	in	hosts	affected	by	 immunosuppression,	 in	neonates	and	 foetuses,	or	 in	alternate	host	species	(Davis-Poynter,	 et	 al.,	 1996).	 A	 characteristic	 of	 these	 viruses	 is	 their	 ability	 to	 form	enlarged	„ballooning“	cells	in	culture,	as	exemplified	by	human	cytomegalovirus	(HCMV)	infection.	
Elephant	Endotheliotropic	Herpesvirus	(EEHV)	belongs	 to	 the	genus	Proboscivirus	 and	is,	phylogenetically,	most	closely,	although	distantly,	related	to	human	cytomegalovirus	(HCMV)	 and	 three	 human	 Roseolo	 viruses	 (human	 herpesvirus-6A,	 -6B,	 and	 -7),	 all	
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members	 of	 the	 subfamily	 Betaherpesvirinae	 (Table	 1.1).	 	 However,	 latest	 EEHV	sequence	studies	on	archived	samples	and	recent	fatalities	indicate	that	EEHVs	may	be	distinct	 from	 other	 Betaherpesviruses	 and	 hence	 a	 new	 subfamily	 for	 the	 viruses	 is	proposed,	 the	subfamily	Deltaherpesvirinae	(Figure	1.2;	Ehlers	et	 al.,	 2001;	Ling	et	al.,	2013;	Pellett,	2014;	Richman	et	al.,	2014;	Zong	et	al.	2014),	but	this	is	yet	to	be	approved	by	the	International	Committee	on	Classification	of	Viruses.	
Gammaherpesvirinae	generally	 replicate	 poorly	 and	 have	 the	most	 limited	 host	 range.	The	 viruses	 replicate	 in	 lymphoblastoid	 cells	 in	vitro	 and	 can	 cause	 lytic	 infections	 in	epithelial	cells,	macrophages,	dendritic	cells,	and	B	cells.	Latent	virus	infection	has	been	demonstrated	 in	 B	 cells,	macrophages,	 dendritic	 cells,	 epithelial	 cells,	 and	 plasma	 cell	(reviewed	by	Penkert	&	Kalejta,	2011).	Common	viruses	belonging	to	the	gammaherpes	subfamily	 are	 listed	 in	 Table	 1.1.	 Further,	 five	 highly	 diverged	 gammaherpesviruses	have	 been	 identified	 in	 elephants	 (EGHVs),	 one	 being	 associated	 with	 self-resolving	tumour-like	lesions	in	the	trunk	(Wellehan	et	al.,	2008;	Latimer	et	al.,	2011;	Masters	et	al.,	2011).	
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Figure	 1.2:	 Phylogenetic	 analysis	 of	 the	 family	 herpesvirinae.	 	 The	 genetic	relationship	was	determined	by	analysis	of	the	sequences	of	the	DNA	polymerase	gene	(U38)	homologues	from	several	mammalian	herpesviruses	including	EEHV-1	(Ehlers	et	al.,	2001).				
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1.1.3. Herpesviruses	Replication	Cycle	Cellular	attachment	of	herpesviruses	 to	 the	cells	 is	generally	 followed	by	 fusion	of	 the	viral	 envelope	 and	 the	 cell	 plasma	membrane.	 Studies	 of	 the	 closely	 to	 EEHV	 related	betaherpesvirus,	 HCMV,	 have	 shown	 that	 the	 heterodimeric	 envelope	 complex	consisting	 of	 the	 transmembrane	 glycoproteins	 gH	 and	 gL,	 together	 with	 a	 third	component,	gO,	is	needed	for	infection	(Huber	and	Compton,	1999).		Different	mechanisms	of	viral	entry	of	HCMV	into	the	uninfected	cell	are	discussed	in	the	literature.	One	mechanism	involves	direct	fusion	between	the	viral	envelope	and	the	cell	plasma	membrane,	whereas	 the	second	 involves	endocytosis	of	 the	enveloped	particle	and	fusion	of	the	envelope	with	the	endosomal	membrane	(Vanarsdall	et	al.,	2012).	Both	mechanisms	result	in	deposition	of	the	nucleocapsid	and	tegument	proteins	directly	into	the	cytoplasm	of	the	cell.		
After	uncoating,	the	capsid	is	led	to	the	nucleus	through	a	microtubule	network,	attaches	to	 a	 nuclear	 pore,	 and	 injects	 the	 genomic	 ds-DNA	 into	 the	 nucleus	where	 viral	 gene	expression	 starts	 in	 a	 regulated	 cascade	 (Mettenleitner	 et	 al.,	 2009).	 There	 are	 three	“phases”	of	gene	expression,	 transcribing	 the	so-called	 immediate-early	 (IE),	early	 (E),	and	late	(L)	genes,	also	referred	to	as	α-,	β-,	and	γ-genes.		
The	 IE	 genes	 and	 their	 products	 are	 involved	 in	 regulating	 viral	 genome	 replication.	During	 transcription,	 some	 IE	 mRNAs	 are	 spliced	 and	 transported	 to	 the	 cytoplasm	where	 the	 translation	 of	 the	 IE	mRNAs	 takes	 place.	 Subsequently,	 the	 IE	 proteins	 are	transported	 back	 into	 the	 nucleus,	 where	 they	 regulate	 transcription	 of	 IE	 genes	 and	activate	 expression	 of	 the	 early	 (E)	 genes.	 The	 E	 gene	 mRNAs	 are	 spliced	 and	transported	to	the	cytoplasm	where	they	are	translated.	Some	of	the	E	gene	proteins	are	transported	to	the	nucleus,	some	of	them	remain	in	the	cytoplasm.	E	gene	products	are	mostly	involved	in	viral	DNA	synthesis,	cleavage,	and	packaging	of	the	viral	genome,	and	
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in	 creating	 an	 environment	 that	 is	 optimal	 for	 viral	 gene	 expression	 and	 replication.		Viral	 DNA	 replication	 and	 recombination	 produces	 concatemeric	 DNA,	 which	 is	 the	template	 for	 L	 genes.	Most	 late	mRNAs	 are	 transported	 to	 the	 cytoplasm	 to	 translate	without	 splicing.	 The	 proteins	 encoded	 by	 L	 genes	 are	 primarily	 virion	 structural	proteins	 and	proteins	 for	 viral	 capsid	 assembly	 and	egress	 (reviewed	by	Weir,	 2001).	Once	new	genomes	and	capsids	are	 formed,	 the	viral	DNA	 is	packaged	 into	 the	empty	capsids	inside	the	nucleus	and	the	process	of	primary	envelopment	can	start.	However,	the	 exact	mechanisms	 of	 betaherpesviruses’	 envelopment	 are	 still	 debated.	 Currently,	the	most	widely	accepted	 theory	 is	 a	 two-stage	envelopment	of	 the	 capsid	and	egress	process	starting	 in	the	nucleus	and	ending	 in	the	release	of	 the	virion	by	exocytosis	at	the	 plasma	 membrane.	 Thus,	 the	 DNA	 containing	 viral	 capsid	 acquires	 the	 primary	envelope	 when	 budding	 through	 the	 inner	 nuclear	 membrane.	 Then	 the	 primary	envelope	fuses	with	the	outer	 leaflet	of	the	nuclear	membrane	and	the	nucleocapsid	is	released	 into	 the	 cytoplasm,	 losing	 the	 primary	 envelope.	 The	 structures	 are	 then	transported	 to	 a	 late	 Golgi-endosome	 compartment	 or	 an	 endosome	 where	 the	tegument	and	envelope	proteins,	 encoded	by	L	genes,	are	added	onto	 the	virions.	The	enveloped	virus	then	buds	into	a	vesicle	transported	to	the	plasma	membrane	and	the	virus	 particle	 is	 released	 by	 exocytosis	 (Mettenleitner,	 2004;	 Mocarski,	 2007).	 An	illustration	of	a	typical	productive	herpesvirus	cycle	is	shown	in	Figure	1.3.		
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Figure	 1.3:	 Replication	 cycle	 of	 a	 productive	 herpesvirus	 infection.	 The	 cycle	 is	showing	viral	binding	to	extracellular	matrix	via	glycoproteins,	membrane	fusion,	viral	nucleocapsid	transportation	to	cell	nucleus,	DNA	release,	viral	DNA	replication,	packing	of	DNA	 into	nucleocapsid,	 virion	envelopment,	 and	 release	of	 virus	by	exocytosis.	The	figure	was	adapted	and	simplified	from	Flint	et	al.	(2009).	
		 	
0 0 0 
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Following	 the	 initial	 replication	 cycle,	 herpesviruses	 are	 known	 to	 establish	 a	 latent	phase,	a	persistent	 life-long	 infection.	Often	undetectable	by	diagnostic	 tests	or	by	 the	host’s	 immune	system,	 the	virus	persists	 in	specific	body	compartments	depending	on	the	 type	of	herpesvirus,	with	HSV-1	 latent	 infection	occurring	 in	ganglia	of	neurons	 in	the	 peripheral	 nervous	 system	 being	 a	 typical	 example.	 Occasionally,	 the	 latent	 virus	reactivates	 and	 resumes	 replication,	 resulting	 in	 the	 dissemination	 of	 progeny	 virus	particles	via	 the	bloodstream,	which	may	 lead	to	 the	 infection	and	damage	of	multiple	organs.	However,	the	exact	mechanisms	causing	reactivation	of	latent	viruses	are	not	yet	fully	understood,	but	 stress	 factors	 are	 likely	 to	play	 a	major	part	 in	 this	 (Perng	et	 a.,	1994).	
	
1.1.4. Epidemiology	and	Pathogenesis	of	human	Betaherpesviruses	Members	of	 the	Betaherpesvirinae	subfamily,	namely	human	cytomegalovirus	 (HCMV)	and	 three	human	Roseolo	viruses	(human	herpesvirus-6A,	 -6B,	 and	 -7),	 are	genetically	most	closely	related	to	EEHV.	HCMV	is	a	ubiquitous	virus	that	infects	almost	all	humans	at	some	point	in	their	lives	and	has	an	estimated	seroprevalence	of	40	to	100%	among	different	populations	worldwide	 (Ho,	1990).	HCMV	was	 first	 isolated	 in	1956	 (Weller,	1970)	and	 is	 the	most	common	congenital	viral	 infection	 in	humans	affecting	between	20,000	and	40,000	infants	each	year	only	in	the	United	States	(Demmler,	1991).		The	virus	replicates	mainly	in	the	salivary	glands	and	kidneys	and	is	shed	in	saliva	and	urine,	 and	 direct	 contact	 with	 such	 infected	 secretions	 is	 the	 most	 common	 route	 of	transmission	(Gautheret-Dejean	et	al.,	1997).	 	In	vitro,	 the	replication	cycle	 is	slow	and	the	 virus	 induces	 characteristic	 giant	 cells	with	 intranuclear	 inclusions	 (Murray	 et	 al.,	2015).	The	great	majority	of	primary	HCMV	infections	in	immunocompetent	hosts	are	clinically	
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asymptomatic	(Pass,	2001);	only	a	very	small	percentage	of	people	develops	symptoms	such	 as	 hepatosplenomegaly,	 retinitis,	 rashes,	 encephalitis,	 or	 suffer	 from	 a	mononucleosis	 syndrome	 (Pass	 &	 Boppana,	 1999).	 Thus,	 a	 primary	 HCMV	 infection	cannot	 generally	 be	 diagnosed	 on	 clinical	 grounds.	 Whether	 a	 pregnancy-associated	immunosuppression	might	play	a	critical	role	in	symptomatic	primary	HCMV	infections	remains	to	be	determined.	Infection	with	HCMV	is	however	believed	to	be	the	number	one	 non-genetic	 cause	 of	 sensorineural	 hearing	 loss	 in	 children	 and	 is	 an	 important	cause	 of	 morbidity	 and	 mortality	 in	 immunocompromised	 hosts	 (Rubin	 et	 al.,	 1985;	Jacobson	et	al.,	1988;	Winston	et	al.,	1990).		The	 roseloviruses,	 human	 herpesvirus	 6A,	 6B	 and	 7	 (HHV-6A,	 6B,	 and	 7)	 are	lymphotropic	betaherpesviruses	and	are	also	widely	spread	among	human	populations	(Tanaka-Taya	 et	 al.,	 1996).	 The	 frequent	 detection	 of	HHV-6	 and	7	DNA	 in	 saliva	 and	salivary	gland	tissue	(Collot	et	al.,	2002)	suggests	that	salivary	glands	are	a	potential	site	for	 latency	 and	 that	 saliva	 is	 a	 vehicle	 for	 transmission	 of	 the	 viruses	 (Mukai	 et	 al.,	1994).	Additionally,	the	possibility	of	intrauterine	transmission	of	the	viruses	also	exists	(Aubin	et	al.,	1992).	The	 vast	majority	 of	 HHV-6	 and	 7	 infections	 are	 clinically	 inapparent	 or	 appear	 as	 a	general	mild	febrile	illness	with	a	benign	and	self-resolving	course	(Murray	et	al.,	2015).	Interestingly,	primary	HHV-6	 infections	 in	children	between	6	and	12	months	account	for	20%	of	their	cases	of	acute	fever	(Hall	et	al.,	1994)	and	are	almost	exclusively	caused	by	HHV-6B,	not	HHV-6A	(Schirmer	et	al.,	1991;	Dewhurst	et	al.,	1993).	 Infections	with	roseoloviruses	 are	 mostly	 associated	 with	 the	 subsequent	 development	 of	 exanthem	subitem	(roseola	 infantum,	sixth	disease)	 (Yamanishi	et	al.,	1988;	Tanaka	et	al.,	1995)	and	 with	 complications	 like	 malaise,	 inflamed	 tympanic	 membranes,	 and	gastrointestinal	 and	 respiratory	 tract	 symptoms	 (Hall	 et	 al.,	 1994).	 More	 severe	 CNS	complications,	 such	 as	 meningoencephalitis	 and	 encephalopathy,	 have	 also	 been	
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reported	on	rare	occasions	(Ishiguro	et	al.,	1990;	Torigoe	et	al.,	1996;	McCullers	et	al.,	1995;	Yoshikawa	&	Asano,	2000;	Kato	et	al.,	2003).	Primary	infections	in	adults	are	very	rare	 and	 can	 cause	 a	 mononucleosis-like	 disease	 and	 haemophagocytic	 syndrome	(Akashi	 et	 al.,	 1993).	 In	 immunocompromised	 patients,	 the	 consequences	 of	 primary	HHV-6	 or	 7	 infections	 may	 be	 fatal	 (Chan	 et	 al.,	 2002;	 Sergi	 et	 al.,	 2007).	 The	 exact	pathogenic	 characteristics	of	 infections	with	 roseoloviruses,	 especially	HHV-7,	 are	 still	poorly	understood.		
1.1.5. Detection	and	management	of	human	betaherpesviruses	Infections	 with	 betaherpesviruses	 cannot	 generally	 be	 diagnosed	 on	 clinical	 grounds	alone,	 as	 the	 great	 majority	 of	 infections	 in	 immunocompetent	 hosts	 are	 clinically	inapparent	(Pass,	2001).	However,	the	potential	clinical	importance	of	invasive	diseases	caused	by	these	viruses	has	led	to	the	development	of	various	diagnostic	assays	for	the	rapid	identification	of	infections	with	HCMV,	HHV-6,	and	7.	The	 most	 commonly	 used	 diagnostic	 method	 for	 the	 betaherpesviruses	 is	 the	Polymerase	 Chain	 Reaction	 (PCR),	 which	 is	 rapid	 and	 sensitive	 (Ross	 et	 al.,	 2011;	Cassina	et	al.,	2013).	PCRs	can	be	either	qualitative	or	quantitative,	in	which	the	amount	of	 viral	 DNA	 in	 a	 respective	 sample	 is	measured.	 A	 real-time	 quantitative	 PCR	 allows	monitoring	of	individuals	for	viral	replication	for	potential	prophylactic	therapy	or	their	response	to	treatment	(Seehofer	et	al.,	2004).	Serological	tests	are	useful	for	determining	whether	a	patient	has	had	a	certain	infection	in	the	past,	or	as	an	indicator	of	an	acute	or	recent	infection,	determined	by	the	presence	or	 absence	 of	 certain	 antibodies.	 Various	 assays	 have	 been	 described	 for	 detection	 of	betaherpesviurs	antibodies	with	enzyme-linked	 immunosorbent	assays	(ELISAs)	being	the	most	widely	used	(Cannon	et	a.,	2010).	The	IgM	capture	ELISA	assays	are	used	for	detection	 of	 acute	 or	 recent	 infections	 and	 are	 based	 on	 selective	 binding	 of	 IgM	
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antibody	to	a	specific	antigen.	IgM	ELISA	assays	using	recombinant	HCMV	proteins	and	peptides	have	been	developed	in	an	attempt	to	standardise	serological	assays	(Revello	&	Gerna,	2002).	However,	it	was	found	that	assays	for	HCMV,	HHV-6,	and	7	IgM	antibody	lack	 specificity	 for	 primary	 infection	 as	 IgM	 can	 persist	 for	 months	 and	 can	 also	 be	detectable	in	reactivated	infections	(Rasmussen	et	al.,	1982;	Bhatia	et	al.,	2004;	Naumnik	et	 al.,	 2007,	 de	 Oliveira	 Vianna	 et	 al.,	 2008).	 Additionally,	 most	 assays	 are	 unable	 to	discriminate	 between	 prior	 infections	with	 HHV-6A	 and	HHV-6B	 (Thäder-Voigt	 et	 al.,	2011).	 It	 was	 further	 shown	 that	 IgM	 tests	 lack	 specificity	 as	 there	 was	 a	 poor	correlation	 of	 results	 obtained	 when	 comparing	 different	 commercial	 kits	 for	 IgM	testing	(Genser	et	al.,	2001).		For	testing	of	previous	infections	with	a	betherpesvirus,	IgG	capture	assays	are	used.	IgG	antibodies	show	a	low	avidity	during	the	first	few	months	of	infection,	but	their	affinity	increases	over	time	reflecting	maturation	of	the	immune	response	to	a	certain	antigen.	Hence,	IgG	avidity	assays	are	used	to	help	distinguish	between	primary	and	subsequent	infections.	Avidity	levels	are	measured	through	the	avidity	index,	which	represents	the	percentage	of	IgG	bound	to	an	antigen	after	treatment	with	a	denaturing	agent	(Revello	&	 Gerna,	 2002).	 Depending	 on	 the	 type	 of	 virus,	 different	 antigens	 are	 acting	 as	 the	immunogentic	compound	for	the	immune	system.	For	many	betaherpesvirus	infections	like	 HCMV,	 HHV-6,	 and	 7,	 antibodies	 to	 the	 glycoprotein	 B	 (gB)	 seem	 to	 enhance	protection	by	curbing	at	least	the	dissemination	of	the	virus	in	the	blood	(Field	&	Hodge,	2013),	and	gB	is	therefore	seen	as	a	potential	candidate	for	ELISA	assays.	Further,	pp65	provides	a	specific	marker	 for	active	HCMV	replication	and	 its	detection	can	 therefore	considerably	improve	disease	management	(Allice	et	al.,	2008).	A	 traditional	 method	 for	 betaherpesvirus	 detection	 has	 been	 the	 conventional	 cell	culture	 (e.g.	 foreskin	 fibroblast	 cell	 line	 for	 HCMV)	 being	 inoculated	 with	 clinical	specimens.	After	 an	 incubation	 of	 2	 to	 21	days,	 the	 virus	 exhibits	 a	 typical	 cytopathic	
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effect	 (CPE)	 (Stagno	 et	 al.,	 1980).	 For	HCMV,	 such	CPE	 is	 characterized	by	 foci	 of	 flat,	swollen	cells,	ballooning	(Paya	et	al.,	1987).	However,	virus	isolation	is	slow,	requiring	2–3	weeks	before	a	result	can	be	reported	as	negative.	The	shell	vial	assay	is	a	modified	viral	 culture	 to	 decrease	 the	 time	 of	 virus	 isolation,	 through	 centrifugation	 of	 the	inoculum	onto	the	cell	monolayer	to	assist	adsorption	of	virus	and	effectively	increasing	infectivity	 (Chou	 &	 Scott,	 1988).	 Using	 this	 assay	 for	 HCMV,	 viral	 antigens	 may	 be	detectable	 after	 16	 hours	 of	 incubation	 using	 monoclonal	 antibodies	 directed	 at	 the	HCMV	immediate-early	(IE)	viral	antigen	(Reina	et	al.,	1997).		Another	method	for	viral	detection	is	immunohistochemistry	or	immunocytochemistry,	for	tissues	and	cells	respectively,	primarily	performed	on	tissue	or	body	fluid	samples.	In	 this	 approach,	 slides	 are	 obtained	 from	 frozen	 sections	 of	 tissue	 samples	 or	 by	centrifuging	cells	onto	a	slide.	Specific	antibodies	against	early	antigens	are	then	applied	and	 visualised	 by	 fluorescently	 labelled	 antibodies	 or	 enzyme	 labelled	 secondary	antibodies,	which	change	the	colour	of	the	substrate	and	can	be	examined	by	fluorescent	or	light	microscopy.	This	method	is	more	sensitive	and	very	specific	compared	to	plain	histological	microscopy	but	is	rarely	used	clinically	as	it	requires	experienced	personnel	and has	 a	 slow	 turn-around	 time	 (Paya	 et	 al.,	 1990).	 However,	 it	 is	 seen	 as	 the	 gold	standard	 for	HCMV	 detection	 in	 formalin-fixed,	 paraffin-embedded	 tissue	 (Mills	 et	 al.,	2013).	
	
1.1.5.1. Antiviral	medications	against	herpesviruses	Ideally,	 anti-herpes	viral	drugs,	 like	any	medication	 in	general,	 should	deliver	benefits	such	 as	 high	 potency,	 low	 amount	 of	 side	 effects	 (e.g.	 nephrotoxicity,	 bone	 marrow	suppression,	neurotoxicity,	fertility	problems,	diarrhoea),	safety	for	long-term	use,	least	or	no	interactions	with	other	drugs,	broad	anti-herpes	spectrum,	and	act	independent	of	cellular	function	(Griffiths,	2004).		
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Historically,	the	biggest	source	of	anti-herpes	agents	has	been	the	nucleoside	analogues,	originating	 from	 basic	 cancer	 research	 programs.	 Herpesvirus-encoded	 kinases	selectively	phosphorylate	 the	various	nucleoside	analogues	 to	 their	active	 form.	These	phosphorylated	activated	forms	in	turn	act	as	competitive	inhibitors	of	e.g.	the	viral	DNA	polymerases,	thus	reducing	the	amount	of	viral	DNA	synthesized	in	infected	cells	(Biron,	2006).	Acyclovir	(ACV),	commercially	known	as	Zovirax	(GlaxoSmithKline),	was	the	first	selective	nucleoside	analogue	with	potent	activity	against	HSV-1	and	2,	VZV,	and	EBV,	and	moderate	activity	against	CMV	in	vitro	(Elion	et	al.,	1993).	This	drug	has	become	the	choice	for	prophylaxis	and	treatment	of	diseases	caused	by	HSV	and	VZV,	and	has	also	provided	benefits	 against	CMV	 infections.	The	discovery	of	ACV	was	 soon	 followed	by	the	discovery	of	the	related	analogues	ganciclovir	(GCV)	and	penciclovir	(PCV),	with	GCV	now	being	the	gold	standard	for	management	of	CMV	diseases.	Other	analogues	with	a	broad	 activity	 across	 herpesviruses	 followed	 (De	 Clercq,	 2001):	 cidofovir	 (CDV),	 a	nucleotide	 analogue	 that	 also	 shows	 anti-CMV	 activity,	 and	 foscarnet	 (PFA),	 another	nucleoside	 analogue,	 have	 broad	 inhibitory	 activity	 across	many	herpesviruses.	 These	agents	 all	 have	 facilitated	 the	 management	 of	 herpesvirus	 infections.	 Table	 1.2	summarises	the	most	commonly	used	anti-herpesviral	medications	used	in	humans.		
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Table	 1.2:	 Anti-viral	 treatments	 for	 herpesvirus	 infections.	 	 List	 of	 anti-virals	indicating	those	approved	by	the	FDA	(adapted	from	Murrey	et	al.,	2015).	Those	drugs	with	FDA	approval	are	in	bold.	Drug	 HSV	 VZV	 HCMV	 EBV	Acyclovir	 x	 x	 x		 x	Valacyclovir	 x	 x	 -	 -	Famciclovir	 x	 x	 -	 -	Ganciclovir	 x	 x	 x	 -	Valganciclovir	 x	 x	 x	 -	Forscarnet	 x	 x	 x	 -	Cidovovir	 x	 x	 x	 -	
FDA,	US	Food	and	Drug	Administration;	HSV,	Herpes	Simplex	Virus;	VZV,	Varicella-Zoster	Virus;	HCMV,	Human	Cytomegalovirus;	EBV,	Epstein-Barr	Virus;	x,	FDA	approved;	-,	not	applicable	
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1.2. Elephant	Endotheliotropic	Herpes	Virus	(EEHV)	in	Asian	elephants	Asian	elephants	are	an	endangered	species	and	they	are	listed	in	the	Appendix	I	of	the	Convention	 on	 International	 Trade	 in	 Endangered	 Species	 (CITES;	www.cites.org/eng/app/appendices).	 Species	 listed	 in	 the	 Appendix	 I	 are	 the	 most	endangered,	 considered	 currently	 threatened	 with	 extinction	 (Nowak,	 1999).	 In	addition	to	factors	such	as	habitat	loss,	poaching,	and	human-animal	conflict,	infectious	diseases	 also	 contribute	 to	 the	 endangered	 status	 of	 the	 Asian	 elephant.	 Elephant	endotheliotropic	 herpesviruses	 are	 considered	 the	major	 health	 threat	 to	 captive	 and	wild	 Asian	 elephants	 (Elephas	 maximus),	 but	 to	 a	 much	 lesser	 extent	 to	 African	elephants	(Loxodonta	africana).	The	disease	caused	by	the	virus	is	responsible	for	about	60%	of	all	fatalities	in	juveniles	(Long	et	al.,	2015),	and	without	a	solution	to	the	threat	caused	by	EEHV,	captive	Asian	elephants	are	predicted	 to	go	extinct	 in	North	America	within	40	to	50	years	(Wiese,	2000).		EEHV	can	cause	a	highly	fatal	haemorrhagic	disease	(EEHV-HD)	and	has	been	occurring	most	frequently	among	young	Asian	elephants	in	human	care	in	North	America,	Europe,	and	Asia,	but	also	in	the	wild	(Reid	et	al.,	2006;	Zachariah	et	al.,	2013;	Sripiboon	et	al.,	2013;	Bouchard	et	al.,	2014).	The	majority	of	EEHV-HD	cases	is	seen	in	Asian	elephants	between	 the	 age	of	1	 and	18	years	with	 a	peak	between	1	 and	4	years	with	only	one	animal,	a	40-year-old	Asian	elephant,	being	older	than	18	(Richman	&	Hayward,	2011;	Hayward,	2012).	
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1.2.1. EEHV	history	The	 majority	 of	 research	 on	 elephant	 herpesviruses	 is	 relatively	 recent,	 since	appropriate	diagnostic	tests	could	only	be	developed	once	the	viral	genome	sequence	of	these	viruses	had	been	characterised.	Herpesviruses	 in	 elephants	 were	 first	 described	 in	 1971	 in	 association	 with	ultrastructural	findings	in	lymphoid	nodules	in	lungs	of	African	elephants	that	appeared	otherwise	healthy	(Basson	et	al.,	1971;	McCully	et	al.	1971).	These	 findings	were	 later	identified	 as	 being	 caused	 by	 the	 strain	 EEHV-2.	 A	 few	 years	 later,	 skin	 lesions	 that	contained	 intranuclear	 inclusions	morphologically	consistent	with	herpesviruses,	were	linked	to	herpesvirus	infections	in	African	elephants	(Jacobson	et	al.,	1986)	and	then	in	Asian	 elephants	 (Pilaski,	 1988).	 Only	 a	 few	 tissues	 or	 blood	 samples	 remain	 from	suspect	cases	prior	to	the	1980s	to	allow	retrospective	analysis.	The	 first	 fatality	 known	 to	 be	 caused	 by	 EEHV	 occurred	 in	 a	 three-year-old	 Asian	elephant	 from	 a	 Swiss	 circus	 in	 1988	 (Ossent	 et	 al.,	 1990).	 Pathological	 examination	revealed	extensive	haemorrhages	throughout	the	carcass,	as	well	as	severe	widespread	oedema.	Histologically	intranuclear	inclusions	were	found	within	the	sinusoidal	cells	of	the	liver	(endothelial	cells	or	hepatocytes)	and	endothelial	cells	of	multiple	tissues.		This	was	 followed	by	 further	 reports	of	EEHV	 infections	 in	 captive	Asian	elephants	 in	North	America	and	Europe	(Ossent	et	al.,	1990;	Richman	et	al.,	1999,	2000;	Fickel	et	al.,	2003;	Zong	et	al.,	2007;	Garner	et	al.,	2009;	Hayward	et	al.,	2012;	Long	et	al.,	2015).			Failing	 to	 propagate	 the	 virus	 in	 established	 laboratory	 cell	 culture	 systems	 has	prompted	 clinicians	 and	 researchers	 to	 explore	 molecular	 techniques	 in	 order	 to	develop	diagnostic	tests.	Richman	et	al.	first	described	an	EEHV	PCR	in	1999	targeting	a	segment	of	the	terminase	gene.	This	publication	further	described	for	the	first	time	the	predilection	of	EEHV	for	the	capillary	endothelium	and	acute	myocardial	failure	due	to	endothelial	cell	damage	as	the	cause	of	death.	They	further	suggested	the	possibility	of	
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EEHV	 transmission	 from	 African	 elephants	 to	 naïve	 Asian	 elephants,	 as	 many	 of	 the	wildlife	 institutions	were	 holding	 both	 Asian	 and	 African	 elephants.	 The	 authors	 also	described	 that	 the	 virus	 had	 pathological	 and	 histomorphological	 similarities	 to	betaherpesviruses.			
1.2.2. Taxonomy,	Genotypes,	and	Phylogenetic	Analysis	of	EEHV	The	EEHVs	are	designated	 to	 the	genus	Proboscivirus,	within	 the	 family	Herpesviridae,	and	 were	 initially	 considered	 members	 of	 the	 Betaherpesvirinae.	 However,	 recent	availability	 of	 several	 complete	 and	 partial	 genome	 sequences	 of	 EEHVs	 has	 refined	their	classification	(Wilkie	et	al.,	2013;	Ling	et	al.,	2013;	Wilkie	et	al.,	2014;	Ling	et	al.,	2016)	and	a	new	subfamily,	 the	Deltaherpesvirinae,	has	been	proposed	 for	 the	viruses	(Figure	1.4)	(Ling	et	al.,	2013;	Pellett,	2014;	Richman	et	al.,	2014;	Zong	et	al.	2014).			
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Figure	1.4:	Phylogenetic	 analysis	 of	 the	 amino-acid	 sequence	of	 the	
glycoprotein	 H	 of	 all	 major	 mammalian	 herpesvirus	 subfamilies.	Elephant	 endotheliotropic	 viruses	 (EEHVs)	 show	 a	 lack	 of	 close	 match	with	 any	 of	 the	 existing	 defined	 subfamilies	 (alpha,	 beta,	 and	 gamma).	Pellett	 (2014),	 Richman	 et	 al.	 (2014),	 and	 Zong	 et	 al.	 (2014)	 therefore	proposed	for	the	Probosciviruses	to	be	classified	into	a	novel	subfamily:	the	
Deltaherpesvirinae	(circled).	Graph	from	Long	et	al.	(2015).			 	
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To	date,	seven	genotypes	of	EEHV	have	been	detected:	EEHV-1,	EEHV-2,	EEHV-3,	EEHV-4,	 EEHV-5,	 EEHV-6,	 and	EEHV-7	with	 EEHV-1	 being	 further	 subdivided	 into	 EEHV-1A	and	 1B.	 Five	 of	 these	 genotypes	 are	 known	 to	 have	 caused	 fatal	 disease	 in	 elephants	(Table	1.1)	(Osset	et	al.,	1990;	Richman	et	al.,	1999;	Richman	et	al.,	2000b;	Garner	et	al.,	2009;	Latimer	et	al.,	2011;	Denk	et	al.,	2012;	Sripiboon	et	al.,	2013).	EEHV	genomes	encode	between	115	and	120	genes,	35	of	these	being	core	genes	shared	among	mammalian	herpesviruses,	60	being	completely	novel	genes,	 and	several	other	genes	 that	 share	 homology	 with	 orthologues	 within	 the	 alpha-,	 beta-,	 or	gammaherpesviruses,	but	never	with	all	three	families	at	once	(Wilkie	et	al.,	2014;	Long	et	al.,	2015).	There	are	2	separate	branches	of	Probosciviruses:	The	AT-rich	 including	EEHV-1,	2,	5,	and	 6,	 and	 the	GC-rich	 branch	with	 EEHV-3,	 4,	 and	 7	 (Figure	1.5)	 (Zong	 et	 al.,	 2014;	Long	et	al.,	2015,	Ling	et	al.,	2016b).			
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Figure	 1.5:	Phylogenetic	 analysis	 of	 the	 seven	 distinct	 genotypes	 of	 elephant	
endotheliotropic	 herpesvirus	 (EEHV).	 Illustration	 of	 the	 AT-rich	 and	 GC-rich	branches	 showing	 average	 levels	 of	 nucleotide	 difference,	 approximate	 estimated	ages	of	last	common	ancestors	in	millions	of	years	(MYA),	name	or	case	code	of	the	index	 case,	 number	 of	 associated	 fatalities,	 number	 of	 documented	 cases,	 and	 the	year	of	 first	discovery	of	each	strain.	LA,	Loxodonta	Africana;	EM,	Elephas	Maximus.	Graph	from	Long	et	al.	(2015).		EEHV-1A	and	1B	are	associated	with	the	vast	majority	of	lethal	cases	worldwide	(Fickel	et	 al.,	 2001;	 Garner	 et	 al.,	 2009;	 Latimer	 et	 al.,	 2011;	Wiedner	 et	 al.,	 2012).	 Recently,	Wilkie	 et	 al.	 (2013)	have	 succeeded	 in	 sequencing	 the	 complete	 genomes	of	EEHV-1A	and	EEHV-1B	using	DNA	extracted	 from	post-mortem	tissue	samples.	The	 two	viruses	are	quite	similar	in	structure	and	size,	and	large	areas	of	their	genome	layout	are	almost	identical,	but	they	do	show	differences	in	many	protein-coding	regions,	for	example	the	
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open	reading	frame	(ORF)	EE54	and	EE56	being	absent	in	EEHV-1A,	and	EE6	and	EE62	in	EEHV-1B	(Wilkie	et	al.,	2013).	New	studies	now	show	that	EEHV-1A	can	 further	be	divided	 into	 many	 strains,	 since	 different	 elephant	 holding	 facilities	 appear	 to	 have	different	 strains	 of	 EEHV-1A	 in	 their	 herds,	 and	 potentially	 there	 are	 even	 different	EEHV-1A	strains	within	one	herd	(Zong	et	al.,	2008,	2009;	Long	et	al.,	2015).	EEHV-2	has	so	far	only	been	detected	in	African	elephants,	from	both	asymptomatic	and	fatal	 cases,	 and	 genetic	 analysis	 of	 segments	 of	 the	 polymerase	 and	 terminase	 genes	showed	a	20%	difference	from	those	of	EEHV-1	(Richman	et	al.,	1999).	Garner	et	al.	(2009)	described	two	additional	genotypes	of	EEHV	referred	to	as	EEHV-3	and	EEHV-4,	from	two	fatal	cases	in	Asian	elephant	calves	in	North	America.	So	far,	this	is	 the	 only	 documented	 fatality	 caused	 by	 EEHV-3	 in	 an	 Asian	 elephant.	 EEHV-3	was	further	 detected	 in	 lung	 nodules	 of	 a	 euthanised	 African	 elephant	 in	 North	 America	(Zong	et	al.,	2016).	The	first	fatal	case	of	EEHV-4	in	a	captive	born	elephant	in	Asia	has	been	described	recently	(Sripiboon	et	al.,	2013).	This	was	followed	by	further	reports	of	the	virus	 in	Asian	elephants	 (Bouchard,	2014;	Fuery	et	al.,	2016).	The	virus’	 complete	genome	is	now	sequenced	(Ling	et	al.,	2016a),	which	is	206	kb	long;	28	kb	larger	than	the	other	EEHVs	sequenced	so	far	(EEHV-1	and	5)	(Long	et	al.,	2015).		EEHV-5	 was	 first	 reported	 from	 blood	 of	 an	 asymptomatic	 wild-born	 Asian	 elephant	during	routine	screening	(Latimer	et	al.,	2011).		This	was	followed	by	the	first	report	of	a	fatal	EEHV-5	 infection	 in	a	 captive	Asian	elephant	 in	 the	United	Kingdom	(Denk	et	al.,	2012).	The	complete	genome	sequence	of	this	virus	has	also	been	determined	(Wilkie	et	al.,	 2014).	 The	 North	 American	 EEHV-5	 shows	 a	 nucleotide	 divergence	 of	 30%	 from	EEHV-1	 and	 22%	 from	 EEHV-2	 in	 the	 DNA	 polymerase	 gene	 (Latimer	 et	 al.,	 2011).	Atkins	 et	 al.	 (2013)	 reported	 the	 virus	 in	 association	 with	 illness	 in	 a	 herd	 of	 Asian	elephants	 in	 a	 zoo	 collection.	 Interestingly,	 they	 found	2	 distinctive	 EEHV-5	 subtypes,	
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EEHV-5A	 and	 EEHV-5B,	 in	 the	 7	 animals	 of	 the	 herd,	 which	 were	 subsequently	characterised	as	being	partially	chimeric	(Zong	et	al.,	2014).		EEHV-6	and	EEHV-7	have	been	identified	in	African	elephants.	EEHV-6	was	detected	in	blood	samples	of	an	African	elephant	calf	 that	showed	clinical	 illness	but	survived	 the	infection	 (Latimer	 et	 al.,	 2011).	 EEHV-7	 has	 so	 far	 not	 been	 associated	 with	 clinical	symptoms	or	lethal	cases	(Latimer	et	al.,	2011;	Zong	et	al.,	2016).	
	
1.2.3. Epidemiology	of	EEHV	EEHV	 infections	 occur	 in	 both	 African	 and	 Asian	 elephants,	 but	 the	 subsequent	haemorrhagic	 disease	 seems	 to	 be	 far	 more	 frequent	 and	 severe	 in	 juvenile	 Asian	elephants.	This	has	initially	prompted	the	suspicion	of	cross-species	transmission	of	the	virus	from	African	to	naïve	Asian	elephants	(Richman	et	al.,	1999,	2000a;	Hildebrandt	et	al.,	 2001).	 However,	 genetic	 distance	 of	 the	 EEHVs	 in	 Asian	 elephants	 from	 those	 in	African	 elephants	 has	 disregarded	 this	 initial	 speculation	 (Zachariah	 et	 al.,	 2013).	Furthermore,	EEHV-1	as	the	major	cause	of	death	in	Asian	elephants	has	so	far	not	been	detected	 in	 African	 elephants,	 and	 EEHV-2,	 on	 the	 other	 hand,	 was	 only	 detected	 in	African	 elephants	 (Richman	 et	 al.,	 1999).	 It	 is	 now	 known	 that	 each	 elephant	 holding	facility	has	its	own	genomic	variations	of	multiple	EEHV	strains	(Zong	et	al.	2008;	Zong	et	al.	2009).	Infections	with	identical	virus	strains	have	only	been	found	in	animals	from	the	 same	 facility,	 and	mostly	occurred	around	 the	 same	 time,	 evident	 from	 fatal	 cases	which	occurred	in	tandem.	It	 has	 been	 proposed	 that	 all	 Asian	 elephants	 in	 captivity	 in	 European	 and	 North	American	 holdings	 (Hardman	 et	 al.,	 2012;	 Long	 et	 al.,	 2016)	 and	 in	 free	 ranging	countries	(Zachariah	et	al.,	2013;	Sripiboon	et	al.,	2013)	might	be	 infected	with	one	or	several	genotypes	of	EEHV.	The	first	fatal	case	of	EEHV	in	Asia,	Cambodia,	was	reported	
	 26	
in	2006	and	 the	strain	was	assigned	as	EEHV-1	(Reid	et	al.,	2006).	Later,	Garner	et	al.	(2009)	also	identified	EEHV-3	and	EEHV-4	associated	with	fatalities	in	elephants	in	Asia.	Recent	 herd	 screenings	 for	 EEHV-1	 using	 a	 real-time	 PCR	 assay	 revealed	 that	 many	asymptomatic	 elephants	 periodically	 shed	 EEHV-1A	 or	 EEHV-1B	 in	 trunk	 secretions	(Stanton	 et	 al.,	 2010,	 2012;	 Hardman	 et	 al.,	 2012).	 A	 recent	 study	 on	 trunk	 washes	reveals	 that	 sequential	 infections	 with	 subtypes	 of	 EEHV-1	 do	 occur,	 concluding	genomic	diversity	of	the	viruses	and	hence	lack	of	cross-protective	immunity	(Stanton	et	al.,	2013).	As	 mentioned	 above,	 EEHV-2,	 EEHV-3,	 EEHV-6,	 and	 EEHV-7	 are	 found	 in	 African	elephants	(Latimer	et	al.,	2011;	Zong	et	al.,	2016),	whereas	EEHV-1A,	EEHV-1B,	EEHV-4,	and	EEHV-5	appear	 in	Asian	elephants	 (Schaftenaar	et	al.,	2010;	Hartman	et	al.,	2012;	Atkins	et	al.,	2013;	Fuery	et	al.,	2016a,	2016b).	The	only	strain	detected	in	both	species	so	 far	 is	 EEHV-3,	which	was	 found	 in	 a	 fatal	 case	 in	 an	Asian	 elephant	 (Garner	 et	 al.,	2009),	 but	 so	 far	 has	 not	 known	 to	 be	 associated	 with	 disease	 in	 African	 elephants	(Table	1.3).		
Table	 1.3:	 Summary	 of	 elephant	 endotheliotropic	 herpesvirus	
(EEHV)	 genotypes	 detected	 in	 healthy	 or	 diseased	 Asian	
(Elephas	maximus)	and	African	elephants	(Loxodonta	africana).	
EEHV	type	
Asian	elephant	 African	elephant	
Healthy	 Disease	&	fatality	 Healthy	
Disease	&	
fatality	
EEHV	1A	 ×	 ×	 	 	
EEHV	1B	 ×	 ×	 	 	
EEHV	2	 	 	 ×	 ×	
EEHV	3	 	 ×	 ×	 	
EEHV	4	 ×	 ×	 	 	
EEHV	5	 ×	 ×	 	 	
EEHV	6	 	 	 ×	 	
EEHV	7	 	 	 ×	 		
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In	 general,	 transmission	 of	 herpesviruses	 needs	 close	 contact,	 as	 the	 virus	 is	 easily	inactivated	 outside	 the	 host’s	 body.	 Also,	 the	 possibility	 of	 vertical	 transmission	 has	been	 discussed	 for	 some	 herpesviruses.	 Shedding	 of	 herpesviruses	 from	 skin	 lesions,	saliva,	or	other	body	fluids,	following	primary	infection	or	reactivation,	is	essential	for	a	successful	 transmission.	 Latent	 infections	 in	 clinically	 normal	 hosts	 can	 therefore	provide	a	reservoir	 for	virus	 transmission	(reviewed	by	Sinclair	&	Sissons,	2006).	The	mechanisms	underlying	the	transmission,	virus	uptake,	 infectious	dosage,	and	route	of	infection	of	EEHV	are	yet	unknown.	Stanton	 et	 al.	 (2010)	were	 first	 to	 link	 the	 death	 of	 an	 Asian	 elephant	 calf	 to	 a	 virus	(EEHV-1)	 being	 shed	 by	 a	 healthy	 adult	 elephant	 from	 the	 same	 group.	 The	 authors	therefore	 suggest	 that	 EEHV-1	 does	 in	 fact	 produce	 latent	 infections	 and	 that	 trunk	secretions	 could	 be	 a	 potential	 route	 of	 viral	 transmission.	 They	 also	 demonstrated	through	genomic	analysis,	that	the	virus	detected	during	viraemia	was	identical	to	that	detected	 subsequently	 in	 trunk	 secretions.	 However,	 the	 reasons	 underlying	 the	outcome	of	EEHV	 infection	are	 still	not	understood	and	 therefore	 it	 is	 vital	 to	gain	an	insight	 into	 the	 viral,	 host,	 and	 environmental	 factors,	 which	 may	 influence	 disease	manifestation.	Recent	 studies	documenting	 incidences	of	EEHV	 in	 zoological	 collections	 clearly	 show	that	viraemia	is	detectable	prior	to	the	onset	of	clinical	signs	and	clinical	disease	often	occurs	around	peak	viral	loads	in	the	blood	or	up	to	eight	days	later.	Furthermore,	viral	shedding	 through	 trunk	mucosa	 seems	 to	 rise	 substantially	 after	 detectable	 viraemia	(Atkins	et	al.,	2013;	Stanton	et	al.,	2013).	To	 date,	 there	 is	 no	 report	 investigating	 the	 virus	 shedding	 in	 semen	or	 transmission	through	breeding,	natural	or	artificial	insemination.			
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1.2.4. EEHV-Haemorrhagic	Disease	and	Pathogenesis	As	 indicated	by	 the	name	“endotheliotropic”,	EEHVs	are	 thought	 to	 show	a	 tropism	to	and	affect	endothelial	cells	and	 in	diseased	elephants	cause	systemic	vascular	collapse	with	 the	 circulatory	 system	 failing	 to	 maintain	 oxygen	 and	 nutritional	 supply	 to	 the	tissues	 due	 to	 extensive	 haemorrhages	 (Richman	 et	 al.,	 2000a).	Most	 animals	 latently	carry	a	number	of	herpesvirus	species	throughout	their	lives	and	clinical	illness	is	rare	in	 immunocompetent	 individuals	(McGeoch	et	al.,	1995;	Contreras	&	Slots,	2000).	This	leaves	EEHV	as	one	of	selected	few	herpesviruses	with	a	rapidly	progressing	and	often	fatal	 disease.	 The	 pathogenesis	 behind	 the	 occurrence	 of	 such	 a	 drastic	 outcome	 for	many	of	the	EEHV	infections	in	juvenile	Asian	elephants	is	still	unknown.	EEHV	haemorrhagic	disease	(EEHV-HD)	is	most	frequently	seen	in	Asian	elephant	calves	between	1	and	4	years	of	age,	but	also	appears	in	animals	up	to	8	years,	and	sometimes	even	thereafter	(Richman	&	Hayward,	2011;	Hayward,	2012).	Animals	under	the	age	of	one	 year	 have	 hardly	 ever	 shown	 any	 clinical	 disease	 associated	 with	 EEHV.	 This	suggests	maternal	 antibodies	 are	 providing	 an	 immune	protection,	maybe	not	 against	the	infections	with	the	virus,	but	against	the	subsequent	disease	(Long	et	al.,	2015).	The	 clinical	 signs	 of	 EEHV	 associated	 disease	 can	 vary	 significantly;	 from	 vague	mild	symptoms	 such	 as	 lethargy,	 anorexia,	 lameness,	 colic,	 and	 discoloured	 patches	 on	tongue	 to	more	 apparent	 symptoms	 such	 as	 oedema	 of	 the	 head,	 thoracic	 limbs,	 oral	ulcerations,	 and	 tongue	 cyanosis.	 These	 prodromal	 signs	 can	 rapidly	 be	 followed	 by	severe	haemorrhages	 in	major	 internal	organs	as	a	 result	of	 extensive	endothelial	 cell	damage	 leading	 to	peracute	death	within	hours	 to	 seven	days	 (Richman	et	 al.,	 2000a;	Garner	et	al.,	2009).	Richman	 et	 al.	 (2000a)	 have	 outlined	 the	 typical	 pathological	 findings	 with	cardiovascular	pathology	being	the	dominant	feature	in	most	cases	of	EEHV-HD	caused	by	EEHV-1.	These	include	pericardial	effusion,	extensive	haemorrhages	on	the	epi-	and	
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endocardial	surface	and	throughout	the	myocardium.	The	authors	also	describe	diffuse	bleedings	 within	 all	 the	 viscera	 and	 parietal	 peritoneal	 serous	 membranes,	 severe	cyanosis	 of	 the	 tongue,	 hepatomegaly,	 variable	 oral,	 laryngeal,	 and	 large	 intestinal	ulcers,	 and	haemorrhages	 in	 other	 internal	 organs	 like	 the	 cranium,	 the	 stomach,	 and	the	small	and	large	intestines.	Furthermore,	histological	findings	also	include	extensive	microhaemorrhages	and	mild	inflammation	of	the	heart,	liver,	and	tongue	together	with	intranuclear	 inclusion	 bodies	 in	 the	 capillary	 endothelium,	 infiltrates	 of	 lymphocytes,	monocytes,	and	heterophils	(neutrophils	in	elephants	are	more	accurately	described	as	heterophils	due	to	the	presence	of	reddish	cytoplasmic	granules).	The	nuclear	inclusion	bodies	of	about	80	–	90	nm	in	diameter	can	also	be	seen	within	the	trophoblastic	layer	of	the	 placenta	 (Richman	 et	 al.,	 1996,	 2000a).	 However,	 the	 extent	 of	 gross	 pathological	findings	 can	vary	drastically	depending	on	 the	duration	of	 the	disease	and	 supportive	treatment.	Interestingly,	 inapparent	 infections	 with	 EEHV	 do	 occur,	 possibly	 more	 frequently	 in	African	elephants	than	in	Asian	elephants.	Up	to	20%	of	all	Asian	elephant	calves	appear	to	 be	 susceptible	 to	 EEHV	 disease,	 whereas	 severe	 EEHV-HD	 is	 hardly	 ever	 seen	 in	African	elephants.	However,	more	than	90%	of	all	fatal	cases	involve	EEHV-1,	which	so	far	has	only	been	found	in	Asian	elephants	(Long	et	al.,	2015).			
1.2.5. Diagnosis	of	EEHV	Infection	Prior	to	the	development	of	molecular	assays,	diagnosis	of	clinical	EEHV	infections	was	solely	reliant	on	the	clinical	signs.	However,	the	onset	of	clinical	disease	in	young	Asian	elephants	can	be	sudden	and/or	non-specific,	and	hence	any	abnormal	clinical	signs,	e.g.	change	in	behaviour,	can	be	indicative	of	an	EEHV	infection.	
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It	 is	 also	 noteworthy	 that	 several	 other	 diseases	 in	 elephants	 can	 be	 presented	 with	similar	 symptoms	 complicating	 the	 diagnosis	 even	 further.	 Elephants	 appear	 to	 be	particularly	susceptible	to	Encephalomyocarditis	virus	(Simpson	et	al.,	1977;	Thomson	et	al.,	2001).	Clostridial	enterotoxaemia,	Anthrax,	Salmonellosis,	and	Hypovitaminosis	E	can	 also	be	 the	 cause	of	 similar	 symptoms	 (Richman	&	Hayward,	2011).	Given	higher	prevalence	 and	 risk	 associated	 with	 EEHV	 infections,	 any	 anomalous	 behaviour	 in	juvenile	 Asian	 elephant	 should	 however	 be	 primarily	 considered	 as	 EEHV	 suspect	(Schmitt	et	al.,	2000;	Schaftenaar	et	al.,	2001;	Wiedner	et	al.,	2012).		
1.2.5.1. Nucleic	acid	detection	assays	Since	 the	 availability	 of	 the	 EEHVs’	 genome	 sequence,	 molecular	 assays,	 e.g.	conventional	 polymerase	 chain	 reactions	 (PCR)	 and	 quantitative	 real-time	 PCRs	(qPCRs),	 have	 been	 used	 extensively	 to	 ratify	 clinical	 suspicion	 of	 the	 disease,	investigate	historic	cases,	and	help	in	early	detection	of	viraemia.	Richman	et	al.	(2001)	were	first	to	describe	PCR	assays	for	the	detection	of	EEHV-1	and	EEHV-2.	 Since	 then,	 further	 PCR	 assays	 have	 been	 employed	 to	 detect	 various	 EEHV	strains	 (Richman	et	 al.,	 1999;	Ehlers	 et	 al.,	 2001;	Latimer	et	 al.,	 2011;	Hardman	et	 al.,	2012).		In	 2010,	 Stanton	 and	 colleagues	 have	 developed	 a	 quantitative	 real-time	 polymerase	chain	reaction	(qPCR)	assay	for	detection	of	EEHV-1A	and	EEHV-1B.	This	was	followed	two	 years	 later	 by	 development	 of	 further	 qPCRs	 for	 EEHV-1	 (Hardman	 et	 al.	 2012),	EEHV-2,	EEHV-3,	EEHV-4,	EEHV-5,	and	EEHV-6	(Stanton	et	al.,	2012).		
1.2.5.2. Serological	assays	PCR-based	 diagnostic	 assays	 are	 limited	 in	 their	 scope	 as	 they	 can	 only	 provide	information	on	the	occurrence	of	virus	genome	in	the	tested	sample	material,	which	is	
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especially	limiting	in	a	virus	which	is	known	to	cause	latent	infections.	Hence	detecting	previously	infected	animals	without	a	current	viraemia	would	be	very	beneficial.	Several	attempts	have	been	made	in	recent	years	to	develop	a	serological	assay	to	determine	the	immune	status	of	the	elephants.	Fickel	et	al.	(2003)	were	first	to	sequence	EEHV	gB	for	its	 potential	 use	 in	 a	 serological	 assay	 development,	 but	 failed	 to	 progress	 into	 an	applicable	product.	An	antibody-ELISA	(Enzyme-Linked	Immunosorbent	Assay)	using	a	synthetic	 epitope	 fragment	 of	 the	 gB	 antigen	 from	 EEHV-1A	was	 also	 developed	 and	used	for	testing	banked	adult	Asian	elephant	sera	(Richman,	2003).		More	recently,	 an	EEHV-1	glycoprotein	B	based	 indirect	ELISA	has	been	developed	by	Van	den	Doel	 et	 al.	 (2015).	However,	 in	 the	 view	 that	 elephant	herpesviruses	 (EEHVs	and	 elephant	 gamma	 herpesviruses	 [EGHVs])	 are	 ubiquitous	 in	 Asian	 elephant	populations,	the	notion	that	these	assays	are	cross-reactive	with	gBs	of	similar	viruses,	e.g.	 EGHV	 or	 other	 unknown	 agents,	 cannot	 be	 excluded	 and	 became	 apparent	 when	screening	 selected	 sera	 from	 African	 elephants	 that	 reacted	 positive	 with	 these	 tests	(Long	et	al.,	2015).	Furthermore,	sole	measurement	of	gB	antibody	may	not	be	a	reliable	indicator	of	protection	against	EEHV,	as	it	is	currently	unknown	which	viral	proteins	are	targeted	by	neutralising	antibodies.		
1.2.5.3. Viral	Isolation	So	far	there	are	no	reports	on	propagation	of	EEHV	in	cell	culture.	The	establishment	of	a	cell	culture	system	to	support	virus	replication	in	vitro	would	be	extremely	beneficial	in	 applications	 such	 as	 evaluating	 efficacy	 of	 antiviral	 drugs,	 vaccine	 development,	antibody	 screening,	 and	 for	 a	 better	 understanding	 of	 the	 virus’s	 pathogenesis	 and	epidemiology.	
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1.2.6. Management	and	Treatment	of	EEHV	Infections	The	greatest	difficulty	in	management	of	EEHV	disease	seems	to	be	the	short	window	of	time	between	the	first	appearance	of	clinical	signs	and	the	death	of	the	animal.	Due	to	regular	use	of	molecular	assays	to	monitor	EEHVs	status	in	juvenile	Asian	elephants	it	is	now	 known	 that	 EEHV	 viraemia	 can	 be	 detected	 up	 to	 28	 days	 prior	 to	 the	 earliest	clinical	 signs	 (Stanton	 et	 al.,	 2013).	 This	 has	 prompted	 recommendations	 on	 routine	testing	 of	 at	 risk	 elephants	 to	 provide	 a	 larger	 window	 for	 potential	 treatment	 of	viraemic	 animals.	 There	 are	 known	 cases	 of	 elephants	 that	 survived	 the	 disease	with	many	 receiving	aggressive	 treatment	 such	as	human	anti-herpesviral	medications,	 e.g.	Famciclovir,	 Ganciclovir,	 or	 Aciclovir,	 despite	 lack	 of	 any	 evidence	 to	 suggest	 the	antiviral	 intervention	can	contribute	 to	 the	elephant’s	 survival	 (Richman	et	al.,	2000a;	Schmitt	et	al.,	2000;	Schaftenaar	et	al.,	2001;	Hayward,	2012;	Atkins	et	al.,	2013;	Stanton	et	al.,	2013;	Boonprasert	et	al.,	2015;	Padilla,	2015;	Tocidlowski	et	al.,	2015;	Fuery	et	al.,	2016a,	 2016b).	 The	 common	 add-on	 treatments	 have	 been	 rectal	 and	 intravenous	administration	 of	 fluids	 to	 maintain	 hydration,	 plasma	 or	 blood	 transfusion,	 oxygen	therapy,	 antibiotics,	 analgesics,	 and/or	 vitamin	 E,	 plus	 pericardiocentesis	 in	 a	 severe	case	of	the	disease	(Schmitt	et	al.,	2000;	Schaftenaar	et	al.,	2001;	Wiedner	et	al.,	2012;	Boonprasert	et	al.,	2015;	Fuery	et	al.,	2016a,	2016b).		
	
	 	
	 33	
	
1.3. Project	aims	and	objectives	In	recent	years,	a	significantly	high	number	of	otherwise	healthy	wild	and	captive-bred	Asian	 elephant	 calves	 have	 succumbed	 to	 EEHV	 infections.	 The	 Asian	 elephant	 is	 a	critically	 endangered	 species	 currently	 considered	 threatened	with	 extinction	 (CITE	 -	www.cites.org/eng/app/appendices).	Therefore,	preventing	future	EEHV	infections	and	improving	 the	 survival	 rate	 of	 affected	 animals	 are	 fundamental	 in	 order	 to	 save	 the	Asian	elephants	from	becoming	extinct.		Despite	 recent	 advances	 in	 molecular	 diagnostics	 and	 identification	 of	 EEHV,	fundamentals	of	EEHV	pathogenesis,	such	as	virus	organ	and	cell	tropism,	viral	and	host	factors	 determining	 disease	 progression	 and	 prognosis	 as	 well	 as	 effectiveness	 of	employed	treatments,	remain	unknown.		The	 inability	 to	 isolate	 and	 propagate	 EEHV	 in	 cell	 culture	 in	 vitro	 has	 also	 greatly	impeded	 scientific	 progress	 in	 answering	 key	 questions	 such	 as	 transmission	mechanisms	of	infectious	virus,	neutralising	antibody	responses	and	protective	immune	mechanisms,	and	ultimately	the	development	of	candidate	vaccines.		This	 study	 therefore	 aims	 to	 further	 elucidate	 the	 pathogenesis	 of	 EEHV	 in	 elephants	through	 a	 comprehensive	 study	 of	 surviving	 and	 fatal	 cases	 of	 the	 EEHV	 infections	combining	 blood	 and	 organ	 viral	 loads	with	 clinical,	 haematological,	 and	 pathological	observations.	 Furthermore,	 the	 project	 also	 aims	 to	 isolate	 and	 establish	 elephant	derived	 cell	 cultures	 and	 to	 use	 them,	 as	well	 as	 several	 established	non-elephant cell	lines,	 to	 investigate	 their	potential	 of	 supporting	EEHV	 replication	 and	propagation	 in	
vitro.				 	
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The	objectives	of	this	study	are:			To	achieve	the	1st	aim:	1.		 Viral	load	in	the	blood	will	be	quantified	in	series	of	archived	blood	samples	from	a	 surviving	 and	 a	 fatal	 case	 of	 EEHV-1A	 infection	 by	 qPCR	 and	 will	 be	 correlated	 to	clinical	 disease,	 haematological	 parameters,	 anti-herpesviral	 plasma	 levels,	 and	 virus	shedding	during	recovery.		2.		 Viral	 DNA	 load	 will	 also	 be	 determined	 for	 a	 wide	 range	 of	 organ	 samples	available	from	several	fatal	cases	of	EEHV-HD	caused	by	different	EEHV	strains.	Where	available,	clinical	and	pathological	observations	of	infected	elephants	will	be	related	to	viral	load	to	further	explore	virus	pathogenesis.		To	achieve	the	2nd	aim;	1.		 Elephant	 cells	 from	blood	 samples,	 post-natal,	 and	post	mortem	 tissues	will	 be	isolated	 and,	where	 possible,	 established	 as	 cell	 lines.	 The	 potential	 of	 these	 elephant	cells	 and	 several	 standard	 cell	 lines	 to	 support	 EEHV	 replication	 in	 vitro	 will	 be	investigated	 in	 conjunction	 with	 several	 cell	 stressors	 in	 order	 to	 trigger	 virus	replication.		 	
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CHAPTER	 2:	 DNAEMIA,	 VIRAL	 SHEDDING,	 PENCICLOVIR	 PLASMA	 LEVEL,	 AND	
RECOMMENDATIONS	 ON	 ANTI-HERPESVIRAL	 THERAPY	 –	 2	 CASES	 OF	 CLINICAL	
EEHV-1	INFECTION	IN	JUVENILE	ASIAN	ELEPHANTS	TREATED	WITH	FAMCICLOVIR	
	
	
Declaration	Parts	of	this	chapter	have	been	published	in	a	peer	reviewed	journal	(Surviving	and	fatal	Elephant	 Endotheliotropic	 Herpesvirus-1A	 infections	 in	 juvenile	 Asian	 elephants	 –	lessons	 learned	 and	 recommendations	 on	 anti-herpesviral	 therapy.	 2016.	 BMC	Veterinary	Research	12(1),	178).		
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Abstract	Elephant	 Endotheliotropic	 Herpesviruses	 (EEHVs)	 can	 cause	 acute	 haemorrhagic	disease	 in	 young	 Asian	 elephants	 (Elephas	 maximus)	 and	 clinical	 EEHV	 infections	account	 for	 the	majority	of	 their	 fatalities.	The	anti-herpesviral	drug	 famciclovir	 (FCV)	has	been	used	routinely	to	treat	viraemic	at-risk	elephants,	but	thus	far	without	proven	efficacy.	 This	 chapter	 presents	 clinical	 and	 virological	 investigations	 of	 two	 EEHV-1A	infected	elephants	 treated	with	FCV	and	discusses	potential	anti-herpesvirus	 therapies	of	viraemic	elephants.	Two	 1.5-year-old	male	 Asian	 elephants	 at	 a	 zoological	 collection	 in	 the	 UK	 developed	clinical	EEHV-1A	infections.	Case	1	showed	signs	of	myalgia	for	the	duration	of	24	hours	before	 returning	 to	 being	 clinically	 unapparent.	 EEHV-1A	DNAemia	was	 confirmed	 on	the	day	of	clinical	signs	and	continued	to	be	present	for	18	days	in	total.	Trunk	shedding	of	 the	 virus	 commenced	 10	 days	 after	 detection	 of	 initial	 DNAemia.	 Case	 2	 tested	positive	 for	EEHV-1A	DNAemia	 in	 a	 routine	 blood	 screening	 sample	 in	 the	 absence	 of	clinical	 signs.	 The	 blood	 viral	 load	 increased	 exponentially	 leading	 up	 to	 fatal	 clinical	disease	 7	 days	 after	 initial	 detection	 of	 DNAemia.	 Both	 calves	 were	 treated	 with	 15	mg/kg	FCV	per	rectum	on	detection	of	DNAemia	and	penciclovir	(PCV),	 the	active	FCV	metabolite,	 could	 be	 detected	 in	 the	 blood	 at	 assumed	 therapeutic	 levels.	 The	 early	indicators	for	clinical	disease	were	a	marked	absolute	and	relative	drop	in	white	blood	cells,	 particularly	 monocytes	 prior	 to	 the	 detection	 of	 viraemia.	 The	 most	 prognostic	haematological	parameter	at	later	stages	of	the	disease	was	the	platelet	count	showing	a	continuous	sharp	decline	throughout,	followed	by	a	dramatic	drop	at	the	time	of	death.	The	EEHV-1A	viraemic	animals	 investigated	here	 further	highlight	 the	on-going	 threat	posed	 by	 this	 virus	 to	 juvenile	 Asian	 elephants.	 The	 findings	 call	 into	 question	 the	efficacy	of	rectal	FCV	treatment	in	clinical	cases	and	direct	towards	the	use	of	alternative	anti-herpesvirus	drugs	and	complementary	 treatments,	 such	as	plasma	 infusions,	 if	no	
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improvement	 in	 either	 viral	 load	 or	 the	 above-mentioned	 blood	 parameters	 are	observed	in	the	initial	days	of	viraemia	despite	anti-herpesvirus	therapy.	
	
	
2.1. Introduction	Elephant	 Endotheliotropic	 Herpesviruses-1	 (EEHV-1)	 induced	 acute	 haemorrhagic	disease	 manifests	 initially	 by	 sudden	 onset	 of	 non-specific	 clinical	 signs,	 which	 often	proceed	quickly	 to	 signs	 typical	of	haemorrhagic	disease	 (oedema,	petechial	bleedings	on	mucosa,	 tongue	cyanosis)	and	ultimately	 to	sudden	death	within	one	 to	seven	days	(Richman	et	al.,	2000;	Long	et	al.,	2015).		EEHVs,	similar	to	viruses	in	the	subfamily	Alphaherpesvirinae	and	Gammaherpesvirinae,	comprise	 of	 a	 genome	 with	 a	 thymidine	 kinase	 (TK)	 and	 a	 serine/threonine	 protein	kinase	 (PK)	 gene, which encode enzymes crucial for processing many anti-herpesviral 
prodrugs into their active derivatives	 (Ehlers	 et	 al.,	 2006;	 Wilkie	 et	 al.,	 2013).	 Based	 on	approaches	in	treatment	of	other	herpesviruses	with	TK	and	PK	genes,	three	nucleoside	analogues,	 famciclovir	 (FCV)	 and	more	 recently	 ganciclovir	 (GCV)	 and	 aciclovir	 (ACV),	have	 been	 administered	 to	 treat	 viraemic	 elephant	 calves,	 with	 the	 aim	 to	 avert	progression	to	clinical	disease,	but	as	yet	without	proven	clinical	efficacy	(Gill	&	Wood,	1996;	 Schmitt	 et	 al.,	 2000;	 Schaftenaar	 et	 al.,	 2001;	 Brock	 et	 al.,	 2010;	 Stanton	 et	 al.,	2013;	 Tocidlowski	 et	 al.,	 2015;	Howard	&	 Cox,	 2015;	 Padilla,	 2015;	 Long	 et	 al.,	 2015;	Fuery	et	al.,	2016a,	2016b).		FCV,	 chemically	 known	 as	 2-[2-(2-amino-9H-purin-9-yl)ethyl]-1,3-propanediol	diacetate,	 is	 a	 synthetic	 acyclic	 guanosine	 analogue	 that	 is	 rapidly	 de-acetylated	 and	oxidized	 in	 the	 body	 to	 its	 active	 metabolite	 penciclovir	 (PCV).	 Activation	 of	 PCV	requires	phosphorylation	of	FCV	in	the	virally	infected	cells	by	viral	and	cellular	kinases.	The	 drug	 has	 a	 half-life	 of	 approximately	 three	 hours	 and	 its	 catabolite	 is	 excreted	
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renally	 (Gill	 &	 Wood,	 1996).	 PCV	 interacts	 with	 herpesvirus	 DNA	 polymerase,	 the	enzyme	 responsible	 for	 creating	 DNA	 molecules	 through	 assembly	 of	 nucleotides	(building	blocks	of	DNA),	and	thus	terminates	DNA	synthesis.	A	study	showed	that	when	administered	 to	 healthy	 young	 Asian	 elephants	 both	 orally	 or	 per	 rectum,	 FCV	 is	absorbed	 and	 metabolised	 to	 PCV	 reaching	 plasma	 levels	 considered	 therapeutic	 in	humans	with	genital	herpes	(Gill	&	Wood,	1996;	Brock	et	al.,	2012;).	Aciclovir	 (ACV),	 another	 guanosine	 analogue	with	 a	 biological	 half-life	 of	 2-4	hours,	 is	still	 used	widely	 for	 treatment	 and	 prevention	 of	 clinical	Herpes	 Simplex	 Virus	 (HSV)	and	Varicella	Zoster	Virus	(VZV)	diseases	in	humans.	Activation	of	ACV	within	cells	via	the	 viral	 and	 cellular	 kinases	 yields	 ACV–triphosphate	 that	 interacts	 adversely	 with	herpesvirus	DNA	synthesis	(Field	&	Hodge,	2013).	Ganciclovir	 (GCV)	 is	 also	 a	 guanosine	 analogue	 that	 is	 activated	 via	 viral	 and	 cellular	kinases.	 Its	oral	prodrug	valganciclovir	 (VGCV)	 is	 the	most	 commonly	prescribed	drug	for	prevention	and	therapy	of	HCMV	in	 immunocompromised	patients	(Field	&	Hodge,	2013).		To	 enable	 early	 therapeutic	 intervention	 in	 response	 to	 detection	 of	 EEHV	 viraemia,	some	 zoological	 facilities	 have	 implemented	 regular	 blood	 sampling	 and	 laboratory	testing	 of	 juvenile	 Asian	 elephants.	 It	 has	 been	 documented	 that	 EEHV	 viraemia	 is	detectable	 at	 least	 several	 days	 before	 the	 onset	 of	 clinical	 signs	 (Atkins	 et	 al.,	 2013;	Stanton	et	al.,	2013).		Viral	 load	 data	 are	 routinely	 used	 in	 clinical	management	 of	 diseases	 associated	with	human	 herpesviruses,	 and	 therefore	 could	 also	 be	 clinically	 relevant	 for	 disease	prediction	in	elephants.	 In	HCMV	infections,	higher	viral	 loads	are	generally	associated	with	 tissue-invasive	 disease,	 while	 lower	 levels	 are	 associated	 with	 asymptomatic	infection.	 However,	 since	 there	 is	 a	 wide	 degree	 of	 overlap	 in	 HCMV	 viral	 load	 and	disease	 development,	 a	 rise	 in	 viral	 load	 over	 time	 is	 a	more	 important	 indicator	 for	
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predicting	 HCMV	 disease	 than	 a	 single	 viral	 load	 measurement	 (Emery	 et	 al.,	 2000).	Therefore,	in	patients	at	risk	of	HCMV	disease,	serial	monitoring	(e.	g.	weekly	intervals)	with	quantitative	PCR	is	recommended	(Razonable	et	al.,	2013).	Further,	the	viral	load	at	the	 time	 of	 diagnosis	 has	 been	 correlated	 with	 antiviral	 treatment	 efficacy,	 with	 the	baseline	(pre-treatment)	viral	load	being	the	only	predictor	significantly	associated	with	viral	load	eradication	(Asberg	et	al.,	2007;	Razonable	et	al.,	2013).	A	higher	viral	load	at	diagnosis	 has	 been	 associated	with	 a	 longer	 course	 of	 treatment	 and	 a	 higher	 risk	 of	treatment	 relapse.	 In	 another	 study,	 the	 total	 duration	 of	 antiviral	 treatment	 was	associated	with	peak	viral	load	at	the	start	of	treatment	(Atabani	et	al.,	2012).	Screenings	of	elephant	herds	also	revealed	widespread	prevalence	of	EEHV	strains	and	their	 periodical	 reactivation	 and	 shedding	 through	 biological	 fluids,	 especially	 trunk	secretions	(Stanton	et	al.,	2010,	2013;	Hardman	et	al.,	2012;	Atkins	et	al.,	2013;	Van	den	Doel	 et	 al.,	 2015;	 Fuery	 et	 al.,	 2016a,	 2016b).	 Hence	 conferring	 from	 herpesviruses’	properties,	 it	 might	 be	 assumed	 that	 once	 an	 elephant	 is	 infected	 it	 remains	 a	 latent	carrier	 for	 life.	 Routes	 of	 EEHVs	 transmission	 to	 naïve	 individuals	 are	 still	 unclear,	however,	 considering	 other	 herpesviruses’	 transmission	 routes,	 contact	 with	 infected	bodily	secretions	is	a	very	likely	possibility	and	potential	vertical	transmission	can	also	not	be	excluded.	This	chapter	describes	the	investigations	into	two	EEHV-1	viraemic	elephants	from	a	UK	zoological	 collection	 that	were	 both	 treated	with	 FCV	 following	 initial	 confirmation	 of	EEHV	infection.	It	also	discusses	findings	of	the	investigations	in	relation	to	anti-herpes	viral	therapies	in	EEHV	viraemic	elephants.	
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2.1.1. Case	1:	Survivor	of	EEHV-1A	infection	after	FCV	treatment	In	 2013,	 a	 1.5-year-old	male	 Asian	 elephant	 calf	was	 presented	with	 unwillingness	 to	bend	either	 foreleg,	swinging	both	 legs	 forward	when	walking.	 Its	ears	were	drooping,	the	head	was	down,	and	the	calf	was	off	solid	food.		The	calf	was	diagnosed	with	EEHV-1	infection	by	qPCR	of	a	whole	blood	sample;	routine	blood	 samples	 and	 trunk	 swabs	 taken	 every	 other	 week	 before	 onset	 of	 clinical	symptoms	tested	negative	for	EEHV-1.		Treatment	with	15	mg/kg	FCV	three	times	daily	(TID)	per	rectum	was	instigated	by	the	zoo	 veterinarians	 immediately	 after	 laboratory	 confirmation,	 eight	 hours	 after	 these	initial	 clinical	 signs	were	noted.	The	 first	 two	 treatments,	 six	hours	apart,	 consisted	of	ground	 FCV	 tablets	 suspended	 in	 ultrasound	 gel	 (Healthlife®,	 Barclays-Swan	 Ltd,	 UK);	however,	most	of	 the	drug	was	expelled	at	 the	next	defecation.	Twelve	hours	after	 the	initial	presentation,	the	calf	started	to	voluntarily	bend	his	right	foreleg	again,	and	by	the	next	morning,	despite	some	stiffness	in	the	shoulders,	the	legs	were	in	normal	use	and	its	appetite	had	returned.	The	dose	of	FCV	was	therefore	reduced	to	12	mg/kg	TID	(Day	1);	this	time	dissolved	in	hand	warm	water	and	placed	1.5	meters	deep	into	the	rectum.	On	 Day	 2,	 all	 the	 clinical	 signs	 resolved	 and	 the	 viral	 blood	 load	 started	 to	 decrease	gradually.	The	FCV	dose	was	further	reduced	to	8	mg/kg	twice	daily	(BID)	on	Day	7.	FCV	treatment	was	 ceased	 on	Day	 21	 after	 3	 days	with	 no	 detectable	 virus	DNA	 in	 tested	whole	blood	samples.	As	 a	 pre-emptive	measure,	 the	 calf’s	 two	 siblings,	 a	 3-year-old	male	 and	 a	 4-year-old	female,	were	treated	simultaneously	with	12	mg/kg	FCV	TID	from	Day	0	to	Day	6,	which	was	tapered	to	8	mg/kg	BID	from	Day	7	to	Day	12,	after	which	treatment	ceased.	Neither	sibling	 was	 positive	 for	 EEHV-1	 DNA	 in	 blood	 or	 bodily	 secretions	 throughout	 this	period.	
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2.1.2. Case	2:	Fatality	caused	by	EEHV-1A	despite	FCV	treatment	In	2015,	a	blood	swab	collected	during	routine	weekly	sampling	of	a	1.5-year-old	male	calf	tested	positive	for	EEHV-1	DNA	by	qPCR	(Day	-33).	A	follow-up	blood	sample	four	days	 after	 initial	 EEHV-1	 detection	 tested	 EEHV-1	 DNA	 negative	 by	 qPCR	 and	subsequently	 the	 calf	 tested	 negative	 for	 EEHV	 DNAaemia	 on	 four	 consecutive	 blood	swabs	taken	during	a	three-week	period.	However,	28	days	after	the	initial	detection	of	EEHV	DNA	in	the	systemic	blood,	viral	DNA	was	once	more	detected	by	qPCR	in	a	blood	swap	sample.	This	was	then	confirmed	by	an	EDTA	whole	blood	sample	with	the	results	becoming	 available	 two	 days	 later,	 and	 despite	 the	 absence	 of	 clinical	 signs	 (Day	 -5)	treatment	was	immediately	instigated	at	15	mg/kg	FCV	TID	per	rectum.	Blood	samples	were	then	taken	regularly	for	EEHV-1	qPCR,	viral	quantification,	and	haematology.		The	calf	had	presented	with	a	swollen	right	temporal	gland	(multi-lobed	sac	behind	the	ears	from	which	male	elephants	secret	a	viscous,	pungent	peptide	liquid	during	the	state	of	musth	or	under	stress	or	excitement),	which	was	painful	on	palpation	and	from	which	purulent	discharge	could	be	expressed,	the	day	prior	to	the	positive	blood	sample	being	taken	 (Day	 -6).	 The	 zoo	 veterinarians	 treated	 the	 gland	 with	 pevidine	 (Sanofi,	 UK)	flushes	 and	 topical	 amoxicillin/clavulanic	 acid	 application	 following	 bacteriological	culture	and	sensitivity	testing.	Five	days	into	the	second	period	of	EEHV-1	DNAemia,	the	calf	started	to	show	signs	of	lethargy.	The	decision	was	made	to	start	i.v.	fluids,	consisting	of	Harmann’s	(15	ml/kg/h,	Vetivex	 11,	 Dechra,	 UK)	 supplemented	with	 Duphalyte	 (1	ml/kg	 BW,	 Pfizer,	 UK),	 and	complement	the	treatment	from	solely	FCV	per	rectum	to	i.v.	plasma	and	GCV.	The	calf	first	displayed	clinical	signs	of	haemorrhagic	disease	six	days	into	the	DNAemia:	oedema	of	 the	head	and	ventral	 abdomen,	 tongue	petechiae	and	progressive	 signs	of	 cyanosis.	Intravenous	cannulas	were	 in	place	 in	both	ears	 for	administration	of	1	ml/kg	plasma	
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TID,	 fluids	 and	 antibiotics	 (2	 mg/kg	 marbofloxacin,	 Marbocyl®,	 Vetoquinol).	 Due	 to	logistics,	GCV	(5	mg/ml)	could	not	be	administered	until	16:00h	that	day.	Clinical	signs	progressed	despite	aggressive	treatment	and	the	calf	subsequently	died	at	midnight	as	a	result	of	hypoxaemia	and	hypovolaemia.			
2.2. Materials	and	Methods	
2.2.1. Animals	and	sample	collection	The	 animals	 included	 in	 this	 study	were	 Asian	 elephants	 from	 a	 European	 zoological	collection	 and	 all	 sample	 collections	 and	 interventions	 were	 part	 of	 routine	 health	surveillance,	EEHV	management	programs,	or	diagnostic	sampling.	Blood	samples	of	EDTA	whole	blood	and	blood	swabs	were	collected	by	zoo	staff	under	trained	behaviour	from	an	ear	vein	after	aseptic	preparation	of	the	medial	aspect	of	the	ear	pinna.	For	whole	EDTA	blood	samples,	the	animal	was	placed	in	lateral	recumbency	and	 the	 lowermost	 ear	 was	 sampled,	 using	 a	 standard	 21G	 1	 inch	 needle	 and	 a	Vacutainer®	blood	 collection	 system.	 For	 blood	 swabs,	 a	 dry	 6-inch	 foam	 tipped	 swab	(Sigma	Aldrich,	UK)	was	used	for	collection	of	a	drop	of	blood	after	puncture	of	an	ear	vein	with	an	insulin	needle,	with	the	elephant	in	standing	position.	Blood	samples	were	kept	 at	 room	 temperature	 before	 being	 shipped	 to	 the	 laboratory,	 where	 they	 were	stored	at	4-8	°C	until	being	processed.	Trunk	secretions	from	the	mucosa	of	each	naris	were	 collected	by	 zoo	 staff	 on	dry	6-inch	 foam	 tipped	 swabs	 (Sigma	Aldrich,	UK)	 at	 a	depth	of	approximately	8-10	cm,	under	trained	behaviour,	and	stored	at	 -20	̊C	prior	to	further	testing.	
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2.2.2. Sample	preparation	and	nucleic	acid	purification	Nucleic	acid	was	extracted	from	140	µl	whole	EDTA	blood	using	the	QIAamp®	Viral	RNA	Mini	kit	(Qiagen,	UK)	according	to	the	manufacturer’s	protocol.	For	blood	swabs,	560	µl	buffer	AVL	from	the	kit	were	directly	added	to	the	foam	tipped	swabs,	left	for	15	min	at	room	 temperature,	 vortexed	 and	 spun	 briefly,	 and	 processed	 as	 per	 manufacturer’s	instructions.	To	process	trunk	swab	samples	for	nucleic	acid	extraction,	300	µl	PBS	and	6-8	 glass	beads	 (3	mm	 in	diameter)	were	 added	 to	 the	 swab	 inside	 a	2	ml	Eppendorf	tube,	vortexed	briefly,	and	incubated	for	30	min	at	room	temperature.	The	tube	content	was	 then	 vortexed	 and	 nucleic	 acid	 was	 extracted	 following	 the	 whole	 EDTA	 blood	protocol	using	140	µl	of	the	cleared	suspension.		At	 the	 zoological	 facility,	 blood	 smears	 were	 made	 of	 freshly	 collected	 EDTA	 blood	samples,	 air-dried,	 and	 stained	 with	 Diff-Quick	 (LabPak,	 UK)	 for	 an	 in-house	 relative	white	blood	cell	(WBC)	differential	count,	carried	out	by	trained	zoo	staff.		
	
2.2.3. Diagnostic	qPCRs	and	measurement	of	viral	genome	copy	numbers		The	 real-time	qPCR	used	 in	 this	 study	was	performed	 as	described	by	Hardman	et	 al.	(2012).	The	PCR	amplifies	a	91	bp	segment	of	 the	 terminase	gene	of	EEHV-1A	and	1B	using	 the	 following	 oligonucleotides:	 hydrolysis	 probe,	 5’-FAM-TCAACGAGGAGATATTAGGCACCACCAACA-BHQ1-3’;	 forward	 primer,	 5’-ACTGCAAAYGCATTCTTAAAAGAAT-3’;	 and	 reverse	 primer,	 5’-AGAATGGGATTRGCTAAGAAGCT-3’;	 All	 primers	 and	 probes	 used	 in	 this	 study	 were	synthesised	by	Eurofins	(Eurofins	MWG	Operon,	GERMANY).	To	perform	the	qPCR,	the	QuantiFast®	Pathogen	PCR	+IC	kit	(Qiagen)	was	used.	Briefly,	2	µl	extracted	DNA	were	added	to	the	PCR	mix	consisting	of	0.1	µl	of	each	forward	and	reverse	 primer	 (100	 pmol/µl),	 0.05	 µl	 hydrolysis	 probe	 (100	 pmol/µl),	 5	 µl	 5×	QuantiFast	Pathogen	Master	Mix,	0.5	µl	50×	High-ROX	Dye	solution,	and	17.25	µl	RNase-
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Free	Water.	The	PCR	was	performed	on	a	MX3005P	machine	(Agilent	Technologies,	UK)	using	the	cycling	conditions	of	1	cycle	of	95	°C	for	5	min	followed	by	45	cycles	of	95	°C	for	15	s,	60	°C	for	30	s,	and	signal	acquisition	at	the	end	of	each	cycle.	Only	whole	blood	samples	were	used	for	viral	load	quantification,	whereas	blood	swab	samples	were	used	as	a	tool	for	fast	and	less	invasive	EEHV	screening.	The	DNA	standard	used	was	a	HPLC	purified	100	bases	long	synthetic	oligonucleotide	(Eurofins	Genomics,	UK)	 diluted	 to	 provide	 serial	 copy	 numbers	 from	106	 to	 101	 copies	 per	 PCR	 test.	 The	synthetic	oligonucleotide	dilutions	were	run	in	triplicate	in	the	PCR	to	create	a	standard	curve	 for	 EEHV	 genome	 quantification.	 The	 viral	 genome	 copy	 numbers	 were	 then	normalised	 to	1	ml	of	blood	or	 compared	 to	 each	other	 as	 vgc	per	 test	 reaction	when	trunk	swabs	were	analysed.		To	assess	specific	gene	segment	sequences	of	 the	detected	EEHV-1As	 in	 the	presented	cases,	 primes	 were	 developed	 for	 a	 conventional	 PCR	 on	 DNA	 polymerase	 (U38),	glycoprotein	M	(gM,	U82),	and	glycoprotein	L	(gL,	U73)	(Table	2.1).		
	
	
Table	 2.1:	 List	 of	 primers	 used	 for	 sequence	 analysis	with	 the	 related	 amplicon	
size	and	accession	number	where	available.		Primer	Name	 Sequence	5’	to	3’	 Primer	Source	 Amplicon	Size	 Accession	No.	EEHV-1A_DNA	POL_F	 GAA	GCA	ATC	ACG	TGT	CCA	TG		 											Stanton	et	al.,	2013	 194	bp	 KT381607	EEHV-1A_DNA	POL_R	 TTC	ATT	GAC	ACT	GGA	ATC	TGT	T	 this	study	 	 	EEHV-1A_gM_F	 CGT	ATC	CAC	TTG	TTA	CAT	CTCC	 this	study	 381	bp	 N/A	EEHV-1A_gM_R	 AAC	TTC	TTC	TTC	ATC	GTC	GTC	 this	study	 	 	EEHV-1A_U73_F	 TTC	ATA	AAC	TCT	CTG	TGC	TGT	C	 this	study	 500	bp	 N/A	EEHV-1A_U73_R	 TAC	TGT	CCC	TCT	GTC	TCT	CC	 this	study	 	 	bp,	base	pairs;	N/A,	not	available	
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2.2.4. Sequencing	The	BigDye®	Terminater	v3.1	Cycle	Sequencing	Kit	 (Applied	Biosystems)	was	used	 for	direct	sequencing	of	extracted	DNA:	4	µl	BigDye	Terminater	Ready	Reaction	Mix,	1	µl	0.1	pmol/µl	of	either	forward	or	reverse	primer,	20-30	ng	of	DNA	template,	and	water	to	the	final	volume	of	10	µl.	The	cycling	conditions	were:	96	°C	for	1	min,	followed	by	25	cycles	of	96	°C	for	10	s,	50	°C	for	5	s,	and	60	°C	for	4	min.		The	PCR	product	was	purified	using	 the	 “DNA	EDTA-ethanol	precipitation	method”	by	adding	 5	 µl	 EDTA	 (125	 mM)	 and	 50	 µl	 of	 100%	 Ethanol	 before	 being	 vortexed	thoroughly,	and	incubated	at	room	temperature	for	15	min.	The	sample	was	centrifuged	for	20	min	at	17,900	x	g	and	the	supernatant	was	carefully	aspirated	not	to	disturb	the	pellet.	250	µl	of	70%	ethanol	were	then	added,	the	tube	was	vortexed,	and	spun	for	20	min	at	17,900	x	g.	After	carefully	aspirating	the	supernatant	off	the	pellet,	the	tube	was	placed	on	a	heating	block	at	50	°C	for	several	mins	to	completely	dry	the	pallet.	12.5	µl	of	HiDi	Formamide	(Applied	Biosystems)	were	added	to	resuspend	the	pellet,	 the	sample	was	 spun	 down,	 and	 transferred	 to	 an	 ABI	 96	 well	 MicroAmp	 plate	 (Applied	Biosystems).	All	samples	were	analysed	on	an	ABI	3130xL	16	capillary	genetic	analyser	(Applied	 Biosystems)	 by	 the	 APHA	 in-house	 sequencing	 laboratory.	 The	 SeqMan	 pro	software	(Lasergene,	DNASTAR,	version	9)	was	used	to	analyse	sequence	traces,	which	were	then	screened	against	available	sequences	 in	the	GenBank	using	the	NCBI	BLAST	tool.	 The	MegAlign	 software	 (DNASTAR)	was	 used	 to	 analyse	 sequence	 traces	 and	 to	then	align	the	consensus	sequences	of	Case	1	(Scott),	Case	2	(Max),	and	two	other	EEHV-1A	fatalities	that	occurred	at	the	same	zoological	institution	in	2009	(Betts	and	Riddle),	where	 stored	 blood	 samples	 were	 used	 for	 DNA	 extraction	 and	 subsequent	 in-house	sequencing,	with	each	other.	
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2.2.5. Supportive	therapy	and	drug	administration	All	 supportive	 treatment	 and	 drug	 administration	 was	 performed	 by	 the	 elephant	keepers	and	veterinarians	of	the	zoological	collection.	Rectal	fluids	were	provided	after	manual	removal	of	all	faeces	from	the	rectum.	Several	litres	 of	 hand-warm	water	were	 then	deposited	 into	 the	distal	 colon	 at	 approximately	one	meter	of	depth,	 through	a	standard	garden	hosepipe.	 Intravenous	(i.v.)	access	was	acquired	after	antiseptic	preparation	of	the	medial	aspect	of	the	ear	pinna,	using	an	18G	6.25	 cm	 indwelling	 catheter	 (Milacath®,	 Mila	 International,	 USA)	 in	 an	 ear	 vein.	 The	catheter	was	 secured	 using	Durapore®	 tape	 and	 superglue.	 Standard	 giving	 sets	were	used	 for	 i.v.	 fluids	 and	 filtered	 giving	 sets	 for	 the	 administration	 of	 blood	 and	 blood	components	 (Baxter,	 UK).	 Plasma	was	 collected	 from	 adult	 herd-mates	 under	 trained	behaviour,	in	lateral	recumbency	from	either	an	ear	vein	or	a	medial	hind	leg	vein,	in	one	litre	 citrate	 blood	 collection	 bags	 (Crusse,	 Denmark),	 stored	 for	 a	 minimum	 of	 eight	hours	at	5	̊C	and	separated	using	manual	pressure.	The	plasma	was	 then	stored	at	5	̊C	and	warmed	to	room	temperature	prior	to	the	administration.	Anti-herpes	 viral	 treatment	 consisted	 of	 either	 FCV	 or	 GCV.	 FCV	 (Novartis	Pharmaceuticals,	 UK)	 250	 and/or	 500	 mg	 tablets	 were	 crushed	 using	 a	 pestle	 and	mortar	and	suspended	in	hand	warm	water.	Using	a	60-ml	syringe	and	a	one	meter	long	tube,	the	suspension	was	administered	in	the	distal	colon	after	removal	of	all	 faeces	as	described	 above.	 GCV	 (Cymevene®	 500	 mg,	 Roche,	 UK)	 was	 diluted	 in	 one	 litre	 of	physiological	 saline	and	attached	 to	a	giving	set	and	an	 i.v.	 catheter,	and	administered	slowly	over	a	period	of	one	hour.	
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2.2.6. Measurement	of	penciclovir	plasma	levels	For	measurement	 of	 the	 plasma	 levels	 of	 GCV	 and	 of	 PCV,	 the	 FCV	metabolite,	 whole	blood	samples	obtained	approximately	six	to	ten	hours	following	drugs	administration,	were	centrifuged	at	800	×g	for	10	min	and	plasma	was	collected	and	stored	at	-20	°C	for	later	 analysis.	 Plasma	 samples	 were	 analysed	 at	 the	 College	 of	 Veterinary	 Medicine,	University	 of	 Tennessee,	 USA,	 using	 a	 reverse	 phase	 HPLC	 method	 with	 solid	 phase	extraction	 (SPE).	 The	 compounds	 were	 separated	 on	 an	 Atlantis	 T3	 (4.6	 ×	 250	 mm)	column	with	 a	mobile	 phase	 of	 10	mM	 ammonium	phosphate	 pH	 2.9	 and	 acetonitrile	(95:5).	The	flow	rate	was	1.2	ml/min	and	fluorescence	was	measured	at	excitation	253	nm	 and	 emission	360	 nm.	 Standard	 curves	 for	 plasma	 analysis	 were	 prepared	 by	fortifying	 untreated,	 pooled	 elephant	 plasma	 with	 the	 drug	 to	 produce	 a	 linear	concentration	 range	 of	 10-5000	 ng/ml.	 Average	 recovery	 was	 100%	 while	 intra	 and	inter-assay	variability ranged	from	0.5	to	5.1%.	The	lower	limit	of	quantification	was	10	ng/ml. 
	
2.3. Results	
2.3.1. DNAemia,	viral	strain,	viral	shedding,	and	haematological	parameters	
2.3.1.1. Case	1	(Scott)		In	Case	1,	an	EDTA	whole	blood	sample	taken	on	the	day	of	the	first	clinical	symptoms	tested	 qPCR	 positive	 for	 EEHV-1	DNA.	 Prior	 to	 this	 event,	 routine	 blood	 samples	 and	trunk	swabs	 tested	negative	 for	EEHV-1.	Using	a	qPCR	assay,	 the	blood	viral	 load	was	determined	as	8.16*103	viral	genome	copies	(vgc)/ml	of	whole	blood	(Figure	2.1).	On	 Day	 2,	 with	 all	 clinical	 signs	 being	 resolved,	 the	 blood	 viral	 load	 peaked	 at	3.61*104	vgc/ml,	 after	 which	 it	 started	 to	 decrease	 gradually.	 Full	 haematological	parameters	were	only	 available	 for	Days	7,	 23,	 and	213	 following	 suspicion	of	 clinical	EEHV-1A	 infection	 (Figure	 2.3	 for	 case	 timeline).	 At	 7	 days	 post	 EEHV	 detection,	 a	
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reduced	monocyte	count	(5.94*109/L,	26%	of	WBC)	was	recorded,	which	had	returned	to	 normal	 (51%	 of	 WBC)	 when	 tested	 three	 weeks	 later	 (Table	 2.2).	 All	 other	haematological	 parameters	 such	 as	 total	 white	 blood	 cells,	 heterophils,	 lymphocytes,	eosinophils,	 basophils,	 red	 blood	 cells,	 haemoglobin,	 haematocrit,	 and	 platelets,	remained	 in	 the	 normal	 expected	 ranges	 throughout	 the	 experiment	 (Table	 2.2).	 No	virus	was	detectable	 in	 the	blood	 from	Day	18	onwards	 (Figure	2.1	and	Figure	2.3).	Viral	DNA	excretion	through	trunk	secretions	commenced	on	Day	10	and	continued	for	at	 least	 two	months,	with	 a	peak	around	Day	48	of	4.66*103	 vgc	per	 test	 reaction.	No	further	 samples	were	 tested	 beyond	Day	 57,	 except	 a	 haematological	 analysis	 on	Day	213,	 where	 all	 parameters	 where	 within	 the	 normal	 range.	 Neither	 sibling	 tested	positive	 for	 EEHV-1	 DNA	 in	 blood	 or	 bodily	 secretions	 in	 any	 of	 the	 weekly	 samples	tested	throughout	this	period.							 	
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Figure	 2.1:	 EEHV-1A	 DNA	 levels	 in	 blood	 and	 trunk	 secretions	 of	 Case	 1	
(Scott).	Clinical	suspicion	of	EEHV	infection	was	confirmed	by	detection	of	EEHV-1A	DNA	 in	blood.	The	animal	 showed	clinical	 signs	 suggestive	of	 active	EEHV-1A	infection	on	Day	0	and	Day	1.	EEHV-1A	DNA	load	in	EDTA	whole	blood	(solid	lines)	and	trunk	secretions	(dashed	 line)	was	measured	using	a	qPCR	assay.	EEHV	DNA	was	detected	in	trunk	secretions	only	once	viral	DNA	levels	had	decreased	rapidly	in	the	systemic	blood.	Viral	DNA	was	detected	in	regular	trunk	swabs	for	at	least	2	months	despite	no	detectable	DNAaemia.			
	
2.3.1.2. Case	2	(Max)	In	 Case	 2,	 a	 blood	 swab	 collected	 during	 routine	weekly	 sampling	 tested	 positive	 for	EEHV-1	 by	 qPCR	 and	 the	 result	 was	 confirmed	 by	 a	 subsequent	 EDTA	 whole	 blood	sample	 that	 tested	 qPCR	 positive	 at	 5.0*102	 vgc/ml	 of	 blood	 (Figure	 2.2).	 The	haematological	 parameters	 and	 viral	 load	 were	 then	 measured	 on	 several	 occasions	from	33	days	prior	 to	 the	observation	of	 signs	 indicative	of	 clinical	EEHV-1A	 infection	
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(Day	0)	to	Day	1	when	the	elephant	succumbed	to	the	infection	at	midnight	(see	Figure	
2.4	 for	 timeline).	At	 first	detection	of	EEHV	DNA	 (day	 -33)	monocytes	were	abundant	(12.46*109/L,	54%	of	WBC)	and	the	platelet	count	was	classed	as	normal	at	950*109	/L	(Table	 2.2,	 Day	 -33).	 A	 follow-up	 blood	 sample	 four	 days	 later	 was	 EEHV-1	 DNA	negative	by	qPCR	and	the	calf	remained	negative	on	four	subsequent	blood	swabs	taken	during	a	 three-week	period.	Four	weeks	after	 the	 initial	positive	EEHV	qPCR	result,	an	EDTA	 whole	 blood	 sample	 tested	 positive,	 with	 a	 viral	 load	 of	 1.2*105	 vgc/ml.	Furthermore,	 the	monocyte	 count	 had	markedly	 reduced	 to	 0.8*109/L	 (13%	 of	WBC)	and	the	platelet	count	almost	halved	to	560*109	/L,	in	the	absence	of	clinical	signs	(Day	-5).	 	 At	 this	 time	 point	 lymphocyte	 count	 has	 also	 shown	 substantial	 reduction	 of	1.85*10e9/L	 (normal	 range	around	5.02*10e9/L)	on	 the	detection	of	DNAemia,	which	consequently	reduced	the	total	white	blood	cell	count.	Other	haematological	parameters,	however,	such	as	heterophils,	eosinophils,	basophils,	red	blood	cells,	haemoglobin,	and	haematocrit	remained	in	their	normal	expected	range	(Table	2.1).	From	 day	 -5	 onwards,	 viral	 load	 increased	 exponentially	 as	 time	 progressed	 (Figure	
2.4),	during	which	the	monocyte	count	stabilised	around	2.54*109/L	(17%	of	WBC),	but	platelet	counts	showed	a	continuous	decline	(Table	2.2).	When	the	calf	 first	displayed	clinical	 signs	 of	 haemorrhagic	 disease	 the	 platelet	 count	 had	 reduced	 drastically	 to	98*109/L	(Table	2.2)	and	viral	 load	had	 increased	to	7.2*106	vgc/ml	of	blood	(Figure	
2.2).	The	lymphocyte	count	remained	at	 low	levels,	but	no	other	changes	were	seen	in	the	 haematological	 parameters.	 Clinical	 signs	 progressed	 despite	 treatment	 and	 the	platelet	count	further	reduced	to	13*109/L	and	viral	load	increased	to	1.9*107	vgc/ml	of	blood	before	the	calf	died	(Figure	2.2).		Haematological	 parameters	 of	 three	 additional	 fatal	 cases	 of	 EEHV-1A	 and	 EEHV-1B	infections	 from	 the	 same	 zoological	 collection	were	 also	 used	 for	 comparison	 and	 are	listed	in	Table	2.3.	
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Figure	 2.2:	 EEHV-1A	DNA	 loads	 in	 EDTA	whole	 blood	 samples	 of	 Case	 2	
(Max)	measured	using	qPCR.	 The	 elephant	 calf	 tested	 qPCR	positive	 6	 days	prior	to	development	of	clinical	signs	(Day	0),	succumbing	to	the	disease	within	less	 than	 48	 hour,	 despite	 aggressive	 anti-viral	 treatment	 initiated	 upon	detection	of	DNAaemia.	EEHV-1A	DNA	load	in	EDTA	whole	blood	samples	was	measured	 using	 a	 qPCR	 assay,	 demonstrating	 a	 rapid	 increase	 of	 viral	 DNA	present	 in	 the	 systemic	 blood	 over	 6	 days	 prior	 to	 death.	
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D
ays:	-14	
0	*	
1	
2	
3	*	
5	*	
6	*	
7	*	
10*	
14	*	
18	*	
21	
23	
48	
57	
213	
•Clinical	signs:	Lethargic,	
stiff	legs 
•EEHV-1A	DNAemia:	
8.16*10 3	vgc/ml 
•Treatment	initiation:	15	
mg/kg	FCV	TID	rectally 
•Clinical	sings:	reduced 
•Treatment:	12	mg/kg	FCV	
TID	rectally	for	the	next	5	
days •No	clincial	signs	
•EEHV-1	DNAemia:	
3.61*10 4	vgc/ml	
•EEHV-1	DNAemia:	7.35*10 3	
vgc/ml	
•Monocytes:	5.94*10 9/L	
(26%	of	WBC)	
•Platelets:	470*10 9/L	
•Treatment:	8	mg/kg	FCV	BID	
rectally	for	the	next	11	days	
•No	detectable	EEHV-1	
DNAemia 
•EEHV-1	trunk	secretion:	76.3	
vgc/test	reaction 
•Treatment	discontinued 
•EEHV-1	trunk	secretion:	
1.41*10 3	vgc/test	reaction 
•EEHV-1	positive	
trunk	secretion:	53.4	
vgc/test	reaction 
•Peak	EEHV-1	shedding	via	
trunk	secretion: 4.66*103	
vgc/test	reaction •End	of	EEHV	testing 
•EEHV-1	trunk	
sectetion:	35.86	
vgc/test	reaction 
Figure	2.3:	Tim
eline	of	EEH
V-1A	infection,	haem
atological	param
eters,	clinical	signs,	and	treatm
ent	pre-	and	post	onset	of	first	
clinical	signs	(D
ay	0)	of	Case	1	(Scott).	EEHV-1A	infection	was	confirmed	following	the	development	of	clinical	signs,	however	the	elephant	
recovered	and	survived	despite	EEHV	positive	trunk	secretions	suggesting	viral	shedding.	*	indicates	days	on	which	plasma	was	collected	for	
penciclovir	plasma	level	analysis;	vgc,	viral	genome	copynumbers	(/ml,	per	ml	of	whole	blood);	FCV,	famcivlovir;	GCV,	ganciclovir;	WBC,	
white	blood	cells.		
•EEHV-1	DNAemia: 1.46*10 4	
vgc/ml 
•All	haematological	
parameters	in	expected	
physiological	range	
•Routine	blood	swab	
EEHV-1	qPCR	negative 
 
•All	haematological	
parameters	in	expected	
physiological	range	
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D
ays:						-33	
-29	
-6	
-5	*	
-3	*	
-1	*	
0	
1	
•Clinical	signs:	oedema	of	head	and	abdomen,	tongue	
petechiae	&	cyanosis	
•EEHV-1	DNAemia:	1.9*10 7	vgc/ml		
•Monocytes:	2.975	*10 9/L	(23%	of	WBC)	
•Platelet	count:	13*10 9/L		
•Treatment:	15	mg/kg	FCV	TID	rectally,	and	1	ml/kg	
plasma,	fluids,	and	5	mg/kg	GCV	i.v.		
•No	detectable	EEHV-1	
•Monocytes:	
13.18*10 9/L	(52%	of	
WBC)	
•Platelets:	760*10 9/L	
•EEHV-1	DNAemia:	1.3*10 6	vgc/ml	
•Monocytes:	0.81*10 9/L	(11%	of	
WBC)	
•Platelets:	183*10 9	/L		
•Presented	with	infection	of	
temporal	gland	
•Treatment	with	topical	
antibiotics	•EEHV-1	DNAemia:	1.2*10 5	
vgc/ml	of	blood	
•Monocytes:	0.8*10 9/L	(13	%	
of	WBC)		
•Treatment	Initiation:	15	
mg/kg	FCV	TID	rectally	for	
the	next	5	days	
•	
•First	clinical	sign:	lethargic	
•EEHV-1	DNAemia:	7.2*10 6	vgc/ml	
•Monocytes:	2.54*10 9/L	(17%	of	WBC)		
•Plateles:	98*10 9/L		
•Treatment:	15	mg/kg	FCV	rectally	TID	
•1	ml/kg	plasma,	fluids,	and	5	mg/kg	GCV	i.v.		
•Death	of	elephant	
calf	around	
midnight	
•EEHV-1	DNAemia:	5.0*10 2	vgc/ml		
•Monocytes:	12.46*10 9/L	(54%	of	
WBC)	
•Platelets:	950*10 9	/L		
	Figure	2.4:	Tim
eline	of	EEH
V-1A	infection,	haem
atological	param
eters,	clinical	signs,	and	treatm
ent	pre-	and	post	onset	of	first	
clinical	signs	(D
ay	0)	of	Case	2	(M
ax).	EEHV-1A	DNA	was	detected	in	the	blood	of	a	young	elephant	during	routine	screening.	Following	a	
period	of	undetectable	viral	latency,	EEHV	DNA	was	once	again	confirmed	about	4	weeks	later,	this	time	resulting	in	severe	clinical	disease	
and	ultimatly	the	death	of	the	elephant.	*	indicates	days	on	which	plasma	was	collected	for	penciclovir	plasma	level	analysis;	vgc,	viral	
genome	copynumbers	(/ml,	per	ml	of	whole	blood);	FCV,	famcivlovir;	GCV,	ganciclovir;	WBC,	white	blood	cells;	
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Table	2.2:	H
aem
atological	param
eters	of	A:	Case	1	(Scott)	and	B:	Case	2	(M
ax)	m
easured	during	clinical	EEH
V-1A	infection.	
Normal	platelet	range	of	live	juveniles	in	the	collection	was	established,	during	a	period	of	seven	months	from	20	blood	samples	of	the	
elephants,	to	be	at	372-878*10e9/L	(mean	of	625*10e9/L).	The	rest	of	the	physiological	parameters	were	from	24	measurements	
established	from	four	individuals	under	eight	years	of	age	(age	range	at	time	of	sampling:	1.5-7y).	Parameter	values	with	a	substantial	
change	are	highlighted	in	bold.	Percentages	of	monocytes	in	the	white	blood	cells	are	also	given	in	the	table.	
A
 D
ays 
EEH
V
-1A
 
(vgc/m
l) 
W
B
C
 
(*10e9/L) 
H
eterophils 
(*10e9/L) 
Lym
phocytes 
(*10e9/L) 
M
onocytes 
(*10e9/L) 
Eosinophils 
(*10e9/L) 
B
asophils 
(*10e9/L) 
7 
7.35 × 10
3 
22.85 
7.77 
8.91 
5.94 (26%
) 
0.23 
0 
23 
N
D
 
13.69 
5.75 
2.87 
6.16 (45%
) 
0 
0 
213 
N
D
 
15.91 
4.61 
5.73 
5.25 (33%
) 
0.32 
0 
Physiological 
m
ean 
(%
 of W
B
C
) 
 
15.51 
3.77 
(25.5%
) 
5.02 
(23.65%
) 
6.46 
(50%
) 
0.24 
(1.55%
) 
0.02 
(0.10%
) 
   
A
 (continued) 
D
ays 
R
B
C
 
(*10e12/L) 
H
G
B
 
(g/dL) 
H
C
T 
(%
) 
M
C
V
 
(fL) 
M
C
H
 
(pg) 
M
C
H
V
 
(g/dL) 
R
D
W
 
(%
) 
PLT 
(*10e9/L) 
PC
V
 
(%
) 
7 
3.54 
13.4 
37.7 
107 
37.8 
35.5 
14.3 
470 
36 
23 
5.06 
19.2 
55.1 
109 
37.9 
34.8 
14.5 
968 
55 
213 
3.62 
13.3 
39.2 
108 
36.8 
33.9 
13.9 
996 
37 
Physiological 
(m
ean) 
3.55 
14.28 
 40.60 
114.25 
40.19 
35.17 
14.33 
617.65 
40.80  
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B
 
D
ays 
EEH
V
-1A
 
(vgc/m
l) 
W
B
C
 
(*10e9/L) 
H
eterophils 
(*10e9/L) 
Lym
phocytes 
(*10e9/L) 
M
onocytes 
(*10e9/L) 
Eosinophils 
(*10e9/L) 
B
asophils 
(*10e9/L) 
-33 
5.0 × 10
2 
23.08 
4.62 
5.77 
12.46 (54%
) 
0 
0 
-29 
N
D
 
25.34 
4.56 
7.6 
13.18 (52%
) 
0 
0 
-5 
1.2 × 10
5 
6.18 
3.46 
1.85 
0.8 (13%
) 
0.06 
0 
-3 
2.7 × 10
6 
7.35 
5.22 
1.32 
0.81 (11%
) 
0 
0 
0 
7.2 × 10
6 
13.25 
8.22 
2.65 
2.25 (17%
) 
0.13 
0 
1 
1.9 ×10
7 
12.925 
7.565 
2 
2.975 (23%
) 
0 
0.195 
Physiological 
m
ean  
(%
 of W
B
C
) 
 
15.51 
3.77 
(25.5%
) 
5.02 
(23.65%
) 
6.46 
(50%
) 
0.24 
(1.55%
) 
0.02 
(0.10%
) 
		
B	(continued)	
D
ays 
R
B
C
 
(*10e12/L) 
H
G
B
 
(g/dL) 
H
C
T 
(%
) 
M
C
V
 
(fL) 
M
C
H
 
(pg) 
M
C
H
V
 
(g/dL) 
R
D
W
 
(%
) 
PLT 
(*10e9/L) 
PC
V
 
(%
) 
-33 
3.65 
14.6 
43.2 
118.3 
39.9 
33.7 
13.9 
950 
42 
-29 
3.58 
14.5 
41.4 
115.5 
40.4 
35 
38.1 
760 
38 
-5 
3.48 
14.2 
41.8 
120.4 
41 
34 
14 
560 
37 
-3 
3.36 
14.2 
38.4 
114.4 
42.4 
37.1 
13.7 
183 
38 
0 
2.89 
12.4 
32.9 
113.7 
42.9 
37.8 
13.8 
98 
34 
1 
3.07 
12.95 
35.05 
114.2 
42.2 
36.9 
13.6 
13 
36.5 
Physiological 
m
ean  
3.55 
14.28 
 40.60 
114.25 
40.19 
35.17 
14.33 
617.65 
40.80  
vgc/ml,	viral	genome	copies	per	millilitre	of	EDTA	whole	blood;	WBC,	white	blood	cell	count;	RBC,	red	blood	cell	
count;	HGB,	haemoglobin;	HCT,	haematocrit;	MCV,	mean	cell	volume;	MCH,	mean	corpuscular	haemoglobin;	
MCHV,	mean	corpuscular	haemoglobin	volume;	RDW,	red	blood	cell	distribution	width;	PLT,	platelet	count;	PCV,	
packed	cell	volume;	ND,	not	detected.	
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		Table	2.3:	H
aem
atological	param
eters	of	three	additional	fatal	cases	of	EEH
V-1A	and	EEH
V-1B	infections	from
	
the	sam
e	zoological	collection.	Blood	samples	were	taken	following	the	observation	of	EEHV-1	infection	clinical	
signs.	WBC,	lymphocyte,	monocyte,	and	platelet	counts	(highlighted	in	bold)	consistently	show	substantial	drop	from	
their	physiological	level	in	the	two	fatalities	caused	by	EEHV-1A.	Percentages	of	monocytes	in	the	white	blood	cells	are	
also	given	in	the	table.	
A
nim
als 
(date of sam
pling) 
 
V
irus type 
W
B
C
 
(*10e9/L) 
H
eterophils 
(*10e9/L) 
Lym
phocytes 
(*10e9/L) 
M
onocytes 
(*10e9/L) 
Eosinophils 
(*10e9/L) 
B
asophils 
(*10e9/L) 
Em
ilia 
 
 
 
 
 
 
 
(18/12/2006) 
EEH
V
-1B
 
17 
11.85 
3.21 
1.9 (11.2%
) 
0.03 
0.02 
R
iddle 
 
 
 
 
 
 
 
(01/05/2009) 
EEH
V
-1A
 
2.71 
1.49 
0.84 
0.27 (10%
) 
0 
0 
B
etts 
 
 
 
 
 
 
 
(15/05/2009) 
EEH
V
-1A
 
5.1 
3.11 
1.02 
0.97 (19%
) 
0 
0 
Physiological 
m
ean  
(%
 of W
B
C
) 
 
15.51 
3.77 
 (25.5%
) 
5.02 
(23.65%
) 
6.46 
(50%
) 
0.24 
(1.55%
) 
0.02 
(0.10%
) 
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				Table	2.3	(continued)	
A
nim
als  
(date of sam
pling) 
 
R
B
C
  
(*10e12/L) 
H
G
B
  
(g/dL) 
H
C
T  
(%
) 
M
C
V
  
(fL) 
M
C
H
 
(pg) 
M
C
H
V
 
(g/dL) 
R
D
W
 
(%
) 
PLT 
(*10e9/L) 
PC
V
 
(%
) 
Em
ilia 
 
 
 	
 
 
 
 
 
	
(18/12/2006) 
 
3.05 
12.8 
39.2 
122 
42 
34.4 
15.7 
34.6 
N
A
 
R
iddle 
 
 
 
 
 
 
 
 
 
 
(01/05/2009) 
 
3.55 
13 
37.7 
106 
36.7 
34.6 
17.4 
25.6 
35 
B
etts 
 
 
 
 
 
 
 
 
 
 
(15/05/2009) 
 
3.16 
12.9 
55.1 
112 
40.8 
36.5 
17.3 
71.5 
N
A
 
Physiological 
(m
ean) 
 
3.55 
14.28 
 40.60 
114.25 
40.19 
35.17 
14.33 
617.65 
40.80  
	W
B
C
, w
hite blood cell count; R
B
C
, red blood cell count; H
G
B
, haem
oglobin; M
C
V
, m
ean cell volum
e; 
M
C
H
, m
ean corpuscular haem
oglobin; M
C
H
V
, m
ean corpuscular haem
oglobin volum
e; R
D
W
, red 
blood cell distribution w
idth; PLT, platelet.		
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2.3.1.3. Genomic	analysis	of	EEHV-1	Three	partial	gene	sequences	for	the	POL	(U38),	gL	(U82),	and	gM	(U73)	genes	were	determined	for	the	two	EEHV-1	viruses	detected	in	Case	1	(Scott	–	May	2013)	and	Case	2	 (Max	–	 June	2015)	 to	 identify	 the	EEHV-1	subtype	and	 to	verify	 that	 there	was	no	cross-reaction	of	the	qPCR	assay	with	another	EEHV	type.	Furthermore,	two	young	Asian	elephants	(Riddle	and	Betts)	had	died	of	haemorrhagic	disease	due	to	EEHV-1A	 infections	 in	 the	 same	 zoological	 facilities	 in	 May	 2009.	 The	 partial	sequences	of	these	three	viral	genes	were	compared	between	all	four	EEHV-1	cases	to	analyse	viral	gene	similarity	between	respective	virus	strains	separated	in	time.		Sequencing	of	PCR	amplicons	of	partial	viral	POL,	gL,	and	gM	genes	and	subsequent	genomic	analysis	 identified	the	viruses	of	both,	Case	1	and	Case	2	(Scott	and	Max)	EEHV	 infections,	 as	 EEHV-1A	 genotype.	 Comparing	 the	 nucleotide	 sequences	 of	these	 two	cases	revealed	 identical	partial	POL	and	gL	genes,	 in	contrast	 to	 the	gM	gene,	which	was	only	99.4	%	similar	due	to	three	synonymous	nucleotide	changes	(Figure	2.5).	The	 comparison	 of	 these	 partial	 gene	 sequences	 with	 those	 of	 the	 two	 EEHV-1A	fatalities	from	2009	(Riddle	and	Betts)	revealed	several	nucleotide	substitutions	in	the	POL	and	gL	gene	segments,	indicating	genomically	divergent	viruses	from	those	in	Riddle	and	Betts	 (Figure	2.5).	These	POL	and	 the	gL	genes	of	Riddle	and	Betts	differed	from	Max	and	Scott	by	one	nucleotide	(identity	99.48%)	and	20	nucleotides	respectively	(identity	94.75%)	(Figure	2.5).	The	partial	gM	gene	sequence	was	identical	between	the	viruses	of	Scott,	Betts,	and	Riddle,	but	all	differed	from	the	respective	viral	sequence	obtained	from	Max	by	the	previously	 described	 three	 nucleotides	 changes	 (identity	 99.4%)	 (Figure	 2.5).	
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Riddle	and	Betts	showed	 identical	 sequences	 for	 the	 three	gene	segments	 (Figure	
2.5).	All	of	the	detected	nucleotide	changes	were	synonymous.	
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A.	U
38/PO
L	
 
 
Figure 2.5 (continued) 
	
	
	61	 	
B.	U
82/gL	
 
Figure 2.5 (continued)
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C.	U
72/gM
	
	
Figure	2.5	(continued)	
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Figure	2.5:	N
ucleotide	sequence	com
parison	of	EEH
V-1A	strains	detected	in	4	cases	of	EEH
V1A	infection	at	the	sam
e	
zoological	facility.	A.	Partial	nucleotide	sequences	of	DNA	polymerase	[U38/POL	(194	bp)],	B.	glycoprotein	L	[U82/gL	(381	bp)],	
and	C.	glycoprotein	M	[U72/gM	(500	bp)]	from	Case	1	(Scott)	and	Case	2	(Max)	were	compared	with	those	of	two	previous	EEHV-1A	
fatalities	(Riddle	and	Betts)	from	2009	that	accoutred	in	the	same	zoological	collection.	Sequences	were	aligned	using	the	MegAlign	
13	software	of	the	DNASTAR	Lasergene	13	package	(DNASTAR	Inc.	Madison,	USA).	Identical	nucleotides	to	those	of	Case	1	are	
denoted	by	dots	in	the	alignments.	Viral	sequence	of	the	three	gene	segments	were	genetically	more	similar	between	those	cases	
which	occurred	in	closer	proximity.	Partial	viral	sequences	obtained	from	Betts	and	Riddle,	which	both	occurred	in	2009	showed	no	
genetic	difference.	Only	small	genetic	changes	in	the	partial	gM	sequence	were	detected	between	the	cases	of	Scott	and	Max,	
highlighted	in	red,	which	occurred	just	over	1	year	apart.	However	multiple	nucleotide	changes	(94.7%	identity)	were	detected	in	the	
partial	gL	gene	sequences	when	comparing	the	two	sets	of	viruses	of	the	historic	cases	from	2009	and	the	more	recent	cases	of	Scott	
and	Max.		
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2.3.2. Anti-herpesviral	Plasma	Levels	 	In	Case	1,	plasma	PCV	levels,	measured	at	trough	levels	eight	to	ten	hours	following	the	latest	FCV	administrations	 in	both	Case	1	(Figure	2.6	and	timeline	Figure	2.3)	and	 its	male	sibling	ranged	between	68-934	ng/ml.	Levels	measured	at	the	dosing	regimens	of	15	mg/kg	TID	and	12	 mg/kg	 TID	 reached	 values	 considered	 therapeutic	 in	 humans	 with	 genital	 herpes	 (>100	ng/ml)	(Gill	&	Wood,	1996).	In	 Case	 2,	 plasma	 PCV	 levels	 as	 high	 as	 934	 ng/ml	 were	 attained	 during	 the	 first	 days	 of	treatment	 (Figure	 2.6	 and	 timeline	 Figure	 2.4).	 When	 the	 calf	 started	 showing	 signs	 of	lethargy,	PCV	plasma	levels	had	dropped	to	303	ng/ml,	about	a	third	of	its	previous	peak.	GCV	(5	mg/ml)	that	was	administered	on	Day	6	post	DNAemia	detection	(Figure	2.4)	and	reached	a	plasma	level	of	2529	ng/ml	following	i/v	injection.							
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Figure	2.6:	Penciclovir,	the	metabolite	of	famciclovir,	plasma	levels	in	2	juvenile	
Asian	 elephants	 with	 EEHV-1A	 DNAemia.	 Famciclovir	 (FCV)	 was	 rectally	administered	in	Case	1	at	15	mg/kg	thrice	daily	(TID)	on	observation	of	clinical	signs	indicative	of	EEHV-1A	infection	(Day	0)	and	continued	at	the	same	dose	rate	until	Day	1,	when	 it	was	reduced	to	12	mg/kg	thrice	daily	(TID).	This	was	 followed	by	 further	reduction	on	Day	7	to	8	mg/kg	BID	and	continued	unchanged	until	Day	18.	In	Case	2,	FCV	was	administered	at	15	mg/kg	TID	following	the	detection	of	EEHV-1A	DNA	in	the	blood	(Day	-5),	five	days	prior	to	observation	of	EEHV-1A	clinical	signs,	and	continued	at	 the	 same	 dosage	 till	 the	 last	 dose	 of	 FCV	 at	 9:00	 am	 on	 Day	 0;	 blood	 was	 only	collected	at	17:00	pm	on	that	day.	The	death	of	Case	2	was	at	midnight	on	Day	1;	six	days	 after	 first	 detection	 of	 EEHV-1	 DNA	 in	 the	 blood.	 Dashed	 line	 indicates	 the	minimum	 level	 of	 PCV	 considered	 therapeutic	 in	 humans	with	 genital	 herpes	 (>100	ng/ml)	(Gill	&	Wood,	1996).		
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2.4. Discussion	The	 early	 clinical	 sings	 of	 EEHV-HD	 are	 non-pathognomonic	 and	 often	manifested	 as	lethargy,	anorexia	and	 lameness.	These	early	clinical	signs	are	 likely	to	be	 followed	by	more	 severe	 and	 generally	 terminal	 signs	due	 to	 the	 generalized	 capillary	 endothelial	cell	damage	caused	by	this	virus	(Richman	et	al.,	2000;	Garner	et	al.,	2009;	Wilkie	et	al.,	2014).	Routine	blood	testing	of	at-risk	juvenile	Asian	elephants	for	EEHV	viraemia	has	been	suggested	as	part	of	a	monitoring	scheme	to	predict	and	potentially	prevent	fatal	disease,	as	the	viral	DNA	can	be	detected	at	least	several	days	prior	to	any	clinical	signs	(Atkins	 et	 al.,	 2013;	 Stanton	 et	 al.,	 2013).	 This	 routine	 monitoring	 was	 proven	 to	 be	valuable	 in	 this	study,	where	Case	2	EEHV-1	DNAemia	was	detected	 five	days	prior	 to	the	earliest	clinical	signs,	although	unfortunately	 the	early	 initiated	treatment	was	not	able	to	prevent	fatality.		In	 addition	 to	 detection	 and	 quantification	 of	 viral	 DNA	 through	 real-time	 qPCR,	 a	decreased	 monocyte	 count	 and	 an	 absolute	 reduction	 of	 the	 platelet	 count	 seem	 to	signify	the	most	useful	prognostic	haematological	parameters	of	EEHV-HD,	although	the	exact	physiological	process	for	this	is	yet	unknown.	It	is	possible	that	the	monocytes	are	subjected	to	virus	induced	cell-death	(Fuery	et	al.,	2016b),	and	that	the	viral	damage	to	the	 endothelial	 cells	 exceeds	 the	 adaptive	 nature	 of	 the	 host	 response,	 leading	 to	 the	development	of	disseminated	intravascular	coagulation	(DIC)	and	hence	critical	 loss	of	platelets.	 In	 Case	 2,	 the	 platelet	 count	 showed	 a	 gradual	 decline	well	 before	 the	 fatal	progressive	viraemia,	reaching	a	dangerously	low	level	before	death.	Archived	data	from	three	 previous	 fatalities	 at	 the	 same	 zoological	 collection	 show	 similar	 critically	 low	platelet	count	following	clinical	EEHV-1	manifestation	(Table	2.3).	Similar	findings	have	also	 been	 recently	 reported	 from	 Asian	 elephants	 affected	 by	 EEHV-1B,	 4,	 and	 5	viraemia	 (Atkins	 et	 al.,	 2013;	 Fuery	 et	 al.,	 2016a,	 2016b).	 It	 is	 noteworthy	 that	mean	
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haematological	 parameters	 vary	 substantially	 in	 Asian	 elephants’	 blood,	 with	 e.g.	 a	reported	 range	 of	 80-975*109/L	 for	 platelets	 (Lewis,	 1974;	 Brown	 &	 White,	 1980;	Niemuller	et	al.,	1990;	Silva & Kuruwita, 1994; Wiedner, 2015)	 and	 the	 low	platelet	count	of	98	*109/L	observed	for	Case	2	a	day	prior	to	its	death	might	hence	still	be	considered	within	the	normal	range.	Therefore,	the	general	trend	of	the	platelet	count	throughout	the	 course	 of	 infection	might	 inform	 the	 clinical	 prognosis	more	 truly.	Monocytes	 are	usually	the	most	abundant	white	blood	cells	in	the	majority	of	juveniles.	In	these	cases,	the	relative	drop	of	monocytes,	compared	to	other	white	blood	cells,	in	the	early	stages	of	 the	disease	could	easily	be	determined	using	well-established	 in-house	white	blood	cell	differentials.	There	are,	however,	individuals	in	which	the	monocytes	are	on	average	less	abundant	and	hence	 this	early	 indicator	will	be	 less	beneficial	 in	 these	cases.	 It	 is	therefore	 advisable	 to	 establish	 individual	 baselines	 for	 at	 least	 the	 abovementioned	haematological	 parameters	 for	 each	 at-risk	 elephant	 in	 advance,	 and	 that	 clinicians	familiarise	themselves	with	in-house	blood	smear	differential.		Monitoring	of	EEHV-1A	load	in	the	two	elephants	revealed	rapid	increase	in	viral	load	in	the	elephant	that	succumbed	to	the	disease	(Case	2)	despite	continuous	anti-herpesviral	following	detection	of	EEHV-1A	DNA	prior	to	the	onset	of	clinical	disease	(Figure	2.4).	From	at	 least	three	days	prior	to	the	onset	of	clinical	signs,	PCV	reached	plasma	levels	suggested	 as	 therapeutic	 for	 treatment	 of	 diseases	 caused	 by	 alphaherpesvirus	infections	in	humans	(Gill	&	Wood,	1996),	but	here	it	failed	to	prevent	viral	replication	and	viral	load	increase.	Considering	the	approximate	three-hour	half-life	of	PCV	(Gill	&	Wood,	1996),	the	peak	levels	could	have	been	up	to	three	times	higher	than	measured,	as	blood	samples	were	taken	6	to	8	hours	following	the	FCV	administration.	
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At	present,	it	is	known	that	several	elephant	calves	have	survived	laboratory	confirmed	clinical	EEHV-1	infections.	These	elephant	calves	were	treated	with	FCV	at	doses	of	5.5-8.0	mg/kg	twice	daily	(BID)	rectally	(Gill	&	Wood,	1996;	Schmitt	et	al.,	2000;	Schaftenaar	et	al.,	2001;	Brock	et	al.,	2010;	Tocidlowski	et	al.,	2015;	Howard	&	Cox,	2015;	Long	et	al.,	2015;	Fuery	et	al.,	2016a,	2016b)	and	with	GCV	at	5	mg/kg	BID	intravenously	followed	by	 oral	 administration	 (Stanton	 et	 al.,	 2013;	 Padilla,	 2015).	 One	 elephant	 calf	 with	advanced	EEHV-1	clinical	signs	has	been	treated	successfully	with	ACV	at	12mg/kg	BID	intravenously	for	a	period	of	15	days	along	with	penicillin	G	and	supportive	treatment	including	 vitamin	 C,	 physiological	 saline,	 and	 5%	 Dextrose	 (Boonprasert et al., 2015).	Apart	from	the	latter	case,	the	length	of	time	taken	to	reach	the	highest	viral	load,	peak	viraemia	 levels,	 and	 recovery	of	 blood	parameters	 suggest	 that	many	of	 the	 surviving	elephant	calves	represent	relatively	mild	clinical	cases,	more	comparable	to	the	EEHV-1	infection	 kinetics	 observed	 here	 for	 Case	 1.	 It	 is	 therefore	 likely	 that	 these	 affected	individuals	might	have	recovered	without	drug	intervention	(Long	et	al.,	2015). The	efficacy	of	FCV	treatment	to	curb	progression	to	EEHV-HD	in	clinical	EEHV	cases	has	always	 been	 debatable,	 as	 compromised	 cellular	 function	 at	 enteric	 level	 could	 affect	absorption.	 This	 was	 indicated	 by	 the	measured	 PCV	 level	 in	 Case	 2,	 which	 dropped	remarkably	 48h	 prior	 to	 the	 onset	 of	 outwardly	 visible	 clinical	 signs.	 Factors	 such	 as	drug	 expulsion	 and	 individual	 differences	 in	 drug	metabolism	 are	 also	 considered	 as	possible	 causes	 of	 this	 drop	 (Howard	&	Cox,	 2015).	 These	 findings	 therefore	 strongly	favour	those	anti-herpesviral	drugs	that	could	be	administered	intravenously,	to	bypass	the	intestinal	absorption	step.	Additionally,	the	available	sequences	for	EEHV	TK	and	PK	have	 only	 25%	 amino	 acid	 identity	 with	 their	 orthologues	 in	 HSV	 and	 HCMV,	 target	viruses	 for	 these	drugs	 (Long	et	 al.,	 2015),	 and	 indirect	 surrogate	 in	vitro	 assays	have	shown	mild	sensitivity	for	only	the	EEHV	PK	against	PCV	(Ackermann	&	Schetle,	2015).	
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Taking	into	account	the	EEHV	viraemia	sequel	following	FCV	administration	in	current	and	previous	studies,	the	efficacy	of	FCV	remains	doubtful.	Therefore,	the	use	of	other,	i.v.	 administered	 and	 potentially	 more	 effective,	 anti-herpesviral	 therapies	 should	 be	explored,	especially	in	cases	where	pre-EEHV-HD	viraemia,	established	through	routine	blood	PCR	monitoring,	 does	 not	 appear	 to	 be	 affected	 by	 FCV	within	 the	 first	 days	 of	treatment.	 In	 the	 absence	 of	 comprehensive	 data	 on	 a	 highly	 effective	 and	 safe	 anti-herpesviral	 drug	 for	 elephants,	 alternative	 drugs	 at	 present	 could	 include	 i.v.	administered	nucleoside	analogues	such	as	GCV	and	ACV.	The	second-line	drugs	could	be	the	pyrophosphate	analogue	foscarnet	and	the	nucleotide	analogue	cidofovir,	taking	into	 account	 the	 safety	 concerns	 for	 each	 of	 these	 drugs.	  The	most	 common	 adverse	effect	during	GCV	therapy	in	humans	has	been	haematological	toxicity,	but	this	appears	to	 be	 readily	 reversible	 on	 discontinuation	 of	 the	 drug	 (Markham	&	 Faulds,	 1994).	 It	should	 also	be	noted	 that	ACV	 is	 a	hundred	 times	more	potent	 than	FCV	 in	 inhibiting	herpesviruses	 replication,	 but	 it	 suffers	 from	 a	 shorter	 half-life	 and	 intracellular	concentration	(Cassady	&	Whitely,	1997).	The	drug	has	been	recommended	for	clinical	situations	 where	 a	 rapid	 decrease	 in	 viral	 load	 is	 desirable,	 and	 could	 be	 of	 similar	therapeutic	value	in	EEHV	clinical	infections.	The	renal	toxicity	of	the	drug	should	also	be	considered	 in	 its	 therapy.	Frequent	measurement	of	EEHV	load	 in	blood	samples	 is	therefore	of	paramount	value	to	establish	the	efficacy	of	the	on-going	therapy.	Complementary	 therapies	 that	 are	 likely	 to	 be	 of	 value	 include	 e.g.	 maintaining	hydration	and	preventing	DIC	and	shock	through	i/v	plasma	administration	from	EEHV	antibody	 positive	 adult	 donors,	 as	 a	 source	 of	 both	 antibodies	 and	 platelets.		Furthermore,	in	case	of	an	indicated	bacterial	infection	that	might	either	have	arisen	as	a	secondary	 infection	 or	 potentially	 represented	 the	 initial	 stress	 factor	 initiating	 viral	
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replication	 in	 latent	 carriers	 or	 predisposing	 juveniles	 to	 EEHV	 infection,	 a	 broad-spectrum	antibiotic	would	be	beneficial	to	combat	concurrent	bacterial	infection.		Intravenous	access	appears	to	be	of	significant	value	for	supportive	treatment	and	anti-viral	drug	administration,	and	 is	 straightforward	 in	 trained	elephants	 that	are	used	 to	being	handled.	The	EEHV	Advisory	Group	currently	recommends	minimum	standards	of	care	 for	 all	 at-risk	 elephants	 irrespective	 of	 management	 systems,	 which	 include	 a	section	 on	 Calf	 Training	 for	 intravenous	 access	 (www.eehvinfo.org).	 In	 elephants	 that	have	 not	 attained	 this	 stage	 of	 training	 at	 the	 time	 of	 infection,	 repeated	 standing	sedations	using	butorphanol	and	detomidine	are	possible,	as	used	successfully	in	other	institutions	(Lauren	Howard,	personal	communication).	The	 presence	 of	 anti-EEHV	 antibodies	 in	 the	 serum	 of	 the	 two	 presented	 cases	 was	determined	at	some	point	during	the	project	by	Petra	Van	den	Doel,	Erasmus	University.		Antibodies	 against	 glycoprotein	B	were	 detected	 in	 the	 serum	of	 Case	 1	 (Scott)	 using	their	in-house	indirect	ELISA	about	9	months	prior	to	the	clinical	signs	and	as	outlined	this	elephant	survived	the	viraemia	(Van	den	Doel	et	al.,	2015).	However,	serum	of	Case	2	(Max)	also	contained	detectable	anti-gB	antibodies	at	the	time	of	EEHV	infection	using	the	same	gB	ELISA	(Van	den	Doel,	pers.	communication),	yet	this	elephant	did	succumb	to	 the	 virus.	 For	 other	 closely	 related	 betaherpesviruses’	 infections	 (e.g.	 HCMV),	antibodies	 to	 the	 gB	 protein	 seemed	 to	 enhance	 protection	 by	 curbing	 at	 least	 the	dissemination	 of	 the	 virus	 in	 blood	 (Field	 &	 Hodge,	 2013).	 However,	 considering	 the	fatality	in	Case	2	despite	clearly	detectable	anti-gB	antibodies,	sole	measurement	of	gB	antibody	may	not	be	an	indicator	of	protection	against	EEHV,	as	it	is	currently	unknown	which	 viral	 epitopes	 are	 recognised	 by	 neutralising	 antibodies.	 Furthermore,	neutralising	 antibodies	 cannot	 be	 determined	 by	 virus	 neutralisation	 tests	 (VNTs)	 as	virus	propagation	in	cell	cultures	has	so	far	been	unsuccessful.	The	possibility	also	exists	
	71		
that	early	 IgG	antibodies	 to	EEHV	gB	show	a	 low	avidity	 for	 the	antigen	and	hence	an	avidity	 test	 is	 required	 to	 determine	 the	 value	 of	 antibodies	 against	 EEHV	 (Prince	 &	Lapé-Nixon,	 2014).	 Also,	 in	 the	 view	 that	 herpesviruses	 (EEHVs	 and	 elephant	 gamma	herpesviruses	 [EGHVs])	 are	 ubiquitous	 in	 Asian	 elephant	 populations,	 the	 notion	 that	the	 above	 mentioned	 ELISA	 is	 cross	 reactive	 with	 anti-	 gB	 antibodies	 raised	 against	similar	viruses	or	other	unknown	agents	cannot	be	excluded	(Long	et	al.,	2015).		Partial	sequences	determined	for	POL,	gL,	and	gM	genes	of	EEHV-1	viral	strains	detected	in	Case	1	and	Case	2	were	identified	as	EEHV-1	type	A,	which	was	expected,	as	this	has	been	 the	 dominant	 type	 causing	 clinical	 fatalities.	 These	 two	 EEHV-1A	 infections	 had	occurred	 13	months	 apart	 in	 the	 same	 elephant	 herd.	 The	 comparison	 of	 the	 partial	sequences	obtained	for	the	three	genes	revealed	identical	POL	and	gL	gene	sequences,	while	 three	 nucleotide	 changes	 were	 determined	 in	 the	 partial	 gM	 sequence,	representing	 a	 0.6%	 difference	 for	 this	 gene	 segment.	 	 	 In	 comparison,	 the	 partial	nucleotide	sequences	of	the	three	genes	analysed	in	this	study	were	completely	identical	for	 the	 EEHV	 strains	 from	 Riddle	 and	 Betts,	 which	was	 not	 unexpected	 as	 these	 two	fatalities	had	occurred	in	2009	within	two	weeks	of	each	other.	However,	it	is	important	to	 note	 that	 this	 analysis	 was	 only	 carried	 out	 for	 a	 short	 stretch	 of	 3	 genes,	 hence	further	work	is	warranted	to	verify	the	overall	genetic	similarity	between	the	latter	two	EEHV-1	strains,	preferably	through	whole	genome	analysis.		Increased	genetic	variation	of	>5%	was	observed	when	comparing	the	viral	gL	sequence	of	Case	1	and	Case	2	to	those	determined	for	the	viruses	of	Riddle	and	Betts,	suggesting	that	 the	 level	 of	 genetic	 variation	 increases	 between	 more	 temporarily	 distant	 viral	infections.	In	contrast,	the	sequence	of	the	gM	gene	determined	for	the	EEHV-1	virus	of	Case	1	was	identical	to	the	ones	found	in	Riddle	and	Betts,	despite	small	genetic	changes	
	72		
in	the	respective	gene	segment	sequence	of	the	temporarily	closer	Case	2.	Why	the	gM	gene	sequence	appears	to	be	different	in	Case	2	compared	to	the	other	three	cases	is	as	yet	unknown.		Analysis	 of	 gene	 sequences	 of	more	 than	 60	 cases	 of	 EEHV	 infections	worldwide	 has	shown	 that	 there	 are	 numerous	 distinct	 and	 highly	 diverged	 EEHVs	 (Richman	 et	 al.,	2014).	 A	 study	 in	 India	 has	 also	 detected	 seven	 different	 EEHV-1A	 strains	 further	highlighting	the	diversity	of	this	pathogenic	genotype	(Zachariah	et	al.,	2013).	In	general,	a	 low	 level	 of	 replication	 errors	 occurs	 during	 DNA	 synthesis	 (Echols	 et	 al.,	 1991;	Roberts	&	Kunkel,	 1996).	These	errors,	 if	 viable,	provide	genetic	diversity	 to	 facilitate	the	adaptation	and	evolution	of	an	organism	(Günthard	et	al.,	1999).	A	recent	study	on	HCMV	mutation	 rates	 showed	a	 genome-wide	average	of	2	×	10−7	mutations	per	base	pair	 per	 generation,	 which	 is	 ∼10-fold	 higher	 than	 the	 in	 vitro	 estimates	 for	 HSV-1	(Drake	et	al.,	2005;	Renzette	et	al.,	2015).	Whether	the	nucleotide	changes	determined	for	the	three	gene	segments	analysed	in	this	study	are	caused	by	spontaneous	mutations	of	 a	persistent	virus	or	whether	 they	 represent	 the	 introduction	of	different	EEHV-1A	strains	into	the	herd,	remains	the	subject	for	future	studies.		In	 the	 study	 presented	 in	 this	 chapter,	 a	 detectable	 EEHV-1	DNAemia	was	 correlated	with	the	disease	symptoms	only	when	the	blood	viral	load	was	around	8.16*103	vgc/ml	of	 blood	 for	 Case	 1	 and	 7.2*106	 vgc/ml	 for	 Case	 2. A previous	 report	 stated	 that	 a	threshold	 of	 around	 1.0*104	 vgc/ml	 of	 blood	 had	 coincided	 with	 apparent	 illness	(Stanton	 et	 al.,	 2013).	 Clinical	 signs	 appeared	 at	 a	 much	 higher	 viral	 load	 in	 Case	 2,	emphasising	a	daily	rapid	increase	in	viral	load	as	a	more	truthful	determinant	of	anti-herpesviral	therapy	success	and	disease	prognosis.	The	results	shown	here	also	further	endorsed	 that	 DNAemia	 precedes	 virus	 shedding	 in	 trunk	 secretions	 of	 EEHV-1A	
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infected	animals,	similar	to	those	reported	previously	(Atkins	et	al.,	2013;	Stanton	et	al.,	2013;	Fuery	et	al.,	2016a,	2016b).	Although	there	is	no	evidence	that	infectious	particles	are	 shed	 at	 a	 level	 sufficient	 to	 infect	 an	 in-contact	 animal,	 the	 potential	 risk	 these	carrier	elephants	may	pose	following	a	clinical	EEHV	case	should	be	considered.		
	The	EEHV	viraemic	cases	investigated	here	further	highlight	the	on-going	threat	posed	by	the	virus	to	juvenile	Asian	elephants,	potentially	leading	to	gradual	disappearance	of	their	 free-living	population	and	an	 inability	 to	maintain	a	viable	 captive	population	 to	safeguard	 the	 species	 from	 extinction.	 Therefore,	 effective	 control	 of	 future	 EEHV	infections	 is	 fundamental	 to	 improve	 survival	 rate	 of	 affected	 animals.	 Routine	 EEHV	testing	 combined	 with	 viral	 quantification,	 WBC,	 monocyte,	 and	 platelet	 counts	following	 confirmed	DNAemia	 in	 at-risk	 elephants	 should	 deliver	 an	 early	warning	 of	the	 clinical	 prognosis,	 providing	 enough	 time	 to	 evaluate	 treatment	 opportunities	 to	avert	 a	 fatal	 outcome.	 This	 investigation	 further	 questions	 the	 efficacy	 of	 the	 rectally	administered	 FCV	 in	 controlling	 the	 viraemia	 and	 urges	 towards	 the	 exploration	 of	alternative	 therapies.	 These	 therapies	 could	 include	 preferably	 i.v.	 administered	 anti-herpes	 viral	 drugs,	 complementary	 plasma	 transfusions,	 and	 antibiotics	 against	potential	secondary	infections.		 	
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CHAPTER	3:	DISTRIBUTION	AND	VIRAL	LOAD	OF	EEHV-1A,	EEHV-1B,	AND	EEHV-5	
DNA	IN	ORGAN	TISSUES	OF	ASSOCIATED	FATALITIES	OF	ASIAN	ELEPHANTS		
	
Declaration	Parts	of	this	chapter	have	been	published	in	a	peer	reviewed	journal	(Distribution	and	load	 of	 elephant	 endotheliotropic	 herpesviruses	 in	 organ	 samples	 from	 associated	fatalities	of	Asian	elephants.	2016.	Virus	research	220,	91-96).		All	laboratory	investigations	and	analyses	of	parameters	presented	in	this	chapter	were	performed	by	Katharina	Seilern-Moy.			All	 post	 mortem	 samples	 used	 in	 this	 study	 were	 provided	 by	 European	 zoos	 and	collected	by	the	zoo	veterinarians	or	pathologists.			The	 drafts	 of	 the	 publication	 that	 resulted	 from	 this	 work	 have	 been	 prepared	 by	Katharina	Seilern-Moy	with	subsequent	contributions	and	comments	by	co-authors.			
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Abstract	Current	 knowledge	 of	 the	 pathogenesis	 of	 EEHV	 infections	 in	 elephants	 is	 still	 very	limited	 and	 has	 been	 restricted	 to	 histopathological	 examination	 of	 EEHV-infected	organs.	However,	 little	 is	known	about	viral	 load	and	distribution	within	the	organs	of	fatal	cases,	crucial	to	understand	virus	pathogenesis	and	identifying	cellular	and	organ	tropism	of	the	virus.	This	study	was	therefore	undertaken	to	assess	the	extent	of	organ	and	 cell	 involvement	 by	 determining	 EEHV	 presence	 and	 quantity	 in	 numerous	 host	organs	obtained	 from	 fatal	 cases	of	EEHV-1A,	1B,	 and	5	using	a	quantitative	 real-time	qPCR.	 EEHV-1	 and	 5	 DNA	 were	 detectable	 in	 all	 the	 organs	 examined,	 albeit	 with	substantial	differences	in	viral	DNA	load.	The	highest	EEHV-1A	DNA	load	was	observed	in	 the	 liver,	 followed	 by	 the	 heart,	 thymus,	 and	 tongue.	 EEHV-1B	 and	 5	 showed	 the	highest	DNA	 load	 in	 the	heart,	 followed	by	 tongue	and	 liver.	This	 study	provides	new	insights	 into	 EEHV	 pathogenesis	 and	 has	 implications	 in	 choice	 of	 sample	 type	 for	disease	investigation	and	virus	isolation.			
3.1. Introduction	Infections	 with	 viruses	 of	 the	 highly	 ubiquitous	 subfamily	Betaherpesvirinae	 are	 very	common	in	their	natural	mammalian	hosts,	usually	without	producing	overt	symptoms.		Routes	of	viral	 transmission	can	vary	 for	members	of	 the	Betaherpesvirinae	 (Luppi	et	al.,	1994).	Human	Cytomegalovirus	(HCMV)	is	genetically	the	most	closely	related	virus	to	EEHV	with	ortholog	ORF	similarities	ranging	from	32	to	100%	(Wilkie	et	al.,	2013).	Hence,	the	pathogenesis	of	this	virus	serves	as	an	indicator	for	what	might	be	happening	in	elephants	post	EEHV	infection.	
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HCMV	 can	 be	 transmitted	 horizontally	 during	 birth	 by	 direct	 contact	 with	 virus-containing	cervical	or	vaginal	secretions,	by	ingestion	of	breast	milk,	direct	contact	with	saliva,	 urine,	 or	 blood	 products	 or	 upon	 receiving	 transplanted	 tissues,	 as	 well	 as	through	sexual	contact	(Table	3.1)	(Greenberg,	1996).	Besides	the	viruses’	direct	effect	to	cause	pathological	damage	in	a	variety	of	organs	as	a	result	of	viral	replication,	HCMV	is	 also	 associated	with	 indirect	 effects	 that	 are	 consequence	 of	 immune	 responses	 of	persistent	 low-level	 viral	 replication	 and	 are	 responsible	 for	 e.g.	 post-transplantation	organ	 rejection	 and	 cardiovascular	 disease	 (Rubin,	 1989).	 More	 recently,	 excess	mortality	 in	 the	 general	 population	 was	 linked	 to	 chronic	 effects	 of	 this	 virus	 hiding	from	a	competent	immune	response	(Simanek	et	al.,	2011).	Therefore,	HCMV	seems	not	to	be	as	innocuous	as	it	originally	appeared.	Upon	entry	into	permissive	cells,	HCMV	temporally	induces	a	regulated	gene	expression	typically	seen	in	herpesvirus	lytic	infections,	enabling	mechanisms	throughout	the	viral	life	cycle	 to	evade	 the	 immune	system	(Miller-Kittrell	et	al.,	2009;	Boeckh	et	al.,	2011;	Jackson	 et	 al.,	 2011;	 Engel	 et	 al.,	 2012).	 However,	 the	 immune	 response	 of	 healthy	individuals	 can	 still	 effectively	 limit	 the	 disease	 caused	 by	 HCMV,	 although	 the	 virus	persists	subclinically	and	establishes	a	lifelong	latent	infection.	Reactivation	of	the	virus	to	lytic	replication	can	then	again	be	the	source	of	disease	outbreak	(Reeves	et	al.,	2008).		The	 effects	 of	 HCMV	 infection	 in	 immunocompromised	 patients	 (post	 organ-transplantation)	 are	 relatively	 well	 studied,	 whereas	 the	 literature	 available	 on	 the	pathogenic	 mechanisms	 during	 acute	 infections	 in	 immunocompetent	 individuals	 is	limited,	and	the	disease	syndromes	in	chronic	or	latent	infections	are	even	less	known.	The	 diverse	 forms	 of	 pathologies	 associated	 with	 HCMV	 infection	 are	 likely	 to	 be	explained	 by	 the	 broad	 cellular	 tropism	 of	 the	 virus.	 In	 new-borns	 with	 HCMV	 fatal	congenital	 inclusion	 diseases,	 the	 virus	 was	 detectable	 in	 all	 organs	 examined:	 lung,	
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pancreas,	kidney,	liver,	spleen,	adrenal,	small	bowel,	placenta,	brain,	bone	marrow,	and	heart	 (Bissinger	 et	 al.,	 2002;	 Jarvis	 and	 Nelson,	 2007).	 The	 highest	 viral	 loads	 were	found	 in	 lung,	 pancreas,	 kidney,	 and	 liver,	 leading	 to	 end-organ	 diseases	 such	 as	pneumonitis,	 gastrointestinal	 ulceration,	 or	 hepatitis.	 HCMV	 latency	 in	 seropositive	individuals	 was	 found	 to	 target	 monocytes	 and	 T-cells	 derived	 from	 bone	 marrow	(Slobedman	et	a.,	1999)	(Table	3.1).			Human	herpesviruses	6A,	 6B,	 and	7,	 the	 so-called	Roseoloviruses,	 are	 also	part	 of	 the	closely	 related	 subfamily	 of	 Betaherpesvirinae	and	 similarly	 show	 a	 very	 broad	 host	tissue	tropism.	The	viruses	were	found	to	replicate	in	various	cells	in	vitro,	for	example	in	T-lymphocytes,	fibroblasts	(Luca	et	al.,	1990),	natural	killer	cells	(Lusso	et	al.,	1991),	liver	cells	(Cermelli	et	al.,	1996),	epithelial	cells	(Chen	et	al.,	1994),	and	endothelial	cells	(Caruso	et	al.,	2002),	mirrored	by	an	extensive	distribution	in	vivo	were	the	virus	was	detected	in	brain	(Luppi	et	al.,	1994;	Chan	et	al.,	2001;	Donati	et	al.,	2003),	liver	(Ozaki	et	al.,	2001;	 Ishikawa	et	al.,	2002;	Harma	et	al.,	2003),	and	 tonsillar	 tissues	(Roush	et	al.,	2001)	 as	well	 as	 in	 salivary	 glands	 (Fox	 et	 al.,	 1990)	 and	 endothelium	 (Caruso	 et	 al.,	2002).	According	 to	 frequent	detection	of	 the	virus	 in	 the	 salivary	gland,	 this	organ	 is	suspected	to	be	the	site	of	viral	persistence	and	saliva	likely	represents	the	main	route	of	 virus	 transmission	 (Mukai	 et	 al.,	 1994;	 van	 Loon	 et	 al.,	 1995;	 Tanaka-Taya	 et	 al.,	1996).	 In	 addition	 to	 salivary	 gland	 cells,	HHV-6	 latency	has	been	 reported	 to	 include	monocytes	and	macrophages	(Le	Cleach	et	al.,	1998)	whereas	the	cell	range	of	true	HHV-7	latency	has	not	been	clarified	yet	(Frenkel	et	al.,	1990;	Katsafanas	et	al.,	1996)	(Table	
3.1).	 These	 sites	 of	 latency	 differ	 between	 the	 herpesviridae	 subfamilies	 as	
Alphaherpesvirinae	establish	 latency	in	neurons,	while	Gammaherpesvirinae	are	able	to	establish	latency	in	cells	of	the	immune	system,	such	as	B-cells.		
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It	 is	 believed	 that	 three	 central	 factors	 are	 essential	 for	 herpesviruses	 disease	development:	 the	 level	of	viraemia,	 the	viral	 load	 in	 the	affected	organ,	 and	 the	host’s	immune	 pressure.	 It	 can	 therefore	 be	 assumed	 that	 these	 factors	 may	 also	 play	 an	important	role	in	EEHV	infections	and	the	associated	haemorrhagic	disease.	The	general	concept	of	 a	 viral	 load	 threshold	 in	an	affected	organ	upon	 infection	with	a	virus	was	first	described	in	1975	and	was	linked	to	disease	development,	implying	that	a	high	viral	load	in	an	organ	would	increase	the	risk	of	end-organ	damage	(Stagno	et	al.,	1975).	The	organ	 tropism	of	EEHVs,	 the	viral	burden	of	various	organ	 tissues,	and	 the	site	of	EEHV	 latency	 are	 so	 far	 unknown.	However,	 EEHV	pathology	 is	well	 described	 and	 is	often	associated	with	generalised	haemorrhages	and	death	(Richman	et	al.,	2000,	2012),	and	cardiovascular	pathology	appears	 to	be	 the	dominant	 feature	displaying	extensive	haemorrhages	 on	 the	 epi-	 and	 endocardial	 surfaces	 and	myocardium	 and	 pericardial	effusions	 (Richman	 et	 al.,	 2000;	Wilkie	 et	 al.,	 2014).	 Other	 pathological	 attributes	 are	diffuse	 bleedings	 within	 all	 viscera,	 cyanosis	 of	 the	 tongue,	 hepatomegaly,	 oral,	laryngeal,	 and	 large	 intestinal	 ulcers,	 and	 haemorrhages	 in	 other	 internal	 organs.	 The	extent	 of	 gross	 pathological	 findings	 can,	 however,	 vary	 drastically	 depending	 on	 the	duration	 of	 the	 disease.	 Histologically	 detectable	 viral	 inclusion	 bodies	 in	 the	endothelium	of	blood	vessels	(see	Chapter	4,	Fig.	4.2)	suggest	that	EEHV	viruses	infect	endothelial	cells,	but	the	possible	extent	of	their	organ	tropism	is	yet	unknown	(Table	
3.1).		Further,	until	recently	the	viral	sequences	were	not	resolved	and	tools	to	measure	viral	 loads,	 for	 example,	 via	 qPCR	 were	 not	 available.	 This	 chapter	 describes	 the	distribution	and	load	of	EEHV-1	and	5	DNA	in	several	host	organ	samples	of	EEHV-1A,	1B,	 and	 5	 associated	 fatal	 cases	 using	 real-time	 quantitative	 PCRs	 and	 discusses	 the	findings	in	relation	to	the	viruses’	cell	and	organ	tropism.		 	
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Table	 3.1:	 List	 of	 betaherpesviruses,	 their	 natural	 hosts	 and	 cell	 tropism,	 and	 site	 of	
latency	as	well	as	 their	route	of	 transmission.	Although	probosciviruses	 infect	 endothelial	cells,	the	extent	of	their	organ	tropism	is	unknown	and	subject	of	this	study.	
Genus	 Hosts	 Cellular	Tropism	 Latency	 Transmission	
Cytomegalovirus	 Humans;	monkeys	 	Epithelial	cells	of	mucosa	of	various	organs		
	Peripheral	blood	cells,	macrophages	 Body	fluids;	organ	transplants	
Roseoloviruses	 Humans	 T-cells,	B-cells,	monocytes,	macrophages,	epithelial	cells,	natural	killer	cells	 	Salivary	gland		 Respiratory	transmission	Probosciviruses	 Elephants	 Endothelial	cells,	possibly	other	cell	types*	 	NK		 Possibly	Direct	contact	*subject	of	this	study;	NK,	not	known				
3.2. Materials	and	Methods	
3.2.1. Samples	and	Sample	Processing	for	Viral	DNA	Extraction	The	 organ	 samples	 used	 in	 this	 study	 were	 from	 EEHV-1	 and	 5	 fatal	 cases	 of	 Asian	elephants	(Table	3.2),	provided	by	several	UK	zoos.	The	samples	were	either	processed	immediately	after	arrival	at	the	laboratory	or	stored	at	-80°C	prior	to	processing.		Approximately	3-5	mm3	of	 organ	 tissue	 (25	mg)	were	 added	 to	 a	 gentleMACS	M	 tube	(Miltenyi	Biotec	Ltd.	UK)	containing	600	µl	of	buffer	RLT	from	EZ1®	RNA	tissue	mini	kit	(Qiagen,	 Germany).	 The	 tissue	 was	 homogenised	 using	 the	 gentleMACS	 Dissociater	(Miltenyi	Biotec)	set	on	the	RNA_01	program.	The	M	tube	was	then	centrifuged	at	2000	×	 g	 for	 2	 min	 and	 350	 µl	 of	 lysate	 were	 transferred	 to	 a	 2-ml	 screw	 capped	 tube	(supplied	 in	 the	kit)	and	5	µl	 Internal	Control	 [(High	Concentration)	Qiagen,	UK]	were	added.	Total	nucleic	acid	was	extracted	from	the	lysate	using	the	EZ1®	XL	robot	(Qiagen)	
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and	the	EZ1®	RNA	tissue	mini	kit	for	all	organ	tissue	samples.	For	blood	samples,	nucleic	acid	was	extracted	 from	140	µl	whole	EDTA	blood,	plus	6	µl	 IC	 from	the	QuantiFast®	Pathogen	 PCR	 +IC	 kit	 (Qiagen),	 using	 the	 QIAamp®	 Viral	 RNA	 Mini	 Kit	 (Qiagen)	according	to	the	manufacturer’s	protocol.	The	extracted	nucleic	acid	was	quantified	on	a	Nanodrop	2000	Spectrophotometer	(Agilent	Technologies,	UK).	
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	 	Table	3.2:	List	of	elephants	and	their	respective	tissue	sam
ples	used	in	this	study.	
Elephant	nam
e	
D
ate	of	birth	
D
ate	of	death	
Gender	
Viral	strain	
Sam
ples	provided	
R
am
an	
12.11.2006	23.07.2009	Male	EEHV-1A	aorta,	blood,	heart,	kidney,	liver,	lung,	lymph	node,	parotid,	salivary	gland,	spleen,	
tongue	
N
ayan	
18.07.2010	29.07.2013	Male	EEHV-1A	artery,	blood,	heart,	intestine,	kidney,	liver,	lung,	mediastinal	lymph	node,	payer’s	
plaque,	spleen,	thymus,	tongue,	trunk	mucosa	
Jam
ila	
22.01.2011	03.07.2013	Female	EEHV-1A	aorta,	blood,	bone	marrow,	heart,	intestine,	kidney,	liver,	lung,	mesenterial	lymph	
nodes,	spleen,	thymus,	tongue,	trunk	mucosa	
M
ax	
13.10.2013	05.06.2015	Male	EEHV-1A	brain,	cerebellum,	cornea	
Bala	
21.01.2013	14.09.2015	Female	EEHV-1A	brain	
Em
elia	
16.03.2004	17.12.2006	Female	EEHV-1B	heart,	kidney,	liver,	lung,	retropharyngeal	lymph	node,	spleen,	tongue	
Vijay	
06.08.2009	13.04.2011	Male	EEHV-5	
heart,	kidney,	liver,	lung,	lymph	node,	salivary	gland,	spleen,	thyroid	gland,	tongue	
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3.2.2. Creating	PCR	Standards	Four	 conventional	 PCRs	 were	 used	 to	 generate	 DNA	 standards	 for	 EEHV-1A,	 1B,	 5,	 and	elephant	TNFα	in	order	to	quantify	viral	genome	copies	in	various	post	mortal	organ	tissues.	The	primers	used	in	this	study	are	listed	in	Table	3.3.	Each	PCR	was	performed	in	a	reaction	mix	 consisting	 of	 10	µl	 Fast	 Cycling	PCR	Master	mix	 (Qiagen),	 2	 µl	DNA	 template	 (known	EEHV-1	 and	 5	 positive	 nucleic	 acid),	 0.1	 µl	 of	 each	 forward	 and	 reverse	 primers	 (100	pmol/µl)	and	RNase-free	water	to	a	volume	of	20	µl.	The	thermocycling	profile	for	each	PCR	was	95	°C	for	5	min	followed	by	35	cycles	of	95	°C	for	15	s,	55	°C	for	30	s	and	68	°C	for	1	min.	The	PCR	amplicons	were	then	separated	on	an	agarose	gel	(1.5	%)	and	the	DNA	bands	of	the	correct	size	were	cut	out	and	cleaned	using	the	MinElute	Gel	Extraction	Kit	as	described	by	the	manufacturer	 (Qiagen).	 The	 purified	 amplicons	 were	 quantified	 on	 a	 Nanodrop	 2000	Spectrophotometer	 (Agilent	 Technologies),	 DNA	 copy	 numbers	 were	 calculated	 via	 the	fragment	 size	 using	 an	 online	 tool	 (http://cels.uri.edu/gsc/cndna.html)	 as	 per	 formula:	number	of	copies	=	[(amount	in	ng	*	6.022x1023)	/	(DNA	length	in	bp	*	1x109	*	650)],	DNA	concentration	was	adjusted	to	106	copies	in	2	µl	volume	and	a	dilution	series	ranging	from	106	to	101	copies	per	2	µl	was	created	and	run	in	triplicate	in	the	real-time	quantitative	PCR.			
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Table	3.3:	List	of	primers	and	probe	used	to	generate	DNA	standards	for	EEHV-1,	5,	
and	elephant	TNFα.	Accession	numbers	represent	the	sequences	used	to	design	the	primers	and	probe.	
			
3.2.3. Real-time	quantitative	PCR	(qPCR)	Various	organ	samples	of	EEHV-1A,	1B,	and	EEHV-5	 fatalities	 (Table	3.2)	were	quantified	for	 their	 viral	 load	 using	 published	 qPCR	 protocols	 for	 EEHV-1A	 and	 1B	 (Hardman	 et	 al.,	2012).	The	EEHV-5	real	time	qPCR	primers	and	probe	are	listed	in	Table	3.3.	Viral	nucleic	acid	within	each	organ	sample	was	quantified	in	duplicates	for	EEHV-1	and	5,	and	the	mean	values	were	 calculated	 using	 the	MxPro	 (Agilent	 Technologies)	 or	 CFX	Manager	 Software	(Bio-Rad,	UK).	The	qPCR	was	performed	using	the	QuantiFast	Pathogen	PCR	+IC	kit	using	5	µl	 5×	 QuantiFast	 Pathogen	Master	Mix,	 2.5	 µl	 10	 ×	 Internal	 Control	 Assay,	 0.1	 µl	 of	 each	forward	and	reverse	primers	 (100	pM/µl),	0.05	µl	probe	 (100	pM/µl),	2	µl	 template	DNA,	and	 water	 to	 a	 volume	 of	 25	 µl.	 The	 qPCR	 was	 performed	 on	 a	 Mx3000P	 (Agilent	Technologies)	or	a	CFX	96	TouchTM	thermal	cycler	(Bio-Rad)	at	95	°C	for	5	min	followed	by	42	cycles	of	95	°C	for	15	sec,	60	°C	for	30	sec	and	signal	capture	at	the	end	of	each	cycle.	The	
Names Sequence	(5'	to	3') Amplicon	Size Accession	No.EEHV-1_STD_F GAAGCAATCACGTGTCCATG 177	bp NC_020474.2EEHV-1_STD_R TTCATTGACACTGGAATCTGTTEEHV-5_STD_F ACGTAGTCACGAACCCAAAACC 344	bp NC_024696.1EEHV-5_STD_R CCTCGCACACGTATGAGATCACTNFα_STD_F CTACTCCCAGGTCCTCTT 294	bp XM_003422213.1TNFα_STD_R CTACTTTGGGATCATTGCEEHV-5_F GGA	CAG	AGY	TTY	AAT	ATA	TTA	C 115	bp NC_024696.1EEHV-5_R GAA	GAT	ATA	AAT	ATT	ATY	TTG	GCEEHV-5_P Texas	Red-GAC	GAA	TCT	AAC	TTT	ATC	AAG	AAA	GAG	G-BHQ2
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whole	sample	set	of	each	EEHV	strain	 including	standards	was	performed	on	one	of	 the	2	different	qPCR	machines	so	values	can	be	compared	to	each	other.		
3.2.4. Normalisation	of	Viral	Genome	Copy	Numbers	The	genome	copy	numbers	measured	 in	 the	real-time	qPCRs	 for	EEHV	and	genomic	TNFα	were	 first	normalised	against	 the	 spiked	 Internal	Control	 to	 compensate	 for	differences	 in	nucleic	acid	extraction	efficiency	for	each	organ	tissue.	The	EEHV-1	and	5	genome	copies	for	each	 organ	 tissue	 were	 then	 normalised	 against	 those	 of	 genomic	 TNFα,	 performed	 in	parallel,	by	dividing	the	two	quantitative	values,	and	against	1	µg	of	extracted	DNA	after	the	extracted	 nucleic	 acid	 was	 quantified	 on	 a	 Nanodrop	 2000	 Spectrophotometer	 (Agilent	Technologies).			
3.3. Results	
3.3.1. Performance	of	the	real-time	qPCR	assay	In	 order	 to	 assess	 the	 qPCR	 assays	 performance,	 several	 standard	 curves	were	 produced	with	known	quantity	of	DNA	standards	over	a	range	of	106	to	101	copies	per	PCR	mix	(Fig.	
3.1).	 	 At	 least	 2	 independent	 calibration	 curves	 were	 created	 for	 each	 of	 EEHV-1,	 5,	 and	TNFα	 to	 quantify	 their	 genome	 copy	 numbers	 in	 the	 organ	 tissues.	 The	 amplification	efficiency	 was	 on	 average	 99	 %	 (R2=0,999),	 98	 %	 (R2=0,992),	 and	 95	 %	 (R2=0,986)	 for	EEHV-1,	5,	and	TNFα	respectively	(Table	3.4).	The	average	Ct	value	for	the	positive	EEHV-1	control	included	in	each	experiment	was	23	±	0.45	standard	deviation.	
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Figure	3.1:	Representative	graphs	 to	 illustrate	 the	 standard	 curves	used	 to	quantify	
EEHV-1,	 EEHV-5,	 and	 elephant	 TNFα	 genome	 copies	 in	 various	 organ	 samples.	 The	standard	curves	were	created	over	a	dilution	range	of	101	to	106	(shown	on	the	x-axis	as	1	to	6)	 DNA	 copies	 per	 PCR	 reaction	 using	 separate	 samples	 for	 each	 elephant.	 (A)	 EEHV-1A	standard	curves	for	Raman,	Nayan,	and	Jamilia,	(B)	EEHV-1B	standard	curve	for	Emelia,	(C)	EEHV-5	 standard	 curve	 for	 Vijay,	 and	 (D)	 elephant	 genomic	 TNFα	 standard	 curves	 for	 all	tested	elephants.	
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Table	3.4:	Efficiency	of	standard	curve	real-time	qPCRs	for	
EEHV-1A,	 EEHV-1B,	 EEHV-5,	 and	 genomic	 TNFα	
quantification.	
Gene	 Standard	curve	slope	 Efficiency	EEHV-1A	 -3.352	 99%	EEHV-1B	 -3.368	 99%	EEHV-5	 -3.392	 98%	Genomic	TNFα	 -3.471	 95%	
	
	
3.3.2. EEHV-1A	DNA	distribution	and	load	in	various	organ	tissues	EEHV-1A	DNA	was	 detectable	 in	 all	 the	 organs	 tested	 (Table	3.2),	 albeit	with	 substantial	differences	 in	virus	DNA	 load.	 In	a	descending	order,	 liver,	heart,	 thymus,	 tongue,	arteries,	and	blood	samples	contained	the	highest	viral	 loads,	whereas	kidney,	spleen,	 lung,	salivary	gland,	 lymph	 nodes,	 bone	 marrow,	 intestines,	 payer’s	 plague,	 and	 trunk	 mucosa	 had	 the	lowest	(Fig.	3.2	A).	Normalising	the	EEHV	genome	copies	to	those	of	TNFα	(Figure	3.2	A2),	the	three	elephants,	which	died	of	EEHV-1A	infection	(Raman,	Nayan	and	Jamilia),	showed	the	highest	viral	load	in	 the	 liver,	 followed	 by	 heart	 and	 thymus	 (Table	3.5).	 The	 ratio	 of	 normalised	 EEHV-1A	genome	 copies	 for	 the	 liver	 (normalised	 to	 TNFα)	was	 1.7	 (Raman),	 8.6	 (Nayan),	 and	 1.4	(Jamilia)	 folds	 higher	 than	 those	 for	 corresponding	 heart	 tissues.	 Furthermore,	 the	 liver	samples	contained	9.9	(Nayan)	and	7.1	(Jamilia)	times	higher	viral	loads	than	those	for	the	thymus.	There	was	no	thymus	sample	available	from	Raman.	Normalising	 the	EEHV-1A	genome	copy	numbers	 to	1	µg	of	 total	nucleic	 acid,	 liver,	 heart,	and	thymus	were	again	the	organs	with	the	highest	viral	load	(Figure	3.2	A).	Raman	showed	
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the	highest	viral	load	in	the	heart,	1.5	times	higher	than	the	liver.	The	liver	sample	of	Nayan	had	2.5	times	higher	viral	load	than	that	of	the	thymus,	which	in	turn	had	a	2.4	times	higher	loads	than	the	heart	 tissue.	 Jamilia’s	 liver	 tissue	contained	1.5	 times	higher	viral	 load	than	the	heart	and	11.2	times	higher	than	the	thymus.	Overall,	the	highest	viral	load	was	observed	in	 the	heart	 tissue	of	Raman	with	 approximately	8.1	×	106	 virus	 genome	 copies	per	µg	of	extracted	nucleic	acid	(Table	3.5).	
	
3.3.3.	 EEHV-1B	DNA	distribution	and	load	in	various	organ	tissues	EEHV-1B	 DNA	 was	 likewise	 detectable	 in	 all	 the	 tested	 organ	 samples	 (Table	 3.2)	 from	Emelia,	 an	 Asian	 elephant	 known	 to	 have	 succumbed	 to	 EEHV-1B,	 although	 with	considerable	 variation	 in	 virus	 DNA	 load	 (Figure	 3.2	 B).	 Interestingly,	 the	 heart	 tissue	showed	the	highest	viral	DNA	load;	57.6	times	higher	than	that	in	the	liver	tissue	and	30.7	times	 higher	 than	 that	 in	 the	 tongue	 tissue	 (normalised	 to	 those	 of	 TNFα).	 Emelia’s	 heart	tissue	contained	approximately	1.96	×	106	virus	genome	copies	per	µg	of	extracted	nucleic	acid	(Table	3.5).		
3.3.4.	 EEHV-5	DNA	distribution	and	load	in	various	organ	tissues	Various	 organ	 samples	 from	 Vijay,	 a	 juvenile	 Asian	 elephant	 that	 succumbed	 to	 EEHV-5,	were	tested	for	their	viral	load	(Table	3.2).	EEHV-5	DNA	was	detectable	in	all	tested	tissues	with	 heart	 tissue	 holding	 the	 highest	 viral	 load,	 26.4	 times	 higher	 than	 in	 the	 liver	 tissue	sample	and	21.9	 times	higher	 than	 in	 the	 tongue	(normalised	 to	TNFα).	Similar	 trend	was	also	observed	when	the	viral	load	values	were	normalised	to	the	NA	concentration	(Figure	
3.2	C).	The	heart	 tissue	 contained	approximately	9.8	×	105	virus	genome	copies	per	µg	of	extracted	nucleic	acid	(Table	3.5).	
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	 Table	3.5:	EEH
V-1A,	-1B,	and	5	viral	loads	quantified	in	various	organ	tissues	of	associated	fatal	cases	using	real-
tim
e	qPCRs.	The	EEHV	genome	copies	in	each	tissue	were	normalised	to	those	of	elephant	TNFα	genomic	DNA	or	to	1	µg	of	
total	nucleic	acid	from	the	respective	tissues.	(A)	Ratio	of	EEHV	genome	copies	to	those	of	genomic	TNFα	(B)	EEHV	genome	
copies	per	µg	of	total	nucleic	acid	of	the	corresponding	tissue.	The	organ	tissues	with	the	highest	viral	load	are	in	bold.	
	A:	Elephant	name	
(EEHV-1	type)	
EEH
V	D
N
A	(average)	in	various	tissues	norm
alised	to	TN
Fα	D
N
A	
Aorta	Blood	
Heart	
Kidney	
Liver	
Lung	 Lymph	Node	 Spleen	Thymus	Tongue	
Raman	(EEHV-1A)	1.98E+02	1.16E+02	1.11E+03	1.40E+00	
1.86E+03	8.01E+01	8.80E+00	1.10E+02		
no	value	
Nayan	(EEHV-1A)		
5.15E+01	1.83E+03	6.20E+00	
1.58E+04	7.40E+02	1.94E+01	1.77E+02	1.60E+03	4.43E+02	
Jamila	(EEHV-1A)	2.02E+01	2.13E+03	2.55E+04	3.67E+01	
4.06E+04	4.37E+02	4.59E+02	1.42E+03	4.90E+03	3.12E+03	
Emelia	(EEHV-1B)			
		
2.88E+02	1.00E-01	5.00E+00	9.00E-01	8.00E-01	1.30E+00		
2.05E+01	
Vijay	(EEHV-5)	
		
		
3.35E+01	9.64E-04	1.27E+00	5.59E-02	1.04E-01	3.80E-02			
1.53E+00	
	B:	Elephant	name	
(EEHV-1	type)	
EEH
V	D
N
A	(average)	in	various	tissues	norm
alised	to	1ug	total	N
A	
Aorta	Blood	
Heart	Kidney	Liver	
Lung	 Lymph	Node	 Spleen	Thymus	Tongue	
Raman	(EEHV-1A)	4.31E+05	5.58E+05	
8.10E+06	1.17E+04	5.29E+06	4.31E+05	1.41E+05	7.85E+05		
no	value	
Nayan	(EEHV-1A)		
1.83E+04	1.11E+06	5.58E+03	
6.52E+06	5.06E+05	2.08E+04	1.99E+05	2.64E+06	5.59E+04	
Jamila	(EEHV-1A)	8.05E+02	9.57E+04	2.52E+06	1.70E+03	
3.93E+06	2.24E+04	7.40E+04	8.92E+04	3.46E+05	1.21E+05	
Emelia	(EEHV-1B)			
		
1.95E+06	2.29E+03	1.41E+05	4.63E+04	2.64E+04	1.55E+04			
4.54E+05	
Vijay	(EEHV-5)	
		
		
9.84E+05	1.51E+02	1.00E+05	1.07E+04	
-
1.43E+03	9.55E+03			
1.07E+05	
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Figure	3.2	(continued)	
	
1.0E+02 
1.0E+03 
1.0E+04 
1.0E+05 
1.0E+06 
1.0E+07 
vgc		/µg	extracted		NA
various	tissues
A1:	Jamila	EEHV-1A
1.0E+02 
1.0E+03 
1.0E+04 
1.0E+05 
1.0E+06 
1.0E+07 
EEHV/TNF	ratio
various	tissues
A2:	Jamila	EEHV-1A
1.0E+02 
1.0E+03 
1.0E+04 
1.0E+05 
1.0E+06 
1.0E+07 
vgc		/µg	extracted		NA
various	tissues
B:	EmeliaEEHV-1B
1.0E+02 
1.0E+03 
1.0E+04 
1.0E+05 
1.0E+06 
1.0E+07 
vgc		/µg	extracted		NA
various	tissues
C:	VijayEEHV-5
	90	
	
Figure	3.2:	EEH
Vs	viral	loads	detected	in	various	organs	of	fatal	cases.	The	Y	axis	values	represent	the	EEHV	viral	genome	
copy	(vgc)	numbers	normalised	to	1	µg	of	extracted	NA	(A1,	B,	C)	or	to	genomic	TNFα	(A2)	of	the	corresponding	organs	as	
described	in	3.3.2	–	3.3.4.	Viral	load	values	of	Jamila	are	shown	as	a	representative	for	the	EEHV-1A	cases	normalised	to	the	
total	amount	of	extracted	NA	(A1)	and	normalised	to	extracted	TNFα	(A2).	For	Emelia	(EEHV-1B,	B)	and	Vijay	(EEHV-5,	C),	vgc	
numbers	normalised	to	the	amount	of	extracted	NA	are	shown.		
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3.4. Discussion	EEHV	is	considered	ubiquitous	in	Asian	elephant	populations	in	captivity	and	in	the	wild	(Reid	et	al.,	2006;	Hardman	et	al.,	2012;	van	den	Doel	et	al.,	2015).	Once	infected,	the	virus	is	 likely	 to	persist	 for	 the	 lifetime	of	 the	elephant.	Genome	analysis	 indicates	 that	EEHV	has	co-speciated	with	 its	respective	host	over	 the	 last	65	million	years	(Shoshani,	1998;	McGeoch	et	al.,	2000).	This	prolonged	period	of	co-evolution	between	herpesviruses	and	their	host	has	established	a	balanced	adaptation	between	them.	However,	occurrence	of	per-acute	 cases	 in	 juvenile	 elephants	 still	 remain	 unexplained	 as	 it	 contradicts	herpesviruses	 survival	 strategy	 as	 being	 exquisitely	 adapted	 for	 persistence	within	 the	host.	 In	 general,	 the	 host–viral	 relationship	 includes	 a	well-regulated	 viremia	with	 only	limited	malaise.	 However,	 it	 is	 known	 that	 there	 are	 certain	 factors	 that	 can	 cause	 this	benign	relationship	to	fault.	One	reason	could	be	an	introduction	to	a	viral	pathogen	when	the	 immune	 system	 has	 already	 adapted	 a	 different	 quality,	 resulting	 in	 a	 misbalance	between	virus	and	immune	system	leading	to	diseases,	with	Epstein-Barr	virus	(HHV-4)	infections	 presumably	 being	 a	 typical	 example	 (Odumade	 et	 al.,	 2011).	 	 The	 balance	between	 viral	 activity	 and	 immune	 response	 in	 elephants	 could	 also	 be	 disturbed	 by	stress	related	 immunosuppression	as	e.g.	described	 for	herpes	simplex	virus	(Chida	and	Mao,	2009).	In	this	chapter	EEHV	DNA	loads	in	various	organs	of	EEHV-1	and	5	associated	fatal	cases	were	measured	and	viral	DNA	of	varying	amount	was	found	to	be	widely	distributed	in	all	organs	 investigated,	with	 the	 exception	of	 brain	 and	 cornea	 tissue.	 The	pathogenesis	 of	the	acute	EEHV	 infections	could	be	greatly	 influenced	by	 this	apparent	broad	target	cell	range.	 These	findings	are	in	line	with	those	of	HCMV	fatal	congenital	inclusion	disease	in	which	infection	was	observed	in	all	organs	examined;	lung,	pancreas,	kidney,	liver,	spleen,	adrenal,	 small	 bowel,	 placenta,	 brain,	 bone	 marrow,	 and	 heart	 (Bissinger	 et	 al.,	 2002;	
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Jarvis	and	Nelson,	2007).	It	is,	however,	noteworthy	to	highlight	that	no	EEHV-1	DNA	was	detectable	 from	 two	 elephant	 brain	 samples,	 a	 cerebellum,	 and	 a	 cornea	 sample,	made	available	from	two	recent	EEHV-1A	fatalities	(Table	3.2).	Unfortunately,	these	where	the	only	organ	samples	provided	for	these	2	elephant	fatalities	and	viral	loads	to	other	organs	could	not	be	compared.	However,	one	of	these	cases,	Max,	had	reached	a	high	viral	load	of	1.9	 ×107	 vgc/ml	 (see	Chapter	 2)	 in	 the	 systemic	 blood,	 and	 brain	 tissue	was	 negative	despite	the	high	level	of	parallel	peak	viraemia.	Lung,	pancreas,	kidney,	and	liver	were	the	major	 target	 organs	 with	 a	 high	 number	 of	 HCMV	 infected	 cells,	 whereas	 the	 highest	numbers	for	EEHV	DNA	were	found	in	liver,	heart,	thymus,	and	tongue.		Infection	of	endothelial	cells	 is	believed	to	play	a	major	role	 in	the	EEHVs`	pathogenesis	concluding	from	the	extensive	haemorrhages	observed	in	acute	cases.	The	process	of	virus	dissemination,	 following	 an	 EEHV	 infection,	 is	 still	 largely	 unknown.	 However,	considering	the	multitude	of	organs	infected,	the	location	of	endothelial	cells	at	the	border	of	 the	 circulatory	 system	 and	 underlying	 tissues	 could	 provide	 advantages	 for	 virus	dissemination	 via	 blood	 stream	 during	 the	 acute	 stage	 of	 infection.	 Factors	 influencing	viral	 replication	 in	 endothelial	 cells	 may	 also	 contribute	 to	 the	 development	 of	vasculopathy.		Endothelial	cells,	in	addition	to	being	target	cells	in	acute	stages	of	the	disease,	may	also	serve	 as	 site	 of	 virus	 latency,	 as	 suggested	 for	 HCMV.	 In	 the	 case	 of	 HCMV,	 analysis	 of	tissue	samples	from	healthy	individuals	 in	the	absence	of	acute	disease	 identified	HCMV	DNA,	mRNA,	 and	antigen	within	 the	 vessel	walls	 of	major	 arteries	 throughout	 the	body	indicating	a	site	for	HCMV	persistent	or	latent	infection	(Melnick	et	al.,	1983;	Gyorkey	et	al.,	1984;	Yamashiroya	et	al.,	1988;	Hendrix	et	al.,	1997).	Interestingly,	the	most	extensive	studies	of	HCMV	endothelial	cell	tropism	have	focused	on	three	ORFs:	UL128,	UL130,	and	UL131A	(Jarvis	and	Nelson,	2007)	with	the	ortholog	genes	being	absent	in	the	EEHV-1	and	5	genomes.	
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Endothelial	cells	are	a	diverse	cell	type	in	terms	of	morphology	and	growth	(Craig	et	al.,	1998)	 and	determining	 the	biologically	 relevant	 types	of	 the	 cells	 is	 essential	 to	 ensure	their	 overall	 relevance	 in	 EEHV	 biology	 in	 the	 host.	 HCMV	 is	 reported	 to	 infect	preferentially	endothelial	 cells	of	 the	major	blood	vessels	 (Jarvis	and	Nelson,	2007)	and	this	 preference	 of	 certain	 endothelial	 cells	 may	 be	 true	 for	 EEHV	 infections	 alike.	 The	endothelial	cells	of	the	large	myocardial	arteries	and	the	endocardium	are	reported	to	be	more	 severely	 affected	 than	 those	 of	 lung,	 liver,	 kidney,	 urinary	 bladder,	 and	 skeletal	muscle	 in	 the	 fatal	 cases	 of	 EEHVs,	 judged	 by	 numbers	 of	 single	 large	 basophilic	intranuclear	 inclusion	 bodies	 (see	 Chapter	 4,	 Figure	 4.2).	 Whether	 a	 preferential	endothelial	 cell	 feature	 is	 accountable	 for	 the	 differences	 seen	 in	 virus	 load	 in	 various	organs	 has	 yet	 to	 be	 explored.	 The	 notion	 of	 whether	 the	 virus	 can	 infect	 other	 cells	irrespective	 of	 pathology	 also	 exists.	 Considering	 higher	 virus	DNA	 load	 in	 organs	with	moderate	vascularity	such	as	heart	and	liver,	compared	to	lung	(Weiss	et	al.,	1980),	it	can	be	postulated	that	other	cell	types,	similar	to	those	for	HCMV	(Gerna	et	al.,	2002),	are	also	supporting	replication	of	this	virus.	If	this	proves	to	be	correct,	then	cells	such	as	elephant	hepatocytes	and	cardiac	myocytes	may	also	support	in	vitro	replication	of	the	virus.	However,	 whether	 EEHV	 tropism	 to	 certain	 organs	 is	 mostly	 influenced	 by	 a	 more	extensive	vascular	system	or	whether	the	virus	targets	other	cells	in	these	tissues	is	yet	to	be	determined.	A	higher	amount	of	blood	in	a	specific	organ	with	subsequent	detection	of	viral	DNA	could	relate	to	the	animal’s	level	of	viraemia	rather	than	DNA	detected	in	tissue	resident	cells.	In	 HCMV,	 genetic	 variations	 among	 strains	 have	 been	 considered	 the	 basis	 for	 cell	 or	organ	differences	in	viral	tropism	(Gerna	et	al.,	2002).	Whether	similar	genetic	variations	between	 EEHV-1A,	 1B,	 and	 5	 have	 caused	 the	 differences	 in	 liver	 and	 heart	 being	 the	organ	with	 the	 highest	 viral	 load	 in	 EEHV-1A,	 or	 1B	 and	 5,	 respectively,	 remains	 to	 be	identified.	
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Normalising	 the	 EEHV	 copy	 numbers	 to	 either	 those	 of	 genomic	 TNFα	 or	 to	 the	 total	amount	of	extracted	NA,	the	ratios	between	the	different	elephant	organs	were	found	to	vary	 considerably	 and	 appeared	 higher	 in	 organs	 with	 a	 longer	 period	 of	 storage.	However,	 with	 the	 exception	 of	 Raman,	 the	 overall	 trend	 of	maximum	 viral	 load	 being	detected	in	liver	tissues	of	EEHV-1A	infected	elephants	and	heart	of	EEHV-1B	and	EEHV-5	infected	 individuals,	 was	 maintained	 independently	 of	 the	 normalisation	 strategy.	 In	Raman,	both	 liver	and	heart	contained	very	similarly	viral	 loads,	again	 independently	of	the	normalisation	methods.	However,	normalisation	to	TNFα	DNA	resulted	in	a	liver:heart	ratio	of	1.6,	while	the	reverse	effect	of	a	heart:liver	ratio	of	1.5	was	observed	when	viral	load	per	1ug	DNA	was	determined.	Therefore,	 it	 is	 reasonable	 to	believe	 that	 long-term	storage	 has	 instigated	 varying	 degree	 of	 tissue	 degeneration	 affecting	 adversely	 the	genomic	 DNA,	 but	 less	 of	 the	 virus	 DNA,	 potentially	 due	 to	 protection	 provided	 by	 the	capsid.	 It	 should	 also	 be	 taken	 into	 account	 that	 the	 extraction	 efficacy	 of	 genomic	 and	viral	 DNA	might	 vary	 in	 different	 organs	 and	might	 therefore	 be	 partly	 responsible	 for	these	variations.		In	conclusion,	the	qPCR	analysis	applied	here	shows	that	all	organs	examined	from	EEHV	fatality	cases	have	some	level	of	detectable	EEHV	DNA,	except	for	brain,	cerebellum,	and	cornea.	In	addition,	liver	tissue	in	EEHV-1A	and	heart	tissue	in	EEHV-1B	and	5	showed	the	highest	 viral	 DNA	 loads	 compared	 to	 other	 examined	 organ	 tissues.	 Extension	 of	 such	studies	will	 provide	 further	 insights	 into	 pathogenesis	 of	 these	 devastating	 herpesvirus	infections	 of	 elephants.	 The	 studies	 can	 include	 in	 situ	 hybridisation	 and	immunohistochemistry	to	locate	the	virus	DNA	and	antigen	in	the	cells	of	various	organs.		 	
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CHAPTER	4:	EEHV-1	AND	4	CO-INFECTION	IN	A	JUVENILE	CAPTIVE	ASIAN	ELEPHANT	
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Abstract	Elephant	Endotheliotropic	Herpesvirus-1	 (EEHV-1)	 is	 the	most	commonly	detected	sub-strain	 of	 the	 EEHVs	 in	 the	 fatal	 cases	 of	 the	 disease	 in	 Asian	 elephants.	 Therefore,	 it	 is	most	 likely	for	the	suspect	cases	of	the	disease	to	be	tested	for	this	strain	of	EEHV	only.	However,	 other	EEHV	genotypes,	 EEHV-3,	 EEHV-4,	 and	EEHV-5,	 have	 occasionally	 been	reported	to	cause	 fatality	 in	Asian	elephants.	 In	 this	chapter,	a	 fatality	case	of	a	 juvenile	Asian	elephant	in	a	European	zoo	with	clinical	signs	resembling	those	of	EEHV	infections	was	investigated	to	resolve	its	aetiology.		This	fatal	case	of	haemorrhagic	disease	was	diagnosed	to	be	co-infected	with	EEHV-1	and	4.	 Further	 investigations	 revealed	 that	 EEHV-4	 had	 a	 wider	 organ	 distribution	 and	 a	higher	viral	load;	both	viruses	presented	the	highest	load	in	the	mesenteric	lymph	nodes.	Detection	of	EEHV-4	in	this	fatal	case	in	Europe	underlines	the	importance	of	including	all	known	 Asian	 elephant	 endotheliotropic	 herpesviruses	 in	 routine	 blood	 monitoring	 to	achieve	a	comprehensive	diagnostic.	
	
	
4.1. Introduction	EEHV-1	has	been	responsible	 for	 the	majority	of	all	herpes-associated	 fatalities	 in	Asian	elephants	 worldwide.	 Many	 elephant	 holding	 facilities	 have	 therefore	 implemented	 a	routine	screening	of	their	herds	for	EEHV-1.	On	occasions,	other	EEHV	genotypes,	EEHV-3	(Garner	 et	 al.,	 2009),	 EEHV-4	 (Garner	 et	 al.,	 2009;	 Sripiboon	 et	 al.,	 2013),	 and	 EEHV-5	(Denk	et	al.,	2012),	have	caused	deaths	of	Asian	elephants	 in	captivity	as	well	as	 in	 free	raging	animals,	with	no	obvious	differences	in	clinical	appearance.	So	far,	there	are	only	2	reported	 fatalities	 of	 captive	 Asian	 elephants	 by	 EEHV-4,	 one	 in	 a	 zoological	 facility	 in	North	 America	 (Garner	 et	 al.,	 2009)	 and	 one	 in	 Thailand,	 Asia	 (Spiriboon	 et	 al.,	 2013).	EEHV-4	 has	 additionally	 been	 detected	 in	 blood	 samples	 of	 Asian	 and	African	 elephant	
	97		
calves	 in	North	America	and	Asia	without	apparent	clinical	 illness	 (Latimer	et	al.,	2011;	Sariya	et	al.,	2012;	Lertwatcharasarakul	et	al.;	2015	Fuery	et	al.,	2016).	The	virus	has	so	far	not	been	reported	in	Elephants	in	zoological	institutions	in	Europe.		In	 general,	 detection	 of	 more	 than	 one	 herpesvirus	 from	 clinical	 specimens	 is	 not	uncommon.	Co-infections	of	humans	with	herpesviruses	in	the	subfamily	Betaherpesvirinae,	the	 genomically	 closest	 to	 EEHVs,	 have	 been	 reported	 for	 HCMV,	 HHV-6A,	 HHV-6B,	 and	HHV-7	 (Ahmed	 et	 al.,	 2014;	 Tang	 et	 al.,	 1997;	 Fillatre	 et	 al.,	 2013).	 In	 Asian	 and	African	elephants,	co-infections	with	EEHVs	and	elephant	gammaherpesviruses	(EGHVs),	as	well	as	co-infections	with	several	EGHVs	have	also	been	described	(Latimer	et	al.,	2011).		Further,	sequential	infections	with	the	two	subtypes	of	EEHV-1	(EEHV-1A	and	EEHV-1B)	have	also	been	reported	recently	(Stanton	et	al.,	2013),	indicating	lack	of	cross	protective	immunity.	New	genetic	studies	revealed	that	EEHV-4	is	about	28	kb	larger	than	the	other	EEHV	strains	with	core	genes	differing	about	40	to	50%	in	their	amino-acid	composition	from	 those	 of	 EEHV-1	 (Long	 et	 al.,	 2015).	 	 This	 genetic	 variation	 suggests	 that	simultaneous	 infections	are	even	more	 likely	 to	occur	and	 that	 there	will	not	be	a	cross	protective	immunity	between	these	two	EEHV	strains.	However,	so	far	there	has	been	no	report	of	simultaneously	detectable	EEHVs	from	disease	incidences.	 Co-infections	 with	 different	 strains	 of	 other	 herpesviruses	 have	 shown	 to	increase	 the	 risks	 of	 disease	 development	 (Chapenco	 et	 al.,	 2000),	 which	 led	 to	 the	assumption	 that	 co-infections	with	different	EEHVs	 in	 elephant	 calves	might	pose	even	a	greater	threat	to	their	survival.	This	chapter	investigates	a	historic	 fatal	case	of	a	 juvenile	Asian	elephant	that	died	of	an	unknown	cause	in	a	European	zoo.			 	
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Disease	history:	A	 fatal	 case	of	EEHV-1A	 infection	 in	a	 two-year-old	male	Asian	elephant	at	Copenhagen	Zoo	in	November	2014	led	to	renewed	investigation	into	a	previous	fatality	in	2003	due	to	similarity	in	symptoms	and	pathological	findings.	All	clinical	and	pathological	analyses	of	this	case	were	provided	by	the	Copenhagen	zoo	veterinarians.	The	 fatal	 case	 from	 2003,	 another	 two-year-old	 male	 Asian	 elephant	 named	 Punjab,	housed	at	the	zoo	along	with	six	other	Asian	elephants,	showed	signs	of	mild	depression	and	 lethargy	on	the	4th	of	October	2003.	The	animal	was	not	 trained	well	enough	to	be	tractable,	and	a	cursory	clinical	examination	did	not	reveal	any	significant	abnormalities.	The	 elephant	 remained	 mildly	 lethargic	 the	 following	 day,	 and	 a	 single	 intramuscular	injection	 of	 Benzylpenicillin	 and	 Streptomycin	 (Tardomyocel®)	was	 administered,	 as	 a	bacterial	 cause	 could	 not	 be	 ruled	 out.	 On	 day	 three,	 the	 animal	 was	 seen	 alive	 on	surveillance	cameras	at	06.48	a.m.,	but	found	dead	at	07.15	a.m.	At	necropsy,	pathological	findings	revealed	severe	vascular	damage	reminiscent	of	those	described	previously	for	fatal	cases	of	EEHV	infections	(Garner	et	al.,	2009;	Wilkie	et	al.,	2014).	The	most	significant	gross	pathological	findings,	reported	by	the	zoo	veterinarian,	included	 5-10	 L	 of	 sero-haemorrhagic	 fluid	 in	 the	 abdomen,	 diffuse	 petechial	haemorrhages	and	extensive	oedema	of	all	visceral	serosae,	multiple	haemorrhages	in	the	heart	and	liver	as	well	as	well-defined	haemorrhagic	lesions	throughout	the	renal	papillae	and	adrenal	cortex	(Fig.	4.1).	The	small	intestine	contained	fluid	ingesta	intermixed	with	blood,	 and	 extensive	 punctuate	 ulcerations	 (Ø	 5-20mm).	 The	 ulcers,	 primarily	 co-localizing	 with	 the	 Peyer’s	 patches,	 were	 present	 particularly	 throughout	 the	 caudal	aspects	of	the	small	intestinal	mucosa.	The	mucosa	of	the	large	intestine	was	oedematous,	dull,	and	showed	generalized	dark	reddening.			
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Figure	4.1.	Gross	pathological	findings	in	the	EEHV-1	and	4	co-infection	fatality.		A	historic	case	of	unexplained	death	in	an	elephant	was	re-examined	for	EEHV	infection.	The	 following	gross	pathological	 findings	had	been	recorded	at	necropsy:	 (a)	Mucosa	of	ileum	showing	necrotic	lesions	(5-20mm	Ø)	and	bloody	intestinal	contents.	(b)	Mucosa	of	the	 large	 intestine	 showing	 oedema	 and	 haemorrhage.	 (c)	 Kidney	 showing	 marked	haemorrhages	 in	 the	 renal	 papillae.	 (d)	 Adrenal	 gland	 showing	 severe	 cortical	haemorrhages.	All	images	were	provided	by	the	Copenhagen	zoo	veterinarians.				 	
a	
c	 d	
b	
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Histopathological	 examination	 of	 the	 tissues,	 performed	 by	 the	 zoo	 veterinarians,	confirmed	widespread	 haemorrhages	 throughout	 all	 organs	 and	 severe	 small	 intestinal	and	 colonic	 submucosal	 oedema.	 The	 small	 intestine	 showed	 mild	 to	 moderate	submucosal	 haemorrhage	 and	 within	 the	 small	 intestinal	 crypts,	 mitotic	 activity	 was	judged	to	be	very	low	(<1	mitotic	figure/10	crypts).	Peyer’s	patches	were	reduced	in	size	and	 showed	 central	 necrosis	 of	 the	 peripheral	 follicles	 as	 well	 as	 marked	 interstitial	haemorrhage.	 The	 overlying	 epithelium	 was	 intact	 but	 had	 collapsed	 into	 the	 space	created	 by	 the	 reduced	 size	 of	 the	 Peyer’s	 patches.	 In	 the	 colon,	 mild	 heterophilic	infiltration	was	seen	 in	 the	 lamina	propria,	associated	with	moderate	 to	severe	mucosal	haemorrhage.		The	 endothelial	 cells	 of	 the	 large	 myocardial	 arteries	 and	 the	 endocardium	 had	remarkably	high	numbers	of	single	 large	basophilic	 intranuclear	 inclusion	bodies	 (up	 to	20	 per	 high	 power	 field)	 (Fig.	 4.2).	 Varying	 degrees	 of	 similarly	 looking	 but	 scattered	inclusions	were	 also	 present	 in	 arteries	 of	 the	 lung,	 liver,	 kidney,	 urinary	 bladder,	 and	skeletal	 muscle.	 Mild	 endarteritis	 with	 sloughing	 of	 endothelial	 cells	 and	 cellular	infiltrates	consisting	of	lymphocytes	and	heterophils	(in	elephants,	neutrophils	are	more	accurately	 described	 as	 heterophils	 because	 of	 the	 presence	 of	 reddish	 cytoplasmic	granules),	 some	 of	 which	were	 necrotic,	 was	 also	 seen	 in	 the	 same	 locations.	 Bacterial	culture	 of	 the	 intestinal	 mucosa	 and	 faeces,	 as	 well	 as	 of	 all	 major	 organs,	 was	unremarkable.		 				
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Figure	 4.2.	 Histo-pathological	 findings	 in	 myocardial	 blood	 vessels	 of	 the	 historical	
EEHV-1	and	4	co-infection	fatality.		Histological	 detail	 of	 a	 large	 myocardial	 blood	 vessel	 (provided	 by	 the	 Copenhagen	 zoo	veterinarians).	 The	majority	 of	 endothelial	 cells	 show	 round	 nuclei	with	 a	 large	 basophilic	intranuclear	inclusion	body	(arrow).	Scale	bar	=	100µm.			
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4.2. Materials	and	Methods	
4.2.1. Animal	and	samples	The	organ	samples	used	in	this	study	included	the	adrenal	gland,	heart,	ileum,	mesenteric	lymph	node,	pulmonary	lymph	node,	lung,	spleen,	testicle,	and	thymus,	and	were	obtained	from	 a	 fatal	 case	 of	 an	 Asian	 elephant	 housed	 at	 the	 Copenhagen	 Zoo	 (Denmark)	 that	succumbed	 in	2003	to	unknown	reasons.	The	tissues	were	stored	at	 -20	 ˚C	on	site	 for	12	years	before	being	analysed	for	EEHV	infection	at	the	APHA.	For	further	analysis	of	potential	EEHV	co-infections,	stored	organ	samples	from	five	Asian	elephants	from	various	European	zoos	(one	from	the	same	facility)	were	tested	for	EEHV-1,	3/4,	 and	 5,	 including	 adrenal	 gland,	 blood,	 brain,	 caecum,	 colon,	 conjunctiva,	 duodenum,	heart,	ileum,	jejunum,	kidney,	liver,	lung,	lymph	nodes,	palate,	pancreas,	spleen,	and	thymus	samples	(Table	4.3).		
4.2.2. DNA	extraction,	diagnostic	PCR,	and	phylogenetic	analysis	DNA	from	the	various	organ	samples	was	extracted	using	the	EZ1®	RNA	tissue	mini	kit	on	the	EZ1®	XL	robot	(QIAGEN)	as	per	manufacturer’s	protocol.	The	various	organ	samples	from	all	elephants	included	in	this	study	were	tested	for	EEHV-1,	3/4,	and	5	using	simplex	real-time	quantitative	PCR	(qPCR)	assays	developed	as	part	of	other	projects	(Hardman	et	al.,	2012;	Jonathan	Haycock,	personal	communication).	The	qPCR	mix	and	the	primers	and	probes	for	EEHV-1	and	5	were	the	same	as	described	in	Chapter	3	(3.2.3).	The	primers	and	probes	for	EEHV-3/4,	which	then	only	can	be	distinguished	via	sequencing,	were	as	follows:	 forward:	 GAT	 CCT	 GAA	 TGT	 CAT	 CTC;	 reverse:	 GGC	 TTA	 TGT	 AAT	 CGG	 TAG;	probe:	CY5-ACG	TGT	GCG	AGG	AGC	ACT	TAT	AT-BHQ2;		To	verify	the	results	of	the	EEHV-1	and	3/4	real	time	qPCRs	and	to	obtain	DNA	sequences	for	 virus	 characterisation,	 several	 primer	 sets	 were	 developed	 for	 use	 in	 conventional	PCRs	to	detect	gene	sequences	of	the	DNA	polymerase	(U38),	glycoprotein	M	(gM;	U72),	
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the	 DNA	 replication	 origin-binding	 helicase	 (U73)	 for	 EEHV-3/4,	 and	 gM	 and	 U73	 for	EEHV-1A	 (Table	4.1).	 The	 primers	 used	 for	 EEHV-1A	DNA	polymerase	were	 published	before	 (Stanton	 et	 al.,	 2013).	 DNA	 sequencing	 of	 these	 conventional	 PCR	 amplicons	derived	 from	 lung	 and	 heart	 tissue	 samples	 was	 carried	 out	 by	 the	 APHA	 central	sequencing	unit	using	an	ABI	3130xL	16	capillary	genetic	analyser	(Applied	Biosystems).	The	SeqMan	pro	software	(DNASTAR,	 inc.)	was	used	to	analyse	sequence	traces	and	the	consensus	sequences	were	screened	against	GenBank	entries	using	the	NCBI	BLAST	tool	(http://blast.ncbi.nlm.nih.gov/Blast.cgi).	 DNA	 extracted	 from	 the	 tissues	 was	 also	extracted	 for	 Next	 Generation	 Sequencing	 (NGS)	 at	 the	 APHA	 central	 sequencing	 unit	using	 a	 Nextera	 XT	 kit	 (Illumina)	 and	 paired	 end	 sequencing	 was	 performed	 on	 an	Illumina	 MiSeq.	 The	 sequences’	 reads	 were	 then	 mapped	 to	 the	 reference	 EEHV-1A	Raman	 strain	 (accession	 number	 KC462165.1)	 and	 several	 EEHV-3/4	 sequences	 in	 the	GenBank	using	the	SeqMan	NGen	software	(DNASTAR).		For	phylogenetic	analysis,	 the	obtained	gene	segment	sequences	of	DNA	polymerase	 for	EEHV-1A	 and	 EEHV-4,	 and	 glycoprotein	 M	 and	 U73	 for	 EEHV-4,	 were	 aligned	 with	corresponding	 sequences	 of	 other	 EEHV	 strains	 from	 GenBank	 using	 the	 MegAlign	software	 (DNASTAR).	 Phylogenetic	 trees	 were	 then	 generated	 using	 neighbour-joining	method	 implemented	 in	 the	MEGA5	 program	 (Tamura	 et	 al.,	 2011)	 (Figures	 4.3).	The	nucleotide	sequences	of	the	EEHV-strains	from	this	study	were	submitted	to	the	GenBank	database.		
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Table	4.1:	List	of	primers	used	to	verify	 the	real-time	qPCR	results	by	sequencing	and	
for	phylogenetic	analysis.		Primer	Name	 Sequence	5’	to	3’	 Primer	Source	 Amplicon	Size	 Accession	No.	EEHV-1A_DNA	POL_F	 GAA	GCA	ATC	ACG	TGT	CCA	TG	 Stanton	et	al.,	2013	 201	bp	 KT381607	EEHV-1A_DNA	POL_R	 TTC	ATT	GAC	ACT	GGA	ATC	TGT	T	 this	study	 	 	EEHV-1A_gM_F	 CGT	ATC	CAC	TTG	TTA	CAT	CTCC	 this	study	 118	 	EEHV-1A_gM_R	 AAC	TTC	TTC	TTC	ATC	GTC	GTC	 this	study	 	 	EEHV-1A_U73_F	 TTC	ATA	AAC	TCT	CTG	TGC	TGT	C	 this	study	 99	bp	 	EEHV-1A_U73_R	 TAC	TGT	CCC	TCT	GTC	TCT	CC	 this	study	 	 	EEHV-4_DNA	POL_F	 GAT	CCT	GAA	TGT	CAT	CTC	 this	study	 301	bp	 	EEHV-4_DNA	POL_R	 GGC	TTA	TGT	AAT	CGG	TAG	 this	study	 	 	EEHV-4_	gM_F	 ATC	TTC	CTG	CTC	CTG	TTC	C	 this	study	 303	bp	 	EEHV-4_	gM_R	 TCT	TCT	TCC	TCG	TCG	TCT	C	 this	study	 	 	EEHV-4_U73_F	 GGG	TTC	AAC	AAC	AAC	GAC	AG	 this	study	 262	bp	 	EEHV-4_U73_R	 ATG	ATG	TGG	TTC	CCG	GTC	AG	 this	study	 	 	
	
	
4.2.3. Screening	for	EEHV	co-infections	in	organ	samples	of	EEHV	infected	elephants		Respective	organ	samples	of	Punjab	as	well	5	additional	Asian	elephants	 (see	Table	4.3)	were	 screened	 for	 EEHV	 1A,	 EEHV	 1B,	 EEHV3/4,	 and	 EEHV5	 to	 look	 for	 potential	 co-infections	 in	 any	 of	 the	 provided	 tissues.	 Viral	 load	 for	 the	 identified	 monotypic	 EEHV	infections	 in	 post	 mortem	 collected	 organs	 of	 Raman,	 Nayan,	 Emelia,	 and	 Vijay	 are	presented	in	Chapter	3.		
	
4.2.4. Measurement	of	viral	loads	EEHV-1A	 viral	 loads	 in	 the	 tissues	 of	 Punjab	were	 quantified	 as	 described	 in	
Chapter	 3	 (3.2).	 A	 new	 DNA	 standard	 was	 generated	 for	 EEHV-4	 DNA	 as	described	 before	 with	 primers	 forward:	 TGG	 GCT	 TAT	 GTA	 ATC	 GGT	 AGC;	reverse:	CGT	GTG	CGA	GGA	GCA	CTT	ATA	T.	This	 standard	was	 then	used	 for	
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quantification	of	the	EEHV-4	viral	load	in	the	different	tissue	samples.	The	viral	genome	 copy	 numbers	 for	 EEHV-1A	 and	 4	 from	 each	 tissue	 were	 then	normalised	to	1	µg	of	extracted	total	nucleic	acid	as	described	before.		
4.3. Results	
4.3.1. qPCR,	EEHV	genotypes,	and	phylogenetic	analysis	The	 viral	 genotypes	 detected	 in	 the	 organs	 of	 the	 case	 under	 study	 were	 identified	 as	EEHV-1A	 and	 EEHV-4	 by	 strain	 specific	 qPCR	 and	 DNA	 sequencing	 of	 PCR	 amplicons	generated	 from	 lung	 and	 heart	 samples.	 The	 BLAST	 search	 of	 201	 nucleotides	 of	 the	EEHV-1A	PCR	amplicon	of	the	DNA	polymerase	gene	(accession	no.	KT381607)	confirmed	the	highest	similarity	(100%)	to	the	DNA	polymerase	gene	(U38)	of	the	reference	EEHV-1A	Raman	strain	and	several	other	EEHV-1A	strains	 in	 the	GenBank,	a	 few	of	which	are	included	 in	 the	phylogenetic	analysis	shown	 in	Figure	4.3A.	 Sequences	of	other	shorter	genome	segments,	which	were	additionally	generated	 through	NGS	 from	 total	 extracted	DNA,	 also	 showed	 the	 highest	 similarity	 to	 EEHV-1A,	 corresponding	 to	 the	 reference	Raman	strain	nucleotides	29,539-29,638	 (U73,	DNA	replication	origin-binding	helicase),	and	31,935-32,053	(U72,	envelope	glycoprotein	M).	Nucleotide	sequences	of	the	EEHV-4,	also	generated	through	NGS	in	addition	to	the	PCR	amplicon	sequence,	DNA	polymerase	(U38,	 301bp)	 (Figure	 4.3A),	 glycoprotein	 M	 (U72,	 303bp)	 (Figure	 4.3B),	 and	 DNA	replication	 origin-binding	 helicase	 (U73,	 262bp)	 (Figure	 4.3C)	 genes’	 segments	(accession	no.	KT334336-8)	were	identical	to	corresponding	sequences	of	EEHV-4	strains	from	 North	 America	 (accession	 no.	 JN983096.1,	 EU658934,	 and	 JN983097.2),	 and	clustered	with	the	reported	EEHV-4	sequences	in	the	phylogenetic	analysis	(Figure	4.3).				
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A:	
	
	
B:	
	
Figure	4.3	(continued)	
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		C:	
	
Figure	 4.3:	 Phylogenetic	 analyses	 of	 three	 different	 gene	 segments	 of	 various	
elephants	to	identify	the	causative	EEHV	strain	of	a	historic	EEHV	fatality.		Sequences	 obtained	 for	 three	 different	 gene	 segments	 from	 the	 EEHV-1A	 and	 4	 co-infection	 case	 Punjab	 were	 compared	 to	 published	 EEHV	 strains	 by	 phylogenetic	analysis	using	either	SeqMan	pro	software	for	PCR	amplicon	consensus	sequences	and	additionally	 SeqMan	NGen	 software	 (DNASTAR)	 for	 sequence	 reads	obtained	by	NGS	sequencing.	 The	 sequences	 established	 from	Punjab	 are	 highlighted	 in	 red,	while	 the	other	 sequences	 were	 obtained	 from	 GenBank.	 The	 scale	 bar	 represents	 number	 of	substitutions	for	a	unit	branch	length.	A:	DNA	Polymerase	(U38)	sequences	of	various	EEHV	strains	found	in	Asian	elephants	including	sequences	of	EEHV-1A	(accession	no.	KT381607)	 and	 EEHV-4	 (accession	 no.	 KT334336)	 from	 Punjab.	 B:	 Glycoprotein	 M	(gM)	 sequences	 of	 various	 EEHV	 strains	 found	 in	 Asian	 elephants	 including	 the	sequence	of	EEHV-4	from	Punjab	case	(accession	no.	KT334337).	C:	U73	sequences	of	various	EEHV	strains	found	in	Asian	elephants	including	the	sequence	of	EEHV-4	from	Punjab	case	(accession	no.	KT334338).	Phylogenetic	analysis	confirmed	data	obtained	by	qPCR	assay	that	the	elephant	was	co-infected	with	strains	of	EEHV-1A	and	EEHV-4.		
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4.3.2. Viral	organ	distribution	Using	 the	 respective	qPCR	assays,	EEHV-1A	DNA	was	only	detectable	 in	 the	heart,	 lung,	mesenteric	 lymph	 node,	 and	 spleen,	 whereas	 EEHV-4	 DNA	was	 detectable	 in	 all	 organ	samples	tested	(adrenal	gland,	heart,	ileum,	lung,	mesenteric	and	pulmonary	lymph	nodes,	spleen,	testicle	and	thymus)	(Table	4.2).	The	highest	number	of	EEHV-4	viral	genome	copies	(vgc),	normalised	to	total	nucleic	acid,	was	found	in	the	mesenteric	lymph	node	(3.38	×	108	vgc/µg	nucleic	acid),	followed	by	the	adrenal	gland,	lung,	spleen,	and	heart	(Table	4.2).	EEHV-1A	viral	loads	appeared	to	be	far	lower	than	those	of	EEHV-4.	The	highest	viral	 load	was	detected	in	the	mesenteric	 lymph	node	(2.02	×	104	vgc/µg	nucleic	acid),	followed	by	heart	and	lung,	however	the	differences	in	viral	load	of	lymph	node	and	heart	were	negligible	(2.02	×	104	vgc/µg	compared	to	1.22	×	104	vgc/µg).	 Irrespective	of	 the	tissues	tested,	 the	viral	 load	 for	EEHV-4	was	between	1.3	and	16,600	times	higher	than	those	for	EEHV-1A,	except	in	the	heart	tissue,	where	the	viral	load	for	both	strains	was	almost	equal,	only	a	negligible	difference	of	0,12	×	104	vgc/µg	of	extracted	nucleic	acid.	The	EEHV-1A	load	was	also	on	average	between	42	and	6,600	times	lower	than	those	previously	determined	in	corresponding	organs	of	other	EEHV-1	fatalities	(see	Chapter	3,	Table	3.5).				
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Table	4.2.	Viral	load	of	respective	EEHV	strains	in	selected	organs	from	an	elephant	
fatality	 co-infected	with	 two	different	 strains.	 	 EEHV-1A	 and	 4	 viral	 genome	 copies,	averaged	 from	 3	 PCR	 replicates,	 in	 various	 tissues	 of	 the	 Punjab	 case	 using	 qPCR.	 The	values	are	normalized	 to	1μg	of	 total	nucleic	 acid	extracted	 from	 the	 respective	 tissues.	The	organ	tissues	with	the	highest	viral	load	are	in	bold.	Strain		 Adrenal	 Heart	 Ileum	 LN*	 LN†	 Lung	 Spleen	 Testicle	 Thymus	EEHV-1A	 ND	 1.2E+04	 ND	 2.0E+04	 ND	 7.5E+03	 5.4E+01	 ND	 ND	EEHV-4	 2.8E+05	 1.1E+04	 1.6E+04	 3.4E+08	 5.7E+03	 5.0E+04	 1.2E+04	 8.0E+03	 4.1E+01	*Mesenteric	lymph	node.	†Pulmonary	lymph	node.	ND,	No	EEHV-1	DNA	detectable.			
4.3.3. Screening	for	EEHV	co-infections	in	tissues	of	other	EEHV	infected	elephants	Stored	organ	tissues	from	5	other	fatal	EEHV	cases	in	Asian	elephants	were	screened	by	qPCR	 for	potential	 co-infections	with	other	EEHV	strains.	For	each	case,	only	one	EEHV	strain	was	detected	in	all	organ	samples	tested.	The	elephants	tested	and	the	EEHV	strain	detected	are	 summarised	 in	Table	4.3.	 The	analysis	of	 the	viral	 loads	 for	 the	 identified	monotypic	EEHV	 infections	 in	 the	respective	organs	of	Raman,	Nayan,	Emelia,	and	Vijay	are	presented	in	Chapter	3.		
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	 Table	4.3:	List	of	five	fatal	EEH
V	cases	in	juvenile	Asian	elephants	tested	for	potential	EEH
V	co-infections	using	individual	qPCRs	
for	EEH
V-1,	EEH
V-3/4,	and	EEH
V-5.	No	animal	tested	positive	for	more	than	one	viral	strain.	
Elephant	N
am
e	
D
ate	of	D
eath	
Gender	
Viral	Strain	D
etected	
O
rgan	tissues	tested	
Ram
an	
23.07.2009	Male	
EEHV-1A	
aorta,	blood,	heart,	kidney,	liver,	lung,	lymph	node,	parotid,	salivary	
gland,	spleen,	tongue	
N
ayan	
29.07.2013	Male	
EEHV-1A	
artery,	blood,	heart,	intestine,	kidney,	liver,	lung,	mediastinal	lymph	
node,	payer’s	plaque,	spleen,	thymus,	tongue,	trunk	mucosa	
K
ao	Sok*	
24.11.2014	Male	
EEHV-1A	
adrenal	gland,	blood,	brain,	caecum,	colon,	conjunctiva,	duodenum,	
heart,	ileum,	jejunum,	kidney,	liver,	lung,	large	intestinal	lymph	node,	
palate,	pancreas,	spleen,	thymus	
Em
elia	
17.12.2006	Female	EEHV-1B	
heart,	kidney,	liver,	lung,	retropharyngeal	lymph	node,	spleen,	
tongue	
Vijay	
13.04.2011	Male	
EEHV-5	
heart,	kidney,	liver,	lung,	lymph	node,	salivary	gland,	spleen,	thyroid	
gland,	tongue	
*Kao	Sok	was	an	Asian	elephant	from	the	same	facility	as	Punjab,	the	co-infection	case.
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4.4. Discussion	The	clinical	picture	as	well	as	the	pathological	findings	of	the	EEHV-1A	and	4	co-infection	in	the	case	reported	here	were	overall	similar	to	those	described	for	fatalities	caused	by	EEHV-1,	 3,	 and	 5	 (Garner	 et	 al.,	 2009;	 Wilkie	 et	 al.,	 2014).	 However,	 characteristic	endothelial	 herpesvirus	 inclusions	 were	 unusually	 prevalent,	 particularly	 in	 the	 larger	vessels	of	the	myocardium,	and	the	amount	of	haemorrhage	in	the	intestinal	mucosa	and	the	presence	of	whole	blood	in	the	ingesta	have	not	been	described	in	this	manner	before.	Interestingly,	 very	 low	mitotic	 activity	was	 observed	 in	 the	 intestinal	 crypts	 along	with	central	lymphoid	necrosis	of	the	Peyer’s	patches,	suggesting	a	radiomimetic	effect,	which	has	not	been	previously	reported	in	EEHV	fatalities.	The	mesenteric	lymph	node,	bearing	the	 highest	 viral	 loads	 detectable	 for	 both	EEHV	 strains	 in	 this	 case,	was	 not	 examined	specifically	 at	 the	 time	 of	 death	 of	 the	 elephant,	 and	 therefore	 particular	 gross	pathological	 observations	 are	 missing.	 However,	 the	 high	 viral	 burden	 coinciding	 with	pathological	changes	could	indicate	the	intestinal	tract	lymph	tissues	to	be	a	site	for	initial	replication	of	the	virus	or	latency.	Stanton	et	al.	 (2013)	have	previously	 suggested	 the	possibility	of	 concurrent	 subclinical	infections	of	elephants	with	different	EEHV	strains.	The	data	presented	here	provides	the	first	 evidence	 of	 simultaneous	 infection	 of	 an	Asian	 elephant	with	 two	 strains	 of	 EEHV.	Testing	 of	 tissues	 from	 other	 fatal	 incidences	 of	 EEHV	 infections	 did	 not	 revealed	 any	further	 EEHV	 co-infection,	 including	 tissues	 of	 another	 fatality	 from	 the	 same	 zoo.	However,	it	is	still	of	considerable	value	to	screen	elephants	for	multiple	EEHVs,	both	for	routine	monitoring	and	disease	investigation.		EEHV-1A	and	EEHV-4	are	genetically	highly	diverse	with	EEHV-1A	falling	into	the	AT-rich	branch	 of	 EEHVs,	 43%	 GC	 content,	 and	 EEHV-4	 into	 the	 GC-rich	 branch	 with	 55%	 GC	content.	The	two	strains	only	share	40%	to	50%	identity	at	the	amino	acid	level	(Zong	et	
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al.,	 2014).	The	partial	 gene	 sequences	used	 for	phylogenetic	 analysis	of	 the	 co-infection	EEHV	 strains	 yielded	 the	 best	 results	when	 generated	 through	NGS.	 The	 sequences	 for	EEHV-4	obtained	 in	 this	 study	 further	highlight	 the	 genetic	divergence	of	EEHV-1A	and	EEHV-4	 (Figures	 4.3).	 Further	 studies	 are	 warranted	 to	 obtain	 additional	 sequences,	either	 from	several	genes	or	 full	genome,	 to	resolve	genetic	diversity	of	EEHV-4	viruses	found	in	different	facilities,	as	suggested	for	EEHV-1	(Zong	et	al.,	2008,	2009;	Long	et	al.,	2015).	 This	 should	 also	 help	 in	 a	more	 robust	 EEHV-4	 phylogeny	 and	 in	 exploring	 the	existence	of	EEHV-4	sub-species.	So	 far,	 only	 a	 very	 small	 number	 of	 EEHV-4	 infections	 have	 been	 identified	 with	most	cases	 being	 non-lethal	 despite	 detectable	 viraemia.	 However,	 it	 still	 needs	 to	 be	established	whether	EEHV-4	is	truly	 less	prevalent	and/or	pathogenic,	or	whether	these	numbers	simply	reflect	the	lower	frequency	of	testing	for	that	strain.		EEHV-4	 was	 previously	 described	 to	 have	 a	 less	 selective	 organ	 tropism	 compared	 to	other	EEHV	strains	(Garner	et	al.,	2009;	Spiriboon	et	al.,	2013).	In	this	fatal	case,	EEHV-4	was	detectable	in	all	the	tested	organs	in	contrast	to	EEHV-1A,	which	was	only	found	in	a	few.	 The	 by	 far	 highest	 EEHV-4	 load	was	 detected	 in	 the	mesenteric	 lymph	 node,	 then	followed	by	the	adrenal	gland,	and	the	lung,	ileum,	spleen,	and	heart.	The	findings	described	in	chapter	3	clearly	showed	that	EEHV-1A	is	also	detectable	in	all	the	 organ	 tissues	 tested	 in	 cases	 of	 single	 EEHV-1A	 infections.	 	 Furthermore,	 those	investigations	also	highlighted	the	highest	viral	EEHV-1A	load	to	be	present	 in	 liver	and	heart	tissues	of	elephants	succumbing	to	the	disease,	whereas	in	this	co-infection	fatality	the	mesenteric	lymph	node	contained	the	highest	EEHV-1A	load.		However,	liver	samples	were	 unfortunately	 not	 available	 for	 this	 historic	 case	 of	 fatal	 EEHV	 infection	 and	 viral	loads	 in	 heart	 and	 mesenteric	 lymph	 node	 for	 EEHV-1A	 were	 comparable.	 In	 other	
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investigated	 EEHV	 fatalities,	 only	 Jamila	 had	mesenteric	 lymph	 node	 samples	 collected	with	a	viral	load	of	7.40	×	104	(see	Chapter	3,	Table	3.2	and	Table	3.5).	Here,	viral	load	in	mesenteric	lymph	nodes	was	2.02	×	104,	suggesting	that	mesenteric	lymph	node	might	represent	another	organ	preferentially	targeted	by	EEHV-1.		Additionally,	the	viral	load	of	EEHV-4	 in	 all	 the	 tested	organ	 tissues	was	 significantly	higher	 than	 those	 for	EEHV-1A,	suggesting	 limited	 EEHV-1A	 replication.	 Whether	 the	 limited	 replication	 and	 organ	distribution	 of	 EEHV-1	 are	 as	 a	 result	 of	 virus	 virulence	 and/or	 differences	 in	 time	 of	infection	or	 reactivation	 is	 currently	unknown.	Also,	 it	 cannot	be	excluded	 that	 the	 long	storage	time	of	organ	samples	from	this	historic	case	at	-20°C	might	have	affected	the	DNA	of	either	EEHV	strain	differently.			In	conclusion,	in	this	fatal	case	of	EEHV	co-infections,	the	histopathological	manifestations	and	 the	determined	viruses	 involved	are	described.	 	The	overall	 findings	suggest	a	dual	infection	with	EEHV-1A	and	4	to	be	the	cause	of	death	in	this	elephant.	This	investigation	provides	the	first	documented	detection	of	a	co-infection	with	two	potentially	pathogenic	genotypes	of	EEHV,	although	with	substantial	differences	in	organ	viral	load.	This	case	is	also	the	first	fatality	in	a	European	zoo	from	which	EEHV-4	could	be	identified.	Detection	of	EEHV-4	in	this	fatal	case	in	Europe	underlines	the	importance	of	inclusion	of	all	known	Asian	elephant	EEHVs	in	routine	blood	monitoring	to	facilitate	therapy	and	gain	a	better	understanding	of	the	virus	epidemiology.	Finally,	observation	of	the	highest	EEHV-1A	and	4	 loads,	 coinciding	with	pathological	 changes	 in	 lymphoid	 tissues	of	 the	 intestinal	 tract,	suggest	that	immune	cells	of	the	intestinal	tract	lymphoid	tissues	could	be	a	site	for	viral	latency	and/or	initial	replication	of	the	virus.		 	
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CHAPTER	5:	ELEPHANT	PRIMARY	ENDOTHELIAL	CELL	AND	EEHV	ISOLATIONS		
	
	
Declaration	
All	laboratory	investigations	and	analyses	of	parameters	presented	in	this	chapter	were	performed	by	Katharina	Seilern-Moy.		
All	blood	and	umbilical	cord	samples	used	in	this	study	were	taken	by	trained	zoo	staff	of	the	according	facility.	Post	mortem	tissue	samples	were	collected	by	Katharina	Seilern-Moy	and	trained	zoo	staff.		
The	isolated	elephant	umbilical	cord	vessel	endothelial	cells	were	immortalised	commercially	(NBS	Biologicals	Ltd,	UK).	
Electron	microscopical	analysis	of	EEHV-1A	inoculated	elephant	endothelial	cells	was	performed	by	Dr.	David	Everest	at	APHA. 	
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Abstract	
In-vitro	 propagation	 of	 viruses	 in	 established	 cell	 lines	 or	 primary	 cells	 substantially	facilitates	 studies	 on	 virus	 structure,	 replication,	 genetics,	 pathogenesis,	 vaccine	development,	and	antiviral	drug	efficacy.	To	date,	there	is	no	report	of	EEHV	strains	being	isolated	and	propagated	in	either	standard	laboratory	cell	lines	or	elephant	derived	cells.	Hence,	 one	of	 the	main	objectives	 of	 this	 study	was	 to	 isolate	 elephant	 cells	 for	 in	vitro	replication	 of	 EEHV.	 Additionally,	 a	 number	 of	 other	 commercially	 available	 cell	 lines,	Swiss	mouse	embryonic	fibroblasts	(3T3),	baby	hamster	kidney	cells	(BHK),	and	monkey	kidney	cells	(Vero),	were	also	to	be	tested	for	their	potential	to	support	EEHV	replication	
in	vitro.		Isolation	 of	 elephant	 peripheral	 blood	 mononuclear	 cells	 (PBMCs)	 and	 umbilical	 cord	endothelial	 cells	was	 achieved	 successfully	 and	 the	 endothelial	 cells	were	 immortalised	commercially.	 PBMCs	 were	 then	 inoculated	 with	 EEHV-1A	 positive	 homogenised	 heart	tissue	to	assess	virus	replication	in	the	presence	and	absence	of	dexamethasone,	included	as	 a	 cell	 stressor.	 The	 results	 indicate	 potential	 viral	 attachment	 or	 up-take	 by	 PBMCs	followed	 by	 slight	 increase	 of	 viral	 DNA,	 detected	 by	 qPCR,	 in	 cell	 culture	 supernatant.	However,	conclusive	evidence	of	viral	replication	could	not	be	detected.	Cell	monolayers	of	the	elephant	umbilical	cord	endothelial	cells	and	other	cell	lines	were	also	inoculated	as	described	 above	 and	 were	 treated	 with	 a	 variety	 of	 cell	 stressors.	 These	 cell	 stressors	included	 bacterial	 lipopolysaccharides	 (LPS),	 serum	 deprivation,	 and	 steroids	(dexamethasone	 and	hydrocortisone).	 Viral	DNA	quantity	was	 assessed	 on	days	 2,	 3,	 6,	and	8	post	inoculations	through	a	real-time	qPCR	assay.	From	 the	 cell	 lines	 tested,	 only	 the	 3T3	 cells	 demonstrated	 a	 continuous	 but	 small	reduction	of	EEHV-1	qPCR	Ct	values	in	culture	supernatant	of	all	wells,	irrespective	of	the	treatment	 method	 used,	 suggestive	 of	 a	 potential	 increase	 in	 EEHV-1	 DNA	 presence.	
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However,	 various	 possible	 scenarios	 also	 exist	 that	 could	 have	 contributed	 to	 a	 similar	outcome	and	hence	warrant	further	research.	The	 results	 of	 this	 study	 provide	 a	 protocol	 for	 elephant	 PBMC	 and	 endothelial	 cell	isolation	 that	 proved	 successful.	 Furthermore,	 preliminary	 experiments	 aiming	 to	propagate	 EEHV	 in	vitro	 indicate	 that	 elephant	 PBMCs	 and	 3T3	 cells	 might	 potentially	support	 limited	 replication	 of	 EEHV-1A,	 and	 warrant	 further	 research	 into	 potential	triggers	for	higher	levels	of	viral	replication.	
	
	
5.1. Introduction	As	 indicated	 by	 its	 name,	 EEHV	 is	 thought	 to	 mostly	 affect	 endothelial	 cells	 of	 infected	elephants,	 causing	 substantial	 vascular	 damage	 in	 fatal	 haemorrhagic	 cases,	which	might	indicate	 that	 these	cells	are	 susceptible	 to	viral	 replication.	 In	addition	 to	being	potential	viral	 target	 cells	during	 the	acute	 form	of	 the	disease,	endothelial	 cells	may	also	serve	as	site	 of	 virus	 latency,	 as	 indicated	 by	 detection	 of	 EEHV-1	 DNA	 in	 umbilical	 cord	 blood	vessels	(A.	Dastjerdi,	Personal	communication).	Virus	 isolation	 from	 clinical	 samples	 and	 subsequent	 in	vitro	 propagation	 in	 laboratory	cell	 culture	 would	 greatly	 enable	 downstream	 research	 e.g.	 	 to	 analyse	 virus	 particle	structure,	 elucidate	 replication	 mechanisms	 and	 subsequent	 effects	 on	 host	 cells.	Furthermore,	viral	replication	in	cell	cultures	would	allow	evaluation	of	antiviral	drugs	in	
vitro,	 quantification	 of	 virus	 infectivity	 and	 neutralising	 properties	 of	 anti-EEHV	antibodies	 and	 greatly	 facilitate	 the	 development	 of	 candidate	 vaccines.	 The	 genetically	most	closely	related	human	herpesvirus	to	EEHV,	HCMV,	has	been	isolated	in	various	cells	
in	 vitro,	 e.g.	 endothelial	 cells,	 fibroblast,	 and	 human	 kidney	 cells	 (Stagno	 et	 al.,	 1980;	Ellsmore	et	al.,	2003;	Mocarski	et	al.,	2007).	Further,	it	was	shown	that	HCMV	replication	
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can	be	reactivated	in	vitro	in	latently	in	vivo	infected	PBMCs	isolated	from	healthy	patients	(Söderberg-Nauclér	et	al.,	1997).	Decreased	 virus	 isolation	 time	 and	 enhanced	HCVM	 infectivity	was	 observed	when	 the	inoculum,	 e.g.	 sterile	 urine	 samples,	 was	 centrifuged	 onto	 cell	 culture	 monolayers,	resulting	in	the	establishment	of	the	shell	vial	assay	for	HCVM	virus	culture	(Gleaves	et	al.,	1985;	Chou	&	Scott,	1988).		Thus	 far,	 all	 attempts	 to	 isolate	 EEHV	 in	 vitro	 have	 been	 unsuccessful	 (Gary	 Hayward,	personal	 communication).	 Lack	 of	 elephant	 cell	 lines	 have	 also	 added	 to	 the	 difficulty	 in	culturing	 the	 virus.	 This	 study,	 therefore,	 has	 focused	 on	 isolation	 of	 elephant	 cells	 that	might	 support	 replication	of	EEHV	 in	vitro.	One	approach	was	 to	 isolate	 the	virus	 in	cells	derived	 from	 EEHV	 negative	 elephants	 after	 inoculation	 with	 EEHV-1	 positive	 tissue	samples.	 Alternatively,	 cells	 from	EEHV-1	 infected	 elephants	were	 cultured	 to	 test	 for	 in	
vitro	virus	replication	within	already	infected	cells.	Several	other	cell	 lines,	routinely	used	in	most	laboratories	to	isolate	viruses,	were	also	evaluated	in	this	study	for	their	potential	to	propagate	EEHV	in	vitro.			
5.2. Materials	and	Methods	
5.2.1. Elephant	PBMC	isolation	and	maintenance	Elephant	 whole	 blood	 samples	 were	 donated	 by	 a	 European	 Zoo	 and	 were	 taken	 by	qualified	zoo	staff	as	part	of	the	institute’s	routine	health	screening.	Approximately	200	ml	of	EDTA	blood	from	a	healthy	adult	 female,	diagnosed	to	be	free	of	EEHV	DNAemia,	were	collected	 in	 a	 blood	 transfusion	 bag.	 Elephant	 PBMCs	were	 isolated	within	 4	 hours	 after	withdrawal	of	blood	by	density	gradient	centrifugation	using	15	ml	of	Percoll	(Sigma)	with	a	density	of	1.090	g/ml.	The	whole	blood	was	diluted	1	in	2	with	PBS	(total	volume	of	blood	
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dilution	was	 35	ml)	 and	was	 layered	 smoothly	 on	 top	 of	 the	 Percoll.	 After	 layering,	 the	blood-	and	Percoll-containing	50	ml	Falcon	 tubes	were	 centrifuged,	with	 the	break	being	disabled,	 at	 340	 x	 g	 for	 30	min	 at	 room	 temperature.	 Subsequently,	 a	 serological	 pipette	was	 used	 to	 aspirate	 PBMCs,	 forming	 a	 thin	 layer	 over	 the	 Percoll,	 and	 the	 cells	 were	transferred	 to	 a	 new	 50	 ml	 centrifuge	 tube.	 The	 tube	 was	 then	 filled	 with	 PBS	 (Life	Technologies)	 to	 a	 final	 volume	 of	 50	ml	 and	 centrifuged	 at	 300	 x	 g	 for	 8	min	 at	 room	temperature.	After	discarding	the	supernatant,	10	ml	of	red	blood	cell	lysis	buffer	(Sigma)	were	added	and	the	cells	were	incubated	at	room	temperature	for	10	min.	The	PBMCs	were	then	washed	3	times	with	PBS	as	described	above	prior	to	re-suspension	in	culture	medium	consisting	of	RPMI-1640	(Life	Technologies),	10%	FBS	(heat	 inactivated	 for	30	min	at	56	°C),	2%	Penicillin/Streptomycin/Nystatin	mix,	and	2%	Amphotericin	B	(Life	Technologies).	The	same	protocol	was	subsequently	used	to	isolate	PBMCs	from	EDTA	blood	of	an	EEHV-1A	 viraemic	 juvenile	 male	 Asian	 elephant,	 a	 post-mortem	 collected	 blood	 sample	 of	 an	EEHV-1A	fatal	case,	and	from	freshly	post-partum	collected	umbilical	cord	blood.	
To	determine	viable	cell	numbers,	100	μl	of	the	cell	suspension	were	mixed	with	100	μl	of	trypan	blue	(0.4%	w/v	solution,	Sigma)	and	viable	cells	were	counted	manually	under	a	light	microscope	using	an	Improved	Neubauer	haemocytometer.	
The	PBMCs	were	then	cultured	in	6-well	culture	plates	using	20	x	106	cells	per	well	 in	a	final	 volume	 of	 2	 ml	 growth	 media	 supplemented	 with	 recombinant	 human	 IL-2	 (100	U/ml;	Sigma).	The	cells	were	stored	 in	a	humidified	 incubator	at	37˚C	and	5%	CO2.	The	media	was	changed	every	alternate	day	and	PBMCs	were	expanded	1	 in	3	 if	cell	density	increased	 beyond	 covering	 the	 plastic	well	 bottom.	 	 For	 cryopreservation,	 PBMCs	were	washed	once	with	PBS	and	 cell	 pellets	 re-suspended	 in	1	ml	of	FBS	 supplemented	with	10%	 dimethyl	 sulfoxide	 (DMSO;	 Sigma).	 Cryovials	were	 transferred	 to	 a	 -80	 °C	 freezer	
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inside	 a	 cryo-freezing	 container	 (Nalgene),	 and	 transferred	 to	 a	 liquid	 nitrogen	 storage	tank	the	following	day.	
	
5.2.2. Elephant	umbilical	cord	vessel	endothelial	cell	isolation	and	maintenance	The	umbilical	 cord	 samples	used	 in	 this	 study	 for	 isolation	of	 elephant	endothelial	 cells	were	provided	by	European	zoos.	The	first	sample	was	an	approximately	25	cm	long	piece	of	umbilical	cord	that	was	collected	about	2	hours	after	birth	due	to	difficulties	accessing	the	 sample	 immediately.	 The	 umbilical	 cord	 was	 rinsed	 with	 tap	 water	 and	 stored	 in	preservation	 fluid	 consisting	 of	 PBS	 (Life	 Technologies)	 and	 2%	Penicillin/Streptomycin/Nystatin	mix	whilst	in	transport	to	the	laboratory.	The	umbilical	cord	sample	was	processed	for	endothelial	cell	isolation	in	the	laboratory	approximately	24	hours	after	birth.		An	approximately	40	cm	piece	of	a	second	umbilical	cord	tissue	was	collected	immediately	after	birth,	 the	outside	rinsed	 in	 tap	water,	and	sealed	on	both	ends	with	suture	thread.	This	 time	 the	 sample	was	 stored	 in	 a	 preservative	 consisting	 of	 PBS,	 heparin	 (5000	 IU,	Sigma),	 and	 increased	 concentration	 of	 antibiotics	 and	 fungicides	 (5%	Penicillin/Streptomycin/Nystatin	mix),	 and	was	 processed	 for	 endothelial	 cell	 isolation	within	four	hours	after	birth.		The	intact	umbilical	cords	were	washed	several	times	with	a	wash	solution	consisting	of	RPMI	 1640	 media,	 2%	 Penicillin/Streptomycin/Nystatin	 mix,	 and	 2%	 Amphotericin	 B.	The	 blood	 vessels	 of	 the	 cords	 were	 cannulated	 and	 flushed	 3	 times	 with	 the	 wash	solution	before	being	flushed	once	with	0.25%	collagenase	(Life	Technologies;	125	mg	in	50	 ml	 PBS,	 filtered	 through	 0.2	 µm	 filter,	 and	 pre-warmed	 to	 37˚C).	 The	 vessels	 were	closed	on	one	end	using	a	sterile	surgical	thread	and	the	other	end	was	cannulated,	filled	
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with	collagenase,	closed	and	incubated	in	a	sterile	container	inside	a	37	°C	water	bath	for	20	min	to	allow	digestion	of	collagen	in	the	extracellular	matrix	and	thus	detachment	of	endothelial	 cells.	 The	 collagenase	 solution,	 potentially	 containing	 elephant	 endothelial	cells,	was	 subsequently	 collected	 in	 50	ml	 Falcon	 tubes	 and	 the	 vessels	were	manually	massaged	and	flushed	further	three	times	with	collagenase	and	added	to	the	original	tube.	The	cells	were	 then	pelleted	 (7	min	at	500	x	g),	 re-suspended	 in	wash	solution	and	 the	process	 was	 repeated	 5	 times.	 Finally,	 the	 cell	 pellet	 was	 re-suspended	 in	 4	 ml	 of	endothelial	cell	growth	medium	(PromoCell)	supplemented	with	10%	FBS,	antibiotics	and	fungicide	 (2%	Penicillin/Streptomycin/Nystatin,	 2%	Amphotericin	 B),	 50	 ng/ml	 human	vascular	endothelial	growth	factor	(EGF,	Sigma),	and	10	ng/ml	human	fibroblast	growth	factor	 (FGF,	 Sigma)	 and	 added	 to	 a	 fibronectin	 coated	 25	 cm2	 flask	 (Sigma).	 Cells	were	allowed	to	settle	and	adhere	overnight	before	 the	medium	was	changed.	Thereafter,	 the	culture	medium	was	changed	on	alternate	days	until	cells	reached	confluency.	Cells	were	passaged	for	expansion	at	80	to	90%	confluency,	or	frozen	and	stored	in	liquid	nitrogen.	For	detachment	of	the	endothelial	cells	from	the	25	cm2	culture	flasks,	the	culture	medium	was	 removed,	 the	 cells	 were	 washed	 twice	 with	 3	 ml	 PBS	 and	 incubated	 with	 0.25	%	trypsin	(Trypsin	EDTA,	PromoCell),	roughly	covering	the	cells,	at	37	°C	until	cells	rounded	and	detached.	The	cell	suspension	was	then	gently	pipetted	several	times	to	break	the	cell	clumps.	Trypsin	was	 inactivated	with	7	ml	 culture	medium	and	 cells	 pelleted	 (5	min	 at	500	x	g).	For	expansion	of	the	culture,	the	cell	pellet	was	re-suspended	into	15	ml	culture	medium	 and	 divided	 between	 three	 25	 cm2	 flasks	 with	 5	 ml	 cell	 suspension	 each	 or	transferred	into	one	75	cm2	culture	flask.	To	plate	cells	for	an	experiment,	the	endothelial	cell	pellet	of	a	90	to	100	%	confluent	T-25	culture	flask	was	re-suspended	in	3	ml	culture	media	and	100	μl	were	transferred	into	each	well	of	a	24-well	culture	plate	and	toped	up	with	culture	media	to	a	total	volume	of	1	ml	per	well.		
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For	long	storage	of	the	cells,	the	cell	pellet	from	each	confluent	25	cm2	culture	flask	was	re-suspended	in	1	ml	of	FBS	supplemented	with	10%	dimethyl	sulfoxide	(DMSO;	Sigma),	transferred	into	a	cryovial,	placed	in	a	freezing	container	(Nalgene),	and	transferred	to	a	-80	 °C	 freezer.	The	 following	day,	 the	 cells	were	 transferred	 to	 a	 liquid	nitrogen	 storage	tank.	These	primary	elephant	endothelial	cells	were	immortalised	by	NBS	Biologicals	Ltd	using	 a	 plasmid	 vector	 coding	 for	 the	 Simian	 virus	 40	 large	 T	 antigen.	 The	 resulting	elephant	umbilical	cord	endothelial	cell	 line	was	used	for	all	the	virus	isolation	attempts	described	in	this	chapter. 
	
5.2.3. Elephant	endothelial	cell	isolation	from	a	costal	artery		A	costal	 artery	of	 a	 fatal	EEHV	case	 from	a	European	zoological	 collection	was	used	 for	attempted	 isolation	 of	 potentially	 EEHV	 infected	 elephant	 endothelial	 cells.	 Two	approximately	 15	 cm	 pieces	 of	 artery	 tissue,	 collected	 upon	 post-mortem	 examination,	stored	and	transported	in	the	preservative	and	processed	in	the	 laboratory	immediately	upon	arrival	(20	hours	after	death	of	the	animal).		The	arteries	were	washed	several	times	with	a	wash	solution	and	endothelial	cells	were	isolated	 as	 described	 above.	 One	 costal	 artery	was	 additionally	 cut	 open	 and	 the	 inner	layer	 of	 the	 vessel	 was	 carefully	 scratched	 into	 the	 collagenase	 solution,	 which	 was	subsequently	filtered	sequentially	through	100	µm,	70	µm,	and	40	µm	cell	strainers	into	a	50	ml	falcon	tube.	The	cells	were	then	washed	and	cultured	as	described	before.	
	
5.2.4. Elephant	hepatocyte	isolation		A	 liver	 sample	of	 a	 fatal	 EEHV	 case	 from	a	European	 zoological	 collection	was	used	 for	isolation	of	potentially	infected	hepatocytes.	Two	liver	samples	of	around	20	g,	collected	upon	 post-mortem	 examination,	 performed	 within	 8	 hours	 of	 death,	 were	 stored	 and	
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transported	in	the	preservative	and	processed	in	the	laboratory	immediately	upon	arrival	(approximately	17	hours	after	death	of	the	animal).		Small	pieces	of	tissue	(about	3	g)	were	put	into	a	petri	dish	filled	with	collagenase	solution	and	 incubated	 for	 an	 hour	 at	 room	 temperature	 until	 the	 tissue	 changed	 to	 a	homogeneously	 brown	 colour.	 The	 sample	 was	 shaken	 thoroughly,	 the	 cell	 suspension	filtered	through	a	100	µm	cell	strainer	into	a	50	ml	Falcon	tube,	and	centrifuged	for	5	min	at	400	x	g	at	4	°C.	The	cell	pellet	was	re-suspended	in	10	ml	Dulbecco’s	modified	Eagle’s	medium	(DMEM,	Life	technologies)	and	10	ml	PBS,	filtered	through	a	70	µm	cell	strainer,	and	 centrifuged	 again.	 The	 washing	 was	 repeated	 twice	 before	 the	 cell	 pellet	 was	 re-suspended	 in	 hepatocyte	 culture	 media	 consisting	 of	 DMEM	 with	 L-Glutamine	 (Life	technologies),	 5	%	 FBS,	 2%	 Penicillin/Streptomycin/Nystatin	mix,	 2%	 Amphotericin	 B,		50	ng/ml	EGF	(Sigma),	0.5	µg/ml	hydrocortisone	(Sigma),	and	100	nM	ITS	 liquid	media	supplement	 (Insulin,	 Transferrin,	 Selenium;	 Sigma).	 The	 cells	 were	 cultured	 in	 a	 T-25	culture	flask	as	described	before.		
	
5.2.5. Elephant	salivary	gland	cell	isolation		Salivary	gland	tissue	from	the	same	elephant	fatality	was	chopped	into	small	pieces	inside	a	petridish,	 collected	 in	 a	 15	ml	 Falcon	 tube	 containing	 a	 digestion	 solution	 (4	ml	 Hank’s	buffer	(Life	technologies)	and	500	µl	collagenase	solution),	and	incubated	in	a	37	°C	water	bath	for	40	min.	The	suspension	was	then	thoroughly	mixed	by	pipetting	and	incubated	for	an	additional	30	min	before	being	centrifuged	at	400	x	g	for	5	min.	The	cell	and	tissue	mix	pellet	was	re-suspended	in	the	digestion	solution	and	incubated	again	in	the	water	bath	for	2	x	20	min.	After	another	2	washing	steps	with	Hanks´	buffer,	the	pellet	was	re-suspended	in	1	ml	Hank´s	buffer,	and	the	cell	mix	filtered	through	a	70	µm	and	a	50	µm	cell	strainer	and	 centrifuged.	 The	 cell	 pellet	 was	 re-suspended	 in	 salivary	 gland	 cell	 culture	 media	
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consisting	of	DMEM	with	L-Glutamine,	5	%	FBS,	2%	Penicillin/Streptomycin/Nystatin	mix,	2%	 Amphotericin	 B,	 50	 ng/ml	 human	 endothelial	 growth	 factor	 (EGF,	 Sigma),	 20	 ng/ml	human	 fibroblast	 growth	 factor	 (FGF;	 Sigma),	0.5	µg/ml	hydrocortisone	 (Sigma),	100	nM	ITS	 liquid	 media	 supplement	 (Insuin,	 Transferrin,	 Selenium;	 Sigma)	 and	 10	 ng/ml	Dexamethasone	(Sigma).	The	cells	were	cultured	in	a	T-25	culture	flask	in	a	total	volume	of	6	ml	as	described	before.	
	
5.2.6. Elephant	leukocyte	isolation	from	lymph	node	suspension		Small	 pieces	 (about	 200	 mg)	 of	 a	 cervical	 lymph	 node,	 collected	 upon	 post-mortem	examination	 from	 the	 fatal	 case	 above,	 were	 minced	 in	 10	 ml	 PBS	 containing	 2%	Penicillin/Streptomycin/Nystatin	mix	 and	 poured	 into	 a	 100	 µm	 cell	 strainer.	 A	 plunger	from	a	syringe	was	carefully	pressed	onto	 the	 tissue	pieces	caught	by	 the	cell	 strainer	 to	force	 tissue	 fragments	 apart	 and	 cells	 to	 pass	 the	 filter.	 The	 cell	 solution	 was	 then	centrifuged	at	250	x	g	for	5	min	and	5	ml	of	the	red	cell	lysis	buffer	were	added	to	the	cell	pellet	 to	 lyse	 the	 remaining	 red	 blood	 cells.	 After	 15	 min	 of	 incubation	 at	 room	temperature,	 the	 solution	 was	 centrifuged,	 the	 cell	 pellet	 re-suspended	 in	 PBS	 with	antibiotics,	and	the	washes	were	repeated	3	times.	The	cell	pellet	was	then	re-suspended	in	DMEM	containing	5	%	FBS,	2%	Penicillin/Streptomycin/Nystatin	mix,	2%	Amphotericin	B	and	cultured	in	a	T-25	culture	flask	in	a	total	volume	of	6	ml	as	described	before.		
	
5.2.7. Elephant	foreskin	fibroblast	isolation	and	maintenance	Elephant	foreskin	tissue	from	the	same	fatal	EEHV	case	was	used	for	isolation	of	elephant	fibroblasts.	The	tissue	was	cut	into	small	squares	of	about	0.5	cm2	and	each	4	squares	were	transferred	into	a	15	ml	Falcon	tube.	One	set	of	tissue	pieces	was	digested	in	10	ml	trypsin	(Sigma)	 and	 one	 in	 10	 ml	 collagenase	 solution,	 both	 containing	 2%	
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Penicillin/Streptomycin/Nystatin	mix	and	2%	Amphotericin	B.	The	 tubes	were	 incubated	horizontally	at	4	°C	over	night	before	transferring	the	digest	into	a	petri	dish,	washing	the	tissue	with	PBS	and	then	gently	separating	the	dermis	from	the	epidermis	whilst	the	tissue	is	covered	in	PBS.	The	dermis	was	then	cut	into	small	pieces,	transferred	into	a	15	ml	tube,	and	 incubated	 in	 1	ml	 pre-warmed	 collagenase	 solution	 for	 20	min	 at	 37	 °C,	 thoroughly	vortexing	the	mixture	every	5	min.	Then	5	ml	of	fibroblast	media	(DMEM	with	L-Glutamine,	5	%	FBS,	4%	Penicillin/Streptomycin/Nystatin	mix,	2%	Amphotericin	B,	50	ng/ml	EGF,	20	ng/ml	FGF,	0.5	µg/ml	hydrocortisone,	and	100	nM	ITS	liquid	media	supplement	was	added	and	 the	 sample	was	 thoroughly	mixed	 by	 forcefully	 pipetting	 the	 solution.	 The	 tube	was	centrifuged	at	250	x	g	for	8	min,	the	cell	pellet	washed	3	times	in	fibroblast	media,	and	the	re-suspended	cells	were	 then	cultured	 in	a	T-25	culture	 flask	 in	6	ml	of	 fibroblast	media.	The	cells	were	incubated	as	described	above	and	half	of	the	cell	media	was	replaced	every	alternate	day.		
	
5.2.8. Other	cell	lines	used	for	EEHV	isolation	attempts	In	 addition	 to	 the	 immortalised	 elephant	 umbilical	 cord	 endothelial	 cells,	 several	 of	 the	routinely	used	standard	cell	lines	were	also	trialled	for	the	in	vitro	isolation	of	EEHV.		The	cell	 lines	 included	 Swiss	 mouse	 embryonic	 fibroblasts	 (3T3	 cells),	 baby	 hamster	 kidney	(BHK	 cells),	 and	 monkey	 kidney	 cells	 (Vero	 cells).	 All	 the	 cells	 were	 grown	 in	 DMEM	supplemented	with	 5%	 FBS	 and	 penicillin/streptomycin.	 For	 3T3	 cells,	 L-glutamine	was	added	to	the	cell	media	at	a	final	concentration	of	2mM.	The	cells	were	grown	in	24-well	plates	and	each	well	was	seeded	with	approximately	5	x	106	cells	per	ml	of	their	respective	growth	media.	The	plates	were	incubated	at	37	°C	in	a	5%	 CO2	incubator	 for	 at	 least	 24	 hours	 and	 observed	 for	 their	 confluency	 before	 being	inoculated	at	a	confluency	of	approximately	70%.	
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5.2.9. Cell	culture	inoculation		
5.2.9.1. Inoculum	Determining	 the	 viral	 load	 in	 tissues	 of	 EEHV-1	 elephant	 fatalities	 had	 highlighted	 heart	and	 liver	 as	 the	 two	 organs	 containing	 the	 highest	 levels	 of	 viral	 DNA	 (see	Chapter	 3),	hence	both	organ	types	were	used	as	inoculum	for	potential	EEHV-1	isolation.		To	prepare	the	inoculum,	heart	and	liver	tissue	samples	of	an	EEHV-1A	positive	fatal	case	were	added	to	gentleMACS	M	tubes	(Miltenyi	Biotec	Ltd.	UK)	containing	PBS	(2	ml	PBS	for	each	approximately	60	mg	of	tissue).	The	tissues	were	homogenised	using	the	gentleMACS	Dissociater	(Miltenyi	Biotec)	and	the	RNA_01	program.	The	M	tube	was	then	centrifuged	at	2000	×	g	for	2	min	and	the	supernatants	of	the	homogenates	were	used	as	inoculum.	A	heart	and	a	liver	tissue	sample	of	an	EEHV	negative	Asian	elephant	was	used	to	prepare	negative	control	inoculums	as	above.	Other	EEHV-1A	positive	materials	used	as	inoculum	for	cell	culture	inoculation	were	urine	and	 pericardial	 fluid.	 Urine	 samples	 have	 been	 successfully	 used	 as	 sterile	 inoculum	 for	HCMV	in	vitro	isolation	and	pericardial	fluid	was	another	EEHV	positive	material	that	could	be	 collected	 under	 sterile	 conditions.	 Both	 samples	 were	 taken	 upon	 post-mortem	examination	via	needle	aspiration	from	the	bladder	and	the	pericardial	sac,	respectively.		
	
5.2.9.2. Inoculation	of	elephant	PBMCs	with	EEHV-1A	The	 PBMCs	 obtained	 from	 an	 EEHV-1A	 viraemic	 juvenile	 Asian	 elephant	 and	 from	 the	EEHV-1A	 fatal	 case	were	 cultured	without	 being	 inoculated	 to	 test	 for	 potential	 EEHV-1	reactivation	from	the	infected	cells.	The	PBMCs	obtained	from	fresh	umbilical	cord	blood	were	used	for	inoculation	trials.	For	inoculation	of	PBMCs	with	EEHV-1A	positive	organ	samples,	approximately	20	x	106	cells	were	cultured	per	well	of	a	6-well	plate.	At	a	cell	density	of	about	70%	well	coverage,	
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the	cell	media	was	removed	carefully	and	the	PBMCs	of	4	wells	were	inoculated	with	500	μl	of	EEHV-1A	positive	inoculum.	One	well	per	plate	was	inoculated	with	EEHV	negative	control	inoculum,	and	the	remaining	well	topped	with	400	μl	sterile	PBS	as	no	inoculum	control.	The	plates	were	incubated	for	2	hours	at	37	°C	to	allow	the	virus	to	adsorb	to	the	cells	before	inoculum	and	floating	PBMCs	were	transferred	into	a	15	ml	Falcon	tube.	The	cells	 were	 washed	 twice	 by	 centrifugation	 with	 PBS	 containing	 2%	Penicillin/Streptomycin/Nystatin	 mix.	 The	 cell	 pellet	 was	 re-suspended	 in	 2	 ml	 PBMC	culture	media	and	transferred	back	into	the	corresponding	wells.	Prior	to	incubation,	150	
μl	culture	media	of	each	well	were	removed	as	background	virus	load	in	the	supernatant	and	stored	at	-20	°C.	
	
5.2.9.3. Inoculation	of	elephant	umbilical	 cord	endothelial	 cells	 line,	3T3	cells,	BHK	
cells,	and	Vero	cells		Twenty-four	hours	prior	to	inoculation,	the	cell	culture	medium	of	all	wells	of	the	24-well	plates	was	replaced	to	exclude	EGF,	where	appropriate.	At	a	confluency	of	about	70%	and	prior	to	infection,	the	cell	media	was	removed	and	each	well	was	rinsed	twice	with	sterile	PBS.	For	inoculation	of	the	cells,	200	μl	of	the	inoculum	was	used	per	well.	Two	wells	on	each	 plate	 were	 also	 inoculated	 with	 a	 control	 homogenate,	 heart	 tissue	 of	 an	 EEHV	negative	case.	Two	additional	wells	were	also	topped	with	200	μl	sterile	PBS.	The	plates	were	 incubated	 for	2	hours	at	37	 °C	 to	allow	 the	virus	 to	adsorb	 to	 the	 cells.	The	wells	were	then	carefully	rinsed	twice	with	PBS	to	remove	un-adsorbed	virus	and	flooded	with	1	 ml	 of	 respective	 maintenance	 medium	 with	 antibiotics	 and	 fungicides.	 Before	 being	incubated,	 the	 plates	 were	 shaken	 gently	 and	 150	 μl	 culture	 media	 of	 each	 well	 were	removed,	 the	 background	 supernatant	 pooled	 for	 each	 plate,	 and	 stored	 at	 -20	 °C	 until	testing.	
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Inoculated	 cells	 were	 observed	 daily	 for	 up	 to	 8	 days	 for	 presence	 of	 cytopathic	 effects	(CPE),	 cell	 culture	 contaminations,	 or	 cell	 death.	 On	 days	 2,	 3,	 6,	 and	 8,	 150	 μl	 of	supernatant	of	each	well	were	removed	and	stored	at	-20		̊C	before	being	analysed.	On	day	8,	 after	 the	 supernatant	 was	 taken	 off,	 the	 cells	 were	 frozen	 and	 thawed	 twice	 and	reconstituted	 in	150	μl	of	cell	media	before	DNA	extraction	and	testing	through	real	 time	PCR.	Nucleic	 acid	 extracted	 from	 all	 the	 cell	 culture	 supernatants	 of	 inoculated	 cells	 were	measured	 for	 EEHV-1A	 DNA.	 The	 DNA	 from	 the	 pure	 inoculum,	 established	 from	homogenised	EEHV-1A	positive	heart	 tissue,	was	extracted	alongside	 the	DNA	 from	cell	culture	supernatants,	using	140	μl	organ	suspension	for	extraction.		
5.2.9.4. Inoculation	 of	 elephant	 umbilical	 cord	 endothelial	 cell	 line	 with	 EEHV-1A	
positive	urine	and	pericardial	fluid	samples	Elephant	endothelial	cells	were	cultured	for	2	days	in	6-well	plates	before	being	inoculated	with	200	μl	of	sterile	urine	or	pericardial	fluid	per	well	as	described	above.	The	plates	were	inoculated	 in	 duplicates	 with	 each	 inoculum,	 one	 plate	 was	 infected	 using	 a	 shell	 vial	protocol,	spinning	the	plate	at	700	x	g	for	1	hr,	and	subsequently	flooding	each	well	with	1.5	ml	of	endothelial	cell	growth	media.	A	second	plate	was	inoculated	as	described	above	with	the	 homogenised	 heart	 tissue.	 One	 well	 on	 each	 plate	 was	 mock	 inoculated	 with	homogenised	heart	tissue	from	an	EEHV	negative	Asian	elephant.		
5.2.9.5. Various	stressing	methods	to	provoke	viral	replication	in	vitro	Dexamethasone	was	 used	 to	 trigger	 virus	 replication	 in	 elephant	 umbilical	 cord	 PBMCs.	Four	 wells	 of	 a	 6-well	 plate	 containing	 EEHV-1A	 inoculated	 and	 one	 well	 containing	negative	 control	 inoculated	 PBMCs	 were	 stressed	 by	 adding	 10	 μg/ml	 dexamethasone	
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every	other	day	 throughout	 the	experiment.	The	cell	 cultures	on	 the	 replicate	plate	were	not	stressed.	Fresh	culture	media	was	added	to	the	wells	as	indicated	in	Table	5.1.	PBMCs	isolated	from	the	EEHV-1A	viraemic	juvenile	Asian	elephant	were	also	stressed	by	adding	10	μg/ml	dexamethasone	every	other	day	until	day	17	post	 inoculation	where	the	amount	of	steroids	was	elevated	to	15	μg/ml	to	trigger	potential	viral	replication	 from	 in	
vivo	infected	cells.	The	 cell	 stressors	used	 to	 trigger	 virus	 replication	 in	 elephant	umbilical	 cord	 endothelial	cells	 were	 bacterial	 lipopolysaccharide	 (E.coli	 LPS),	 nutrient	 deprivation	 by	 serum	starvation,	 dexamethasone,	 and	 hydrocortisone.	 Each	 cell	 stressor	 was	 tested	 in	quadruplicates	 for	each	EEHV	inoculated	cell	 type	cultured	on	one	plate.	Four	wells	were	pre-treated	with	LPS	at	500	ng/ml	of	growth	media	24	hours	prior	to	inoculation.	Further	4	wells	were	incubated	with	endothelial	cell	growth	media	excluding	the	FBS	following	EEHV	inoculation	and	washing,	in	order	to	stress	the	cells	through	nutritional	deprivation.	Cells	in	the	 remaining	 8	 wells	 were	 stressed	 by	 adding	 10	 μg/ml	 dexamethasone	 or	 500	 ng/ml	hydrocortisone	 post	 inoculation,	 and	 replenished	 every	 other	 day	 throughout	 the	experiment.	On	day	4,	300	μl	of	fresh	corresponding	media	were	added	to	each	well.		
5.2.10. Nucleic	acid	extraction	and	real-time	qPCR	for	viral	DNA	detection	Nucleic	 acid	 from	 all	 supernatants	 and	 lysed	 cells	 of	 the	 PBMC	 cultures	were	 extracted	using	the	EZ1®	XL	robot	(Qiagen)	and	the	EZ1®	RNA	tissue	mini	kit	as	per	manufacturer’s	instructions.	Nucleic	 acid	 from	 all	 supernatants	 and	 lysed	 cells	 of	 all	 remaining	 virus-inoculated	 cell	cultures	 was	 extracted	 using	 QIAamp	 viral	 RNA	 mini	 kit	 (Qiagen)	 following	 the	manufacturer’s	 instructions.	 In	 brief,	 140	 μl	 of	 supernatant	 or	 140	 μl	 of	 the	 lysed	 cell	suspension	were	mixed	with	560	μl	of	AVL	lysis	buffer,	vortexed	briefly,	and	incubated	for	
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15	minutes	at	room	temperature	followed	by	the	addition	of	560	μl	of	100	%	ethanol	and	brief	vortexing.	This	mixture	was	passed	through	QIAamp	spin	columns	followed	by	two	washes	 with	 500	 μl	 of	 the	 washing	 buffers	 (AW1	 and	 AW2).	 DNA	 bound	 to	 the	 spin	columns	was	eluted	 in	60	μl	of	AVE	elution	buffer.	The	nucleic	acid	was	stored	at	–20	̊C	until	being	tested.		Molecular	detection	of	EEHV-1A	DNA	was	performed	by	real-time	qPCR	as	described	by	Hardman	et	al.	(2012).	A	91	bp	segment	of	the	terminase	gene	of	EEHV-1A	was	amplified	using	 the	 following	 oligonucleotides:	 hydrolysis	 probe,	 5’-FAM-TCAACGAGGAGATATTAGGCACCACCAACA-BHQ1-3’;	 forward	 primer,	 5’-ACTGCAAAYGCATTCTTAAAAGAAT-3’;	 and	 reverse	 primer,	 5’-AGAATGGGATTRGCTAAGAAGCT-3’;	 the	 qPCR	 mix	 was	 set	 up	 using	 the	 QuantiFast®	Pathogen	PCR	+IC	kit	(Qiagen).	In	brief,	2	µl	of	extracted	DNA	were	added	to	the	PCR	mix	consisting	of	0.1	µl	of	each	forward	and	reverse	primer	(100	pmol/µl),	0.05	µl	hydrolysis	probe	(100	pmol/µl),	5	µl	5×	QuantiFast	Pathogen	Master	Mix,	0.5	µl	50×	High-ROX	Dye	solution,	and	17.25	µl	RNase-Free	Water.	The	PCR	was	performed	on	a	CFX	96	TouchTM	thermal	cycler	(Bio-Rad)	using	the	cycling	conditions	of	1	cycle	of	95	°C	for	5	min	followed	by	45	cycles	of	95	°C	for	15	s,	60	°C	for	30	s,	and	signal	acquisition	at	the	end	of	each	cycle.		
	
5.3. Results	
5.3.1. Establishing	elephant	derived	cell	cultures		a) PBMCs:	The	isolation	of	elephant	PBMCs	from	fresh	blood	samples	and	umbilical	cord	blood	was	carried	out	 successfully.	Clustering	of	 the	cells	was	observed	on	day	4	of	culturing	 and	 some	 cell	 proliferation	 lead	 to	 80	 to	 90%	 of	 the	 well	 surface	 being	
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covered	by	day	6,	when	they	were	expanded	1	in	3.	The	cells	could	be	maintained	for	around	5	passages	before	high	levels	of	cell	death	were	observed.	The	 isolation	of	PBMCs	 from	an	EEHV-1A	viraemic	 juvenile	Asian	elephant	was	also	successful	and	the	cells	were	kept	in	culture	for	potential	virus	isolation	as	they	were	thought	to	be	already	infected	with	EEHV-1A.	Although	PBMCs	could	be	isolated	from	post-mortem	blood	 of	 an	 EEHV-1A	 fatal	 case,	 cell	 cultures	 could	 not	 be	maintained	due	to	high	levels	of	bacterial	contamination.	
	b) Umbilical	cord	endothelial	cells:	The	assumed	endothelial	cells	from	the	first	umbilical	cord	sample	showed	severe	contamination	observed	on	day	2	after	isolation	and	were	discarded.	 	 It	 was	 therefore	 decided	 to	 apply	 a	 higher	 dose	 of	 antibiotics	 and	fungicides	 during	 storage	 and	 transport	 of	 the	 tissues	 and	 increase	 numbers	 of	washes	 prior	 to	 collagen	 digest.	 	 This	 modified	 protocol	 has	 proven	 to	 eliminate	environmental	contaminations	and	led	to	successful	isolation	of	presumed	endothelial	cells	 from	the	second	umbilical	 cord.	Following	culture	of	 isolated	cells,	distinct	 cell	clusters	were	clearly	visible	on	day	6	of	culture	and	reached	a	confluency	of	80	%	to	90	%	by	day	12.	Cells	were	identified	as	endothelial	cells	by	morphological	criteria:	A	uniform	 characteristic	 cobblestone	 appearance	 was	 seen	 after	 day	 9	 (Figure	 5.1).	These	primary	cells	could	be	passaged	at	least	8	times	before	microscopical	changes	in	 cell	 morphology	 and	 increase	 in	 cell	 death;	 known	 as	 biological	 ageing	 or	senescence.	 Elephant	 endothelial	 cells	 were	 successfully	 immortalised	 by	 NBS	Biologicals	 Ltd	 using	 the	 SV40	 large	 T	 antigen.	 These	 immortalised	 cells	 could	 be	passaged	for	over	25	times	without	any	obvious	morphological	changes	or	cell	death.			
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Figure	5.1:	Cell	morphology	 of	 primary	 elephant	 endothelial	 cells.	 Primary	elephant	umbilical	 cord	endothelial	 cells	 at	 full	 confluency	on	Day	12	of	 culture	demonstrating	 the	 for	 endothelial	 cells	 morphologically	 typical	 cobblestone	appearance.				c) Other	 organ	 derived	 elephant	 cells:	 In	 order	 to	 promote	 virus	 reactivation	 and	replication	from	potentially	in	vivo	 infected	cells	of	a	fatal	EEHV	case,	various	organs	were	used	 for	cell	 isolation.	Twenty-four	hours	after	 the	 isolation	attempts	of	costal	artery	 endothelial	 cells,	 hepatocytes,	 salivary	 gland	 cells,	 and	 leucocytes	 from	 an	EEHV-1	 fatality	case,	 the	cell	cultures	showed	heavy	bacterial	contamination	and	all	flasks	had	to	be	discarded.		d) Foreskin	 fibroblasts:	 Potential	 elephant	 foreskin	 fibroblasts,	 identified	 by	 their	morphological	 characteristics,	 were	 successfully	 isolated	 with	 no	 visible	contamination.	 On	 day	 5	 of	 culture,	 some	 level	 of	 cell	 clustering	 was	 observed,	
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however	no	further	cell	division	was	observed,	and	no	cell	monolayer	was	achieved.	From	day	14	onwards,	cells	started	to	die	and	the	culture	attempt	was	discontinued	after	20	days.		
5.3.2. Determining	suitable	EEVH	inoculum	material		Inoculation	 of	 primary	 and	 immortalised	 elephant	 umbilical	 cord	 endothelial	 cells	with	various	 homogenised	 EEHV-1A	 positive	 heart	 and	 liver	 tissue	 samples	 showed	 higher	levels	of	cell	death	in	the	cells	inoculated	with	liver	homogenate.	However,	a	similar	level	of	 endothelial	 cell	 death	 was	 observed	 in	 the	 cells	 inoculated	 with	 negative	 liver	homogenate,	indicating	that	liver	tissue	might	be	toxic	to	the	endothelial	cells.	The	EEHV	negative	homogenised	heart	tissue	did	not	cause	any	obvious	harm	to	the	cells.	Therefore,	EEHV-1A	positive	heart	tissue	was	used	as	inoculum	throughout	subsequent	studies.		
5.3.3. Assessment	 of	 EEHV-1A	 isolation	 trials	 from	 numerous	 elephant	 and	
standard	cell	types	
5.3.3.1. PBMCs	 inoculated	with	EEHV-1A	positive	heart	homogenate	and	culture	
of	in	vivo	infected	PBMCs	The	background	Ct	value	of	EEHV-1A	DNA	detected	in	pooled	PBMC	culture	supernatants,	following	 inoculation	 and	 several	 washes,	 was	 determined	 as	 25.82	 for	 PBMCs	subsequently	 cultured	 in	 the	 presence	 and	 27.34	 for	 those	 cultured	 in	 the	 absence	 of	dexamethasone	(Table	5.1).	On	day	1	post	inoculation	(pi),	the	Ct	values	in	the	steroid	stressed	cultures	were	elevated	by	 an	 average	 of	 4.764	 and	 in	 the	 untreated	 cultures	 by	 an	 average	 of	 5.41.	 In	 both	experiments	 the	 Ct	 values	 then	 started	 to	 decrease	 thereafter	 (Table	 5.1,	 Figure	 5.2),	indicating	higher	levels	of	EEHV-1	DNA	being	detectable	in	the	cell	culture	supernatants.	
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Lower	Ct	values	were	maintained	until	 termination	of	 the	experiment	and	did	not	show	any	obvious	elevation	even	after	fresh	cell	media	was	added	to	the	wells.	Trendlines	of	Ct	value	 means	 of	 4	 technical	 replicates	 over	 time	 displayed	 a	 reasonable	 fit	 of	 R2>	 0.9	(Figure	5.2)	and	corroborated	an	overall	trend	of	EEHV	DNA	increase	(Ct	value	decrease)	in	the	supernatants	during	this	period.				The	highest	Delta-Ct	 (∆Ct)	value	decrease	 (defined	as	difference	between	 the	maximum	and	minimum	Ct	value	mean)	observed	between	day	1	and	29	dpi	in	the	supernatants	was	determined	as	2.84	for	PBMCs	cultured	in	the	absence,	and	3.51	for	those	cultured	in	the	presence	of	dexamethasone.	The	lysed	cells	of	the	wells	showed	on	average	a	1.35	lower	Ct	value	compared	to	the	associated	cell	culture	supernatant	in	both	experiments	(Table	
5.1).	However,	 EEHV	DNA	 levels	detected	 in	 supernatants	of	 dexamethasone	 treated	or	untreated	PBMC	cultures	never	exceeded	 the	DNA	baseline	 levels	determined	 in	pooled	supernatants	on	day	0	following	inoculum	removal	and	washes.				 	
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	 Table	5.1:	EEH
V	D
N
A	detected	in	the	supernatant	of	elephant	PBM
Cs	inoculated	w
ith	EEH
V	heart	hom
ogenate.	Mean	Ct	values	and	
the	according	standard	deviations	(STD)	of	four	technical	replicates	of	EEHV	isolation	in	vitro	in	elephant	umbilical	cord	PBMCs	inoculated	
with	an	EEHV-1A	positive	heart	tissue	homogenate	and	stressed	with	10	μg/ml	dexamethasone	post	infection	every	alternate	day	(A)	or	left	
untreated	(B).	The	DNA	of	the	positive	control	that	was	extracted	alongside	the	supernatant	samples	and	was	run	in	triplicates	producing	Ct	
values	of	23.43,	23.	62,	and	24.12,	(23.72	±	0.35	mean	plus	STD;	max.	∆Ct	0.69)	and	no	Ct	value	was	recorded	for	the	mock-infected	cells.	-	no	
Ct-value	tested;	*values	for	the	lysed	cells 
A
: 
 
 
 
 
 
 
 
 
 
 
B
: 
Days	post	
inoculation	
M
ean	Ct	value	
STD	
Supplem
ented	
fresh	m
edia	in	μl	
	
Days	post	
inoculation	
M
ean	Ct	value	
STD	
Supplem
ented	
fresh	m
edia	in	μl	
0	
								25.82		
0	
-	
	
0	
								27.34		
0	
-	
1	
								30.46		
0.90	
100	
	
1	
								32.75		
0.63	
100	
2	
								29.11		
1.08	
700	
	
2	
								31.69		
0.95	
700	
5	
-	
-	
400	
	
5	
-	
-	
400	
8	
								28.09	
0.64	
700	
	
8	
								31.26	
0.84	
700	
16	
-	
-	
200	
	
16	
-	
-	
200	
23	
								27.63		
1.38	
400	
	
23	
								30.12		
0.89	
400	
26	
								26.81		
0.97	
200	
	
26	
								29.93		
1.27	
200	
29	
								26.95		
0.92	
-	
	
29	
								29.91		
0.97	
-	
29*	
								25.55*	
0.40*	
-	
	
29*	
								28.65*	
0.67*	
-	
				
	
	135	
	 	
A:	
	
	
	
	
	
	
	
	
	
B:	
					
	
Figure	5.2:	D
etection	of	EEH
V	D
N
A	in	the	supernatant	of	elephant	PBM
Cs	inoculated	w
ith	EEH
V	positive	heart	hom
ogenate.	
EEHV-1A	qPCR	mean	Ct	values	and	standard	deviations	of	cell	culture	supernatants	of	four	technical	replicates	of	elephant	umbilical	
cord	PBMCs	inoculated	with	an	EEHV-1A	positive	heart	tissue	homogenate	stressed	with	10	μg/ml	dexamethasone	post	infection	
every	alternate	day	(A)	and	untreated	(B)	shown	for	days	1,	2,	8,	23,	26,	and	29	post	inoculation	(data	in	Table	5.1).	Following	a	
decrease	of	EEHV	DNA	detection	between	the	day	0	baseline	and	1	dpi	supernatant,	viral	DNA	seemed	to	increase	in	the	supernatant	
of	PBMCs	post	culture	over	time,	represented	by	decreasing	Ct	values	and	respective	declining	trendlines.	R 2	represents	the	coefficient	
of	determination	of	the	trend	lines.	
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	PBMCs	isolated	and	cultured	from	an	EEHV-1A	viraemic	juvenile	Asian	elephant	failed	to	show	 any	 indication	 of	 increase	 in	 EEHV-1A	 DNA	 quantity	 in	 vitro,	 regardless	 of	treatment	 with	 steroids.	 At	 the	 time	 of	 culturing,	 the	 PBMCs,	 suspended	 in	 culture	media,	 had	 a	 Ct	 value	 of	 35.38,	 but	 none	 of	 the	 tested	 supernatants	 throughout	 the	experiment	 showed	 detectable	 EEHV-1	 DNA	 except	 one	 well	 of	 the	 four	 technical	replicates	showing	a	Ct	value	of	42.46	on	Day	15	post	culturing.	The	PBMCs	 isolated	 from	an	EEHV-1A	 fatal	 case	 exhibited	 bacterial	 contamination	 on	day	2	post	isolation	and	the	experiment	was	terminated.		
	
5.3.3.2. Elephant	 endothelial	 cell	 line	 inoculated	with	 EEHV-1A	 positive	 heart	
homogenate	or	secreted	body	fluids		EEHV-1A	DNA	baseline	was	detected	in	pooled	endothelial	cell	culture	(ECs)	supernatants	after	 inoculation	 of	 the	 cells	 with	 EEHV-1A	 positive	 heart	 homogenate	 and	 follow-up	washes	at	a	Ct	value	of	38.32	(Table	5.2	A).	At	2	dpi,	however,	this	Ct	value	was	reduced	on	average	by	2.4	in	ECs	supernatant	of	all	respective	treatments	(mean	STD	mean	0.63).	Subsequently,	 EEHV	 DNA	 levels	 decreased	 (as	 signified	 by	 increasing	 Ct	 values)	 in	supernatants	of	all	treatment	conditions	except	for	endothelial	cells	that	were	deprived	of	FBS	in	the	culture	media	(Figure	5.3	A).	Although	trendlines	of	mean	Ct	values	implied	an	overall	 increase	 of	 Ct	 values	 over	 time	 for	 all	 treatment	 conditions	 other	 than	nutrient	deprivation,	R2	values	indicated	a	poor	fit	for	Ct	values	detected	for	untreated	EC	cultures	and	those	treated	with	dexamethasone,	suggesting	more	fluctuating	viral	DNA	detection	in	respective	supernatants	(Figure	5.3	A).	The	reduction	in	Ct	value	for	the	FBS	deprived	cells	was	maintained	till	day	8	post	 infection	when	the	experiment	was	terminated.	The	pooled,	 washed,	 and	 lysed	 cells	 of	 the	 different	 stressing	 methods	 all	 showed	 an	 on	
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average	 2.66	 lower	 Ct	 value	 (mean	 STD	 0.67),	 compared	 to	 the	 associated	 cell	 culture	supernatants	 (Table	 5.2	 A),	 showing	 that	 there	 still	 was	 viral	 DNA	 detectable	 in	 the	inoculated	cells.	Two	untreated	EEHV-1A	inoculated	EC	pellets	of	a	preliminary	experiment	were	further	analysed	by	electron	microscopy	at	APHA,	examining	multiple	ultra-thin	sections	(70-100	nm),	but	no	viral	particles	could	be	visualised	within	these	elephant	endothelial	cells.		Inoculation	of	elephant	endothelial	cells	with	urine	and	pericardial	fluid	using	either	shell	vial	 or	 the	 standard	 protocol	 did	 not	 result	 in	 any	 discernible	 changes	 in	 EEHV-1DNA	levels	 signified	 by	 constant	 or	 increasing	 Ct	 values	 in	 the	 cell	 culture	 supernatants	collected	on	several	occasions	post	inoculation	over	a	period	of	8	days.		
5.3.3.3. Established	 laboratory	 cell	 lines	 inoculated	 with	 EEHV	 heart	
homogenate	The	 supernatants	 of	 all	 3T3	 cells	 showed	 an	 overall	 reduction	 in	 Ct	 values	 for	 EEHV-1	DNA	between	day	2	and	6	dpi,	 independent	of	 the	 stressing	method	used.	 Initially	 	 	 an	increase	 in	 the	 Ct	 value	 was	 observed	 for	 all	 cell	 culture	 supernatants	 between	 the	baseline	 EEHV	DNA	 value	 determined	 on	 day	 0	 and	 levels	 detected	 at	 2	 dpi,	with	 a	 Ct	average	of	2.05	(STD	1.8)	(Table	5.2	B).	Ct	values	obtained	then	reduced	in	the	following	days	in	all	tested	supernatants	to	or	below	the	level	of	the	day	0	baseline	value,	despite	the	 addition	 of	 300	 μl	 of	 fresh	 cell	 media	 4	 dpi.	 Overall	 trendlines	 of	 mean	 Ct	 values	suggest	an	increase	in	viral	DNA	levels	in	the	supernatant	of	all	differentially	treated	3T3	cell	cultures	over	 time,	however	as	Ct	values	once	again	 increased	at	 the	 final	sampling	time	point	at	8dpi	 (viral	DNA	decrease),	 the	overall	R2	value	of	 respective	 trendlines	 is	low	 (Figure	 5.3	 B).	 	 The	 pooled,	 washed,	 and	 lysed	 cells	 of	 the	 different	 stressing	
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methods	showed	to	carry	EEHV	DNA	with	an	on	average	2.61	lower	Ct-value	(STD	0.53)	than	corresponding	cell	culture	supernatants	(Table	5.2	B).		An	 overall	 decline	 in	 Ct	 values	 for	 EEHV-1	 DNA	 was	 also	 observed	 in	 the	 culture	supernatant	of	the	BHK	and	Vero	cells	which	were	FBS	deprived;	a	similar	picture	to	the	inoculated	elephant	endothelial	cells	(Figure	5.3).	Trendlines	of	mean	Ct	values	obtained	for	EEHV-1	DNA	in	supernatants	of	the	BHK	and	Vero	cell	lines,	cultured	in	the	presence	of	no	or	any	other	treatments,	suggested	a	decline	in	detectable	viral	DNA	levels	over	time	for	all	respective	culture	conditions	(Figure	5.3	C	and	D,	Table	5.2	C	and	D).	The	pooled	and	 lysed	 cells	 of	 the	 different	 treatment	 methods	 at	 the	 end	 of	 the	 experiment	 only	showed	a	slightly	lower	Ct-value	of	an	average	of	0.49	(STD	of	0.46)	for	the	BHK	cells	and	1.6	(STD	of	0.67)	for	the	Vero	cells	compared	to	the	associated	cell	culture	supernatants	(Table	5.2	C	and	D).	
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Table	5.2:		EEHV	DNA	detected	in	the	supernatant	of	elephant	endothelial	cells	and	
standard	cell	lines	inoculated	with	EEHV	heart	homogenate.	EEHV	isolation	in	vitro	in	elephant	 endothelial	 cells	 (A),	 Swiss	 mouse	 embryonic	 fibroblasts	 (3T3)	 (B),	 baby	hamster	 kidney	 (BHK)	 (C),	 and	monkey	 kidney	 cells	 (Vero)(D)	 inoculated	with	 a	 heart	tissue	homogenate	positive	for	EEHV-1A	(Ct=25)	and	stressed	pre	(LPS)	or	post	infection	(all	 other	 treatments).	 The	mean	 Ct	 values	 for	 the	 two	 positive	 controls	 on	 each	 plate	were	 28.36	 (A),	 28.89	 (B),	 27.97	 (C),	 and	 28.46	 (D)	 respectively.	 No	 Ct	 value	 was	recorded	for	the	mock-infected	cells.	*only	one	well	remained	for	testing	(contamination	of	replicate	wells)	
A. Elephant	endothelial	cells:	
	Cell	treatment	
Day	0	 Day	2	 Day	3	 Day	6	 Day	8	 Pooled	
cells	pooled	 Mean	 STD	 Mean	 STD	 Mean	 STD	 Mean	 STD	
No	treatment	 38.32 35,56	 0,27	 35,74	 0,32	 38,88	 0,54	 36,50	 0,00*	 34.84 
LPS	pre-treated	 38.32 35,53	 0,18	 35,39	 0,94	 37,01	 1,72	 37,18	 0,82	 34.21 
Nutrient	deprived	 38.32 36,97	 0,15	 36,51	 1,45	 36,14	 1,46	 35,49	 1,78	 32.21 
Dexamethasone	 38.32 36,07	 1,16	 36,75	 1,86	 37,68	 0,39	 36,50	 1,51	 33.41 
Hydrocortisone	 38.32 35,49	 0,54	 36,72	 1,84	 37,39	 0,30	 38,89	 0,88	 36.61 
	
	
B. 3T3	cells:	
	Cell	treatment	
Day	0	 Day	2	 Day	3	 Day	6	 Day	8	 Pooled	
cells	pooled	 Mean	 STD	 Mean	 STD	 Mean	 STD	 Mean	 STD	
No	treatment	 31.75	 32,43	 0,19	 30,53	 0,57	 29,25	 0,12	 31,47	 1,12	 29.24	
LPS	pre-treated	 31.75	 32,05	 0,38	 30,93	 0,38	 29,38	 0,09	 30,83	 0,52	 28.07	
Nutrient	deprived	 31.75	 33,22	 1,90	 31,18	 0,64	 30,70	 0,83	 30,77	 0,50	 28.86	
Dexamethasone	 31.75	 36,44	 0,26	 32,30	 0,39	 29,88	 0,29	 31,09	 0,47	 27.92	
Hydrocortisone	 31.75	 34,87	 2,02	 31,77	 0,93	 29,72	 0,55	 31,22	 0,73	 28.22	
	
	
C. BHK	cells:	
	Cell	treatment	
Day	0	 Day	2	 Day	3	 Day	6	 Day	8	 Pooled	
cells	pooled	 Mean	 STD	 Mean	 STD	 Mean	 STD	 Mean	 STD	
No	treatment	 29.42 29,37	 0,23	 30,12	 1,09	 30,36	 0,85	 33,25	 0,58	 32.29 
LPS	pre-treated	 29.42 29,21	 0,12	 29,91	 1,21	 30,27	 0,61	 34,52	 0,91	 34.08	
Nutrient	deprived	 29.42 31,23	 0,19	 31,28	 0,25	 30,71	 0,67	 30,14	 0,12	 29.52	
Dexamethasone	 29.42 29,41	 0,54	 29,51	 0,44	 30,75	 0,63	 31,96	 1,04	 31.26	
Hydrocortisone	 29.42 30,23	 0,78	 30,04	 0,46	 30,46	 0,48	 32,09	 1,18	 32.34	
continued	
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D. Vero	cells:	
	Cell	treatment	
Day	0	 Day	2	 Day	3	 Day	6	 Day	8	 Pooled	
cells	pooled	 Mean	 STD	 Mean	 STD	 Mean	 STD	 Mean	 STD	
No	treatment	 31.11 32,08	 0,72	 31,30	 0,25	 31,86	 0,67	 32,88	 0,63	 30.34	
LPS	pre-treated	 31.11 31,76	 0,29	 31,32	 0,52	 31,33	 0,30	 32,70	 0,26	 31.77	
Nutrient	deprived	 31.11 32,54	 0,65	 31,56	 1,12	 32,87	 1,37	 31,55	 1,53	 30.62	
Dexamethasone	 31.11 31,61	 0,37	 31,69	 0,41	 32,90	 0,85	 33,53	 0,39	 31.82	
Hydrocortisone	 31.11 31,55	 0,12	 31,83	 0,75	 33,07	 0,48	 34,14	 0,55	 32.49	
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Figure	5.3	(continued)	 	
2930
3132
3334
3536
37
2 3 6 8
qP
CR
	C
t	v
al
ue
s
Days	post	inoculation
No	treatmentLPS	pre-treatedNutrient	deprivedDexamethasoneHydrocortisone
3T3	cells
R2 =	0.15491
R2 =	0.37773
R2 =	0.72449
R2 =	0.69991
R2 =	0.60084
A	
	142			
2728
2930
3132
3334
35
2 3 6 8
qP
CR
	C
t	v
al
ue
s
Days	post	inoculation
No	treatmentLPS	pre-treatedNutrient	deprivedDexamethasoneHydrocortisone
BHK	cells
R2 =	0.81212
R2 =	0.76651
R2 =	0.86314
R2 =	0.91213
R2 =	0.67799
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	5.3	(continued)	 	
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Figure	5.3:	Detection	of	EEHV-1	DNA	 in	 the	 supernatant	of	 varying	 cell	 cultures	
inoculated	with	EEHV	positive	heart	homogenate.		EEHV	DNA	was	detected	using	a	qPCR	assay	in	the	supernatant	of	varying	cell	cultures	inoculated	 with	 an	 EEHV-1A	 positive	 heart	 tissue	 homogenate	 and	 cultured	 in	 the	absence	or	presence	of	numerous	stressors	given	in	each	legend.	The	mean	Ct	values	of	4	 technical	 replicates	obtained	 for	 the	 supernatant	of	A.	 Elephant	 endothelial	 cells	B.	3T3	 cells,	 C.	 BHK	 cells,	 and	 D.	 Vero	 cells	 are	 given	 in	 respective	 graphs	 including	representative	 trendlines.	 EEHV	 DNA	 levels	 detected	 in	 the	 supernatant	 at	 day	 0	following	 the	 removal	 of	 the	 heart	 homogenate	 inoculum	 and	 several	 washes	 are	included	 in	 the	 graph	 as	 threshold	 line.	 The	 post	 inoculation	 supernatant	 collection	days	are	 listed	on	 the	X-axes.	 In	 the	3T3	cell	 line,	 viral	DNA	seems	 to	 increase	 in	 the	supernatant	of	cells	of	all	treatment	conditions	as	well	as	the	untreated	cell	culture	at	least	 between	 2	 and	 6	 dpi	 as	 indicated	 by	 the	 declining	 Ct	 value	 trendlines.	 In	 the	supernatant	 of	 the	 endothelial	 cells,	 BHK	 cells,	 and	 Vero	 cells,	 a	 trend	 decline	 in	 Ct	values	was	only	observed	for	cultures	deprived	of	nutrients	(no	serum).	R2	represents	the	coefficient	of	determination	of	the	trend	lines.	
		
	 	
	144			
5.4. Discussion	To	date,	there	are	no	reports	of	established	elephant	cell	lines	or	protocols	for	elephant	primary	 cell	 isolations.	 However,	 as	 EEHV	 could	 thus	 far	 not	 be	 propagated	 in-vitro,	elephant	 cell	 cultures	might	 provide	 the	 needed	 resource	 to	 permit	 EEHV	 replication	and	hence	virus	isolation.		Whole	 blood,	 either	 from	 umbilical	 cord	 or	 elephant,	 is	 one	 of	 the	 easily	 accessible	samples	 that	 can	 be	 routinely	 taken	 from	 trained	 captive	 elephants.	 Considering	 that	human	CMV	has	also	been	shown	to	propagate	in	PBMC,	elephant	PBMCs	were	isolated	and	 used	 to	 assess	 their	 potential	 in	 isolating	 EEHV	 in	vitro.	 The	 successfully	 isolated	PBMCs	were	used	for	various	experiments	to	attempt	EEHV	propagation	in	cell	culture.	Umbilical	cord	PBMCs	that	were	inoculated	with	EEHV-1A	positive	heart	tissue	did	show	some	 overall	 Ct	 value	 reduction,	 indicative	 of	 viral	 DNA	 increase,	 in	 the	 culture	supernatants	regardless	whether	they	were	stressed	with	steroids	or	not.	However,	the	level	of	qPCR	detectable	EEHV-1	DNA	never	exceeded	that	in	the	inoculum,	which	would	have	conclusively	demonstrated	viral	replication.	It	is	therefore	unclear	whether	limited	EEHV	 replication	 was	 observed	 or	 whether	 virus	 adsorbed	 to	 the	 outside	 of	 cellular	membranes	detached	over	time	to	be	detected	in	the	supernatant.	Alternatively,	higher	level	 of	 detectable	 EEHV	 DNA	 in	 the	 supernatant	 might	 also	 occur	 if	 PBMCs	 initially	permit	virus	entry,	however	without	enabling	virus	replication,	to	subsequently	release	viral	DNA	upon	cell	death.	Blood	samples	collected	from	an	EEHV-1A	viraemic	juvenile	Asian	elephant	were	also	cultured	in	an	attempt	to	trigger	viral	replication	in	already	in	
vivo	 infected	 blood	 cells,	 but	 no	 increase	 of	 viral	 DNA	 was	 observed.	 This	 viraemic	elephant	 only	 showed	unspecific	 signs	 of	 ill	 health	during	 the	 first	 2	 days	 of	 detected	viraemia	 with	 viral	 load	 levels	 considered	 potentially	 self-limiting	 (see	 Chapter	 2).	
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Therefore,	 the	 low	 amount	 of	 potentially	 infectious	 viral	 particles	 in	 isolated	 PBMCs	might	have	impeded	successful	in	vitro	viral	replication.	EEHV	 is	 now	 known	 to	 be	 detectable	 in	 high	 levels	 in	 all	 organs	 in	 fatal	 incidences	(Chapter	 3),	 therefore	 it	was	 thought	 that	 already	 infected	 elephant	 cells,	 e.g.	 PBMCs,	endothelial	 cells,	hepatocytes,	 salivary	gland	cells,	 lymph	cells,	or	 fibroblasts,	 could	be	used	for	in	vitro	 isolation	of	the	virus.	However,	the	experiments,	unfortunately,	had	to	be	terminated	because	of	severe	contamination	of	the	cultures.	For	future	cell	isolation	attempts	from	organs	of	fatal	EEHV	cases,	as	evidenced	for	the	endothelial	cell	isolation,	higher	concentrations	of	antibiotics	and	fungicides	especially	in	the	preservative	and	the	wash	solution,	and	increased	number	of	washes	may	eliminate	such	contamination	and	are	highly	recommended.	Acute	 cases	 of	 EEHV	 infections	 lead	 to	 extensive	 haemorrhages	 and	 it	 is	 therefore	thought	 that	 endothelial	 cells	 might	 be	 susceptible	 to	 virus	 infection	 and	 replication.	Although	 it	 is	 still	 unknown	 whether	 the	 vascular	 damage	 observed	 is	 a	 direct	consequence	 of	 EEHV	 replication	 in	 endothelial	 cells	 or	 occurs	 indirectly	 due	 to	 the	release	of	 vascular	mediators	and	cytokines	by	other	 cellular	 targets,	 endothelial	 cells	seem	to	be	an	obvious	choice	to	assess	their	susceptibility	to	EEHV	in	vitro	infection	and	replication,	especially	considering	relative	ease	of	access	to	umbilical	cord	tissues	after	birth.	Applying	 the	 lessons	 learned	 from	 the	 initial	 attempt	 in	 isolation	 of	 endothelial	 cells	from	umbilical	cord,	increasing	antimicrobial	concentration	and	washes	has	resulted	in	successful	 isolation	 of	 the	 cells	 from	 the	 2nd	 umbilical	 cord	 and	 established	 as	 an	endothelial	cell	line	as	inferred	by	the	observed	cell	morphology.	The	cells	demonstrated	a	clear	cobblestone	appearance,	which	is	a	typical	indication	for	endothelial	cells.	
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Another	 factor	 thought	 to	 have	 significantly	 facilitated	 the	 isolation	 of	 the	 endothelial	cells	 from	 the	umbilical	 cord	was	 the	addition	of	heparin	 to	 the	preservation	 fluid	 for	tissue	 transport.	 This	 prevented	 the	 blood	 in	 the	 cord	 vessels	 from	 coagulating	 and	could	 therefore	 easily	 be	 flushed	 out	 of	 the	 umbilical	 cord	 vessels,	 leaving	 a	 much	cleaner	access	for	the	collagenase	to	the	inner	walls	of	the	vessels.	Having	 isolated	 cells	 from	an	umbilical	 cord	vessel,	 a	 co-culture	or	 cell-contamination	with	 fibroblasts	was	a	considered	possibility,	 and	although	some	non-endothelial	 cells	were	seen	 in	early	culture	days,	 the	specific	growth	medium	enriching	endothelial	cell	growth	seemed	to	have	inhibited	contaminating	cells	quickly.	Fibroblasts	demonstrate	a	more	spindle-like	and	stretched	appearance,	which	was	not	seen	in	any	of	the	confluent	isolated	 cell	 cultures.	 However,	 for	 a	 definite	 conclusion,	 additional	 tests	 should	 be	applied.	Due	to	the	lack	of	knowledge	of	elephant	endothelial	cell	specific	markers	and	respective	 antibodies,	 the	 ones	 available	 for	 other	 species	 should	 be	 screened	 for	potential	cross-reactions	in	order	to	detect	markers	considered	specific	for	endothelial	cells,	 e.g.	 von	 Willebrandt	 Factor,	 junction	 adhesion	 molecule	 (JAM-A),	 intracellular	adhesion	 molecule	 (ICAM),	 or	 platelet-endothelial	 cell	 adhesion	 molecule	 (PECAM)	(Müller	et	al.,	2002).	Preliminary	 results	 from	 early	 inoculation	 attempts	 of	 primary	 and	 immortalized	elephant	umbilical	cord	endothelial	cells	with	various	homogenised	EEHV-1A	positive	or	negative	 heart	 and	 liver	 tissue	 samples	 demonstrated	 that	 even	 negative	 liver	homogenate	 induced	unacceptable	 levels	 of	 endothelial	 cell	 death.	On	 the	 other	 hand,	cell	viability	did	not	seem	to	be	negatively	affected	by	heart	homogenate,	hence	EEHV-1A	positive	heart	tissue	was	used	as	inoculum	throughout	the	study.	This	 study	 investigated	 the	 potential	 of	 the	 elephant	 derived	 endothelial	 cell	 line	 and	routine	laboratory	cell	lines,	e.g.	Vero,	BHK,	and	3T3	cells,	to	support	EEHV	replication	
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in	vitro.	 Less	 viral	DNA	was	detected	by	qPCR	 in	 the	 supernatant	 of	 the	 commercially	available	cell	cultures	on	the	2nd	dpi	compared	to	the	baseline	Ct-values	determined	at	D0	following	inoculum	removal	and	washes.	This	initial	drop	of	viral	DNA	detectable	in	culture	supernatants	between	day	0	and	day	2	might	indicate	further	viral	attachment	as	EEHV	 entry	 mechanisms	 are	 unknown	 and	 could	 potentially	 be	 slow.	 Alternatively,	some	 viral	 DNA	 might	 initially	 have	 degraded	 due	 to	 unsuccessful	 cell	 infection,	although	 dsDNA	 is	 known	 to	 be	 relatively	 stable.	 	 In	 contrast,	 in	 the	 endothelial	 cell	culture	 the	 qPCR	 EEHV-1A	 Ct	 value	 decreased	 between	 Day	 0	 and	 2,	 indicating	 an	increase	of	EEHV-1A	DNA	in	the	supernatant.	 	This	could	be	explained	by	e.g.	a	higher	level	of	cell	death	compared	to	 the	potentially	more	stable	commercial	cell	 lines	or	by	more	unbound	virus	particles	in	the	supernatant	following	insufficient	attachment	to	the	cells.	On	day	4	post	 inoculation,	 fresh	cell	media	was	added	to	each	well,	however	given	the	overall	 low	 dilution	 factor	 this	was	 not	 expected	 to	 have	 any	 significant	 influence	 on	viral	DNA	measurements	by	qPCR.	All	inoculated	3T3	cells	showed	consistently	changes	in	Ct	value	levels	indicating	a	higher	amount	of	detectable	EEHV-1A	DNA	in	the	culture	supernatants	up	to	6	dpi,	whereas	the	other	cells	lines,	elephant	endothelial	cells,	BHK	cells,	 and	 Vero	 cells,	 only	 showed	 subsequent	 reduction	 in	 Ct	 values	 in	 the	 nutrient	deprived	cell	cultures.	Whether	these	EEHV-1	DNA	qPCR	Ct	value	changes	observed	in	the	 3T3	 cell	 cultures	 are	 caused	 by	 limited	 viral	 replication	 or	 other	 factors	 is	 yet	unclear.	 However,	 since	 the	 reduction	 in	 Ct	 values	 was	 observed	 independent	 of	 the	stressing	method	used,	these	cells	might	be	susceptible	to	EEHV	infection	independently	of	stress	triggers.	Alternatively,	as	discussed	previously	 for	PBMCs,	EEHV	might	attach	to	the	surface	of	 the	cultured	cells	without	entering	them	completely.	Hence,	 the	virus	might	detach	from	cell	membranes	at	a	later	state	causing	free	viral	particles	to	re-enter	
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cell	culture	supernatant.	Similarly,	cell	death	of	either	successfully	infected	cells	or	cells	with	attached	viral	particles	might	lead	to	higher	levels	of	viral	DNA	in	the	cell	culture	supernatant,	 detected	 as	 decreased	 Ct	 values.	 Interestingly	 some	 unspecific	 and	 low	levels	of	morphological	changes	in	EEHV-1A	inoculated	3T3	and	elephant	umbilical	cord	endothelial	cells	that	were	nutrient	deprived	were	also	observed.	Whether	this	potential	low	degree	of	 ballooning	 followed	by	 increased	 cell	 death	observed	only	 in	 these	 two	starved	cell	cultures	is	virus	specific	or	caused	by	lack	of	nutrients	alone,	needs	further	investigation.		In	this	preliminary	experiment,	mock	infected	control	cells	receiving	the	same	stress	treatment	for	comparison	were	notincluded.	However,	viral	DNA	seemed	to	increase	over	time	in	the	supernatant	of	all	adherent	cell	cultures	included	in	this	study	when	deprived	of	serum	post	 inoculation.	This	might	 indicate	that	 the	 lower	Ct	values	obtained	 for	 supernatants	 of	 this	 treatment	 condition	 are	 associated	 with	 unspecific	decreased	cell	viability.		Further	 studies	 are	 required	 to	 confirm	 EEHV	 viral	 replications	 in	 primary	 cells	 or	standard	 cell	 lines.	 This	 could	 be	 achieved	 by	 developing	 a	 qPCR	 assay	 to	 specifically	detect	mRNA	 transcription	 of	 immediate	 early	 or	 late	 EEHV	 genes	 or	 viral	 protein	 by	immune	staining	once	EEHV	specific	antibodies	become	available.	Also,	further	attempts	to	 visualise	 the	 presence	 of	 virus	 particles	 inside	 susceptible	 cells	 using	 electron	microscopy	could	provide	further	proof	for	EEHV	being	present	in	the	cells.	Nonetheless	electron	microscopy	might	not	be	a	suitable	technology	if	viral	infection	and	replication	rates	remain	low	in	tested	cell	culture	systems.		EEHV-1A	 positive	 urine	 samples	 were	 also	 used	 as	 inoculum	 for	 EEHV	 isolation	 in	elephant	 endothelial	 cells	 as	 studies	 have	 shown	 good	 yields	 of	 viral	 isolation	 when	using	HCMV	positive	urine	in	shell	vial	assays	(De	Vries	et	al.,	2012).	Additionally,	sterile	pericardial	 fluid	 of	 a	 positive	 EEHV-1A	 fatal	 case	 was	 also	 used	 as	 inoculum	 for	 cell	
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inoculation.	 	 However,	 elephant	 endothelial	 cells	 inoculated	 with	 EEHV-1A	 positive	urine	or	pericardial	 fluid	 samples	 failed	 to	 support	 infection	or	 replication	of	EEHV-1,	independent	of	the	 inoculation	method	used.	This	might	be	explained	by	the	relatively	low	viral	loads	in	the	specimens	used	for	inoculation.		It	 should	 be	 noted	 that	 endothelial	 cells	 are	 very	 diverse	 with	 regard	 to	 their	morphology	 and	 growth	 (Craig	 et	 al.,	 1998)	 and	 using	 the	 biologically	 relevant	 types	could	 be	 essential	 when	 attempting	 EEHV	 isolation	 in	 vitro	 in	 this	 cell	 type.	 HCMV,	genetically	 most	 closely	 related	 to	 EEHV,	 is	 reported	 to	 preferentially	 infect	 vascular	endothelial	 cells	 (Jarvis	 and	 Nelson,	 2007).	 In	 fatal	 cases	 of	 EEHV-1	 infections,	 the	endothelial	 cells	 of	 the	 large	 myocardial	 arteries	 and	 the	 endocardium	 appear	 to	 be	more	 severely	 affected	 by	 EEHV,	 judged	 by	 numbers	 of	 single	 large	 basophilic	intranuclear	 inclusion	bodies	 (see	Chapter	4).	 It	 is	 therefore	possible	 that	endothelial	cells	 from	different	blood	vessels	or	other	selected	organs	might	still	 support	EEHV	 in	
vitro	replication	and	should	be	considered	in	future	research	for	isolating	the	virus.	Considering	higher	virus	DNA	load	in	tissues	such	as	heart	and	liver	(Chapter	3),	it	can	be	postulated	that	these	cell	types,	similar	to	those	for	HCMV	(Gerna	et	al.,	2002),	may	support	 replication	 of	 this	 virus	 in	vivo.	 Therefore,	 cells	 such	 as	 elephant	 hepatocytes	and	cardiac	myocytes	may	also	support	in	vitro	replication	of	the	virus.	It	is,	however,	a	challenging	task	to	access	these	EEHV	free	organs	for	cell	isolation	in	a	timely	manner	in	case	of	 e.g.	 euthanasia	or	other	 reasons	 for	 sudden	death	of	 an	elephant.	 It	 is	 thought	that	 a	 more	 timely	 post-mortem	 tissue	 collection,	 and	 a	 higher	 concentration	 of	antibiotics,	 fungicides,	 and	 heparin	 in	 the	 tissue	 preservation	 fluid	 could	 prevent	bacterial	 contamination	 in	 future	 attempts	 of	 cell	 isolation	 from	post-mortem	 tissues.	Although	 increased	 antibiotic	 concentrations	 prevented	 contamination	 of	 foreskin	fibroblast	 cultures,	 cell	 division	 of	 potentially	 isolated	 fibroblasts	 halted	 for	 unknown	
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reasons	 and	 the	 cells	 died	 after	 14	 days	 of	 isolation.	 Since	 fibroblasts	 show	 a	 great	potential	for	HCMV	isolation	(Sinzger	et	al.,	1995;	Mocarski	et	al.,	2007),	they	could	be	another	cell	 type	to	be	considered	for	 future	virus	 isolation	attempts	 including	further	optimisation	 of	 fibroblast	 isolation	 from	 foreskin	 e.g.	 higher	 levels	 of	 fibroblast	stimulating	reagents.	The	mechanism	of	HCMV	entry	to	various	cells	 in	vitro	has	been	shown	to	vary.	HCMV	enters	epithelial	cells	via	endocytosis,	whereas	fibroblasts	are	entered	via	direct	fusion	of	the	viral	envelope	with	the	plasma	membrane	(Ryckman	et	al.,	2006;	2008).	The	ease	of	the	initial	virus-cell	attachment	could,	partly,	explain	why	some	cell	types	support	a	more	readily	viral	replication	 in	vitro	 than	others	(Sinzger	et	al.,	1995;	Mocarski	et	al.,	2007).	 In	 the	 case	 of	 HCMV,	 for	 example,	 various	 cell	 types	 display	 different	susceptibility	with	some	cell	types			supporting	productive	HCMV	replication	and	release	of	new	infectious	virus	(reviewed	by	Penkert	&	Kalejta,	2011).	Other	cell	types,	however,	such	as	polymorphonuclear	cells,	allow	in	vitro	infection,	but	replication	is	aborted	and	no	 progeny	 virus	 is	 produced	 (Grefte	 et	 al.,	 1994;	 Sinzger	 &	 Jahn,	 1996).	 The	 results	presented	 in	 this	 study	 may	 also	 indicate	 a	 partially	 aborted	 EEHV	 replication	 in	elephant	PBMCs	and	3T3	cells.	In	 conclusion,	 elephant	 cells	 that	 might	 have	 the	 potential	 to	 support	 EEHV-1A	replication	 in	vitro	were	 successfully	 isolated	 in	 this	 study.	Higher	 levels	of	detectable	EEHV-1A	DNA	in	the	cell	supernatants	of	EEHV-1A	inoculated	elephant	PBMC	and	3T3	cells	might	indicate	susceptibility	of	these	cells	to	EEHV-1A	infection	in	vitro.	However,	various	 possible	 scenarios	 also	 exist	 that	 could	 have	 resulted	 in	 a	 similar	 outcome.	Future	 research	 should	 consider	 modifying	 inoculation	 method,	 adsorption	 time	 and	incubation	period,	and	use	alternative	inoculums	and	cell	stressors.		 	
	151			
CHAPTER	6:	GENERAL	DISCUSSION	AND	FUTURE	WORK	
	Several	scientific	studies	in	recent	years	have	significantly	advanced	our	knowledge	on	the	 molecular	 identification	 and	 characterisation	 of	 different	 EEHV	 strains.	 However,	key	 knowledge	 gaps	 especially	 concerning	 the	 pathogenesis	 of	 EEHV	 induced	haemorrhagic	 disease	 still	 remain	 unexplored.	 Pathogenesis	 studies	 of	 EEHV	 are,	 in	particular,	 hampered	 by	 lack	 of	 a	 virus	 culture	 system,	 animal	model	 and	 absence	 of	specific	EEHV	and	elephant	reagents	e.g.	monoclonal	or	polyclonal	antibodies.	This	PhD	study	 therefore	 aimed	 to	 gain	 a	 better	 understanding	 of	 the	 viruses’	 pathogenesis	through	 a	 comprehensive	 insight	 into	 several	 surviving	 and	 fatal	 cases	 of	 EEHV	infections.			The	 lack	of	an	EEHV	tissue	culture	system	has	specifically	 impeded	evaluation	of	anti-viral	 therapies	 in	vitro,	quantification	of	 infectious	virus,	and	serological	studies	 to	e.g.	identify	 neutralising	 antibodies	 that	 elicit	 the	 anti-EEHV	 immune	 responses,	 vital	 in	EEHV	 vaccinology.	 Hence,	 this	 study	 further	 aimed	 to	 establish	 elephant	 cell	 culture	systems	and	to	isolate	the	virus	in	vitro.			As	part	of	achieving	the	first	aim	of	this	study,	several	fatal	and	surviving	cases	of	EEHV	were	investigated	to	explore	pathogenic	characteristics	of	EEHV,	including	ascertaining	potential	 correlation	 between	 the	 kinetics	 of	 virus	 load	 and	 disease	 development,	characterising	 viral	 and	 host	 parameters	 informing	 disease	 diagnosis	 and	 prognosis,	evaluating	 current	 anti-herpesvirus	 drug	 efficacy,	 and	 determining	 virus	 distribution	and	load	in	affected	tissues	to	identify	target	organs	and	ultimately	those	cells	that	may	support	viral	replication.	
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Clinical	and	virological	 investigations	of	 two	EEHV-1A	infected	elephants,	a	 fatal	and	a	surviving	case,	have	revealed	that	clinical	disease	does	correlate	strongly	with	the	viral	load	in	blood,	but	 levels	of	virus	 load	varied	substantially	at	the	onset	of	clinical	signs.	Whilst	 virus	 load	 in	 the	 surviving	elephant	peaked	at	 around	78*103	vgc/ml	of	whole	blood,	 this	 level	 was	 much	 higher	 in	 the	 fatal	 case	 with	 1.9*107	 vgc/ml	 of	 blood.	 A	previous	study	from	North	America	has	reported	a	threshold	of	1.0*104	vgc/ml	of	blood	to	coincide	with	apparent	illness	(Stanton	et	al.,	2013).	It	was	also	noted	that	the	virus	load	in	the	fatal	case	increased	at	a	much	faster	rate	compared	to	the	surviving	case,	and	viral	 kinetics	 over	 time	 could	 therefore	 be	 considered	 a	more	 reliable	 determinant	 of	disease	prognosis	than	a	specified	threshold	of	viraemia.			Trunk	shedding	of	the	virus	in	the	surviving	case	commenced	10	days	after	detection	of	initial	DNAemia,	which	was	in	agreement	with	what	was	reported	previously	in	5	Asian	elephants,	 juveniles	 and	 adults,	 from	 North	 America	 (Stanton	 et	 al.,	 2013).	 This,	 in	particular,	has	implications	in	control	of	the	disease	as	the	surviving	shedders	may	pose	a	 threat	 to	other	at-risk	 juvenile	elephants	 in	 the	herd.	 It	 is,	however,	yet	 to	be	 tested	whether	the	shed	virus	is	infectious	and	secreted	in	quantities	required	for	subsequent	infection	of	naïve	elephants.	Until	then,	revised	intensive	testing	of	the	at-risk	juveniles	following	 a	 surviving	 case	 of	 an	 EEHV	 infection	 is	 highly	 recommended	 for	 early	detection	 and	 potential	 control	 of	 infection.	 Currently,	 most	 elephant	 facilities	implement	a	weekly	testing	of	their	at-risk	elephants.	Considering	that	in	the	fatal	case	death	 occurred	 within	 8	 days	 of	 detectable	 viraemia,	 the	 testing	 interval	 should	 be	shortened	to	2-3	days	as	long	as	trunk	shedding	of	the	EEHV	survivor	shows	a	high	viral	load.		
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The	zoological	collection	of	these	two	elephants	had	already	implemented	weekly	blood	sampling	 of	 their	 at-risk	 juveniles	 to	 test	 for	 EEHV	 DNA	 by	 real	 time	 qPCR,	 as	recommended	 by	 the	 EEHV	 Advisory	 Group.	 Here,	 this	 approach	 was	 able	 to	 detect	EEHV	viremia	in	one	of	the	elephants,	8	days	prior	to	the	onset	of	clinical	signs.	There	are	 further	reports	 indicating	that	the	virus	DNA	could	even	be	detected	much	earlier,	up	 to	 28	 days	 (Stanton	 et	 al.,	 2013)	 before	 the	 development	 of	 noticeable	 clinical	manifestation.	 It	 is	 also	 worth	 highlighting	 that	 this	 testing	 procedure	 may	 not	 be	applicable	 in	 institutions	 where	 a	 contactless	 approach	 is	 in	 place	 due	 to	 safety	implications.	 Early	 training	 for	 blood	 sampling	 of	 juvenile	 elephants	 in	 “protected	contact”	 facilities	 and	 direct	 contact	 with	 sick	 juveniles	 seem	 vital	 and	 is	 currently	subject	 of	 discussion	within	 the	Elephant	TAG	 (Taxon	Advisory	Group)	 and	 the	EEHV	Advisory	Group.	Also,	some	institutions	may	not	have	easy	access	to	a	EEHV	diagnostic	reference	 laboratory.	 In	 the	 latter	 case,	 a	 differential	whole	 blood	 cell	 count	 is	 highly	recommended	 as	 described	 in	 Chapter	 2.	 It	 was	 found	 that	 the	 early	 indicators	 for	clinical	 disease	 were	 a	 marked	 absolute	 and	 relative	 drop	 in	 white	 blood	 cells,	particularly	monocytes,	prior	to	the	detection	of	viraemia.				 	In	 this	 study,	 quantification	 by	 qPCR	 of	 virus	 load	 DNA	was	 further	 utilised	 to	 guide	clinicians	 on	 antiviral	 therapy.	 Both	 calves	were	 receiving	 FCV	 following	 detection	 of	DNAemia	 and	 the	 FCV	 metabolite,	 PCV,	 could	 be	 detected	 in	 the	 blood	 at	 assumed	therapeutic	 levels	 (Gill	 &	 Wood,	 1996;	 Brock	 et	 al.,	 2012),	 but	 virus	 load	 remained	unaffected	for	the	fatal	case.	Based	on	findings	of	this	study	and	others	reported	in	the	literature	(Long	et	al.,	2015;	Fuery	et	al.,	2016a,	2016b),	it	could	be	concluded	that	FCV	lacks	 efficacy	 against	 EEHV.	 Therefore,	 use	 of	 alternative	 anti-herpesvirus	 drugs	 (e.g.	GCV,	 Foscarnet)	 and	 complementary	 treatments,	 such	 as	 plasma	 infusions,	 are	
	154			
recommended	 at	 present.	 The	 most	 suitable	 anti-herpesvirus	 treatment	 might	 also	strongly	be	 influenced	by	 the	administration	route	of	 selected	medication.	Treatments	administered	 rectally	 in	 elephants	 developing	 EEHV-HD	might	 not	 reach	 or	 maintain	therapeutic	levels	due	to	expulsion	or	pathological	changes	of	the	intestine	obliterating	drug	 absorption,	 hence	 anti-herpesvirus	 drugs	 given	 intra-venous	might	 have	 distinct	advantages.	The	substantial	 level	of	EEHV	induced	pathological	damages	to	the	enteric	system	(Garner	et	al.,	2009)	has	been	once	more	highlighted	here	 in	a	 retrospectively	analysed	historical	case	of	EEHV-HD	caused	by	EEHV-1	and	4	co-infection.			Examination	of	viral	distribution	and	quantity	of	EEHV-DNA	by	qPCR	within	organs	of			fatal	cases	of	EEHV-1	and	5	revealed	a	widespread	distribution	of	the	virus	throughout	numerous	 organs	 of	multiple	 body	 systems,	 albeit	 with	 substantial	 differences	 in	 the	viral	 DNA	 load.	 Generally	 liver,	 heart,	 and	 tongue	 harboured	 the	 highest	 viral	 load,	although	specific	organ	preferences	might	be	influenced	by	the	specific	strain	of	EEHV.		For	example,	the	highest	viral	loads	in	elephants	infected	with	EEHV-1A	were	detected	in	the	liver,	closely	followed	by	the	heart,	while	the	heart	contained	approximately	10	x	more	viral	DNA	than	the	next	EEHV	positive	organ	in	elephants	succumbed	to	infections	with	EEHV-1B	or	EEHV5.	Additionally,	EEHV-4	DNA	in	the	mesenteric	lymph	node	of	the	elephant	co-infected	with	EEHV-4	and	EEHV-1A,	exceeded	viral	DNA	detected	 in	other	organs	 by	more	 than	 1000	 times.	 Direct	 comparison	 of	 distinct	 organ	 preferences	 of	different	EEHV	strains	 is	 impeded	since	organ	samples	submitted	 for	EEHV	diagnostic	following	 the	 death	 of	 an	 elephant	 varied	 substantially.	 Hence,	 occasionally	 critical	organs	 for	 viral	 load	 comparison	 such	 as	 liver	 and	mesenteric	 lymph	 node	 were	 not	collected.	 A	 standard	 post	 mortem	 and	 sample	 collection	 protocol	 adhered	 to	 by	 all	participating	zoological	collections	would	greatly	improve	case	comparability.			
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The	 question	 still	 remained	 unanswered	 whether	 this	 tropism	 to	 certain	 tissues	originates	from	a	more	extensive	vascular	system,	i.e.	more	endothelial	cells,	or	whether	the	virus	targets	other	cells	in	these	tissues.	The	qPCR	used	here	to	quantify	viral	nucleic	acid	in	various	organ	tissues	cannot	identify	the	specific	target	cells.	Techniques	such	as	
in	situ	 hybridisation	would	 reveal	 virus	nucleic	 acid	presence	within	 specific	 cells	 and	further	 improve	 current	 understanding	 of	 cell	 tropism	 of	 EEHV	 strains.	 Similarly,	 the	availability	 of	 anti-EEHV	 antibodies,	 especially	 those	 recognising	 non-structural	proteins,	 would	 further	 enable	 immunofluorescence	 based	 technologies	 of	 tissue	sections,	such	as	confocal	microscopy	or	immunohistochemistry	for	the	same	purpose.				In	 addition	 to	 EEHV-1	 as	 the	major	 cause	 of	 fatality,	 other	 EEHV	 genotypes,	 EEHV-3,	EEHV-4,	 and	 EEHV-5,	 have	 also	 occasionally	 been	 reported	 to	 cause	 fatality	 in	 Asian	elephants.	Confirmation	that	a	fatal	case	of	EEHV-HD	was	found	to	be	co-infected	with	EEHV-1	and	4	underlines	the	importance	of	including	all	known	EEHVs	in	routine	blood	monitoring	by	qPCR.		Virus	 isolation	 is	 routinely	 applied	 to	 identify	 viruses	 in	 clinical	 samples	 with	 added	benefits	 that	 the	 isolates	 could	 substantially	 facilitate	 studies	 on	 virus	 structure,	replication,	 genetics,	 pathogenesis,	 vaccine	 development	 as	well	 as	 evaluating	 antiviral	drug	efficacy.	So	far,	there	is	no	report	on	in	vitro	isolation	of	EEHV	using	either	elephant	or	 other	 commercially	 available	 cell	 lines.	 Hence,	 one	 of	 the	 aims	 of	 this	 study	was	 to	isolate	 elephant	 cells,	 especially	 endothelial	 cells	 to	 develop	 a	 laboratory	 tissue	 culture	system	capable	of	supporting	EEHV	replication.	Preliminary	 investigations	were	carried	out	to	elucidate	if	elephant	cells	or	a	number	of	other	commercial	cell	lines,	Swiss	mouse	embryonic	fibroblasts	(3T3),	baby	hamster	kidney	cells	(BHK),	and	monkey	kidney	cells	
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(Vero),	could	support	in	vitro	replication	of	EEHV.	So	far,	all	efforts	to	propagate	the	virus	
in	 vitro	 have	 been	 unsuccessful.	 In	 this	 study,	 however,	 lower	 Ct	 values	 measured	 by	qPCR,	detected	in	the	supernatants	of	EEHV-1A	inoculated	elephant	PBMCs	and	the	3T3	cells,	 indicate	an	 increase	of	EEHV-1A	DNA	 in	 these	cells	culture	systems,	albeit	 lacking	conclusive	 evidence	 for	 active	 viral	 replication.	 Efforts	 to	 find	 a	 suitable	 cell	 culture	system	for	EEHV	isolation	should	remain	one	of	the	major	future	scientific	aims.	Future	research	should	include	screening	of	additional	cell	types	for	EEHV	susceptibility	as	well	as	 developing	 methodologies	 to	 detect	 active	 viral	 replication,	 for	 example	 measuring	mRNA	 transcription	of	EEHV	genes	by	PCR.	The	preliminary	observation	of	EEHV	DNA	increase	 in	 fibroblastic	3T3	cells	 together	with	data	published	 for	HCMV	(Sinzger	et	al.,	1995;	Mocarski	et	al.,	2007)	suggests	that	elephant	fibroblasts	might	represent	the	next	most	 suitable	 cell	 culture	 to	 be	 established.	 Furthermore,	 susceptibility	 of	 elephant	fibroblasts	and	endothelial	cells	of	various	tissues	should	be	specifically	addressed,	where	feasible,	 by	 establishing	 cell	 cultures	 from	 different	 organs	 and	 blood	 vessels.	Additionally,	 specific	 cellular	 systems	 might	 only	 support	 EEHV	 replication	 when	appropriate	 triggers	are	applied,	hence	screening	of	additional	cellular	stressors	should	be	included	in	EEHV	infection	trials.		Elephant	PBMCs	are	a	heterogeneous	cell	population	of	which	only	one	cell	subset	might	be	susceptible	to	EEHV	infection.	The	lack	of	specific	antibodies	recognising	these	cellular	markers	has	so	far	prevented	further	progress	through	e.g.	magnetic	cell	sorting	(MACS)	or	 Fluorescence-activated	 cell	 sorting	 (FACS)	 to	 isolate	 and	 enrich	 such	 cell	 subsets.	However,	 some	 antibodies	 e.g.	 the	 human	 CD14	molecule	 recognising	monocytes,	 have	demonstrated	a	wide	range	of	species	cross-reactivity	and	this	antibody	is	currently	used	to	isolate	bovine	and	ovine	monocytes,	but	have	failed	to	recognise	elephant	monocytes	in	PBMCs	 isolated	 in	 this	 study.	 Efforts	 should	 continue	 to	 test	 cross-reactivity	 of	 other	
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antibodies	to	elephant	monocytes	and	the	subsequent	possibility	to	specifically	isolate	e.g.	elephant	monocytes	or	other	PBMCs	subsets	to	enrich	for	virus	isolation.		Viruses	often	require	distinct	cellular	structure	and	polarised	orientation	for	attachment	and	entry	(Gardner	and	Herbst-Kralovetz,	2016).	Three-dimensional	cell	culture	systems,	e.g.	 rotary	 wall	 vessel	 (RWV)	 bioreactors,	 were	 found	 to	 more	 accurately	 reproduce	features	 of	 tissues	 in	 vivo.	 A	 wide	 variety	 of	 tissues	 have	 been	 grown	 in	 the	 RWV	bioreactors	and	have	 shown	 to	 support	productive	viral	 infection	 for	many	viruses,	 e.g.	hepatitis	E	virus,	that	are	difficult	to	grow	in	ordinary	culture	vessels	(Berto	et	al.,	2013).	Future	studies	should	also	consider	such	3D	bioreactors	as	an	option	to	isolate	EEHVs.		EEHV	is	claimed	to	be	ubiquitous	in	Asian	elephant	populations	(Hardman	et	al.,	2012),	however	 it	 is	 yet	 unknown	 why	 some	 individuals	 succumb	 to	 the	 infection	 and	 the	underlying	 factors	 for	 infection	 outcome.	 A	 critical	 point	 that	 still	 needs	 to	 be	determined	 is	whether	 previous	 infections	with	 another	 strain	 of	 EEHV	 can	 stimulate	the	 immune	 system	 to	prevent	 the	 animal	 from	 the	disease	 caused	by	EEHV-1A.	Also,	another	 unsolved	 question	 is,	 whether	 EEHV-HD	 is	 caused	 by	 primary	 infection	 or	reactivation	 of	 the	 latent	 virus.	 It	 has	 been	 suggested	 that	 severe	 viraemic	 disease	involve	primary	 infections,	 as	no	example	exist	of	 a	 virus	 strain	being	 identical	 to	 the	one	detected	in	an	earlier	viraemic	episode	from	the	same	animal	or	a	herd	mate	(Long	et	al.,	2015).	A	similar	 finding	was	also	observed	 in	this	study	as	EEHV-1A	detected	 in	the	Max	fatal	case	was	genomically	different	from	those	in	the	Betts	and	Riddle	cases.	So	far,	 only	 two	 potentially	 reactivated	 infections	 are	 documented	 where	 a	 subsequent	downstream	primary	infection	in	herd	mate	was	initiated	(Atkins	et	al.	2013;	Stanton	et	al.	2013).		
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Overall,	 it	would	be	very	 informative	 to	determine	 the	 immune	 status	of	 the	elephant	prior	 and	 following	 EEHV	 infection	 to	 gain	 an	 understanding	 of	 the	 virus	 source	(primary	 infection	 or	 reactivation)	 and	 to	 further	 determine	 efficacy	 and	 duration	 of	immunity.	 Therefore,	 the	 development	 of	 EEHV	 specific	 serological	 or	 cellular	 assays	should	 be	 another	 future	 priority	 of	 EEHV	 research.	 Serologic	 screening	 would	 be	 of	great	 value	 for	 Herd	 Monitoring	 Programs,	 as	 it	 provides	 a	 means	 of	 detecting	antibodies	 in	 individual	 elephants.	 The	 serological	 assay	 could	 also	 be	 beneficial	 for	evaluating	 the	animal’s	humoral	responses	 to	a	prototype	vaccine,	 should	one	become	available.	 The	 two	 so	 far	 existing	ELISA	 assays	 (Reid	 et	 al.,	 2008;	Van	den	Doel	 et	 al.,	2015)	are	based	on	EEHV-1A	gB	and	are	suspected	to	cross-react	with	other	EEHVs	 if	not	elephant	gammaherpesviruses.	Other	potential	genes	of	choice	to	serve	as	antigens	in	an	ELISA	could	be	gH,	gL,	EE6,	EE62,	EE54,	or	EE5.	The	 first	 two	glycoproteins	are	thought	 to	 be	 highly	 immunogenic	 (Huber	 and	Compton,	 1999)	with	 a	 relatively	 high	degree	 of	 similarity	 between	 EEHV-1A	 and	 EEHV-1B	 (Wilkie	 et	 al.,	 2014),	 but	 would	most	 likely	 be	 suitable	 for	 a	 pan-EEHV	 serological	 assay.	 As	 a	 contrasting	 approach,	EEHV-1A	 and	 EEHV-1B	 encode	 unique	 novel	 proteins,	 EE6,	 EE62	 and	 EE54,	 EE56,	respectively	(Wilkie	et	al.,	2013),	which	could	offer	a	potential	target	for	strain-specific	ELISA	assays.		In	 conclusion,	 this	 PhD	 project	 achieved	 its	 aims	 by	 addressing	 correlation	 between	blood	 EEHV	 load	 and	 disease	 development,	 identifying	 elephant	 blood	 parameters	indicative	 of	 virus	 infection	 and	disease	prognosis,	 and	providing	 evidence	 for	 lack	 of	efficacy	 of	 famciclovir.	 The	 study	 also	 revealed	 information	 on	 EEHV	 load	 and	distribution	 in	tissues	of	EEHV-HD	fatalities,	which	have	 implications	 in	choice	of	cells	for	 virus	 isolation.	 Finally,	 PBMCs	 and	 elephant	 endothelial	 cells	 were	 successfully	
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isolated	and	used	along	with	several	other	established	non-elephant	cell	lines	for	in	vitro	isolation	of	EEHV-1A.	This	study,	however,	could	not	achieve	a	tangible	virus	replication,	but	provided	directions	for	such	efforts	in	the	future.			 	
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Surviving and fatal Elephant
Endotheliotropic Herpesvirus-1A infections
in juvenile Asian elephants – lessons
learned and recommendations on anti-
herpesviral therapy
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Abstract
Background: Elephant Endotheliotropic Herpesviruses (EEHVs) can cause acute haemorrhagic disease in young
Asian elephants (Elephas maximus) and clinical EEHV infections account for the majority of their fatalities. The anti-
herpesviral drug famciclovir (FCV) has been used routinely to treat viraemic at-risk elephants, but thus far without
proven efficacy. This paper presents clinical and virological investigations of two EEHV-1A infected elephants treated
with FCV, and discusses anti-herpesvirus therapies of viraemic elephants.
Cases presentations: Two 1.5 year old male Asian elephants at a zoological collection in the UK developed clinical
EEHV-1A infections. Case 1 showed signs of myalgia for the duration of 24 hours before returning back to normal.
EEHV-1A DNAemia was confirmed on the day of clinical signs and continued to be present for 18 days in total.
Trunk shedding of the virus commenced 10 days after detection of initial DNAemia. Case 2 tested positive for
EEHV-1A DNAemia in a routine blood screening sample in the absence of clinical signs. The blood viral load
increased exponentially leading up to fatal clinical disease seven days after initial detection of DNAemia. Both calves
were treated with 15 mg/kg FCV per rectum on detection of DNAemia and penciclovir, the FCV metabolite, could
be detected in the blood at assumed therapeutic levels. The early indicators for clinical disease were a marked
absolute and relative drop in white blood cells, particularly monocytes prior to the detection of viraemia. The most
prognostic haematological parameter at later stages of the disease was the platelet count showing a continuous
sharp decline throughout, followed by a dramatic drop at the time of death.
Conclusions: The EEHV-1A viraemic animals investigated here further highlight the ongoing threat posed by these
viruses to juvenile Asian elephants. The findings call into question the efficacy of rectal FCV in clinical cases and
direct towards the use of alternative anti-herpesvirus drugs and complementary treatments such as plasma
infusions if no improvement in either viral load or the above-mentioned blood parameters are observed in the
initial days of viraemia despite anti-herpesvirus therapy.
Keywords: EEHV-1, elephantid herpesvirus, EEHV-haemorrhagic disease, EEHV-HD, famciclovir, ganciclovir
Abbreviations: BID, Bis in die (twice a day); DNA, Deoxyribonucleic acid; EDTA, Ethylenediaminetetraacetic acid;
HPLC, High performance liquid chromatography; i/v, Intravenous; PBS, Phosphate buffered saline; PCR, Polymerase
chain reaction; qPCR, Quantitative PCR; TID, Ter in die (thrice a day)
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Background
Elephant Endotheliotropic Herpesviruses (EEHVs) or
Elephantid Herpesviruses (ElHVs) belong to the genus
Proboscivirus of the family Herpesviridae [1, 2] and fall
into 7 genotypes [3–9]. Phylogenetically, the viruses are
most closely, although distantly, related to human cyto-
megalovirus (HCMV) and three human Roseolo viruses
(human herpesvirus-6A, -6B, and -7), all members of the
subfamily Betaherpesvirinae [1].
EEHVs, in particular EEHV-1, are the cause of acute
haemorrhagic disease (EEHV-HD) in young Asian ele-
phants (Elephas maximus), and clinical EEHV infec-
tions account for most of the fatalities in juvenile Asian
elephants, both in their natural habitat and in captivity
[7–13]. EEHV-1 induced acute haemorrhagic disease is
manifested initially by sudden onset of non-specific
clinical signs, which often develop into haemorrhagic
disease and sudden death within 1 to 7 days [9, 12]. It
has also been documented that EEHV viraemia is de-
tectable at least several days before the onset of clinical
signs [13, 14]. To enable early therapeutic intervention
in response to detection of EEHV viraemia, some zoo-
logical collections have implemented regular blood
sampling and laboratory testing of juvenile Asian
elephants.
Conferring from herpesviruses’ properties, it could be
assumed that once an elephant is infected it remains a
latent carrier for life. Screenings of elephant herds have
revealed widespread prevalence of the viruses and their
periodical reactivation and shedding through biological
fluids, especially trunk secretions [13–19]. Routes of
EEHVs transmission to naïve individuals are still unclear,
however, considering other herpesviruses’ transmission
routes, contact with infected bodily secretions is a very
likely possibility and vertical transmission cannot be
excluded.
EEHVs, similar to viruses in the subfamily Alphaherpes-
virinae and Gammaherpesvirinae, comprise of a genome
with a thymidine kinase (TK) and a serine/threonine pro-
tein kinase (PK) [7, 20], which encode enzymes crucial for
processing many anti-herpesviral prodrugs into their active
derivatives. Based on approaches in treatment of other her-
pesviruses with TK and PK genes, three nucleoside ana-
logues [famciclovir (FCV) and more recently ganciclovir
(GCV) and aciclovir (ACV)] have been administered to
treat viraemic elephant calves, with the aim to avert pro-
gression to clinical disease, but as yet without proven clin-
ical efficacy. It is known that several elephant calves have
survived laboratory confirmed EEHV infections. These ele-
phant calves were treated with FCV at doses of 5.5-8.0 mg/
kg twice daily (BID) rectally [9, 18, 19, 21–24] or with
GCV at 5 mg/kg BID intravenously followed by oral
administration [14, 25]. One elephant calf with advanced
EEHV-1 clinical signs has been treated successfully with
ACV at 12mg/kg BID intravenously for 15 days along with
penicillin G and supportive treatment including vitamin C,
physiological saline and 5 % Dextrose [26]. Apart from the
latter case, it seems likely that many of surviving elephant
calves represent relatively mild cases, in view of length of
time taken to reach the highest viral load, level of viraemia
at this point and recovery of blood parameters. It is there-
fore likely that these affected individuals might have recov-
ered without drug intervention [9].
FCV, chemically known as 2-[2-(2-amino-9H-purin-9-
yl)ethyl]-1,3-propanediol diacetate, is a synthetic acyclic
guanosine analogue that is rapidly de-acetylated and
oxidized in the body to its metabolite penciclovir (PCV).
Activation of PCV requires phosphorylation in the
virally infected cells by viral and cellular kinases. The
drug has a half-life of approximately three hours and its
catabolite is excreted renally [27]. PCV interacts with
herpesvirus DNA polymerase, the enzyme responsible
for creating DNA molecules through assembly of nucle-
otides (building blocks of DNA), and thus terminates
DNA synthesis. A recent study showed that when
administered to healthy young Asian elephants both
orally or per rectum, FCV is absorbed and metabolised
to PCV with plasma levels considered therapeutic in
humans [27, 28]. ACV, another guanosine analogue with
a biological half-life of 2-4 hours, is still used widely for
the treatment and prevention of clinical Herpes Simplex
Virus (HSV) and Varicella Zoster Virus (VZV) diseases
in humans. Activation of ACV within cells via the viral
and cellular kinases yields ACV–triphosphate, which
interacts adversely with herpesvirus DNA synthesis [29].
GCV is another guanosine analogue that is activated via
viral and cellular kinases. Its oral prodrug valganciclovir
(VGCV) is the most commonly prescribed drug for the
prevention and therapy of HCMV in immunocomprom-
ised patients [29].
This paper describes the investigations into two
EEHV-1A viraemic elephants from a UK zoological
collection that were both treated with FCV. It also dis-
cusses findings of the investigations in relation to anti-
herpes viral therapies in EEHV viraemic elephants.
Case presentations
Virus screening
Blood samples of EDTA whole blood and blood swabs
were collected under trained behaviour from an ear vein
after aseptic preparation of the medial aspect of the ear
pinna. For EDTA whole blood samples, the animal was
placed in lateral recumbency and the lowermost ear was
sampled, using a standard 21G 1-inch needle and a
Vacutainer® blood collection system. For blood swabs, a
dry 6-inch foam tipped swab (Sigma Aldrich, UK) was
used for collection of a drop of blood after puncture of
an ear vein with an insulin needle, with the elephant in
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standing position. Blood samples were kept at room
temperature before being shipped to the laboratory,
where they were stored at 4–8 °C until being processed.
Under trained behaviour, conjunctival swabs and trunk
swabs were collected. Conjunctival swabs were collected
using a sterile dry swab for each eye, running these on
the inside of the lower palpebra. Trunk secretions from
the mucosa of each naris were collected on a dry 6-inch
foam tipped swab at a depth of approximately 8–10 cm,
under trained behaviour, and stored at −20 °C prior to
further testing. Blood smears were made of freshly col-
lected EDTA blood samples, air dried and stained with
Diff-Quick (LabPak, UK) for an in-house relative white
blood cell (WBC) differential count.
Nucleic acid was extracted from 140 μl EDTA whole
blood using the QIAamp® Viral RNA Mini kit (Qiagen,
UK) according to the manufacturer’s protocol. For blood
swabs, 560 μl buffer AVL from the kit were directly added
to the foam tipped swabs, left for 15 minutes at room
temperature, vortexed and spun briefly, and processed as
per the manufacturer’s instructions. To process trunk
swab samples for nucleic acid extraction, 300 μl PBS and
6–8 glass beads (3 mm in diameter) were added to the
swab inside a 2 ml Eppendorf tube, vortexed briefly and
incubated for 30 minutes at room temperature. The tube
content was then vortexed and nucleic acid was extracted
following the EDTA whole blood protocol using 140 μl of
the cleared suspension.
The qPCR used in this study was performed as described
[16] using the QuantiFast® Pathogen PCR + IC kit (Qiagen).
Briefly, 2 μl extracted DNA was added to 0.1 μl each for-
ward and reverse primer (100 pmol/μl), 0.05 μl hydrolysis
probe (100 pmol/μl), 5 μl 5× QuantiFast Pathogen Master
Mix, 0.5 μl 50× High-ROX Dye solution, and 17.25 μl
RNase-Free Water. The qPCR was performed on a
MX3005P machine (Agilent Technologies, UK) using the
cycling conditions of one cycle of 95 °C for five minutes
followed by 45 cycles of 95 °C for 15 seconds, 60 °C for 30
seconds, and signal acquisition at the end of each cycle.
The conventional PCRs were carried out as described [30]
using several primer pairs to amplify partial sequences of
polymerase (POL), glycoprotein L (gL) and gM genes.
The DNA standard used was a HPLC purified 100 bases
synthetic oligonucleotide (Eurofins Genomics, UK),
identical to the sequence of the qPCR target, diluted to
provide serial copy numbers from 106 to 101 copies per
PCR test. The synthetic oligonucleotide dilutions were run
in triplicate in the PCRs to create a standard curve for
EEHV genome quantification.
Supportive therapy and drug administration
Rectal fluids were provided after manual removal of all
faeces from the rectum. Several litres of hand-warm
water were then deposited into the distal colon at
approximately one meter depth, through a standard gar-
den hose pipe. Intravenous (i/v) access was acquired
after antiseptic preparation of the medial aspect of the
ear pinna, using an 18G 2.5-inch indwelling catheter
(Milacath®, Mila International, USA) in an ear vein. The
catheter was secured using Durapore® tape and super-
glue. Standard giving sets were used for i/v fluids and
filtered giving sets for the administration of blood and
blood components (Baxter, UK). Plasma was collected
from adult herdmates under trained behaviour, in lateral
recumbency from either an ear vein or a medial hind leg
vein, in one litre citrate blood collection bags (Crusse,
Denmark), stored for a minimum of eight hours at 5 °C
and separated using manual pressure. The plasma was
then stored at 5 °C and warmed to room temperature
prior to administration.
Anti-herpes viral treatment consisted of either FCV or
GCV. FCV (Novartis Pharmaceuticals, UK) 250 and/or
500 mg tablets were crushed using a pestle and mortar
and suspended in hand warm water. Using a 60 ml
syringe and a meter long tube, the suspension was ad-
ministered in the distal colon after removal of all faeces
as described above. GCV (Cymevene® 500 mg, Roche,
UK) was diluted in one litre of physiological saline
attached to a giving set and an i/v catheter, and adminis-
tered slowly over a period of one hour.
For measurement of plasma levels of GCV and PCV, the
FCV metabolite, whole blood samples obtained approxi-
mately 6-10 hours following drugs administration, were
centrifuged at 800 × g for 10 minutes and plasma was col-
lected and stored at −20 °C for later analysis. Plasma sam-
ples were analysed at the College of Veterinary Medicine,
University of Tennessee, USA using a reverse phase HPLC
method with solid phase extraction (SPE). The compounds
were separated on an Atlantis T3 (4.6 × 250 mm) column
with a mobile phase of 10 mM ammonium phosphate pH
2.9 and acetonitrile (95:5). The flow rate was 1.2 ml/min
and fluorescence was measured at excitation 253 nm and
emission 360 nm. Standard curves for plasma analysis were
prepared by fortifying untreated, pooled elephant plasma
with the drug to produce a linear concentration range of
10-5000 ng/ml. Average recovery was 100 % while intra
and inter-assay variability ranged from 0.5 to 5.1 %. The
lower limit of quantification was 10 ng/ml.
Case 1
In 2013, 1.5 year old male Asian elephant calf ‘Scott’
was presented with unwillingness to bend either fore-
leg, swinging both legs forward when walking. Its ears
were drooping, the head was down and the calf was off
solid food. An EDTA whole blood sample taken on the
day tested qPCR positive for EEHV-1 DNA. Prior to
this event, routine blood samples and trunk swabs
tested negative for EEHV-1. Using a qPCR assay, the
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blood viral load was determined as 8.16*103 viral gen-
ome copies (vgc)/ml (Fig. 1). Genomic analysis of this
EEHV-1 by sequencing of PCR amplicons of partial
viral POL, gL and gM genes identified the virus as
EEHV-1A genotype. The sequences comparison with
those of two EEHV-1A fatalities in 2009 (Riddle and
Betts) at the collection revealed several nucleotide
substitutions in the POL, gL and gM gene segments, in-
dicating a genomically different virus from those in
Riddle and Betts (Fig. 2).
Treatment with 15 mg/kg FCV three times daily
(TID) per rectum was instigated eight hours after
these initial clinical signs. The first two treatments,
six hours apart, consisted of ground FCV tablets sus-
pended in ultrasound gel (Healthlife®, Barclays-Swan
Ltd, UK); however, most of the drug was expelled at
the next defaecation. Twelve hours after the initial
presentation, the calf started to voluntarily bend his
right foreleg again, and by the next morning, despite
some stiffness in the shoulders, the legs were in nor-
mal use and its appetite had returned. The dose of
FCV was therefore reduced to 12 mg/kg TID (Day 1);
this time dissolved in hand warm water and placed
1.5 meters deep into the rectum. All clinical signs
were resolved by Day 2, when the blood viral load
peaked at 3.61*104 vgc/ml, after which it started to
decrease gradually. The FCV dose was further re-
duced to 8 mg/kg BID on Day 7. Full haematology at
this point showed a relatively low monocyte count
(5.94*109/L, 26 % of WBC), but was normal (51 % of
WBC) when tested three weeks later (Table 1a). No
virus was detectable in the blood from Day 18 on-
wards (Fig. 1), and FCV treatment ceased on Day 21.
Viral DNA excretion through eye (data not shown)
and trunk secretions commenced on Day 10 and con-
tinued for at least two months, with a peak at around
Day 48 of 4.66*103 vgc/test reaction. No further sam-
ples were tested beyond Day 57.
As a pre-emptive measure, the calf ’s two siblings, a 3-
year old male and a 4-year old female, were treated sim-
ultaneously with 12 mg/kg FCV TID from Day 0 to Day
6, which was tapered to 8 mg/kg BID from Day 7 to Day
12, after which treatment ceased. Neither sibling was
positive for EEHV-1 DNA in blood or bodily secretions
throughout this period.
Plasma PCV levels, measured at trough levels 8-10
hours following the latest FCV administrations in both
Case 1 (Fig. 3) and its male sibling (data not shown),
ranged between 68 and 934 ng/ml. Levels measured at
the dosing regimens of 15 mg/kg TID and 12 mg/kg
TID reached values considered therapeutic in humans
with genital herpes (>100 ng/ml) [27].
Case 2
In 2015, a blood swab collected during routine weekly
sampling of 1.5 year old male calf ‘Max’ tested positive
for EEHV-1 DNA by qPCR. This result was confirmed
by a subsequent EDTA whole blood sample that tested
qPCR positive at 5.0*102 vgc/ml of blood. At this point
monocytes were abundant (12.46*109/L, 54 % of WBC)
and the platelet count was 950*109/L. (Table 1b, Day
-33). A follow-up blood sample four days later was
EEHV-1 DNA negative by qPCR and the calf remained
negative on four subsequent blood swabs taken during a
three-week period. On week 4 and one day prior to the
calf being diagnosed again with EEHV-1 DNAemia the
calf was presented with a swollen right temporal gland,
which was painful on palpation and from which purulent
discharge could be expressed. The gland was treated
with pevidine (Sanofi, UK) flushes and topical amoxicil-
lin/clavulanic acid application following bacteriological
culture and sensitivity testing. After this positive EEHV
Fig. 1 EEHV-1A DNA levels in blood and trunk secretions of Case 1. Clinical suspicion of EEHV infection was confirmed by detection of EEHV-1A
DNA in blood. The animal showed clinical signs suggestive of active EEHV-1A infection on Day 0 and Day 1. EEHV-1A DNA load in EDTA whole
blood (solid line) and trunk secretions (dashed line) was measured using a qPCR
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Fig. 2 Nucleotide sequence comparison of the EEHV-1A detected. Partial nucleotide sequences of DNA polymerase [U38/POL (194 bp)], glycoprotein
L [U82/gL (381 bp)] and glycoprotein M [U72/gM (500 bp)] from Case 1 and Case 2 were compared with those of two previous EEHV-1A fatalities
(Riddle and Betts) from the same zoological collection. Sequences were aligned using the MegAlign 13 software of the DNASTAR Lasergene 13
package (DNASTAR Inc. Madison, USA). Identical nucleotides to those of Case 1 are denoted by dots in the alignments
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qPCR result from a blood swab, an EDTA whole blood
sample also tested positive, with a viral load of 1.2*105
vgc/ml, the monocyte count had markedly reduced to
0.8*109/L (13 % of WBC) and the platelet count almost
halved to 560*109 /L, in the absence of clinical signs
(Day -5). PCR results for this sample became available
two days after the actual sampling date and treatment
was immediately instigated at 15 mg/kg FCV TID per
rectum. Blood samples were then taken regularly for
EEHV-1 qPCR, viral quantification and haematology.
Table 1 Haematological parameters of Case 1 and Case 2 measured during clinical EEHV-1A infection
A
Days WBC
(*10e9/L)
Neutrophils
(*10e9/L)
Lymphocytes
(*10e9/L)
Monocytes
(*10e9/L)
Eosinophils
(*10e9/L)
Basophils
(*10e9/L)
7 22.85 7.77 8.91 5.94 (26 %) 0.23 0
23 13.69 5.75 2.87 6.16 (45 %) 0 0
213 15.91 4.61 5.73 5.25 (33 %) 0.32 0
Physiological mean
(% of WBC)
15.51 3.77 (25.5 %) 5.02
(23.65 %)
6.46
(50 %)
0.24
(1.55 %)
0.02
(0.10 %)
Days RBC
(*10e12/L)
HGB
(g/dL)
HCT
(%)
MCV
(fL)
MCH
(pg)
MCHV
(g/dL)
RDW
(%)
PLT
(*10e9/L)
PCV
(%)
7 3.54 13.4 37.7 107 37.8 35.5 14.3 470 36
23 5.06 19.2 55.1 109 37.9 34.8 14.5 968 55
213 3.62 13.3 39.2 108 36.8 33.9 13.9 996 37
Physiological
(mean)
3.55 14.28 40.60 114.25 40.19 35.17 14.33 617.65 40.80
B
Days EEHV-1A
(vgc/ml)
WBC
(*10e9/L)
Neutrophils
(*10e9/L)
Lymphocytes
(*10e9/L)
Monocytes
(*10e9/L)
Eosinophils
(*10e9/L)
Basophils
(*10e9/L)
-33 5.0 × 102 23.08 4.62 5.77 12.46 (54 %) 0 0
-29 ND 25.34 4.56 7.6 13.18 (52) % 0 0
-5 1.2 × 105 6.18 3.46 1.85 0.8 (13 %) 0.06 0
-3 2.7 × 106 7.35 5.22 1.32 0.81 (11 %) 0 0
0 7.2 × 106 13.25 8.22 2.65 2.25 (17 %) 0.13 0
1 1.9 × 107 12.925 7.565 2 2.975 (23 %) 0 0.195
Physiological mean
(% of WBC)
15.51 3.77 (25.5 %) 5.02 (23.65 %) 6.46 (50 %) 0.24 (1.55 %) 0.02 (0.10 %)
Days RBC
(*10e12/L)
HGB
(g/dL)
HCT
(%)
MCV
(fL)
MCH
(pg)
MCHV
(g/dL)
RDW
(%)
PLT
(*10e9/L)
PCV
(%)
-33 3.65 14.6 43.2 118.3 39.9 33.7 13.9 950 42
-29 3.58 14.5 41.4 115.5 40.4 35 38.1 760 38
-5 3.48 14.2 41.8 120.4 41 34 14 560 37
-3 3.36 14.2 38.4 114.4 42.4 37.1 13.7 183 38
0 2.89 12.4 32.9 113.7 42.9 37.8 13.8 98 34
1 3.07 12.95 35.05 114.2 42.2 36.9 13.6 13 36.5
Physiological mean 3.55 14.28 40.60 114.25 40.19 35.17 14.33 617.65 40.80
The haematological parameters for Case 1 (A) were only available for Days 7, 23 and 213 following suspicion of clinical EEHV-1A infection. The haematological
parameters and viral load for Case 2 (B) were measured on several occasions from 33 days prior to the observation of signs indicative of clinical EEHV-1A infection
(Day 0) to the Day 1 when the elephant succumbed to the infection at midnight. Normal platelet range of live juveniles in the collection was established, during a
period of seven months from 20 blood samples of the elephants, to be at 372-878*10e9/L (mean of 625*10e9/L). The rest of the physiological parameters were
from 24 measurements from four individuals under eight years of age (age range at time of sampling: 1.5-7y). Parameter values with a substantial change are
highlighted in bold. Percentages of monocytes in the white blood cells are also given in the table
vgc/ml, viral genome copies per millilitre of EDTA whole blood; WBC, white blood cell count; RBC, red blood cell count; HGB, haemoglobin; HCT, haematocrit;
MCV, mean cell volume; MCH, mean corpuscular haemoglobin; MCHV, mean corpuscular haemoglobin volume; RDW, red blood cell distribution width; PLT,
platelet count; PCV, packed cell volume; ND, not detected
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Genomic analysis of this EEHV-1 by sequencing of
PCR amplicons of partial viral POL, gL and gM genes
identified the virus as EEHV-1A genotype. However,
comparing these nucleotide sequences to those of Case
1, it was revealed that the virus was genomically slightly
different, but both cases were more dissimilar to Riddle
and Betts (Fig. 2). Nucleotide sequences of the partial
segments of the three genes for Riddle and Betts were
identical. This was not unexpected as the two fatalities
occurred within two weeks of each other, but longer se-
quence reads would be necessary to verify this further.
Viral load increased exponentially as time progressed,
during which the monocyte count stabilised around
2.54*109/L (17 % of WBC), but platelet counts showed a
continuous decline (Table 1b). Lymphocyte count has
also shown substantial reduction on the detection of
DNAemia, but other haematological parameters such as
neutrophil and basophil counts remained unchanged.
PCV plasma levels as high as 934 ng/ml were attained
during the first days of treatment (Fig. 3). Five days into
the DNAemia, the calf started to show signs of lethargy.
At this point, PCV plasma levels had dropped to 303
ng/ml, about a third of its previous peak.
The decision was made to start i/v fluids, consisting of
Harmann’s (15 ml/kg/h, Vetivex 11, Dechra, UK) supple-
mented with Duphalyte (1 ml/kg BW, Pfizer, UK), and
complement the treatment from solely FCV per rectum to
i/v plasma and GCV. The calf first displayed clinical signs
of haemorrhagic disease six days into the DNAemia:
oedema of the head and ventral abdomen, tongue pe-
techiae and progressive signs of cyanosis. The platelet
count had also reduced drastically at this point to 98*109/
L and viral load had increased to 7.2*106 vgc/ml of blood.
Intravenous cannulas were in place in both ears for ad-
ministration of 1 ml/kg plasma TID, fluids and antibiotics
(2 mg/kg marbofloxacin, Marbocyl®, Vetoquinol). Due to
logistics, GCV (5 mg/ml) could not be administered until
16:00h that day, but achieved plasma levels of 2529 ng/ml
following i/v injection. Clinical signs progressed despite
treatment and the platelet count further reduced to
13*109/L and viral load increased to 1.9*107 vgc/ml of
blood. The calf subsequently died at midnight, just into
the next day as a result of hypoxaemia and hypovolaemia.
Discussion
The early clinical signs of EEHV-HD are non-
pathognomonic and often manifested as lethargy, anorexia
and lameness. As a consequence of generalized capillary
endothelial cell damage, these early clinical signs are likely
to be followed by more severe and generally terminal signs
[5, 8, 12]. Routine blood testing of at-risk Asian elephants
for EEHV viraemia has been suggested as part of a
Fig. 3 Penciclovir, the metabolite of famciclovir, plasma levels in 2 juvenile Asian elephants with EEHV-1A DNAemia. Famciclovir (FCV) was rectally
administered in Case 1 at 15 mg/kg twice daily (BID) on observation of clinical signs indicative of EEHV-1A infection (Day 0) and continued at the
same dose rate until Day 1, when it was reduced to 12 mg/kg thrice daily (TID). This was followed by further reduction on Day 3 to 8 mg/kg BID
and continued unchanged until Day 18. In Case 2 FCV was administered at 15 mg/kg TID for two days following the detection of EEHV-1A DNA
in the blood (Day -5), five days prior to observation of EEHV-1A clinical signs, and continued at the same dosage till the last dose of FCV at 9:00
am on Day 0; blood was only collected at 17:00 pm on that day. The death of Case 2 was at midnight on Day 1; seven days after first detection
of EEHV-1 DNA in the blood. Dashed line indicates the minimum level of PCV considered therapeutic in humans with genital herpes
(>100 ng/ml) [27]
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monitoring scheme to predict and potentially prevent fatal
disease, as the viral DNA can be detected at least several
days prior to any clinical signs [13, 14]. This routine
monitoring was proven to be valuable in this study, where
Case 2 continuous EEHV-1 DNAemia was detected five
days prior to the earliest clinical signs, although unfortu-
nately this early initiated treatment was not able to pre-
vent fatality.
In addition to detection and quantification of viral DNA
through real-time qPCR, drop in the monocyte/neutrophil
ratio, and absolute reduction of the platelet count, make
both the monocytes and platelets the most useful prognos-
tic haematological parameters of EEHV-HD, although the
exact physiological process for these changes is as yet un-
known. It is possible that the monocytes are subjected to
immediate assault of the virus [19], and that the viral dam-
age to the endothelial cells beyond the adaptive nature of
the host response leads to the development of dissemi-
nated intravascular coagulation (DIC) and hence critical
loss of platelets. In Case 2, the platelet count showed a
gradual decline well before the fatal progressive viraemia,
reaching a dangerously low level before death. Archived
data from three previous EEHV fatalities at the same col-
lection show a similar critically low platelet count following
clinical EEHV-1 manifestation (Table 2). Similar findings
have also been recently reported from Asian elephants
affected by EEHV-1B, 4 and 5 viraemia [13, 18, 19]. It is
noteworthy that mean haematological parameters vary
substantially in Asian elephants’ blood, e.g. a reported
range of 80-975*109/L for platelets [31–35]. Monocytes are
usually the most abundant white blood cells in the majority
of juveniles. In these cases, the relative drop of monocytes,
compared to neutrophils, in the early stages of the disease
could easily be identified on straightforward in-house white
blood cell differentials. There are, however, individuals in
which the monocytes are on average less abundant and
hence this early indicator will be less beneficial in these
cases. It is therefore advisable to establish individual base-
lines for at least the abovementioned haematological
parameters for each at-risk elephant in advance, and that
clinicians familiarise themselves with in-house blood smear
differentials.
Monitoring kinetics of EEHV-1A load in the two
elephants revealed rapid increase in viral load in the ele-
phant that succumbed to the disease (Case 2) despite con-
tinuous anti-herpesviral treatment up to the EEHV-1
clinical signs. From at least three days prior to onset of
clinical signs, PCV reached plasma levels suggested as
therapeutic for treatment of diseases caused by alphaher-
pesviruses infections in humans [27], but here it had failed
to control virus replication as the virus load continued to
increase. Considering the approximate three hour half-life
Table 2 Haematological parameters of three additional fatal cases of EEHV-1A and EEHV-1B infections from the same zoological
collection
Animals
(date of sampling)
Virus type WBC
(*10e9/L)
Neutrophils
(*10e9/L)
Lymphocytes
(*10e9/L)
Monocytes
(*10e9/L)
Eosinophils
(*10e9/L)
Basophils
(*10e9/L)
Emilia
(18/12/2006) EEHV-1B 17 11.85 3.21 1.9 (11.2 %) 0.03 0.02
Riddle
(01/05/2009) EEHV-1A 2.71 1.49 0.84 0.27 (10 %) 0 0
Betts
(15/05/2009) EEHV-1A 5.1 3.11 1.02 0.97 (19 %) 0 0
Physiological mean
(% of WBC)
15.51 3.77
(25.5 %)
5.02
(23.65 %)
6.46
(50 %)
0.24
(1.55 %)
0.02
(0.10 %)
Animals
(date of sampling)
RBC
(*10e12/L)
HGB
(g/dL)
HCT
(%)
MCV
(fL)
MCH (pg) MCHV
(g/dL)
RDW
(%)
PLT
(*10e9/L)
PCV
(%)
Emilia
(18/12/2006) 3.05 12.8 39.2 122 42 34.4 15.7 34.6 NA
Riddle
(01/05/2009) 3.55 13 37.7 106 36.7 34.6 17.4 25.6 35
Betts
(15/05/2009) 3.16 12.9 55.1 112 40.8 36.5 17.3 71.5 NA
Physiological (mean) 3.55 14.28 40.60 114.25 40.19 35.17 14.33 617.65 40.80
Blood samples were taken following the observation of EEHV-1 infection clinical signs. WBC, lymphocyte, monocyte and platelet counts (highlighted in bold)
consistently show substantial drop from their physiological level in the two fatalities caused by EEHV-1A. Percentages of monocytes in the white blood cells are
also given in the table
WBC, white blood cell count; RBC, red blood cell count; HGB, haemoglobin; MCV, mean cell volume; MCH, mean corpuscular haemoglobin; MCHV, mean
corpuscular haemoglobin volume; RDW, red blood cell distribution width; PLT, platelet count; PCV, packed cell volume; NA, not available
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of PCV [27], the peak levels could have been up to three
times higher than measured, as blood samples were taken
6-8 hours following the FCV administration.
The efficacy of FCV treatment to curb progression to
EEHV-HD in clinical EEHV has always been debatable,
as compromised cellular function at enteric level could
affect absorption. This was indicated by the measured
PCV level in Case 2, which dropped remarkably 48
hours prior to the onset of outwardly visible clinical
signs. Factors such as drug expulsion and individual dif-
ferences in drug metabolism are also considered possible
causes of this drop [24]. These findings therefore favour
those anti-herpesviral drugs that could be administered
intravenously, to bypass the intestinal absorption step.
Additionally, the available sequences for EEHV TK and
PK have only 25 % amino acid identity with their ortho-
logues in HSV and HCMV, target viruses for these drugs
[9] and indirect surrogate in vitro assays have shown
mild sensitivity for only the PK against PCV [36].
Taking into account the EEHV viraemia sequel follow-
ing FCV administration in current and previous studies,
the efficacy of FCV remains doubtful. Therefore the use
of other, i/v administered and potentially more effective,
anti- herpesviral therapies should be explored, especially
in cases where pre-EEHV-HD viraemia, established
through routine blood PCR monitoring, does not appear
to be affected by FCV within the first days of treatment.
In the absence of comprehensive data on a highly effect-
ive and safe anti-herpesviral drug, alternative drugs at
present could include i/v administered nucleoside ana-
logues such as GCV and ACV. The second-line drugs
could be the pyrophosphate analogue foscarnet and the
nucleotide analogue cidofovir, but these drugs all have
their own safety issues. The most common adverse effect
during GCV therapy in humans has been haematological
toxicity, but this appears to be readily reversible on dis-
continuation of the drug [37]. It should also be noted
that ACV is a hundred times more potent than FCV in
inhibiting herpesviruses replication, but it suffers from a
shorter half-life and intracellular concentration [38].
This drug has been recommended for clinical situations
in humans where a rapid decrease in viral load is desir-
able, and could be of similar therapeutic value in EEHV
clinical infections. The renal toxicity of the drug should
also be considered in its therapy. Frequent measurement
of EEHV load in blood samples is therefore of para-
mount value to establish the efficacy of ongoing therapy.
Complementary therapies that are likely to be of value
include supportive therapies e.g. maintaining hydration
and actions to prevent DIC and shock, such as i/v
plasma administration from EEHV antibody positive
adult donors, as a source of both antibodies and plate-
lets, and a broad spectrum antibiotic to combat potential
concurrent bacterial infections that might possibly be at
the root of triggering the viral replication, predisposing
to the infection or arise as a secondary infection.
Intravenous access appears to be of significant value
for supportive treatment and anti-viral drug administra-
tion, and is straightforward in trained elephants that are
used to being handled. The EEHV Advisory Group
convened to debate this in 2014 and currently recom-
mends minimum standards of care for all at-risk elephants
irrespective of management systems, which include a
section on Calf Training for intravenous access (www.eeh
vinfo.org). In elephants that have not attained this stage of
training at the time of infection, repeated standing seda-
tions using butorphanol and detomidine are possible, as
used successfully in other institutions (Lauren Howard,
personal communication).
As far as antibodies are concerned, Case 1 had been
positive on an indirect ELISA for glycoprotein B (gB)
about 9 months prior to the clinical signs and survived
the viraemia [17]. On the other hand, Case 2 was also
highly positive on the same gB ELISA (van den Doel,
pers. communication) at the time of EEHV infection,
but succumbed to the virus. For other closely related
betaherpesvirus infections (e.g. HCMV), antibodies to
the gB protein seemed to enhance protection by curbing
at least the dissemination of the virus in the blood [29].
However, considering the fatality in Case 2 despite high
anti-gB antibody, sole measurement of gB antibody may
not be an indicator of protection against EEHV, as it is
currently unknown which viral proteins are targeted by
neutralising antibodies. The possibility also exists that
early IgG antibodies to EEHV show a low avidity for the
antigen and hence an avidity test is required to deter-
mine the value of antibodies against EEHV [39]. Also, in
the view that herpesviruses (EEHVs and elephant gamma
herpesviruses [EGHVs]) are ubiquitous in Asian elephant
populations, the notion that the above mentioned ELISA
is cross reactive with gB of similar viruses or other un-
known agents cannot be excluded [9].
In this study, a detectable EEHV-1 DNAemia was corre-
lated with the disease symptoms only when the blood viral
load was at around 8.16*103 vgc/ml of blood for Case 1 and
7.2*106 vgc/ml for Case 2. A previous report states that a
threshold of around 1.0*104 vgc/ml of blood had coincided
with apparent illness [14]. Clinical signs appeared at a much
higher viral load in Case 2, emphasising a daily rapid increase
in viral load as a more favourable determinant of initiating
anti-herpesviral therapy, its success and disease prognosis.
Our results also further endorse that DNAemia precedes
virus shedding in trunk secretions of EEHV-1A infected
animals, similar to those reported previously [13, 14, 18, 19].
Although there is no evidence that infectious particles are
shed at a level sufficient to infect an in-contact animal, the
potential risk these carrier elephants may pose following a
clinical EEHV case should be considered.
Dastjerdi et al. BMC Veterinary Research  (2016) 12:178 Page 9 of 11
Conclusions
The EEHV viraemic cases investigated here further high-
light the ongoing threat posed by the virus to the juvenile
Asian elephants, potentially leading to gradual disappear-
ance of their free-living population and an inability to
maintain a viable captive population to safeguard the spe-
cies from extinction. Therefore, effective control of future
EEHV infections is fundamental to improve the survival
rate of affected animals. Routine EEHV testing combined
with viral quantification, WBC, monocyte and platelet
counts following confirmed DNAemia in at-risk elephants
should deliver an early warning of the clinical disease and
prognosis, providing enough time to evaluate treatment
opportunities to avert a fatal outcome. This investigation
further questions the efficacy of the rectally administered
FCV in controlling the viraemia and urges towards the ex-
ploration of alternative therapies. These therapies could in-
clude preferably i/v administered anti-herpes viral drugs,
complementary plasma transfusions and antibiotics against
potential secondary infections.
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a b s t r a c t
Elephant endotheliotropic herpesvirus 1 (EEHV1), a member of the Betaherpesvirinae subfamily, has
recently emerged as an important viral pathogen of Asian elephants that can cause a severe, often fatal,
hemorrhagic disease. EEHV1 does not replicate in culture and little is currently known about the
molecular biology of this emerging pathogen, with the notable exception of its genomic DNA sequence.
Here, we have used small RNA deep sequencing to determine whether EEHV1, like other human and
murine betaherpesviruses, expresses viral microRNAs in infected tissues in vivo. Our data provide
evidence supporting the existence of at least three novel viral microRNAs encoded by EEHV1 and one of
these, miR-E3-5p, is shown to repress target mRNA expression. Moreover, miR-E3-5p expression was
readily detectable in tissue samples derived from two infected elephants, including in whole blood. These
data shed new light on the biology of EEHV1 and identify small RNAs that have the potential to be useful
in the diagnosis of sub-clinical infections in captive Asian and African elephants.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Elephant endotheliotropic herpesvirus (EEHV) can cause
a severe hemorrhagic disease in Asian elephants (Elephas maximus)
(Richman et al., 1999). This disease, which is now believed to be
endemic in Asian elephants (Zachariah et al., 2013), has resulted in
a mortality rate of !80% among the approximately 80 known
infections over the last 20 years, and is especially serious in younger
animals (Hayward, 2012). EEHV1 is now recognized as a threat to
the continued survival of the endangered Asian elephant and EEHV1
is a particular problem among captive animals. The virus species
involved in most cases of fatal disease is elephant endotheliotropic
herpesvirus 1 (EEHV1), which exists as two genotypes, EEHV1A and
EEHV1B (Fickel et al., 2001). EEHV1 is classiﬁed as a member of the
Betaherpesvirinae subfamily (Pellett et al., 2011), members of which
also include viruses in the genera Cytomegalovirus (e.g., human
cytomegalovirus; HCMV) and Roseolovirus (e.g., human herpesvirus
7: HHV7). EEHV1 is somewhat more closely related to the Roseolo-
virus family, but is grouped as the separate genus Proboscivirus
(Wilkie et al., 2013). Importantly, it has not yet proven possible
to grow EEHV1 in culture, so relatively little is known about the
molecular biology of EEHV1, with the important exception that the
genomic DNA sequence of both EEHV1A and EEHV1B has been
reported (Wilkie et al., 2013).
MicroRNAs (miRNAs) are a large family of !22 nucleotide (nt)
regulatory RNAs that function to post-transcriptionally down-
regulate the expression of target mRNAs (reviewed in Bartel,
2009). They are typically transcribed as part of one arm of an
!80-nt RNA stem-loop located within a longer capped, polyade-
nylated transcript, referred to as a primary miRNA (pri-miRNA)
(Cullen, 2004). This stem-loop is recognized by the RNase III
enzyme Drosha, which cleaves !22 bp away from the terminal
loop to generate an !60-nt RNA hairpin, bearing an !2-nt 30
overhang, referred to as the pre-miRNA intermediate. The pre-
miRNA is exported to the cytoplasmwhere it is recognized by Dicer,
a second RNase III enzyme which cleaves the pre-miRNA !22 bp
from the base of the pre-miRNA, leaving a second !2-nt 30
overhang, to generate a short RNA duplex. One strand of this duplex
is incorporated into the RNA-induced silencing complex (RISC) as a
mature miRNA while the second, passenger strand is degraded. The
mature miRNA then guides RISC to complementary target sites
located predominantly in the 30UTR of target mRNAs, resulting in
their translational repression and/or mRNA degradation (Bartel,
2009). While the choice of which strand of the miRNA duplex is
incorporated into RISC usually strongly favors one strand over the
other, this discrimination is rarely absolute and recovery of not only
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the miRNA strand but also the passenger strand is often a hallmark
of an authentic miRNA.
Many herpesviruses, including members of the Betaherpesvirinae,
are known to encode viral miRNAs (Buck et al., 2007; Cullen, 2009;
Dolken et al., 2007; Grey et al., 2005; Pfeffer et al., 2005; Tuddenham
et al., 2012). Yet, the existence of miRNAs encoded by EEHV1 has not
been previously addressed. Here, we examine the expression and
function of several candidate miRNAs expressed by EEHV1A in vivo.
Results
Deep sequencing of small RNAs from cardiac tissue derived
post-mortem from an EEHV1A-infected elephant (Raman) yielded
15,762,214 reads. Of these, 15,424,380 reads (97.9%) mapped to the
elephant genome and 6513 (0.04%) reads mapped to the EEHV1A
genome. As expected from an in vivo sample, the proportion of
reads that mapped to the viral genome was quite low. This likely
results from the fact that only a small percentage of the cells
recovered by tissue necropsy was actually infected with EEHV1, as
also observed previously by deep sequencing of in vivo samples
obtained post-mortem from HSV-1 or HSV-2 infected patients
(Umbach et al., 2009; Umbach et al., 2010).
A key characteristic of authentic miRNAs is that their size
clusters at !22 nt (Bartel, 2009) and indeed reads that mapped to
the elephant genome revealed a peak size of !22 nt in length
(Fig. 1A). Although little is currently known about elephant
miRNAs, we could readily identify several elephant miRNAs that
are conserved across vertebrate species, including humans. The 20
most frequently recovered elephant miRNAs are listed in
Supplementary Table 1. The most abundantly expressed elephant
miRNA was miR-486, which is known to be enriched in muscle
tissue (Small et al., 2010). This is as expected, as the tissues
analyzed were of cardiac origin. Importantly, reads that mapped
to the EEHV1 genome also showed a pronounced peak at !22 nt,
consistent with the hypothesis that EEHV1 encodes authentic viral
miRNAs (Fig. 1A). Many of these small RNAs (3053, 47% of the
total) were derived from 5 discrete locations within the EEHV1A
genome, here termed E1 through E5 (Fig. 1B), while the remainder
were scattered across the EEHV1A genome, as expected for viral
mRNA degradation products. The ﬁnding that many of these small
RNA reads derive from ﬁve discrete locations in the viral genome
again suggests that these represent authentic viral miRNAs.
Of note, the sequence of these ﬁve candidate miRNAs and their
immediate ﬂanking regions is fully conserved between EEHV1A
and EEHV1B (Wilkie et al., 2013). As for the other known subtypes
of EEHV, i.e., EEHV2, EEHV3, EEHV4, EEHV5 and EEHV6, the
currently available sequence data is not adequate to determine
whether these candidate miRNAs are also conserved in these virus
species.
A further characteristic of authentic viral miRNAs is that they
generally have a discrete 50 end, due to the importance of the
miRNA seed sequence (nt 2 through 8) in target mRNA recogni-
tion, while the 30 end is more variable (Bartel, 2009). As shown in
Table 1, which lists all potential EEHV1-derived miRNA and miRNA
passenger strand reads, the ﬁve putative EEHV1-derived mature
miRNAs E1-3p, E2-3p, E3-5p, E4-5p and E5-3p all exhibit an
invariant 50 end (E1 and E4), or two possible 50 ends (E2, E3
and E5), while there was considerable 30 end variation. In contrast,
small mRNA degradation products usually exhibit a range of
different 50 and 30 ends (Whisnant et al., 2013). This result is again
consistent with the idea that some or all of these small RNAs are
authentic EEHV1 miRNAs.
To further conﬁrm the existence of these small EEHV1-derived
RNAs, we also analyzed small RNAs isolated from an EEHV1-
infected necropsy sample of the liver of a second Asian elephant
(Nayan) that succumbed to an EEHV1A infection at the same zoo.
We extracted RNA from the liver tissue and conducted deep-
sequencing of small RNAs, resulting in !21.9 million reads that
could be mapped to either the elephant or EEHV1 genome. We
again detected small RNAs that mapped to the same ﬁve read
clusters E1 to E5 identiﬁed in the sample obtained from Raman,
the other elephant analyzed. These reads are listed in Table 1.
Of note, while the pattern of small RNAs obtained from were quite
similar in both samples, we did note that the dominant isoform of
miR-E1-3p, miR-E4-5p and miR-E5-3p recovered from the Nayan
sample all differed by 1 nt from that seen in the Raman sample
(Table 1). In contrast, the dominant isoform of miR-E3-5p was
identical in both samples.
As noted above, miRNAs form part of one arm of a stem-loop
and deep sequencing often recovers not only the mature miRNA
but also a passenger strand that is offset in the stem by !2 nt (e.g.,
Umbach and Cullen, 2010). In Fig. 2, we show computationally
predicted RNA secondary structures adopted by four of these ﬁve
small RNAs along with their viral ﬂanking sequences. The ﬁfth
small RNA, E4, appeared incapable of forming such a structure.
Moreover, the E4 reads were mostly shorter than the canonical
19–25nt size range for authentic miRNAs (Table 1) and E4 is
therefore likely not an authentic miRNA. In contrast, the other
candidate EEHV1 miRNAs did yield potential stem-loop structures
and, at least for E1, E2 and E3, these RNA structures are of the
approximately correct size and shape (Han et al., 2006; Zeng et al.,
2005). Moreover, for E1, E2 and E3 we recovered not only a
potential mature viral miRNA species but also possible passenger
strands that are indeed derived from the other arm of the stem
and offset by !2 nt (Fig. 2). In contrast, the reads obtained for
miR-E5 were overlapping on the predicted pre-miRNA stem,
which is not expected for an authentic pre-miRNA (Han et al.,
2006; Zeng et al., 2005).
Next, we cloned segments of the EEHV1A genome encompassing
each putative EEHV1A pri-miRNA sequence (the mature miRNA
along with !240 bp of 50 and 30 ﬂanking sequence; i.e. !500 bp of
viral DNA) into an expression vector, transfected them into human
293T cells and then used Northern blot analysis to test for mature
miRNA expression (Gottwein et al., 2006). This experiment showed
that pri-miR-E3 is efﬁciently processed into an !60-nt pre-miRNA
and an !22-nt mature miRNA in these transfected human cells
(Fig. 3). In contrast, we detected neither pre-miRNA nor mature
Fig. 1. Results of deep-sequencing. (A) Length distribution of reads that map to the
elephant or EEHV1A genome. (B) Site-by-site coverage (read counts at each site) of
the EEHV1A genome by deep-sequencing. The X-axis shows read positions from
the 50 end to the 30 end of the EEHV1A genome (GenBank; KC462165). Five
prominent sites of read origin (E1 through E5) were subjected to further analyses
and are designated by an arrow.
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miRNA production for the other four candidate EEHV1 pri-miRNAs
(data not shown).
We next asked if we could obtain evidence that these putative
EEHV1 miRNAs are biologically active. For this purpose, we
generated indicator vectors in which two fully complimentary
target sites for each of the ﬁve candidate EEHV1 miRNAs was
inserted into the 30UTR of a Renilla luciferase (RLuc) reporter gene
(Gottwein et al., 2006). We then transfected the human 293T cell
line with each miRNA expression vector and each viral miRNA
indicator construct and measured expression of RLuc and of the
ﬁreﬂy luciferase (FLuc) internal control. Co-transfection of any of
the putative EEHV1 miRNA expression vectors had no effect on
RLuc activity when no target sites had been inserted into the
30 UTR. In contrast, co-transfection of the miR-E3 expression vector
reduced luciferase activity dramatically when cognate target
sequences were cloned into 30 UTR of RLuc (Fig. 4). However, none
of the other four putative EEHV1 miRNA expression vectors,
encompassing E1, E2, E4 or E5 (Fig. 2), showed any activity. This
negative result is consistent with our inability to detect mature
miRNA expression by Northern blot of total RNA derived from
293T cells transfected with these same vectors.
Because many EEHV1 infections, especially in African
elephants, appear to be asymptomatic, there has been consider-
able interest in developing diagnostic reagents to detect EEHV1 in
Table 1
List of putative EEHV1A miRNAs.
Spot Origin Arm Sequence Length (nt) Positiona Read count
Beginning End Raman 15.4Mb Nayan 21.9Mb
E1 Non coding region 5p AAUUGCCUGCAGUGUUCACAGUA 23 6490 6468 1 0
UGCCUGCAGUGUUCACAGUAGC 22 6487 6466 1 0
3p UACUGAGAACACUGCAUCCC 20 6453 6434 134 37
UACUGAGAACACUGCAUCCCA 21 6453 6433 388 218
UACUGAGAACACUGCAUCCCAA 22 6453 6432 405 120
UACUGAGAACACUGCAUCCCAAU 23 6453 6431 381 139
E2 ORFc (U60) 5p ACAGGCAGCGUCUGUUAAGAU 21 42515 42535 0 1
ACAGGCAGCGUCUGUUAAGAUAG 23 42515 42537 0 1
ACAGGCAGCGUCUGUUAAGAUAGC 24 42515 42538 3 0
3p UCACUUAUCAGACUCUGCCU 20 42554 42573 7 0
UCACUUAUCAGACUCUGCCUGU 22 42554 42575 7 2
UCACUUAUCAGACUCUGCCUGUA 23 42554 42576 3 5
UCACUUAUCAGACUCUGCCUGUAU 24 42554 42577 168 15
CACUUAUCAGACUCUGCCUGUAU 23 42555 42577 193 22
CACUUAUCAGACUCUGCCUGUAUC 24 42555 42578 2 15
E3 Antisense of ORF (U42) 5p AACGGCGCUACUGUUGACUCGC 22 99533 99554 278 173
AACGGCGCUACUGUUGACUCGCU 23 99533 99555 106 39
ACGGCGCUACUGUUGACUCGC 21 99534 99554 5 6
ACGGCGCUACUGUUGACUCGCU 22 99534 99555 61 34
3p AAGAUUUAACGGUAGCGCCAUU 22 99567 99588 5 1
AAGAUUUAACGGUAGCGCCAUUC 23 99567 99589 1 0
AGAUUUAACGGUAGCGCCAUU 21 99568 99588 1 0
AGAUUUAACGGUAGCGCCAUUC 22 99568 99589 8 2
E4 Antisense of ORF (EE46) 5p CUUGAUCAUGAUGGUC 16 161228 161213 0 110
CUUGAUCAUGAUGGUCU 17 161228 161212 57 7
CUUGAUCAUGAUGGUCUU 18 161228 161211 51 2
CUUGAUCAUGAUGGUCUUU 19 161228 161210 35 1
3p Not detected
E5 ORF (EE63) 5p CACAGUCAAUGGUAUCGAGCC 21 177047 177027 0 21
AGUCAAUGGUAUCGAGCC 18 177044 177027 6 2
AGUCAAUGGUAUCGAGCCUCUCA 23 177044 177022 10 2
GUCAAUGGUAUCGAGCC 17 177043 177027 5 0
AAUGGUAUCGAGCCUCUCACAAGC 24 177040 177017 8 37
AAUGGUAUCGAGCCUCUCACAAGCU 25 177040 177016 21 192
3p CACAAGCUCGAUACCAUUGA 20 177023 177004 59 21
CACAAGCUCGAUACCAUUGAC 21 177023 177003 282 315
CACAAGCUCGAUACCAUUGACU 22 177023 177002 384 154
ACAAGCUCGAUACCAUUGAC 20 177022 177003 44 72
ACAAGCUCGAUACCAUUGACU 21 177022 177002 40 28
The most abundant miRNA read for Raman at each viral genomic location is bolded.
a 50 and 30 end positions refer to the genomic sequence of EEHV1A (Genbank; KC462165).
b Number of total reads mapped to either the elephant or EEHV1A genome. M; million.
c ORF; open reading frame.
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infected animals (Hardman et al., 2012; Sariya et al., 2012; Stanton
et al., 2010). MiRNAs, including viral miRNAs, are often expressed at
very high levels, are released into the serum and can be readily
detected using RT-PCR assays (Kuwabara et al., 2011; Tanaka et al.,
2013; Turchinovich et al., 2011; Tzimagiorgis et al., 2011) and we
therefore wondered if miR-E3-5p could be detected in vivo by RT-PCR.
We have access to a range of tissue samples derived from both
deceased Asian elephants, Raman and Nayan, as well as tissue derived
post-natally from an uninfected animal and we therefore designed a
TaqMan probe speciﬁc for miR-E3-5p and tested whether we could
indeed detect this viral miRNA in these in vivo samples.
For this purpose, we isolated total RNA from these tissue
samples, including whole blood, and then measured miR-E3-5p
expression by quantitative RT-qPCR (Table 2). As may be observed,
we failed to detect any miR-E3-5p expression in the negative
control tissue or in a tongue tissue sample derived from Raman,
but otherwise we were able to detect miR-E3-5p expression in all
samples analyzed, including most importantly whole blood. Parti-
cularly high levels of miR-E3-5p were detected in the heart and
liver of both animals (Table 2). We therefore conclude that miR-
E3-5p has the potential to serve as a biomarker for detection of
subclinical EEHV1 infections.
Discussion
A number of herpesviruses, including several human and non-
human Betaherpesviruses, have been shown to express viral miRNAs
in infected cells in culture or in vivo (Cullen, 2011; Grundhoff and
Sullivan, 2011). Here we have asked whether EEHV1, a pathogenic
Betaherpesvirus that causes a severe hemorrhagic disease in Asian
elephants, also has the potential to express viral miRNAs. Our initial
datawere very encouraging, as deep sequencing of small RNAs derived
from cardiac or liver tissue obtained from two Asian elephants that
had died from natural EEHV1A infections revealed several thousand
reads of EEHV1A origin that were tightly clustered around the
predicted !22 nt size for authentic viral miRNAs (Fig. 1A). Moreover,
many of these reads derived from ﬁve discrete locations in the EEHV1
genome (Fig. 1B), again as predicted for authentic viral miRNAs.
Analysis of the sequence of these small viral RNAs showed that they
displayed deﬁned 50 ends and also revealed several possible miRNA
passenger strands (Table 1). However, attempts to fold these miRNA,
along with its ﬂanking sequences, into the expected hairpin structure
was only successful in the case of candidate miRNAs E1, E2 and E3
(Fig. 2), with E4 lacking the ability to fold into any form of stable RNA
structure while E5 could only give rise to a stem-loop that was too
short to be an authentic pri-miRNA stem-loop (Han et al., 2006; Zeng
et al., 2005). Nevertheless, it was striking that E1, E2 and E3 not only
folded into a believable RNA structure with the candidate mature
miRNA located, as expected, immediately adjacent to the terminal loop
but also with the putative miRNA passenger strands offset on the
opposite side of the stem by !2 nt (Han et al., 2006; Zeng et al., 2005).
These ﬁndings led us to believe that E1, E2 and E3 are indeed
authentic EEHV1 miRNAs.
We next attempted to further validate this hypothesis by
generating expression vectors for all ﬁve candidate EEHV1 miRNAs,
E1 through E5, and asking if these could indeed give rise to
functional mature miRNAs as determined by Northern blot analysis
Fig. 2. Secondary structure of putative pri-miRNAs. Schematic stem-loop RNA structures predicted for the putative EEHV1A pri-miRNAs E1, E2, E3 and E5 are shown. The
bold line indicates the putative mature miRNA and the thin line indicates its possible passenger strand, based on deep sequencing (Table 1).
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and indicator assays using transfected human 293T cells. In the case
of EEHV1 miR-E3, we were able to both detect mature miR-E3, as
well as pre-miR-E3, by Northern blot (Fig. 3) and we were also able
to readily detect miR-E3 function by indicator assay (Fig. 4). In
contrast, the other four candidate EEHV1 miRNAs, E1, E2, E4 and E5,
were neither expressed as a mature miRNA nor functional in the
indicator assay.
The results presented in this manuscript identify miR-E3-5p as
the ﬁrst authentic EEHV1 miRNA. It is possible that all four of the
other candidate EEHV1 miRNAs are simply some form of stable
mRNA breakdown product and indeed that seems likely for E4,
which gives rise to reads that are mostly too short to be miRNAs,
fails to fold into an appropriate stem-loop structure and lacks a
potential passenger strand (Table 1). Similarly, the only stem-loop
we can derive for E5 is too small to form in a functional pri- or
even pre-miRNA (Fig. 2) and the potential passenger strands
overlap with E5 in this structure. So, while E4 and E5 are likely
not viral miRNAs, we remain persuaded that miR-E1 and miR-E2
are real. In particular, the reads obtained for miR-E1 and miR-E2
are all in the 20–24 nt size window (Table 1) and the predicted
structures adopted by these putative miRNAs are the right size and
reveal passenger strands offset by the predicted 2 nt on the
opposite arm of the stem (Fig. 2) (Han et al., 2006; Zeng et al.,
2005). This is very unlikely to occur by chance. The question then
is why these miRNAs do not express in transfected 293T cells.
In fact, while most viral miRNAs will express when inserted, along
with their native ﬂanking sequences, into an expression vector,
others fail to do so, including several miRNAs encoded by HSV-1
and a small number of the miRNAs encoded by KSHV or EBV (data
not shown). Why this is the case is unclear, but it appears possible
that they fail to fold appropriately when inserted into a hetero-
logous RNA sequence context. In any event, we have clearly shown
that EEHV1 expresses at least one functional miRNA, miR-E3-5p,
and we have presented evidence that we believe argues for at least
two others, here called miR-E1-3p and miR-E2-3p.
As EEHV1 miR-E3-5p is derived from the antisense strand of
a viral U42 ORF (Table 1), this miRNA could certainly post-
transcriptionally regulate the expression of this viral gene, as
previously reported for HSV-1 and EBV-encoded miRNAs (Barth
et al., 2008; Flores et al., 2013; Pfeffer et al., 2004; Umbach et al.,
2008). It is also possible that this viral miRNA regulates host mRNA
expression, as seen with several other herpesviruses (Cullen, 2009;
Grundhoff and Sullivan, 2011). We could not ﬁnd any homology of
the seed sequence of EEHV1 miR-E3-5p to that of other miRNAs
expressed by other betaherpesviruses, such as HCMV or HHV-6B.
However, it does share a partial seed sequence (positions 2 to 7;
ACGGCG) with a murine miRNA, mmu-miR-6241. Although the
miRNAs expressed by elephants have not yet been studied
extensively, it is possible that this EEHV1 miRNA could target
many of the same mRNAs that are targeted by a cellular miRNA, as
previously also reported for several other viral miRNAs with seed
homology to cellular miRNAs (Grundhoff and Sullivan, 2011).
While the observed EEHV1 miRNA(s) are unlikely to represent
targets for intervention in EEHV-induced disease, they may have
potential as diagnostics and we were indeed able to readily detect
miR-E3-5p expression in in vivo-derived samples, including whole
blood, by RT-PCR (Table 2). Many EEHV1 infections appear to be
sub-clinical and there is considerable interest in developing
diagnostic tests for EEHV1 to prevent infection of naïve animals
(Hardman et al., 2012; Sariya et al., 2012; Stanton et al., 2010).
In several human diseases, speciﬁc viral or cellular miRNAs are
found at high levels in serum, most likely due to release by cells
inside exosomes (Kuwabara et al., 2011; Tanaka et al., 2013;
Turchinovich et al., 2011; Tzimagiorgis et al., 2011). It is therefore
possible that miR-E3-5p, which is likely expressed at high levels in
EEHV1 infected cells, may also be released into the circulation in
animals that are asymptomatically infected with EEHV1 at levels
that can be detected by RT-PCR. This information, if obtainable,
would allow animal handlers to avoid exposing uninfected ele-
phants to infected, asymptomatic individuals.
Fig. 3. Northern blot detection of miR-E3 expression. 293T cells were transfected
with a miR-E3 expression vector or an empty vector (“-”), and the potential
expression of the pre-miRNA or mature viral miR-E3-5p analyzed by Northern blot.
U6 RNA served as a loading control. White and black arrows show the predicted
location of the miR-E3-5p pre-miRNA and mature miRNA, respectively.
Fig. 4. Inhibitory activity of putative viral miRNAs. An RLuc-based indicator, with or
without two copies of a perfectly complementary target sequence for a putative
EEHV1 miRNA inserted into the 30 UTR, was co-transfected into 293T cells, along
with a putative viral miRNA expression vector, as indicated. Relative RLuc activity
was measured at 48 h post-transfection and then normalized to a vector-only
control and to FLuc, which is present in the same vector and was used here as an
internal control. Error bars indicate standard deviation of 3 independent
experiments.
Table 2
Detection of miR-E3-5p in tissue samples derived from two EEHV1A-infected
elephants using a TaqMan small RNA RT-qPCR assay.
Elephant tissues Threshold cycle (Ct) values
Plus RT enzyme Minus RT enzyme
Raman heart 30.90 No Ct
Raman liver 32.92 No Ct
Raman lung 37.11 No Ct
Raman tongue No Ct No Ct
Raman aorta 39.26 No Ct
Raman blood 37.73 No Ct
Nayan heart 33.97 No Ct
Nayan liver 28.60 No Ct
EEHV-1 negative tissue No Ct No Ct
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Materials and methods
RNA and DNA samples
RNA and DNA were puriﬁed from frozen host cardiac or liver
tissue derived from necropsy specimens of two juvenile Asian
elephants that died as a result of a natural EEHV1A infection. The
heart and liver tissues had 8.1"106 and 6.5"106 EEHV1A genome
copies per mg of total nucleic acid, respectively.
Small RNA deep sequencing
Total RNA was extracted using TRIzol (Ambion). Small RNAs
were sequentially ligated to adapters and reverse-transcribed
using a TruSeq Small RNA Sample Prep Kit (Illumina) and SSIII
(Invitrogen), as previously described (Umbach and Cullen, 2010)
and the resultant cDNAs ampliﬁed by PCR. The number of PCR
cycles was determined by pilot experiments to ﬁnd a point at
which amplicons showed logarithmic ampliﬁcation. Deep sequen-
cing of the PCR products was performed using an Illumina
HiSeq2500.
Bioinformatics
Sequence data were analyzed using the FASTX-Toolkit and
aligned with the genome of EEHV1A (GenBank accession number:
KC462165) and the African elephant genome (Ensemble accession
number: GCA_000001905) by Bowtie (Langmead et al., 2009).
Results of mapping were analyzed by SAMtools (Li et al., 2009).
RNA secondary structure was predicted by mfold (Zuker, 2003).
TaqMan-based RT-PCR
To extract nucleic acid from elephant tissues for miRNA
RT-qPCR, 25 mg of each tissue was added to a gentleMACS M tube
(Miltenyi Biotec) containing 600 ml of buffer RLT from EZ1 RNA
tissue mini kit (Qiagen). The tissue was homogenized using the
gentleMACS Dissociater (Miltenyi Biotec) and RNA_01 program. The
M tube was then centrifuged at 2000g for 2 min and 350 ml of lysate
was transferred on to the EZ1 XL robot (Qiagen) using the EZ1 RNA
tissue mini kit (Qiagen). Nucleic acid from whole blood was
extracted using the QIAamp Viral RNA Mini Kit (QIAGEN) according
to the manufacturer0s protocol. The miR-E3-5p primers and probe
were designed and synthesized using the Custom TaqMan Small
RNA service (Life Technologies). The RT-qPCR was performed
according to the TaqMan Small RNA Assays protocol using Super-
Script III Reverse Transcriptase (Life Technologies) and QuantiFast
Pathogen PCR þ IC Kit (Qiagen).
Northern blots
Putative mature miRNA sequences, with !240 bp of 50 and 30
ﬂanking sequences, were ampliﬁed by PCR from EEHV1A genomic
DNA, and cloned into the 30 UTR of a gfp gene in the pcDNA3
expression vector. The resultant vectors were transfected into
293T cells using polyethylenimine (Boussif et al., 1995). RNA was
extracted 48 h after transfection and resolved on a 15% denaturing
polyacrylamide gel, transferred to a nylon membrane at 400 mA
for 1 h and then UV crosslinked at 250,000 μJ/cm2. Oligonucleo-
tide probes representing the reverse complement sequence of
putative mature EEHV1 miRNAs were labeled with γ-ATP, hybri-
dized to the nylon membrane using ExpressHyb (Clonetech) and
viewed by autoradiogram.
Luciferase assay
Oligonucleotides bearing two copies of a perfect, full length
target sequence for each putative viral miRNAwere cloned into the
30 UTR of the RLuc gene in psiCHECK2 (Promega). This vector also
includes an FLuc gene, under the control of a different promoter, to
permit normalization of transfection efﬁciency. 293T cells were co-
transfected with an indicator vector and an EEHV1 miRNA expres-
sion vector, as described above, using polyethylenimine. Dual
luciferase assays were performed 24 h after transfection using
a Dual-Luciferase Reporter Assay System (Promega), according to
the manufacturer's protocol.
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Case Report Fatal elephant endotheliotropic herpesvirus-1
and -4 co-infection in a juvenile Asian elephant
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Introduction: Elephant endotheliotropic herpesvirus-1 (EEHV-1) is one of the major causes
of fatality in juvenile Asian elephants (Elephas maximus). On occasions, other EEHV genotypes,
i.e. EEHV-3, -4 and -5, have also been reported as the cause of Asian elephant deaths.
In this case report we describe the investigation into a juvenile Asian elephant fatality in a
European zoo.
Case Presentation: A fatal case of haemorrhagic disease in a juvenile Asian elephant from
a European zoo was diagnosed with co-infection of EEHV-1 and -4. EEHV-4 had a wider
organ distribution and a higher viral load; both viruses presented the highest load in the
mesenteric lymph nodes.
Conclusion: Detection of EEHV-4 in this fatal case in Europe underlines the importance of
inclusion of all known Asian EEHVs in routine blood monitoring to facilitate early therapeutic
intervention.
Keywords: Asian elephant; co-infection; elephant endotheliotropic herpesvirus; Europe;
haemorrhagic disease; multiple haemorrhages.
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Introduction
Elephant endotheliotropic herpesviruses (EEHVs; also
known as elephantid herpesviruses), in the genus Probosci-
virus, are one of the leading causes of mortality in juvenile
Asian elephants (Elephas maximus). The viruses are con-
sidered as a significant threat to conservation of Asian ele-
phant populations and are now thought to be ubiquitous
in Asian elephant populations (Reid et al., 2008; Hardman
et al., 2012; van den Doel et al., 2015). EEHV-1 has been
responsible for the majority of herpes-associated fatalities
in Asian elephants worldwide. On occasions, other EEHV
genotypes, i.e. EEHV-3 (Garner et al., 2009), -4 (Sripiboon
et al., 2013) and -5 (Denk et al., 2012), have also been
reported as the cause of Asian elephant deaths in the
USA, Asia and Europe, respectively. In this case report
we describe the investigation into a juvenile Asian elephant
fatality in a European zoo.
Case report
A fatal case of EEHV-1A infection in a 2-year-old male Asian
elephant at Copenhagen Zoo in November 2014 led to
renewed investigation into a previous fatality in 2003. This
case, another 2-year-old male Asian elephant, housed at
the zoo along with six other Asian elephants, showed signs
of mild depression and lethargy on 4 October 2003. The
animal was not tractable and a cursory clinical examination
did not reveal any significant abnormalities. The elephant
remained mildly lethargic the following day, and a single
intramuscular injection of benzylpenicillin and streptomycin
(Tardomyocel) was administered, as a bacterial cause could
not be ruled out. On day 3, the animal was seen alive on sur-
veillance cameras at 06.48 a.m., but found dead at 07.15 a.m.
Investigations
At necropsy, pathological findings revealed severe vascular
damage reminiscent of that described previously for fatalAbbreviation: qPCR, quantitative PCR.
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cases of EEHV infections (Garner et al., 2009; Wilkie et al.,
2014). The most significant gross pathological findings
included 5–10 l of serohaemorrhagic fluid in the abdomen,
diffuse petechial haemorrhages and extensive oedema of all
serosal surfaces, multiple haemorrhages in the heart and
liver as well as well-defined haemorrhagic lesions through-
out the renal papillae and adrenal cortex (Fig. 1). The small
intestine contained fluid ingesta intermixed with blood
and extensive punctuate ulcerations (5–20 mm diameter).
The ulcers, primarily co-localizing with the Peyer’s patches,
were present particularly throughout the aboral portion of
the small intestinal mucosa. The mucosa of the large intes-
tine was oedematous, dull and showed generalized dark
reddening.
Histopathological examination of the tissues confirmed
widespread haemorrhages, and severe small intestinal and
colonic submucosal oedema. In the small intestine, there
was mild-to-moderate submucosal haemorrhage and
within the small intestinal crypts, mitotic activity was
judged to be very low (less than one mitotic figure per
10 crypts). Peyer’s patches were reduced in size and
showed central necrosis of the peripheral follicles as well
as marked interstitial haemorrhage. The overlying epi-
thelium was intact, but had collapsed into the space created
by the reduced size of the Peyer’s patches. In the colon,
mild heterophilic infiltrates were seen in the lamina
propria, associated with moderate-to-severe mucosal
haemorrhage.
The endothelial cells of the large myocardial arteries and
the endocardium had remarkably high numbers of single
large basophilic intranuclear inclusion bodies (up to 20
per high-power field) (Fig. 2). Similarly appearing, but
few and scattered inclusions were also present in arteries
of the lung, liver, kidney, urinary bladder and skeletal
muscle. Mild endarteritis with sloughing of endothelial
cells and cellular infiltrates consisting of lymphocytes and
Fig. 1. Gross pathological findings in the EEHV-1 and -4 co-infection fatality. (a) Mucosa of ileum showing necrotic lesions
(5–20 mm diameter) and bloody intestinal contents. (b) Mucosa of the large intestine showing oedema and haemorrhage.
(c) Kidney showing marked haemorrhages in the renal papillae. (d) Adrenal gland showing severe cortical haemorrhages.
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heterophils, some of which were necrotic, was also seen in
the same locations. Bacterial culture of the intestinal
mucosa, faeces and major organs was unremarkable.
DNA from the various organ samples, stored at 220 uC
until processing, was extracted using an EZ1 RNA Tissue
Mini kit on an EZ1 XL robot (Qiagen) and tested for
EEHV-1, -3, -4 and -5 using simplex real-time quantitative
PCR (qPCR) assays (Hardman et al., 2012; unpublished
data). DNA sequencing of conventional PCR amplicons
derived from lung and heart tissue samples was carried
out using an ABI 3130xL 16 capillary genetic analyser
(Applied Biosystems). SeqMan (DNASTAR) was used to
analyse sequence traces and the consensus sequences
were screened against GenBank entries using BLAST
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). The EEHV DNA
was prepared for next-generation sequencing libraries
using a Nextera XT kit (Illumina). Paired-end sequencing
was performed on an Illumina MiSeq. The sequences
were then mapped to the reference EEHV-1A Raman
strain (GenBank accession number KC462165.1) and sev-
eral EEHV-4 sequences in GenBank using SeqMan NGen
software (DNASTAR). Several conventional PCRs were
also used to generate DNA standards for EEHV-1A and
-4 to quantify the viral loads in the tissues. The genome
copies for EEHV-1A and -4 from each tissue were then
normalized to 1 mg extracted total nucleic acid.
Diagnosis
The viral genotypes identified in the organs by qPCR and
DNA sequencing were EEHV-1A and -4. The BLAST
search of 201 nt of the EEHV-1A PCR amplicon (GenBank
accession number KT381607) revealed the highest simi-
larity (100 %) to the DNA polymerase gene (U38) of refer-
ence EEHV-1A Raman strain and several other EEHV-1A
strains in GenBank. Sequences of other shorter genome
segments, corresponding to nt 29 539–29 638 (U73, DNA
replication origin-binding helicase), 31 935–32 053 (U72,
envelope glycoprotein M) and 50 617–50 750 (U56,
capsid triplex subunit 2) on the Raman strain genome,
produced similar results in the BLAST search. Nucleotide
sequences of the EEHV-4 DNA polymerase (U38,
301 bp), glycoprotein M (U72, 303 bp) and DNA replica-
tion origin-binding helicase (U73, 262 bp) gene segments
(GenBank accession numbers KT334336–KT3343368)
were identical to corresponding sequences of EEHV-4
strains from North America (GenBank accession numbers
JN983096.1, EU658934 and JN983097.2). Using qPCR,
EEHV-1A DNA was only detectable in the heart, mesen-
teric lymph node, lung and spleen, whereas EEHV-4
DNA was detectable in all organ samples tested (adrenal
gland, heart, ileum, mesenteric and pulmonary lymph
nodes, lung, spleen, testicle and thymus) (Table 1).
The highest number of EEHV-4 viral genome copies, nor-
malized to 1 mg total nucleic acid, was found in the mesen-
teric lymph node (3.38|108 copies mg21), followed by the
adrenal gland, lung, spleen and heart (Table 1). EEHV-1A
viral loads appeared to be far lower than those of EEHV-4.
The highest viral load was detected in the mesenteric
lymph node (2.02|104 copies mg21), followed by heart
and lung; however, the differences in viral load of lymph
node and heart were negligible (2.02|104 versus
1.22|104 copies mg21). Irrespective of the tissues tested,
the viral load for EEHV-4 was always higher, between 1.3
and 16 600 times, than those of EEHV-1A. The EEHV-1A
load was also on average between 42 and 6600 times lower
than that typically seen in corresponding organs of other
EEHV-1 fatalities (unpublished data). However, whether
Fig. 2. Detail of a large myocardial blood vessel. The majority of
endothelial cells show round nuclei with a large basophilic intra-
nuclear inclusion body (arrows). Bar, 100 mm.
Table 1. EEHV-1A and -4 mean viral genome copies in various tissues of a juvenile Asian elephant using qPCR
The values are normalized to 1 mg total nucleic acid from the respective tissues.
Virus type Adrenal Heart Ileum Lymph node of the
large intestine
Pulmonary lymph
node
Lung Spleen Testicle Thymus
EEHV-1A ND 1.226104 ND 2.026104 ND 7.536103 5.416101 ND ND
EEHV-4 2.816105 1.106104 1.606104 3.386108 5.656103 5.016104 1.166104 8.046103 4.076101
ND, Not detectable.
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this resulted from variable stability of the two viruses and
longer-term storage of the samples is yet to be explored.
Discussion
Detection of more than one herpesvirus from clinical spe-
cimens is not uncommon. Co-infections of humans with
herpesviruses in the subfamily Betaherpesvirinae, the clo-
sest to EEHVs, have been reported for human herpesvirus
(HHV)-5 (human cytomegalovirus), -6A, -6B and -7
(Tang et al., 1997; Fillatre et al., 2013; Ahmed, 2014).
In Asian and African elephants, co-infections with several
EEHVs, EEHVs and elephant gammaherpesviruses
(EGHVs), as well as co-infections with several EGHVs
have also been described (Latimer et al., 2011; Ortega
et al., 2015). However, there are no reports of simul-
taneous detectable probosciviruses in clinical infections.
Stanton et al. (2013) recently suggested the possibility of
concurrent and subclinical infections of elephants with
different EEHV strains, and the data presented here pro-
vide the first evidence of such EEHV co-infection. Dual
herpesvirus infections in humans have been suggested to
increase the risk of viral syndromes and disease develop-
ment (Chapenko et al., 2000); therefore, it seems to
be of considerable value to screen elephants for multiple
herpesviruses both for routine monitoring and disease
investigation.
The clinical picture as well as the pathological findings of
the EEHV-1A and -4 co-infection in the case reported
here were overall similar to those described for fatalities
caused by EEHV-1, -3 and -5 (Garner et al., 2009;
Wilkie et al., 2014). However, characteristic endothelial
herpesvirus inclusions were unusually prevalent, particu-
larly in the larger vessels of the myocardium, and the
amount of haemorrhage in the intestinal mucosa and the
presence of whole blood in the ingesta has not been a clas-
sical finding. Interestingly, very low mitotic activity was
observed in the intestinal crypts along with central lym-
phoid necrosis of the Peyer’s patches, suggesting a radio-
mimetic effect, which has not been previously reported
in EEHV fatalities.
In conclusion, we have presented a fatal case of EEHV co-
infection, described its histopathological manifestations
and determined the viruses involved. The overall findings
confirm EEHV-1A and -4 to be the cause of death in
this elephant. To the best of our knowledge, this is the
first documented fatality of a juvenile Asian elephant
caused by co-infection of two pathogenic genotypes of
EEHV, although with substantial differences in organ
viral load. This case is also the first fatality in a European
zoo from which EEHV-4 could be identified. Detection
of EEHV-4 in this fatal case in Europe underlines the
importance of inclusion of all known Asian elephant
EEHVs in routine blood monitoring to facilitate early
therapeutic intervention. Finally, observation of the high-
est EEHV-1A and -4 loads, coinciding with pathological
changes in lymphoid tissues of the intestinal tract, suggest
that immune cells of the intestinal tract lymphoid tissues
could be a site for viral latency and/or initial replication
of the virus.
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Elephant Endotheliotropic Herpesviruses (EEHVs) are the cause of a highly fatal haemorrhagic disease
in elephants primarily affecting young Asian elephants (Elephas maximus) in both captivity and in the
wild. The viruses have emerged as a significant threat to Asian elephant conservation, critically affecting
overall sustainability of their population. So far insight into the pathogenesis of EEHV infections has
been restricted to examination of EEHV-infected tissues. However, little is known about distribution and
burden of the viruses within the organs of fatal cases, crucial elements in the understanding of the virus
pathogenesis. This study was therefore undertaken to assess the extent of organ and cell involvement in
fatal cases of EEHV-1A, 1B and 5 using a quantitative real-time PCR. EEHV-1 and 5 DNA were detectable
in all the tissues examined, albeit with substantial differences in the viral DNA load. The highest EEHV-1A
DNA load was observed in the liver, followed by the heart, thymus and tongue. EEHV-1B and 5 showed
the highest DNA load in the heart, followed by tongue and liver. This study provides new insights into
EEHV pathogenicity and has implications in choice of sample type for disease investigation and virus
isolation.
Crown Copyright © 2016 Published by Elsevier B.V. All rights reserved.
1. Introduction
Elephant Endotheliotropic Herpesvirus genotype 1 (EEHV-1) is
one of the major causes of fatality in juvenile Asian elephants (Ele-
phasmaximus) and considered as a significant threat to the future of
Asian elephant populations. The virus is a large 180 kbp DNA virus
which belongs to the genus Proboscivirus in the subfamily Beta-
herpesvirinae (Davison et al., 2009; Richman and Hayward, 2012;
Wilkie et al., 2013), although suggestions that the virus may clus-
ter into a new subfamily are also made (Richman et al., 2014; Zong
et al., 2014). To date, three other genotypes of EEHV have also been
detected in the Asian elephants: EEHV-3, EEHV-4 and EEHV-5, all
with the potential to cause fatal disease in their host (Garner et al.,
2009; Denk et al., 2012; Sripiboon et al., 2013; Seilern-Moy et al.,
2015). Phylogenetically, the viruses are most closely related to, but
still highly diverged from the human cytomegalovirus (HCMV) and
the three human Roseolo viruses (HHV-6A, HHV-6B, and HHV-7),
allmembers of the subfamilyBetaherpesvirinae (Wilkie et al., 2014).
The viruses’ pathology is often associated with generalised
haemorrhages and death (Richman et al., 2000). Cardiovascular
∗ Corresponding author.
E-mail address: akbar.dastjerdi@apha.gsi.gov.uk (A. Dastjerdi).
pathology is the dominant feature displaying extensive haemor-
rhages on the epi- and endocardial surfaces and myocardium and
pericardial effusions (Richman et al., 2000; Wilkie et al., 2014).
Other pathological attributes are diffuse bleedings within all vis-
cera, cyanosisof the tongue,hepatomegaly, oral, laryngeal and large
intestinal ulcers, and haemorrhages in other internal organs. The
extent of gross pathological findings can, however, vary drastically
depending on the disease duration.
Information on organ and cell tropism and sites of replication
and latency are fundamental in understanding pathogenesis of her-
pesviruses on the whole. Little is known about distribution of the
EEHVs within the organs of the fatally affected elephants. Identifi-
cation of target organs and cells can provide guidance on choice of
sample type for virus isolation and disease investigation and shed
lights into pathogenesis of the virus. Further, until recently the viral
sequences were not resolved and tools to measure viral loads, for
example, via qPCRwere not available. Here, we have examined dis-
tribution and load of EEHV-1 and 5 DNA in several organ materials
of associated fatal cases using real-time quantitative PCRs.
http://dx.doi.org/10.1016/j.virusres.2016.04.012
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Table 1
List of elephants and their respective samples used in this study.
Elephant name Date of birth Date of death Gender Viral strain Tissues tested
Raman 12.11.2006 23.07.2009 Male EEHV-1A Aorta, blood, heart, kidney, liver, lung, lymph node,
parotid, salivary gland, spleen, tongue
Nayan 18.07.2010 29.07.2013 Male EEHV-1A Artery, blood, heart, intestine, kidney, liver, lung,
mesenterial, mandibular and retropharyngeal lymph
nodes, payer’s plaque, spleen, thymus, tongue, trunk
mucosa
Jamila 22.01.2011 03.07.2013 Female EEHV-1A Aorta, blood, bone marrow, heart, intestine, kidney, liver,
lung, mesenterial and mediastenal lymph nodes, spleen,
thymus, tongue, trunk mucosa
Emelia 16.03.2004 17.12.2006 Female EEHV-1B Heart, kidney, liver, lung, retropharyngeal lymph node,
spleen, tongue
Vijay 06.08.2009 13.04.2011 Male EEHV-5 Heart, kidney, liver, lung, lymph node, salivary gland,
spleen, thyroid gland, tongue
2. Materials and methods
2.1. Samples and sample processing
The organ samples used in this study were from EEHV-1 and
5 fatal cases of Asian elephants (Table 1). To process the sam-
ples for analysis, approximately 3–5mm3 of tissue (25mg) were
added to a gentleMACS M tube (Miltenyi Biotec Ltd. UK) contain-
ing 600!l of buffer RLT from EZ1® RNA tissue mini kit (Qiagen,
Germany). The tissuewas homogenised using the gentleMACS Dis-
sociater (Miltenyi Biotec) and RNA 01 program. The M tube was
then centrifuged at 2000g for 2min and 350!l of lysatewere trans-
ferred to a 2ml screw capped tube (supplied in the kit) and 5!l
Internal Control [(High concentration) Qiagen, UK], were added.
Total nucleic acid was extracted from the lysate using the EZ1® XL
robot (Qiagen) and the EZ1® RNA tissue mini kit for all the tissues.
For blood samples, nucleic acid was extracted from 140!l whole
EDTA blood, plus 6!l of the Internal Control (Qiagen), using the
QIAamp® Viral RNA Mini Kit (Qiagen) as described by the manu-
facturer. The extracted nucleic acid was quantified on a Nanodrop
2000 Spectrophotometer (Agilent Technologies, UK).
2.2. Creating PCR standards
Three conventional PCRs were used to generate DNA standards
for EEHV-1, 5 and elephant TNF" in order to quantify viral genome
copies in various postmortal organ tissues. The primers used in this
study are listed in Table 2. Each PCR was performed in a reaction
mix consisting of 10!l Fast Cycling PCR Master mix (Qiagen), 2!l
DNA template (known EEHV-1 and 5 positive nucleic acid), 0.1!l
of each forward and reverse primers (100pmol/!l) and RNase-free
water to a volume of 20!l. The thermocycling profile for each PCR
was 95 ◦C for 5min followed by 35 cycles of 95 ◦C for 15 s, 55 ◦C for
30 s and 68 ◦C for 1min. The PCR amplicons were then run on an
agarose gel (1.5%) and the DNA bands of the correct size were cut
out and cleaned using theMinElute Gel Extraction Kit (Qiagen). The
purified amplicons were quantified on the Nanodrop 2000 Spec-
trophotometer (Agilent Technologies), DNA copy numbers were
calculated via the fragment size using an online tool http://cels.uri.
edu/gsc/cndna.html as per formula: number of copies = [(amount
in ng * 6.022×1023)/(DNA length in bp * 1×109 * 650)] and DNA
concentrationwas adjusted to 106 copies in 2!l volume and a dilu-
tion series ranging from 106 to 101 copies per 2!l was created and
run in triplicate in the real-time quantitative PCR.
2.3. Real-time quantitative PCR (qPCR)
Various organ samples of EEHV-1A, 1B, and EEHV-5 fatalities
(Table 1) were quantified for their viral load using published qPCR
protocols for EEHV-1A and B (Hardman et al., 2012). The EEHV-5
real time qPCR primers and probe are listed in Table 3. The nucleic
acid from each organ was measured in duplicate for EEHV-1 and
5 and the mean values were calculated using the MxPro (Agilent
Technologies) or CFX Manager Software (Bio-Rad, UK). The qPCR
was performed using the QuantiFast Pathogen PCR +IC kit using
5!l 5×QuantiFast Pathogen Master Mix, 2.5!l 10× Internal Con-
trol Assay, 0.1!l of each forward and reverse primers (100pM/!l),
0.05!l probe (100pM/!l), 2!l template DNA and water to a vol-
ume of 25!l. The qPCR was performed on a Mx3000P (Agilent
Technologies) or aCFX96TouchTM thermal cycler (Bio-Rad) at 95 ◦C
for 5min followed by 42 cycles of 95 ◦C for 15 s, 60 ◦C for 30 s and
signal capture at the end of each cycle.
2.4. Normalisation of viral genome copy numbers
The EEHV genome copy numbers measured in the real-time
qPCRs for EEHV and genomic TNF" were first normalised against
the spiked Internal Control to compensate for differences in nucleic
acid extraction efficiency for each tissue. The EEHV-1 and 5 genome
copies for each tissue were then normalised against those of
genomic TNF" performed in parallel and 1!g of extracted DNA.
3. Results
3.1. Performance of the real-time qPCR assay
In order to assess the real-time qPCRs performance and quan-
tify EEHV-1 and 5 genomes in various tissues, several calibration
curves were producedwith known quantity of DNA standards over
a range of 106–101 copies per PCR mix (Fig. 1). At least 2 inde-
pendent calibration curves were created for each of the EEHV-1, 5
and TNF" to quantify their genome copy numbers in the tissues.
The amplification efficiency was on average 99% (R2 =0.999), 98%
(R2 =0.992) and 95% (R2 =0.986) for EEHV-1, 5 and TNF" respec-
tively. TheaverageCtvalue for thepositiveEEHV-1control included
in each experiment was 23±0.45.
3.2. EEHV-1A DNA distribution and load in various tissues
Genomic EEHV-1A DNA was detectable in all the tissues tested
(Table 3), albeit with substantial differences in virus DNA load. In a
descending order, liver, heart, thymus, tongue, arteries, and blood
samples contained the highest viral loads, whereas kidney, spleen,
lung, salivary gland, lymph nodes, bonemarrow, intestines, payer’s
plague, and trunk mucosa had the lowest (Fig. 2).
Normalising theEEHVgenomecopies to thoseof TNF", the three
elephants which died of EEHV-1A infection (Raman, Nayan and
Jamilia) showed the highest viral load in the liver, followedbyheart
and thymus (Table 3). The ratio of normalised EEHV-1A genome
copies for the liver (normalised to TNF") were 1.7 (Raman), 8.6
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(Nayan), and 1.4 (Jamilia) folds higher than those for corresponding
heart tissues. Furthermore, the liver samples contained 9.9 (Nayan)
and 7.1 (Jamilia) times higher viral loads than those for the thymus.
There was no thymus sample available from Raman.
Normalising the EEHV-1A genome copynumbers to 1!g of total
nucleic acid, liver, heart and thymuswere again the tissueswith the
highest viral load. Raman showed thehighest viral load in theheart,
1.5 timeshigher than that of the liver. The liver sampleofNayanhad
2.5 times higher viral load than that of the thymus, which in turn
had a 2.4 times higher loads than the heart tissue. Jamilia’s liver
tissue contained 0.1 fold higher viral load than the heart and 11.2
times higher than the thymus. Overall, the highest viral load was
observed in the heart tissue of Ramanwith approximately 8.1×106
virus genome copies per !g of extracted nucleic acid (Table 3).
3.3. EEHV-1B DNA distribution and load in various tissues
EEHV-1B DNA was likewise detectable in all the tested tissues
(Table 2) from Emelia, an Asian elephant known to have suc-
cumbed to EEHV-1B, although with considerable variation in virus
DNA load. Interestingly, the heart tissue showed the highest viral
DNA load; 57.6 times higher than that in the liver tissue and 30.7
times higher than that in the tongue tissue (normalised to those
of TNF"). Emelia’s heart tissue contained approximately 1.96×106
virus genome copies per !g of extracted nucleic acid (Table 3).
3.4. EEHV-5 DNA distribution and load in various tissues
Various tissues from Vijay, a juvenile Asian elephant that suc-
cumbed toEEHV-5,were tested for their viral load (Table2). EEHV-5
DNA was detectable in all tested tissues with heart tissue holding
the highest viral load, 26.4 times higher than in the liver tissue sam-
ple and 21.9 times higher than in the tongue (normalised to TNF").
Similar trend was also observed when the viral load values were
normalised to the DNA concentration. The heart tissue contained
approximately 9.8×105 virus genome copies per !g of extracted
nucleic acid (Table 3).
4. Discussion
EEHV is considered ubiquitous in Asian elephant populations in
captivity and in free range countries (Reid et al., 2006; Hardman
et al., 2012; van den Doel et al., 2015). Once infected, the virus is
likely to persist for the life of the elephant. Genome analysis indi-
cates that EEHV have co-speciated with its respective host over
the last 65 million years (Shoshani, 1998; McGeoch et al., 2000).
This prolonged period of co-evolution between herpesviruses and
their host has established a balanced adaptation between them.
However, occurrence of per-acute cases in juvenile elephants still
remains unexplained as it contradicts herpesviruses survival strat-
egy as being exquisitely adapted for persistence within the host.
In the present study, we measured EEHV DNA loads in vari-
ous organs of EEHV-1 and 5 associated fatal cases and viral DNA
of varying burdens were found to be widely distributed in all
organs investigated. These findings are in line with those of HCMV
fatal congenital inclusion disease in which infection was being
observed in all organs examined; lung, pancreas, kidney, liver,
spleen, adrenal, small bowel, placenta, brain, bone marrow and
heart (Bissinger et al., 2002; Jarvis and Nelson, 2007). Lung, pan-
creas, kidney and liver were the major target organs with a high
Table 2
List of primers and probe used in this study. Accession numbers represent the sequences used to design the primers and probe.
Names Sequence (5′ to 3′) Amplicon size Accession No.
EEHV-1 STD F GAAGCAATCACGTGTCCATG 177 bp NC 020474.2
EEHV-1 STD R TTCATTGACACTGGAATCTGTT
EEHV-5 STD F ACGTAGTCACGAACCCAAAACC 344 bp NC 024696.1
EEHV-5 STD R CCTCGCACACGTATGAGATCAC
TNF" STD F CTACTCCCAGGTCCTCTT 294 bp XM 003422213.1
TNF" STD R CTACTTTGGGATCATTGC
EEHV-5 F GGA CAG AGY TTY AAT ATA TTA C 115 bp NC 024696.1
EEHV-5 R GAA GAT ATA AAT ATT ATY TTG GC
EEHV-5 P Texas Red-GAC GAA TCT AAC TTT ATC AAG AAA GAG G-BHQ2
Table 3
EEHV-1A, -1B and 5 viral loads quantified in various organ tissues of associated fatal cases using real-time qPCRs. The EEHV genome copies in each tissue were normalised
to those of elephant TNF" genomic DNA or to 1!g of total nucleic acid from the respective tissues. (A) Ratio of EEHV genome copies to those of genomic TNF" (B) EEHV
genome copies per !g of total nucleic acid of the corresponding tissue. The tissues with the highest viral load are in bold.
A:
Elephant name (EEHV-1 type) EEHV DNA (mean) in various tissues normalised to TNF"
Aorta Blood Heart Kidney Liver Lung Lymph Node Spleen Thymus Tongue
Raman (EEHV-1A) 1.98E+02 1.16E+02 1.11E+03 1.40E+00 1.86E+03 8.01E+01 8.80E+00 1.10E+02 NAa NA
Nayan (EEHV-1A) NA 5.15E+01 1.83E+03 6.20E+00 1.58E+04 7.40E+02 1.94E+01 1.77E+02 1.60E+03 4.43E+02
Jamila (EEHV-1A) 2.02E+01 2.13E+03 2.55E+04 3.67E+01 4.06E+04 4.37E+02 4.59E+02 1.42E+03 4.90E+03 3.12E+03
Emelia (EEHV-1B) NA NA 2.88E+02 1.00E-01 5.00E+00 9.00E-01 8.00E-01 1.30E+00 NA 2.05E+01
Vijay (EEHV-5) NA NA 3.35E+01 9.64E-04 1.27E+00 5.59E-02 1.04E-01 3.80E-02 NA 1.53E+00
B:
Elephant name(EEHV-1 type) EEHV DNA (mean) in various tissues normalised to DNA input (!g)
Aorta Blood Heart Kidney Liver Lung Lymph Node Spleen Thymus Tongue
Raman (EEHV-1A) 4.31E+05 5.58E+05 8.10E+06 1.17E+04 5.29E+06 4.31E+05 1.41E+05 7.85E+05 NA NA
Nayan (EEHV-1A) NA 1.83E+04 1.11E+06 5.58E+03 6.52E+06 5.06E+05 2.08E+04 1.99E+05 2.64E+06 5.59E+04
Jamila (EEHV-1A) 8.05E+02 9.57E+04 2.52E+06 1.70E+03 3.93E+06 2.24E+04 7.40E+04 8.92E+04 3.46E+05 1.21E+05
Emelia (EEHV-1B) NA NA 1.95E+06 2.29E+03 1.41E+05 4.63E+04 2.64E+04 1.55E+04 NA 4.54E+05
Vijay (EEHV-5) NA NA 9.84E+05 1.51E+02 1.00E+05 1.07E+04 1.43E+03 9.55E+03 NA 1.07E+05
a Not available.
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Fig. 1. Representative graphs to illustrate the calibration curves used to quantify EEHV-1, EEHV-5 and elephant TNF" genome copies in various organ tissues. The calibration
curves were created over a range of 101 to 106 (shown on the x-axis as 1–6) DNA copies per PCR reaction. (A) EEHV-1A, (B) EEHV-1B, (C) EEHV-5 and (D) elephant genomic
TNF" calibration curves.
number of HCMV infected cells. It is, however, noteworthy to high-
light that two cerebrum, a cerebellum and a cornea samples, made
available fromtworecentEEHV-1 fatalities (datanot shown), tested
negative for the EEHV-1 DNA.
Infection of endothelial cells is believed to play a major role in
the EEHVs’ pathogenesis concluding from the extensive haemor-
rhages observed in acute cases. The process of virus dissemination,
following an EEHV infection, is still largely unknown, but infection
and spread through peripheral blood, serum and circulating EEHV-
infected endothelial cells is a possibility, considering themultitude
of organs infected. The location of endothelial cells at the border of
the circulatory system and underlying tissues can provide advan-
tages for virus dissemination via blood stream during the acute
stage of infection. Factors influencing viral replication in endothe-
lial cells may also contribute to the development of vasculopathy.
Endothelial cells, in addition to being target cells in acute stages of
the disease,may also serve as site of virus latency, verifiedbydetec-
tion of EEHV-1 DNA in umbilical cord blood vessels (unpublished
data). In the case of HCMV, analysis of tissues from healthy individ-
uals in the absence of acute disease identified HCMV DNA, mRNA,
and antigen within the vessel walls of major arteries throughout
the body indicating a site for HCMV persistent or latent infection
(Melnick et al., 1983;Gyorkey et al., 1984; Yamashiroyo et al., 1988;
Hendrix et al., 1997). Interestingly, the most extensive studies of
HCMV endothelial cell tropism have focused on three ORFs: UL128,
UL130, and UL131A (Jarvis and Nelson, 2007) with the ortholog
genes being absent in the EEHV-1 and 5 genomes.
Endothelial cells are diverse cell types in terms of morphology
and growth (Craig et al., 1998) and the use of biologically relevant
types of the cells is essential to ensure relevance to EEHV biol-
ogy in the host. HCMVwas reported to infect preferentially certain
endothelial cells (Jarvis and Nelson, 2007) and this may be true
for EEHV infection alike. The endothelial cells of the large myocar-
dial arteries and the endocardium are reported to bemore severely
affected than those of lung, liver, kidney, urinary bladder and skele-
tal muscle in the fatal cases of EEHVs, judged by numbers of single
large basophilic intranuclear inclusion bodies (Seilern-Moy et al.,
2015). Whether a preferential endothelial cell feature is account-
able for the differences seen in virus load in various tissues has
yet to be explored. Considering higher virus DNA load in tissues
with moderate vascularity such as heart and liver, compared to
lung (Weiss et al., 1980), it can be postulated that other cell types,
similar to those for HCMV (Genra et al., 2002), are also support-
ing replication of this virus. If this proves to be correct then cells
such as elephant hepatocytes and cardiac myocytes may also sup-
port in vitro replication of the virus in addition to peripheral blood
mononuclear cells (PBMC).
In HCMV, genetic variations among the virus strains have been
considered the basis for cell or tissue differences in viral tropism
(Genra et al., 2002). Whether the genetic variation between EEHV-
1A, 1B and 5 has caused the differences in liver and heart being the
organwith the highest virus load in EEHV-1A, 1B and 5 respectively
remain to be identified.
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Fig. 2. EEHVs viral loads detected in various tissues of fatal cases. The Y axis values represent the EEHV viral genome copy (vgc) numbers normalised to 1!g of extracted
DNA or to those of genomic TNF" of the corresponding tissues as described in 2.4. EEHV-1A (A1, A2), EEHV-1B (B) and EEHV-5 (C).
Normalising the EEHV copy numbers to those of genomic TNF"
or total amount of extracted DNA, the ratios were found to vary
considerably between the different elephant tissues and appeared
higher in tissues with a longer period of storage. Therefore, it is
reasonable to believe that long term storage has instigated vary-
ing degree of tissue degeneration affecting adversely the genomic
DNA, but less so the virus DNA due to protection provided by
the capsid. It should also be taken into account that the extrac-
tion efficacy of genomic and viral DNA can vary in different
tissues and might therefore be partly responsible for these varia-
tions.
In conclusion, herewehave applied a real-timeqPCR and shown
that all tissues examined from EEHV fatality cases have some level
of detectable EEHV DNA except for cerebrum, cerebellum and
cornea. In addition, liver tissue in EEHV-1A and heart tissue in
EEHV-1B and 5 showed the highest viral loads, compared to other
organ tissues examined. Extension of such studies will provide fur-
ther insights into pathogenesis of these devastating herpesvirus
infections of elephants.
Acknowledgements
Thisworkwaspartly supported by the Zoological Society of Lon-
don (ZSL), Chester zoo and Rotterdam zoo. We specially would like
to thank Fieke Molenaar, Javier Lopez, Nic Masters, pathologists
and elephant keepers at ZSL Whipsnade zoo and Chester zoo for
provision of post mortem tissues. We also acknowledge Daniela
Denk at the International Zoo Veterinary Group (IZVG) Pathology
and Twycross zoo for provision of tissues from the EEHV-5 fatality.
References
Bissinger, A.L., Sinzger, C., Kaiserling, E., Jahn, G., 2002. Human cytomegalovirus as
a direct pathogen: correlation of multiorgan involvement and cell distribution
with clinical and pathological findings in a case of congenital inclusion disease.
J. Med. Virol. 67, 200–206.
Craig, L.E., Spelman, J.P., Strandberg, J.D., Zink, M.C., 1998. Endothelial cells from
diverse tissues exhibit differences in growth and morphology. Microvasc. Res.
55 (1), 65–76.
Davison, A.J., Eberle, R., Ehlers, B., Hayward, G.S., McGeoch, D.J., Minson, A.C., Pellet,
P.E., Roizman, B., Studdert, M.J., Thiry, E., 2009. The order Herpesvirales. Arch.
Virol. 154, 171–177.
Denk, D., Stidworthy, M.F., Redrobe, S., Latimer, E., Hayward, G.S., Cracknell, J.,
Claessens, A., Steinbach, F., McGowan, S., Dastjerdi, A., 2012. Fatal elephant
endotheliotropic herpesvirus type 5 infection in a captive Asian elephant. Vet.
Rec. 171 (15), 380–381.
Garner, M.M., Helmick, K., Ochsenreiter, J., Richman, L.K., Latimer, E., Wise, A.G.,
Maes, R.K., Kiupel, M., Nordhausen, R.W., Zong, J.C., Hayward, G.S., 2009.
Clinico-pathological features of fatal disease attributed to new variants of
endotheliotropic herpesvirus in two Asian elephants (Elephas maximus). Vet.
Pathol 46, 97–104.
Genra, G., Percivalle, E., Sarasini, A., Baldanti, F., Revello, M.G., 2002. The attenuated
Towne strain of human cytomegalovirus may revert to both endothelial cell
tropism and leuko- (neutrophil- and monocyte-) tropism in vitro. J. Gen. Virol.
83, 1993–2000.
Gyorkey, F., Melnick, J.L., Guinn, G.A., Gyorkey, P., Debakey, M.E., 1984.
Herpesviridae in the endothelial and smooth muscle cells of the proximal aorta
in arteriosclerotic patients. Exp. Mol. Pathol. 40, 328–339.
Hardman, K., Dastjerdi, A., Gurrala, R., Routh, A., Banks, M., Steinbach, F., Bouts, T.,
2012. Detection of elephant endotheliotropic herpesvirus type 1 in
asymptomatic elephants using TaqMan real-time PCR. Vet. Rec. 170 (8), 205.
Hendrix, R.M., Wagenaar, M., Slobbe, R.L., Bruggeman, C.A., 1997. Widespread
presence of cytomegalovirus DNA in tissues of healthy trauma victims. J. Clin.
Pathol. 50, 59–63.
Jarvis, M.A., Nelson, J.A., 2007. Human cytomegalovirus tropism for endothelial
cells: not all endothelial cells are created equal. J. Virol. 81 (5), 2095.
McGeoch, D.J., Dolan, A., Ralph, A.C., 2000. Toward a comprehensive phylogeny for
mammalian and avian herpesviruses. J. Virol. 74, 10401–10406.
96 K. Seilern-Moy et al. / Virus Research 220 (2016) 91–96
Melnick, J.L., Petrie, B.L., Dreesman, G.R., Burek, J., McCollum, C.H., Debakey, M.E.,
1983. Cytomegalovirus antigen within human arterial smooth muscle cells.
Lancet 2, 644–647.
Reid, C.E., Hildebrandt, T.B., Marx, N., Hunt, M., Thy, N., Reynes, J.M., Schaftenaar,
W., Fickel, J., 2006. Endotheliotrophic elephant herpes virus (EEHV) infection:
the first PCR-confirmed case in asia. Vet. Quart. 28, 61–64.
Richman, L.K., Hayward, G.S., 2012. Elephant herpesviruses. In: Fowler, M.E.,
Miller, R.E. (Eds.), Zoo and Wild Animal Medicine. Saunders, pp. 496–502.
Richman, L.K., Montali, R.J., Cambre, R.C., Schmitt, D., Hardy, D., Hildebrandt, T.B.,
Bengis, R.G., Hamzeh, F.M., Shahkolahi, A., Hayward, G.S., 2000. Clinical and
pathological findings of a newly recognised disease of elephants caused by
endotheliotrophic herpesviruses. J. Wildlife Dis. 36, 1–12.
Richman, L.K., Zong, J.C., Latimer, E.M., Lock, J., Fleischer, R.C., Heaggans, S.Y.,
Hayward, G.S., 2014. Elephant endotheliotropic herpesviruses EEHV1A,
EEHV1B, and EEHV2 from cases of hemorrhagic disease are highly diverged
from other mammalian herpesviruses and may form a new subfamily. J. Virol.
88 (23), 13523–13546.
Seilern-Moy, K., Bertelsen, M.F., Leifsson, P.S., Perrin, K.L., Haycock, J., Dastjerdi, A.,
2015. Fatal elephant endotheliotropic herpesvirus-1 and -4 co-infection in a
juvenile Asian elephant in Europe. JMM Case Rep., http://dx.doi.org/10.1099/
jmmcr.0.005005.
Shoshani, J., 1998. Understanding proboscidean evolution. A formidable task.
Trends. Ecol. Evol. 13, 480–487.
Sripiboon, S., Tankaew, P., Lungka, G., Thitaram, C., 2013. The occurrence of
elephant endotheliotropic herpesvirus in captive Asian elephants (Elephas
maximus): First case of EEHV4 in Asia. J. Zoo Wildlife Med. 44 (1), 100–104.
van den Doel, P.B., Prieto, V.R., van Rossum-Fikkert, S.E., Schaftenaar, W., Latimer,
E., Howard, L., Chapman, S., Masters, N., Osterhaus, A.D., Ling, P.D., Dastjerdi, A.,
Martina, B., 2015. A novel antigen capture ELISA for the specific detection of
IgG antibodies to elephant endotheliotropic herpes virus. BMC Vet. Res. 14
(11), 203.
Weiss, L., Haydock, K., Pickren, J.W., Lane, W.W., 1980. Organ vascularity and
metastatic frequency. Am. J. Pathol. 101, 101–113.
Wilkie, G.S., Davidson, A.J., Kerr, K., Stidworthy, M.F., Redrobe, S., Steinbach, F.,
Dastjerdi, A., Denk, D., 2014. First fatality associated with elephant
endotheliotropic herpesvirus 5 in an asian elephant: pathological findings and
complete viral genome sequence. Sci. Rep. 4, 6299.
Wilkie, G.S., Davidson, A.J., Watson, M., Kerr, K., Sanderson, S., Bouts, T., Steinbach,
F., Dastjerdi, A., 2013. Complete genome sequences of elephant
endotheliotropic herpesviruses 1A and 1B determined directly from fatal
cases. J. Virol. 87, 6700–6712.
Yamashiroyo, H.M., Ghosh, L., Yamg, R., Robertson, A.L., 1988. Herpesviridae in the
coronary arteries and aorta of young trauma victims. Am. J. Pathol 130, 71–79.
Zong, J.C., Latimer, E.M., Long, S.Y., Richman, L.K., Heaggans, S.Y., Hayward, G.S.,
2014. Comparative genome analysis of four elephant endotheliotropic
herpesviruses, EEHV3, EEHV4, EEHV5, and EEHV6, from cases of hemorrhagic
disease or viremia. J. Virol. 88 (23), 13547–13569.
View publication stats
